0	DDI-false	@DRUG$: Concomitant @DRUG$ administration decreased the mean AUC of total ezetimibe approximately 55%.
1	DDI-false	@DRUG$: Concomitant cholestyramine administration decreased the mean AUC of total @DRUG$ approximately 55%.
2	DDI-mechanism	Cholestyramine: Concomitant @DRUG$ administration decreased the mean AUC of total @DRUG$ approximately 55%.
3	DDI-effect	The incremental LDL-C reduction due to adding @DRUG$ to @DRUG$ may be reduced by this interaction.
4	DDI-advise	Patients who take both @DRUG$ and @DRUG$ should be carefully monitored.
5	DDI-false	Carcinogenesis, Mutagenesis, Impairment of Fertility A 104-week dietary carcinogenicity study with @DRUG$ was conducted in rats at doses up to 1500 mg/kg/day (males) and 500 mg/kg/day (females) (~20 times the human exposure at 10 mg daily based on AUC0-24hr for total @DRUG$).
6	DDI-false	A 104-week dietary carcinogenicity study with @DRUG$ was also conducted in mice at doses up to 500 mg/kg/day (>150 times the human exposure at 10 mg daily based on AUC0-24hr for total @DRUG$).
7	DDI-false	In oral (gavage) fertility studies of @DRUG$ conducted in rats, there was no evidence of reproductive toxicity at doses up to 1000 mg/kg/day in male or female rats (~7 times the human exposure at 10 mg daily based on AUC0-24hr for total @DRUG$).
8	DDI-false	@DRUG$: The safety and effectiveness of @DRUG$ administered with fibrates have not been established.
9	DDI-false	@DRUG$: The safety and effectiveness of ezetimibe administered with @DRUG$ have not been established.
10	DDI-false	Fibrates: The safety and effectiveness of @DRUG$ administered with @DRUG$ have not been established.
11	DDI-false	In rabbits treated with @DRUG$, an increased incidence of extra thoracic ribs was observed at 1000 mg/kg/day (150 times the human exposure at 10 mg daily based on AUC0-24hr for total @DRUG$).
12	DDI-false	Multiple dose studies of @DRUG$ given in combination with @DRUG$ (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures.
13	DDI-false	Multiple dose studies of @DRUG$ given in combination with HMG-CoA reductase inhibitors (@DRUG$) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures.
14	DDI-false	Multiple dose studies of @DRUG$ given in combination with HMG-CoA reductase inhibitors (statins) in rats and rabbits during organogenesis result in higher @DRUG$ and statin exposures.
15	DDI-false	Multiple dose studies of ezetimibe given in combination with @DRUG$ (@DRUG$) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures.
16	DDI-false	Multiple dose studies of ezetimibe given in combination with @DRUG$ (statins) in rats and rabbits during organogenesis result in higher @DRUG$ and statin exposures.
17	DDI-false	Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors (@DRUG$) in rats and rabbits during organogenesis result in higher @DRUG$ and statin exposures.
18	DDI-false	When @DRUG$ is administered with an @DRUG$ in a woman of childbearing potential, refer to the pregnancy category and package labeling for the HMG-CoA reductase inhibitor.
19	DDI-false	When @DRUG$ is administered with an HMG-CoA reductase inhibitor in a woman of childbearing potential, refer to the pregnancy category and package labeling for the @DRUG$.
20	DDI-false	When ZETIA is administered with an @DRUG$ in a woman of childbearing potential, refer to the pregnancy category and package labeling for the @DRUG$.
21	DDI-advise	Co-administration of @DRUG$ with @DRUG$ is not recommended until use in patients is studied.
22	DDI-false	@DRUG$: In a pharmacokinetic study, concomitant @DRUG$ administration increased total ezetimibe concentrations approximately 1.5-fold.
23	DDI-false	@DRUG$: In a pharmacokinetic study, concomitant fenofibrate administration increased total @DRUG$ concentrations approximately 1.5-fold.
24	DDI-mechanism	Fenofibrate: In a pharmacokinetic study, concomitant @DRUG$ administration increased total @DRUG$ concentrations approximately 1.5-fold.
25	DDI-false	@DRUG$: In a pharmacokinetic study, concomitant @DRUG$ administration increased total ezetimibe concentrations approximately 1.7-fold.
26	DDI-false	@DRUG$: In a pharmacokinetic study, concomitant gemfibrozil administration increased total @DRUG$ concentrations approximately 1.7-fold.
27	DDI-false	Gemfibrozil: In a pharmacokinetic study, concomitant @DRUG$ administration increased total @DRUG$ concentrations approximately 1.7-fold.
28	DDI-false	@DRUG$: No clinically significant pharmacokinetic interactions were seen when @DRUG$ was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin.
29	DDI-false	@DRUG$: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with @DRUG$, simvastatin, pravastatin, lovastatin, or fluvastatin.
30	DDI-false	@DRUG$: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, @DRUG$, pravastatin, lovastatin, or fluvastatin.
31	DDI-false	@DRUG$: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, @DRUG$, lovastatin, or fluvastatin.
32	DDI-false	@DRUG$: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, @DRUG$, or fluvastatin.
33	DDI-false	@DRUG$: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or @DRUG$.
34	DDI-false	HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when @DRUG$ was co-administered with @DRUG$, simvastatin, pravastatin, lovastatin, or fluvastatin.
35	DDI-false	HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when @DRUG$ was co-administered with atorvastatin, @DRUG$, pravastatin, lovastatin, or fluvastatin.
36	DDI-false	HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when @DRUG$ was co-administered with atorvastatin, simvastatin, @DRUG$, lovastatin, or fluvastatin.
37	DDI-false	HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when @DRUG$ was co-administered with atorvastatin, simvastatin, pravastatin, @DRUG$, or fluvastatin.
38	DDI-false	HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when @DRUG$ was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or @DRUG$.
39	DDI-false	HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with @DRUG$, @DRUG$, pravastatin, lovastatin, or fluvastatin.
40	DDI-false	HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with @DRUG$, simvastatin, @DRUG$, lovastatin, or fluvastatin.
41	DDI-false	HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with @DRUG$, simvastatin, pravastatin, @DRUG$, or fluvastatin.
42	DDI-false	HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with @DRUG$, simvastatin, pravastatin, lovastatin, or @DRUG$.
43	DDI-false	HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, @DRUG$, @DRUG$, lovastatin, or fluvastatin.
44	DDI-false	HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, @DRUG$, pravastatin, @DRUG$, or fluvastatin.
45	DDI-false	HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, @DRUG$, pravastatin, lovastatin, or @DRUG$.
46	DDI-false	HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, @DRUG$, @DRUG$, or fluvastatin.
47	DDI-false	HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, @DRUG$, lovastatin, or @DRUG$.
48	DDI-false	HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, @DRUG$, or @DRUG$.
49	DDI-false	@DRUG$: The total @DRUG$ level increased 12-fold in one renal transplant patient receiving multiple medications, including cyclosporine.
50	DDI-false	@DRUG$: The total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications, including @DRUG$.
51	DDI-mechanism	Cyclosporine: The total @DRUG$ level increased 12-fold in one renal transplant patient receiving multiple medications, including @DRUG$.
52	DDI-false	Interaction with @DRUG$: Although @DRUG$ does not itself cause orthostatic hypotension, its administration to patients already receiving guanethidine can result in profound orthostatic effects.
53	DDI-false	Interaction with @DRUG$: Although minoxidil does not itself cause orthostatic hypotension, its administration to patients already receiving @DRUG$ can result in profound orthostatic effects.
54	DDI-effect	Interaction with Guanethidine: Although @DRUG$ does not itself cause orthostatic hypotension, its administration to patients already receiving @DRUG$ can result in profound orthostatic effects.
55	DDI-advise	If at all possible @DRUG$ should be discontinued well before @DRUG$ is begun.
56	DDI-false	In a study in which 34 different drugs were tested, therapeutically relevant concentrations of @DRUG$, @DRUG$ and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent.
57	DDI-false	In a study in which 34 different drugs were tested, therapeutically relevant concentrations of @DRUG$, sodium salicylate and @DRUG$ displaced protein-bound teniposide in fresh human serum to a small but significant extent.
58	DDI-mechanism	In a study in which 34 different drugs were tested, therapeutically relevant concentrations of @DRUG$, sodium salicylate and sulfamethizole displaced protein-bound @DRUG$ in fresh human serum to a small but significant extent.
59	DDI-false	In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, @DRUG$ and @DRUG$ displaced protein-bound teniposide in fresh human serum to a small but significant extent.
60	DDI-mechanism	In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, @DRUG$ and sulfamethizole displaced protein-bound @DRUG$ in fresh human serum to a small but significant extent.
61	DDI-mechanism	In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and @DRUG$ displaced protein-bound @DRUG$ in fresh human serum to a small but significant extent.
62	DDI-false	Therefore, caution should be used in administering @DRUG$ (@DRUG$ injection) to patients receiving these other agents.
63	DDI-false	There was no change in the plasma kinetics of @DRUG$ when coadministered with @DRUG$.
64	DDI-mechanism	An increase in intracellular levels of @DRUG$ was observed in vitro in the presence of @DRUG$.
65	DDI-false	@DRUG$ AND OTHER @DRUG$ WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS.
66	DDI-effect	@DRUG$ AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO @DRUG$ AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS.
67	DDI-false	@DRUG$ AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF @DRUG$ TO TOXIC LEVELS.
68	DDI-effect	ASPIRIN AND OTHER @DRUG$ WILL BE ADDITIVE TO @DRUG$ AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS.
69	DDI-false	ASPIRIN AND OTHER @DRUG$ WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF @DRUG$ TO TOXIC LEVELS.
70	DDI-false	ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO @DRUG$ AND MAY INCREASE PLASMA CONCENTRATIONS OF @DRUG$ TO TOXIC LEVELS.
71	DDI-effect	@DRUG$ given concomitantly with @DRUG$ may predispose to systemic bleeding.
72	DDI-effect	@DRUG$ may enhance the hypoglycemic effect of oral @DRUG$ of the sulfonylurea class.
73	DDI-mechanism	@DRUG$ competes with a number of drugs for protein binding sites, notably @DRUG$, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.
74	DDI-mechanism	@DRUG$ competes with a number of drugs for protein binding sites, notably penicillin, @DRUG$, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.
75	DDI-mechanism	@DRUG$ competes with a number of drugs for protein binding sites, notably penicillin, thiopental, @DRUG$, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.
76	DDI-mechanism	@DRUG$ competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, @DRUG$, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.
77	DDI-mechanism	@DRUG$ competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, @DRUG$, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.
78	DDI-mechanism	@DRUG$ competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, @DRUG$, naproxen, warfarin, methotrexate, and possibly corticosteroids.
79	DDI-mechanism	@DRUG$ competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, @DRUG$, warfarin, methotrexate, and possibly corticosteroids.
80	DDI-mechanism	@DRUG$ competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, @DRUG$, methotrexate, and possibly corticosteroids.
81	DDI-mechanism	@DRUG$ competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, @DRUG$, and possibly corticosteroids.
82	DDI-mechanism	@DRUG$ competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly @DRUG$.
83	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably @DRUG$, @DRUG$, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.
84	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably @DRUG$, thiopental, @DRUG$, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.
85	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably @DRUG$, thiopental, thyroxine, @DRUG$, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.
86	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably @DRUG$, thiopental, thyroxine, triiodothyronine, @DRUG$, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.
87	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably @DRUG$, thiopental, thyroxine, triiodothyronine, phenytoin, @DRUG$, naproxen, warfarin, methotrexate, and possibly corticosteroids.
88	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably @DRUG$, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, @DRUG$, warfarin, methotrexate, and possibly corticosteroids.
89	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably @DRUG$, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, @DRUG$, methotrexate, and possibly corticosteroids.
90	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably @DRUG$, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, @DRUG$, and possibly corticosteroids.
91	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably @DRUG$, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly @DRUG$.
92	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, @DRUG$, @DRUG$, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.
93	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, @DRUG$, thyroxine, @DRUG$, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.
94	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, @DRUG$, thyroxine, triiodothyronine, @DRUG$, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.
95	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, @DRUG$, thyroxine, triiodothyronine, phenytoin, @DRUG$, naproxen, warfarin, methotrexate, and possibly corticosteroids.
96	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, @DRUG$, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, @DRUG$, warfarin, methotrexate, and possibly corticosteroids.
97	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, @DRUG$, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, @DRUG$, methotrexate, and possibly corticosteroids.
98	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, @DRUG$, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, @DRUG$, and possibly corticosteroids.
99	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, @DRUG$, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly @DRUG$.
100	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, @DRUG$, @DRUG$, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.
101	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, @DRUG$, triiodothyronine, @DRUG$, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.
102	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, @DRUG$, triiodothyronine, phenytoin, @DRUG$, naproxen, warfarin, methotrexate, and possibly corticosteroids.
103	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, @DRUG$, triiodothyronine, phenytoin, sulfinpyrazone, @DRUG$, warfarin, methotrexate, and possibly corticosteroids.
104	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, @DRUG$, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, @DRUG$, methotrexate, and possibly corticosteroids.
105	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, @DRUG$, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, @DRUG$, and possibly corticosteroids.
106	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, @DRUG$, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly @DRUG$.
107	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, @DRUG$, @DRUG$, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.
108	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, @DRUG$, phenytoin, @DRUG$, naproxen, warfarin, methotrexate, and possibly corticosteroids.
109	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, @DRUG$, phenytoin, sulfinpyrazone, @DRUG$, warfarin, methotrexate, and possibly corticosteroids.
110	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, @DRUG$, phenytoin, sulfinpyrazone, naproxen, @DRUG$, methotrexate, and possibly corticosteroids.
111	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, @DRUG$, phenytoin, sulfinpyrazone, naproxen, warfarin, @DRUG$, and possibly corticosteroids.
112	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, @DRUG$, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly @DRUG$.
113	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, @DRUG$, @DRUG$, naproxen, warfarin, methotrexate, and possibly corticosteroids.
114	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, @DRUG$, sulfinpyrazone, @DRUG$, warfarin, methotrexate, and possibly corticosteroids.
115	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, @DRUG$, sulfinpyrazone, naproxen, @DRUG$, methotrexate, and possibly corticosteroids.
116	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, @DRUG$, sulfinpyrazone, naproxen, warfarin, @DRUG$, and possibly corticosteroids.
117	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, @DRUG$, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly @DRUG$.
118	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, @DRUG$, @DRUG$, warfarin, methotrexate, and possibly corticosteroids.
119	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, @DRUG$, naproxen, @DRUG$, methotrexate, and possibly corticosteroids.
120	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, @DRUG$, naproxen, warfarin, @DRUG$, and possibly corticosteroids.
121	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, @DRUG$, naproxen, warfarin, methotrexate, and possibly @DRUG$.
122	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, @DRUG$, @DRUG$, methotrexate, and possibly corticosteroids.
123	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, @DRUG$, warfarin, @DRUG$, and possibly corticosteroids.
124	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, @DRUG$, warfarin, methotrexate, and possibly @DRUG$.
125	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, @DRUG$, @DRUG$, and possibly corticosteroids.
126	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, @DRUG$, methotrexate, and possibly @DRUG$.
127	DDI-false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, @DRUG$, and possibly @DRUG$.
128	DDI-false	In elderly patients concurrently receiving certain @DRUG$, primarily @DRUG$, an increased incidence of thrombopenia with purpura has been reported.
129	DDI-false	It has been reported that @DRUG$ may prolong the prothrombin time in patients who are receiving the @DRUG$ warfarin.
130	DDI-effect	It has been reported that @DRUG$ may prolong the prothrombin time in patients who are receiving the anticoagulant @DRUG$.
131	DDI-false	It has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the @DRUG$ @DRUG$.
132	DDI-mechanism	@DRUG$ may inhibit the hepatic metabolism of @DRUG$.
133	DDI-mechanism	At a 1.6-g dose, @DRUG$ produced a slight but significant increase in the half-life of @DRUG$ but did not produce a corresponding decrease in the metabolic clearance rate.
134	DDI-mechanism	@DRUG$ can also displace @DRUG$ from plasma protein-binding sites, thus increasing free methotrexate concentrations.
135	DDI-false	@DRUG$ can also displace methotrexate from plasma protein-binding sites, thus increasing free @DRUG$ concentrations.
136	DDI-false	Sulfonamides can also displace @DRUG$ from plasma protein-binding sites, thus increasing free @DRUG$ concentrations.
137	DDI-mechanism	Mutual inhibition of metabolism occurs with concurrent use of @DRUG$ and @DRUG$;
138	DDI-false	The effect of @DRUG$ on oral @DRUG$ is variable.
139	DDI-effect	There are reports of enhanced as well as diminished effects of @DRUG$ when given concurrently with @DRUG$.
140	DDI-effect	convulsions have been reported with concurrent use of @DRUG$ and @DRUG$.
141	DDI-false	Drugs that induce hepatic enzymes such as @DRUG$, @DRUG$, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response.
142	DDI-false	Drugs that induce hepatic enzymes such as @DRUG$, phenytoin, and @DRUG$ may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response.
143	DDI-mechanism	Drugs that induce hepatic enzymes such as @DRUG$, phenytoin, and rifampin may increase the clearance of @DRUG$ and may require increased in methylprednisolone dose to achieve the desired response.
144	DDI-advise	Drugs that induce hepatic enzymes such as @DRUG$, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in @DRUG$ dose to achieve the desired response.
145	DDI-false	Drugs that induce hepatic enzymes such as phenobarbital, @DRUG$, and @DRUG$ may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response.
146	DDI-mechanism	Drugs that induce hepatic enzymes such as phenobarbital, @DRUG$, and rifampin may increase the clearance of @DRUG$ and may require increased in methylprednisolone dose to achieve the desired response.
147	DDI-advise	Drugs that induce hepatic enzymes such as phenobarbital, @DRUG$, and rifampin may increase the clearance of methylprednisolone and may require increased in @DRUG$ dose to achieve the desired response.
148	DDI-mechanism	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and @DRUG$ may increase the clearance of @DRUG$ and may require increased in methylprednisolone dose to achieve the desired response.
149	DDI-advise	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and @DRUG$ may increase the clearance of methylprednisolone and may require increased in @DRUG$ dose to achieve the desired response.
150	DDI-false	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of @DRUG$ and may require increased in @DRUG$ dose to achieve the desired response.
151	DDI-false	Drugs such as @DRUG$ and @DRUG$ may inhibit the metabolism of methylprednisolone and thus decrease its clearance.
152	DDI-mechanism	Drugs such as @DRUG$ and ketoconazole may inhibit the metabolism of @DRUG$ and thus decrease its clearance.
153	DDI-mechanism	Drugs such as troleandomycin and @DRUG$ may inhibit the metabolism of @DRUG$ and thus decrease its clearance.
154	DDI-mechanism	@DRUG$ may increase the clearance of chronic high dose @DRUG$.
155	DDI-false	This could lead to decreased @DRUG$ serum levels or increase the risk of @DRUG$ toxicity when methylprednisolone is withdrawn.
156	DDI-false	This could lead to decreased @DRUG$ serum levels or increase the risk of salicylate toxicity when @DRUG$ is withdrawn.
157	DDI-effect	This could lead to decreased salicylate serum levels or increase the risk of @DRUG$ toxicity when @DRUG$ is withdrawn.
158	DDI-advise	@DRUG$ should be used cautiously in conjunction with @DRUG$ in patients suffering from hypoprothrombinemia.
159	DDI-false	Patients receiving @DRUG$ and @DRUG$ generally should not be treated with ganglion blockers.
160	DDI-advise	Patients receiving @DRUG$ and sulfonamides generally should not be treated with @DRUG$.
161	DDI-advise	Patients receiving antibiotics and @DRUG$ generally should not be treated with @DRUG$.
162	DDI-effect	The action of @DRUG$ may be potentiated by anesthesia, other @DRUG$ and alcohol.
163	DDI-effect	The action of @DRUG$ may be potentiated by anesthesia, other antihypertensive drugs and @DRUG$.
164	DDI-false	The action of Mecamylamine may be potentiated by anesthesia, other @DRUG$ and @DRUG$.
165	DDI-mechanism	However, @DRUG$, a potent inhibitor of cytochrome P450 3A4, may increase plasma levels of @DRUG$ during concomitant dosing.
166	DDI-advise	patients receiving @DRUG$ and @DRUG$ should have more frequent monitoring of neutrophil counts.
167	DDI-false	@DRUG$ @DRUG$ may increase sensitivity to oral anticoagulants.
168	DDI-false	@DRUG$ Anabolic steroids may increase sensitivity to oral @DRUG$.
169	DDI-effect	Anticoagulants @DRUG$ may increase sensitivity to oral @DRUG$.
170	DDI-false	@DRUG$ or @DRUG$ In patients with edema, concomitant administration with adrenal cortical steroids or ACTH may increase the edema.
171	DDI-false	@DRUG$ or ACTH In patients with edema, concomitant administration with @DRUG$ or ACTH may increase the edema.
172	DDI-false	@DRUG$ or ACTH In patients with edema, concomitant administration with adrenal cortical steroids or @DRUG$ may increase the edema.
173	DDI-false	Adrenal steroids or @DRUG$ In patients with edema, concomitant administration with @DRUG$ or ACTH may increase the edema.
174	DDI-false	Adrenal steroids or @DRUG$ In patients with edema, concomitant administration with adrenal cortical steroids or @DRUG$ may increase the edema.
175	DDI-false	Adrenal steroids or ACTH In patients with edema, concomitant administration with @DRUG$ or @DRUG$ may increase the edema.
176	DDI-false	@DRUG$: A multidose study of @DRUG$, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected.
177	DDI-false	@DRUG$: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with @DRUG$, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected.
178	DDI-false	@DRUG$: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in @DRUG$ half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected.
179	DDI-false	@DRUG$: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in @DRUG$ half-life and AUC were also detected.
180	DDI-mechanism	Warfarin: A multidose study of @DRUG$, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with @DRUG$, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected.
181	DDI-false	Warfarin: A multidose study of @DRUG$, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in @DRUG$ half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected.
182	DDI-false	Warfarin: A multidose study of @DRUG$, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in @DRUG$ half-life and AUC were also detected.
183	DDI-false	Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with @DRUG$, resulted in a mean increase in @DRUG$ half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected.
184	DDI-false	Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with @DRUG$, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in @DRUG$ half-life and AUC were also detected.
185	DDI-false	Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in @DRUG$ half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in @DRUG$ half-life and AUC were also detected.
186	DDI-false	A 5.5-fold decrease in the mean @DRUG$ dose from 6.13 mg/day to 1.13 mg/day (approximately 80-85% reduction of @DRUG$ dose), was necessary to maintain a target INR of 1.5.
187	DDI-advise	When @DRUG$ therapy is initiated in a patient already receiving treatment with @DRUG$, the INR or prothrombin time (PT) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved.
188	DDI-false	When @DRUG$ therapy is initiated in a patient already receiving treatment with warfarin, the INR or prothrombin time (PT) should be monitored closely and the dose of @DRUG$ adjusted as necessary until a stable target INR or PT has been achieved.
189	DDI-false	When oxandrolone therapy is initiated in a patient already receiving treatment with @DRUG$, the INR or prothrombin time (PT) should be monitored closely and the dose of @DRUG$ adjusted as necessary until a stable target INR or PT has been achieved.
190	DDI-advise	Furthermore, in patients receiving both drugs, careful monitoring of the INR or PT, and adjustment of the @DRUG$ dosage if indicated are recommended when the @DRUG$ dose is changed or discontinued.
191	DDI-false	Oral @DRUG$ @DRUG$ may inhibit the metabolism of oral hypoglycemic agents.
192	DDI-false	Oral @DRUG$ Oxandrolone may inhibit the metabolism of oral @DRUG$.
193	DDI-mechanism	Oral hypoglycemic agents @DRUG$ may inhibit the metabolism of oral @DRUG$.
194	DDI-effect	The following agents may increase certain actions or side effects of @DRUG$: @DRUG$, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
195	DDI-effect	The following agents may increase certain actions or side effects of @DRUG$: amantadine, @DRUG$ (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
196	DDI-effect	The following agents may increase certain actions or side effects of @DRUG$: amantadine, antiarrhythmic agents of class I (e.g., @DRUG$), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
197	DDI-effect	The following agents may increase certain actions or side effects of @DRUG$: amantadine, antiarrhythmic agents of class I (e.g., quinidine), @DRUG$, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
198	DDI-effect	The following agents may increase certain actions or side effects of @DRUG$: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, @DRUG$ (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
199	DDI-effect	The following agents may increase certain actions or side effects of @DRUG$: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., @DRUG$), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
200	DDI-effect	The following agents may increase certain actions or side effects of @DRUG$: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), @DRUG$, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
201	DDI-effect	The following agents may increase certain actions or side effects of @DRUG$: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, @DRUG$, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
202	DDI-effect	The following agents may increase certain actions or side effects of @DRUG$: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, @DRUG$ (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
203	DDI-effect	The following agents may increase certain actions or side effects of @DRUG$: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., @DRUG$), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
204	DDI-effect	The following agents may increase certain actions or side effects of @DRUG$: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), @DRUG$ and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
205	DDI-effect	The following agents may increase certain actions or side effects of @DRUG$: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and @DRUG$, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
206	DDI-effect	The following agents may increase certain actions or side effects of @DRUG$: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity.
207	DDI-effect	The following agents may increase certain actions or side effects of @DRUG$: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity.
208	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, @DRUG$ (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
209	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, antiarrhythmic agents of class I (e.g., @DRUG$), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
210	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, antiarrhythmic agents of class I (e.g., quinidine), @DRUG$, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
211	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, @DRUG$ (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
212	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., @DRUG$), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
213	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), @DRUG$, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
214	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, @DRUG$, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
215	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, @DRUG$ (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
216	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., @DRUG$), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
217	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), @DRUG$ and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
218	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and @DRUG$, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
219	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity.
220	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity.
221	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, @DRUG$ (e.g., @DRUG$), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
222	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, @DRUG$ (e.g., quinidine), @DRUG$, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
223	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, @DRUG$ (e.g., quinidine), antihistamines, @DRUG$ (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
224	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, @DRUG$ (e.g., quinidine), antihistamines, antipsychotic agents (e.g., @DRUG$), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
225	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, @DRUG$ (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), @DRUG$, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
226	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, @DRUG$ (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, @DRUG$, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
227	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, @DRUG$ (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, @DRUG$ (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
228	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, @DRUG$ (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., @DRUG$), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
229	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, @DRUG$ (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), @DRUG$ and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
230	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, @DRUG$ (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and @DRUG$, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
231	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, @DRUG$ (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity.
232	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, @DRUG$ (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity.
233	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., @DRUG$), @DRUG$, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
234	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., @DRUG$), antihistamines, @DRUG$ (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
235	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., @DRUG$), antihistamines, antipsychotic agents (e.g., @DRUG$), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
236	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., @DRUG$), antihistamines, antipsychotic agents (e.g., phenothiazines), @DRUG$, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
237	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., @DRUG$), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, @DRUG$, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
238	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., @DRUG$), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, @DRUG$ (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
239	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., @DRUG$), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., @DRUG$), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
240	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., @DRUG$), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), @DRUG$ and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
241	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., @DRUG$), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and @DRUG$, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
242	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., @DRUG$), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity.
243	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., @DRUG$), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity.
244	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), @DRUG$, @DRUG$ (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
245	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), @DRUG$, antipsychotic agents (e.g., @DRUG$), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
246	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), @DRUG$, antipsychotic agents (e.g., phenothiazines), @DRUG$, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
247	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), @DRUG$, antipsychotic agents (e.g., phenothiazines), benzodiazepines, @DRUG$, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
248	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), @DRUG$, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, @DRUG$ (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
249	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), @DRUG$, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., @DRUG$), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
250	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), @DRUG$, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), @DRUG$ and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
251	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), @DRUG$, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and @DRUG$, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
252	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), @DRUG$, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity.
253	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), @DRUG$, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity.
254	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, @DRUG$ (e.g., @DRUG$), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
255	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, @DRUG$ (e.g., phenothiazines), @DRUG$, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
256	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, @DRUG$ (e.g., phenothiazines), benzodiazepines, @DRUG$, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
257	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, @DRUG$ (e.g., phenothiazines), benzodiazepines, MAO inhibitors, @DRUG$ (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
258	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, @DRUG$ (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., @DRUG$), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
259	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, @DRUG$ (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), @DRUG$ and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
260	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, @DRUG$ (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and @DRUG$, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
261	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, @DRUG$ (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity.
262	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, @DRUG$ (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity.
263	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., @DRUG$), @DRUG$, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
264	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., @DRUG$), benzodiazepines, @DRUG$, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
265	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., @DRUG$), benzodiazepines, MAO inhibitors, @DRUG$ (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
266	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., @DRUG$), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., @DRUG$), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
267	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., @DRUG$), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), @DRUG$ and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
268	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., @DRUG$), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and @DRUG$, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
269	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., @DRUG$), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity.
270	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., @DRUG$), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity.
271	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), @DRUG$, @DRUG$, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
272	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), @DRUG$, MAO inhibitors, @DRUG$ (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
273	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), @DRUG$, MAO inhibitors, narcotic analgesics (e.g., @DRUG$), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
274	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), @DRUG$, MAO inhibitors, narcotic analgesics (e.g., meperidine), @DRUG$ and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
275	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), @DRUG$, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and @DRUG$, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
276	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), @DRUG$, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity.
277	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), @DRUG$, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity.
278	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, @DRUG$, @DRUG$ (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
279	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, @DRUG$, narcotic analgesics (e.g., @DRUG$), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
280	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, @DRUG$, narcotic analgesics (e.g., meperidine), @DRUG$ and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
281	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, @DRUG$, narcotic analgesics (e.g., meperidine), nitrates and @DRUG$, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
282	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, @DRUG$, narcotic analgesics (e.g., meperidine), nitrates and nitrites, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity.
283	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, @DRUG$, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity.
284	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, @DRUG$ (e.g., @DRUG$), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
285	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, @DRUG$ (e.g., meperidine), @DRUG$ and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
286	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, @DRUG$ (e.g., meperidine), nitrates and @DRUG$, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
287	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, @DRUG$ (e.g., meperidine), nitrates and nitrites, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity.
288	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, @DRUG$ (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity.
289	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., @DRUG$), @DRUG$ and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
290	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., @DRUG$), nitrates and @DRUG$, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
291	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., @DRUG$), nitrates and nitrites, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity.
292	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., @DRUG$), nitrates and nitrites, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity.
293	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), @DRUG$ and @DRUG$, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
294	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), @DRUG$ and nitrites, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity.
295	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), @DRUG$ and nitrites, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity.
296	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and @DRUG$, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity.
297	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and @DRUG$, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity.
298	DDI-false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, @DRUG$, @DRUG$, and other drugs having anticholinergic activity.
299	DDI-effect	@DRUG$ antagonize the effects of @DRUG$.
300	DDI-effect	@DRUG$ in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as @DRUG$.
301	DDI-mechanism	@DRUG$ may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of @DRUG$;
302	DDI-effect	@DRUG$ may antagonize the effects of drugs that alter gastrointestinal motility, such as @DRUG$.
303	DDI-mechanism	Because @DRUG$ may interfere with the absorption of @DRUG$, simultaneous use of these drugs should be avoided.
304	DDI-false	Since @DRUG$ (@DRUG$) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).
305	DDI-advise	Since @DRUG$ (methsuximide) may interact with concurrently administered @DRUG$, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).
306	DDI-false	Since @DRUG$ (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg @DRUG$ may increase the plasma concentrations of phenytoin and phenobarbital).
307	DDI-false	Since @DRUG$ (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of @DRUG$ and phenobarbital).
308	DDI-false	Since @DRUG$ (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and @DRUG$).
309	DDI-advise	Since Celontin (@DRUG$) may interact with concurrently administered @DRUG$, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).
310	DDI-false	Since Celontin (@DRUG$) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg @DRUG$ may increase the plasma concentrations of phenytoin and phenobarbital).
311	DDI-false	Since Celontin (@DRUG$) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of @DRUG$ and phenobarbital).
312	DDI-false	Since Celontin (@DRUG$) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and @DRUG$).
313	DDI-false	Since Celontin (methsuximide) may interact with concurrently administered @DRUG$, periodic serum level determinations of these drugs may be necessary (eg @DRUG$ may increase the plasma concentrations of phenytoin and phenobarbital).
314	DDI-false	Since Celontin (methsuximide) may interact with concurrently administered @DRUG$, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of @DRUG$ and phenobarbital).
315	DDI-false	Since Celontin (methsuximide) may interact with concurrently administered @DRUG$, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and @DRUG$).
316	DDI-mechanism	Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg @DRUG$ may increase the plasma concentrations of @DRUG$ and phenobarbital).
317	DDI-mechanism	Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg @DRUG$ may increase the plasma concentrations of phenytoin and @DRUG$).
318	DDI-false	Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of @DRUG$ and @DRUG$).
319	DDI-false	@DRUG$: @DRUG$ and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes.
320	DDI-false	@DRUG$: Furosemide and probably other @DRUG$ given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes.
321	DDI-false	@DRUG$: Furosemide and probably other loop diuretics given concomitantly with @DRUG$ can cause unusually large or prolonged losses of fluid and electrolytes.
322	DDI-false	Diuretics: @DRUG$ and probably other @DRUG$ given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes.
323	DDI-effect	Diuretics: @DRUG$ and probably other loop diuretics given concomitantly with @DRUG$ can cause unusually large or prolonged losses of fluid and electrolytes.
324	DDI-effect	Diuretics: Furosemide and probably other @DRUG$ given concomitantly with @DRUG$ can cause unusually large or prolonged losses of fluid and electrolytes.
325	DDI-false	Other @DRUG$: When @DRUG$ Tablets are used with other antihypertensive drugs, care must be taken, especially during initial therapy.
326	DDI-false	Other @DRUG$: When MYKROX Tablets are used with other @DRUG$, care must be taken, especially during initial therapy.
327	DDI-advise	Other Antihypertensives: When @DRUG$ Tablets are used with other @DRUG$, care must be taken, especially during initial therapy.
328	DDI-false	@DRUG$ and Other @DRUG$: May decrease the antihypertensive effects of MYKROX Tablets.
329	DDI-effect	@DRUG$ and Other Non-Steroidal Anti-Inflammatory Drugs: May decrease the antihypertensive effects of @DRUG$ Tablets.
330	DDI-effect	Salicylates and Other @DRUG$: May decrease the antihypertensive effects of @DRUG$ Tablets.
331	DDI-false	@DRUG$: @DRUG$ may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.
332	DDI-false	@DRUG$: Metolazone may decrease arterial responsiveness to @DRUG$, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.
333	DDI-effect	Sympathomimetics: @DRUG$ may decrease arterial responsiveness to @DRUG$, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.
334	DDI-effect	@DRUG$: Efficacy may be decreased due to urinary alkalizing effect of @DRUG$.
335	DDI-false	@DRUG$: @DRUG$, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to anticoagulants;
336	DDI-false	@DRUG$: Metolazone, as well as other @DRUG$, may affect the hypoprothrombinemic response to anticoagulants;
337	DDI-false	@DRUG$: Metolazone, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to @DRUG$;
338	DDI-false	Anticoagulants: @DRUG$, as well as other @DRUG$, may affect the hypoprothrombinemic response to anticoagulants;
339	DDI-effect	Anticoagulants: @DRUG$, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to @DRUG$;
340	DDI-false	Anticoagulants: Metolazone, as well as other @DRUG$, may affect the hypoprothrombinemic response to @DRUG$;
341	DDI-false	@DRUG$, @DRUG$, and Narcotics: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy.
342	DDI-false	@DRUG$, Barbiturates, and @DRUG$: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy.
343	DDI-false	@DRUG$, Barbiturates, and Narcotics: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with @DRUG$ therapy.
344	DDI-false	Alcohol, @DRUG$, and @DRUG$: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy.
345	DDI-false	Alcohol, @DRUG$, and Narcotics: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with @DRUG$ therapy.
346	DDI-false	Alcohol, Barbiturates, and @DRUG$: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with @DRUG$ therapy.
347	DDI-false	@DRUG$: @DRUG$-induced hypokalemia can increase the sensitivity of the myocardium to digitalis.
348	DDI-false	@DRUG$: Diuretic-induced hypokalemia can increase the sensitivity of the myocardium to @DRUG$.
349	DDI-effect	Digitalis Glycosides: @DRUG$-induced hypokalemia can increase the sensitivity of the myocardium to @DRUG$.
350	DDI-false	@DRUG$ or @DRUG$: May increase the risk of hypokalemia and increase salt and water retention.
351	DDI-false	@DRUG$: Serum @DRUG$ levels may increase.
352	DDI-false	@DRUG$: @DRUG$-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea.
353	DDI-false	@DRUG$: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of @DRUG$ (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea.
354	DDI-false	@DRUG$: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as @DRUG$) the most serious effect would be respiratory depression which could proceed to apnea.
355	DDI-effect	Curariform Drugs: @DRUG$-induced hypokalemia may enhance neuromuscular blocking effects of @DRUG$ (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea.
356	DDI-effect	Curariform Drugs: @DRUG$-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as @DRUG$) the most serious effect would be respiratory depression which could proceed to apnea.
357	DDI-false	Curariform Drugs: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of @DRUG$ (such as @DRUG$) the most serious effect would be respiratory depression which could proceed to apnea.
358	DDI-mechanism	Coadministration of @DRUG$ with @DRUG$ resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%).
359	DDI-false	Coadministration of @DRUG$ with clarithromycin resulted in increased plasma @DRUG$ concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%).
360	DDI-false	Coadministration of @DRUG$ with clarithromycin resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased @DRUG$ plasma concentrations (31%).
361	DDI-false	Coadministration of TRITEC with @DRUG$ resulted in increased plasma @DRUG$ concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%).
362	DDI-false	Coadministration of TRITEC with @DRUG$ resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased @DRUG$ plasma concentrations (31%).
363	DDI-false	Coadministration of TRITEC with clarithromycin resulted in increased plasma @DRUG$ concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased @DRUG$ plasma concentrations (31%).
364	DDI-false	Coadministration with @DRUG$ results in a slight decrease in the rate of @DRUG$ absorption that is clinically unimportant.
365	DDI-mechanism	Coadministration with a high dose of @DRUG$ (170 mEq) results in a 28% decrease in plasma concentrations of @DRUG$ and may decrease plasma concentrations of bismuth from TRITEC.
366	DDI-mechanism	Coadministration with a high dose of @DRUG$ (170 mEq) results in a 28% decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from @DRUG$.
367	DDI-false	Coadministration with a high dose of antacid (170 mEq) results in a 28% decrease in plasma concentrations of @DRUG$ and may decrease plasma concentrations of bismuth from @DRUG$.
368	DDI-false	For information on drug interactions associated with @DRUG$, refer to the @DRUG$     package insert.
369	DDI-advise	@DRUG$ should be used with caution in patients receiving other local @DRUG$ or agents structurally related to amide-type local anesthetics, since the toxic effects of these drugs are additive.
370	DDI-false	@DRUG$ should be used with caution in patients receiving other local anesthetics or agents structurally related to @DRUG$, since the toxic effects of these drugs are additive.
371	DDI-false	Ropivacaine should be used with caution in patients receiving other local @DRUG$ or agents structurally related to @DRUG$, since the toxic effects of these drugs are additive.
372	DDI-mechanism	In vivo, the plasma clearance of @DRUG$ was reduced by 70% during coadministration of @DRUG$ (25 mg bid for 2 days), a selective and potent CYP1A2 inhibitor.
373	DDI-int	Thus strong inhibitors of cytochrome P4501A2, such as @DRUG$, given concomitantly during administration of @DRUG$, can interact with Ropivacaine leading to increased ropivacaine plasma levels.
374	DDI-false	Thus strong inhibitors of cytochrome P4501A2, such as @DRUG$, given concomitantly during administration of Ropivacaine, can interact with @DRUG$ leading to increased ropivacaine plasma levels.
375	DDI-false	Thus strong inhibitors of cytochrome P4501A2, such as @DRUG$, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased @DRUG$ plasma levels.
376	DDI-false	Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of @DRUG$, can interact with @DRUG$ leading to increased ropivacaine plasma levels.
377	DDI-false	Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of @DRUG$, can interact with Ropivacaine leading to increased @DRUG$ plasma levels.
378	DDI-false	Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with @DRUG$ leading to increased @DRUG$ plasma levels.
379	DDI-false	Possible interactions with drugs known to be metabolized by CYP1A2 via competitive inhibition such as @DRUG$ and @DRUG$ may also occur.
380	DDI-false	Coadministration of a selective and potent inhibitor of CYP3A4, @DRUG$ (100 mg bid for 2 days with @DRUG$ infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.
381	DDI-false	Coadministration of a selective and potent inhibitor of CYP3A4, @DRUG$ (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after @DRUG$) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.
382	DDI-mechanism	Coadministration of a selective and potent inhibitor of CYP3A4, @DRUG$ (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of @DRUG$.
383	DDI-false	Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with @DRUG$ infusion administered 1 hour after @DRUG$) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.
384	DDI-false	Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with @DRUG$ infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of @DRUG$.
385	DDI-false	Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after @DRUG$) caused a 15% reduction in in-vivo plasma clearance of @DRUG$.
386	DDI-false	@DRUG$ and @DRUG$ are incompatible with sodium bicarbonate solution.
387	DDI-int	@DRUG$ and dobutamine are incompatible with @DRUG$ solution.
388	DDI-int	norepinephrine and @DRUG$ are incompatible with @DRUG$ solution.
389	DDI-false	The addition of @DRUG$ to parenteral solutions containing @DRUG$ should be avoided, except where compatibility has been previously established.
390	DDI-false	Drug-Drug Interactions Effect of @DRUG$    (@DRUG$) on the Metabolism of Other Drugs: Rivastigmine is primarily metabolized through hydrolysis by esterases.
391	DDI-false	Drug-Drug Interactions Effect of @DRUG$    (rivastigmine tartrate) on the Metabolism of Other Drugs: @DRUG$ is primarily metabolized through hydrolysis by esterases.
392	DDI-false	Drug-Drug Interactions Effect of Exelon    (@DRUG$) on the Metabolism of Other Drugs: @DRUG$ is primarily metabolized through hydrolysis by esterases.
393	DDI-false	No pharmacokinetic interaction was observed between @DRUG$ and @DRUG$, warfarin, diazepam, or fluoxetine in studies in healthy volunteers.
394	DDI-false	No pharmacokinetic interaction was observed between @DRUG$ and digoxin, @DRUG$, diazepam, or fluoxetine in studies in healthy volunteers.
395	DDI-false	No pharmacokinetic interaction was observed between @DRUG$ and digoxin, warfarin, @DRUG$, or fluoxetine in studies in healthy volunteers.
396	DDI-false	No pharmacokinetic interaction was observed between @DRUG$ and digoxin, warfarin, diazepam, or @DRUG$ in studies in healthy volunteers.
397	DDI-false	No pharmacokinetic interaction was observed between rivastigmine and @DRUG$, @DRUG$, diazepam, or fluoxetine in studies in healthy volunteers.
398	DDI-false	No pharmacokinetic interaction was observed between rivastigmine and @DRUG$, warfarin, @DRUG$, or fluoxetine in studies in healthy volunteers.
399	DDI-false	No pharmacokinetic interaction was observed between rivastigmine and @DRUG$, warfarin, diazepam, or @DRUG$ in studies in healthy volunteers.
400	DDI-false	No pharmacokinetic interaction was observed between rivastigmine and digoxin, @DRUG$, @DRUG$, or fluoxetine in studies in healthy volunteers.
401	DDI-false	No pharmacokinetic interaction was observed between rivastigmine and digoxin, @DRUG$, diazepam, or @DRUG$ in studies in healthy volunteers.
402	DDI-false	No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, @DRUG$, or @DRUG$ in studies in healthy volunteers.
403	DDI-false	The elevation of prothrombin time induced by @DRUG$ is not affected by administration of @DRUG$.
404	DDI-false	Effect of Other Drugs on the Metabolism of @DRUG$: Drugs that induce or inhibit CYP450 metabolism are not expected to alter the metabolism of @DRUG$.
405	DDI-false	Single dose pharmacokinetic studies demonstrated that the metabolism of @DRUG$ is not significantly affected by concurrent administration of @DRUG$, warfarin, diazepam, or fluoxetine.
406	DDI-false	Single dose pharmacokinetic studies demonstrated that the metabolism of @DRUG$ is not significantly affected by concurrent administration of digoxin, @DRUG$, diazepam, or fluoxetine.
407	DDI-false	Single dose pharmacokinetic studies demonstrated that the metabolism of @DRUG$ is not significantly affected by concurrent administration of digoxin, warfarin, @DRUG$, or fluoxetine.
408	DDI-false	Single dose pharmacokinetic studies demonstrated that the metabolism of @DRUG$ is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or @DRUG$.
409	DDI-false	Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of @DRUG$, @DRUG$, diazepam, or fluoxetine.
410	DDI-false	Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of @DRUG$, warfarin, @DRUG$, or fluoxetine.
411	DDI-false	Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of @DRUG$, warfarin, diazepam, or @DRUG$.
412	DDI-false	Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, @DRUG$, @DRUG$, or fluoxetine.
413	DDI-false	Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, @DRUG$, diazepam, or @DRUG$.
414	DDI-false	Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, @DRUG$, or @DRUG$.
415	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of @DRUG$ were not influenced by commonly prescribed medications such as @DRUG$ (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).
416	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of @DRUG$ were not influenced by commonly prescribed medications such as antacids (n=77), @DRUG$ (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).
417	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of @DRUG$ were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), @DRUG$ (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).
418	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of @DRUG$ were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), @DRUG$ (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).
419	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of @DRUG$ were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), @DRUG$ (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).
420	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of @DRUG$ were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), @DRUG$ (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).
421	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of @DRUG$ were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), @DRUG$ (n=177), antianginals (n=35), and antihistamines (n=15).
422	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of @DRUG$ were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), @DRUG$ (n=35), and antihistamines (n=15).
423	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of @DRUG$ were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and @DRUG$ (n=15).
424	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as @DRUG$ (n=77), @DRUG$ (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).
425	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as @DRUG$ (n=77), antihypertensives (n=72), @DRUG$ (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).
426	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as @DRUG$ (n=77), antihypertensives (n=72), calcium channel blockers (n=75), @DRUG$ (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).
427	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as @DRUG$ (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), @DRUG$ (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).
428	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as @DRUG$ (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), @DRUG$ (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).
429	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as @DRUG$ (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), @DRUG$ (n=177), antianginals (n=35), and antihistamines (n=15).
430	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as @DRUG$ (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), @DRUG$ (n=35), and antihistamines (n=15).
431	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as @DRUG$ (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and @DRUG$ (n=15).
432	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), @DRUG$ (n=72), @DRUG$ (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).
433	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), @DRUG$ (n=72), calcium channel blockers (n=75), @DRUG$ (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).
434	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), @DRUG$ (n=72), calcium channel blockers (n=75), antidiabetics (n=21), @DRUG$ (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).
435	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), @DRUG$ (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), @DRUG$ (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).
436	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), @DRUG$ (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), @DRUG$ (n=177), antianginals (n=35), and antihistamines (n=15).
437	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), @DRUG$ (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), @DRUG$ (n=35), and antihistamines (n=15).
438	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), @DRUG$ (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and @DRUG$ (n=15).
439	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), @DRUG$ (n=75), @DRUG$ (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).
440	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), @DRUG$ (n=75), antidiabetics (n=21), @DRUG$ (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).
441	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), @DRUG$ (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), @DRUG$ (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).
442	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), @DRUG$ (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), @DRUG$ (n=177), antianginals (n=35), and antihistamines (n=15).
443	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), @DRUG$ (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), @DRUG$ (n=35), and antihistamines (n=15).
444	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), @DRUG$ (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and @DRUG$ (n=15).
445	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), @DRUG$ (n=21), @DRUG$ (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).
446	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), @DRUG$ (n=21), nonsteroidal anti-inflammatory drugs (n=79), @DRUG$ (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).
447	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), @DRUG$ (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), @DRUG$ (n=177), antianginals (n=35), and antihistamines (n=15).
448	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), @DRUG$ (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), @DRUG$ (n=35), and antihistamines (n=15).
449	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), @DRUG$ (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and @DRUG$ (n=15).
450	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), @DRUG$ (n=79), @DRUG$ (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).
451	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), @DRUG$ (n=79), estrogens (n=70), @DRUG$ (n=177), antianginals (n=35), and antihistamines (n=15).
452	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), @DRUG$ (n=79), estrogens (n=70), salicylate analgesics (n=177), @DRUG$ (n=35), and antihistamines (n=15).
453	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), @DRUG$ (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and @DRUG$ (n=15).
454	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), @DRUG$ (n=70), @DRUG$ (n=177), antianginals (n=35), and antihistamines (n=15).
455	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), @DRUG$ (n=70), salicylate analgesics (n=177), @DRUG$ (n=35), and antihistamines (n=15).
456	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), @DRUG$ (n=70), salicylate analgesics (n=177), antianginals (n=35), and @DRUG$ (n=15).
457	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), @DRUG$ (n=177), @DRUG$ (n=35), and antihistamines (n=15).
458	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), @DRUG$ (n=177), antianginals (n=35), and @DRUG$ (n=15).
459	DDI-false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), @DRUG$ (n=35), and @DRUG$ (n=15).
460	DDI-false	Use with @DRUG$: Because of their mechanism of action, @DRUG$ have the potential to interfere with the activity of anticholinergic medications.
461	DDI-false	Use with @DRUG$: Because of their mechanism of action, cholinesterase inhibitors have the potential to interfere with the activity of @DRUG$.
462	DDI-int	Use with Anticholinergics: Because of their mechanism of action, @DRUG$ have the potential to interfere with the activity of @DRUG$.
463	DDI-false	Use with @DRUG$ and Other @DRUG$: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.
464	DDI-false	Use with @DRUG$ and Other Cholinesterase Inhibitors: A synergistic effect may be expected when @DRUG$ are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.
465	DDI-false	Use with @DRUG$ and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with @DRUG$, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.
466	DDI-false	Use with @DRUG$ and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar @DRUG$ or cholinergic agonists such as bethanechol.
467	DDI-false	Use with @DRUG$ and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or @DRUG$ such as bethanechol.
468	DDI-false	Use with @DRUG$ and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as @DRUG$.
469	DDI-false	Use with Cholinomimetics and Other @DRUG$: A synergistic effect may be expected when @DRUG$ are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.
470	DDI-false	Use with Cholinomimetics and Other @DRUG$: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with @DRUG$, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.
471	DDI-false	Use with Cholinomimetics and Other @DRUG$: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar @DRUG$ or cholinergic agonists such as bethanechol.
472	DDI-false	Use with Cholinomimetics and Other @DRUG$: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or @DRUG$ such as bethanechol.
473	DDI-false	Use with Cholinomimetics and Other @DRUG$: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as @DRUG$.
474	DDI-effect	Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when @DRUG$ are given concurrently with @DRUG$, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.
475	DDI-effect	Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when @DRUG$ are given concurrently with succinylcholine, similar @DRUG$ or cholinergic agonists such as bethanechol.
476	DDI-effect	Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when @DRUG$ are given concurrently with succinylcholine, similar neuromuscular blocking agents or @DRUG$ such as bethanechol.
477	DDI-effect	Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when @DRUG$ are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as @DRUG$.
478	DDI-false	Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with @DRUG$, similar @DRUG$ or cholinergic agonists such as bethanechol.
479	DDI-false	Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with @DRUG$, similar neuromuscular blocking agents or @DRUG$ such as bethanechol.
480	DDI-false	Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with @DRUG$, similar neuromuscular blocking agents or cholinergic agonists such as @DRUG$.
481	DDI-false	Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar @DRUG$ or @DRUG$ such as bethanechol.
482	DDI-false	Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar @DRUG$ or cholinergic agonists such as @DRUG$.
483	DDI-false	Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or @DRUG$ such as @DRUG$.
484	DDI-false	@DRUG$ Reports suggest that @DRUG$ may diminish the antihypertensive effect of angiotensin-converting enzyme (ACE) inhibitors.
485	DDI-false	@DRUG$ Reports suggest that NSAIDs may diminish the antihypertensive effect of @DRUG$.
486	DDI-effect	ACE inhibitors Reports suggest that @DRUG$ may diminish the antihypertensive effect of @DRUG$.
487	DDI-advise	This interaction should be given consideration in patients taking @DRUG$ concomitantly with @DRUG$.
488	DDI-false	@DRUG$: Concomitant administration of 200 mg @DRUG$ QID did not alter the single-dose pharmacokinetics of 30 mg meloxicam.
489	DDI-false	@DRUG$: Concomitant administration of 200 mg cimetidine QID did not alter the single-dose pharmacokinetics of 30 mg @DRUG$.
490	DDI-false	Cimetidine: Concomitant administration of 200 mg @DRUG$ QID did not alter the single-dose pharmacokinetics of 30 mg @DRUG$.
491	DDI-false	@DRUG$: @DRUG$ 15 mg once daily for 7 days did not alter the plasma concentration profile of digoxin after b-acetyldigoxin administration for 7 days at clinical doses.
492	DDI-false	@DRUG$: Meloxicam 15 mg once daily for 7 days did not alter the plasma concentration profile of @DRUG$ after b-acetyldigoxin administration for 7 days at clinical doses.
493	DDI-false	Digoxin: @DRUG$ 15 mg once daily for 7 days did not alter the plasma concentration profile of @DRUG$ after b-acetyldigoxin administration for 7 days at clinical doses.
494	DDI-false	In vitro testing found no protein binding drug interaction between @DRUG$ and @DRUG$.
495	DDI-false	@DRUG$: Clinical studies, as well as post-marketing observations, have shown that @DRUG$ can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients.
496	DDI-false	@DRUG$: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of @DRUG$ and thiazide diuretics in some patients.
497	DDI-false	@DRUG$: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and @DRUG$ in some patients.
498	DDI-effect	Furosemide: Clinical studies, as well as post-marketing observations, have shown that @DRUG$ can reduce the natriuretic effect of @DRUG$ and thiazide diuretics in some patients.
499	DDI-effect	Furosemide: Clinical studies, as well as post-marketing observations, have shown that @DRUG$ can reduce the natriuretic effect of furosemide and @DRUG$ in some patients.
500	DDI-false	Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of @DRUG$ and @DRUG$ in some patients.
501	DDI-false	Studies with @DRUG$ agents and @DRUG$ have not demonstrated a reduction in natriuretic effect.
502	DDI-false	@DRUG$: single and multiple dose pharmacodynamics and pharmacokinetics are not affected by multiple doses of @DRUG$.
503	DDI-advise	Nevertheless, during concomitant therapy with @DRUG$ and @DRUG$, patients should be observed closely for signs of declining renal function, as well as to assure diuretic efficacy.
504	DDI-false	@DRUG$: In clinical trials, @DRUG$ have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.
505	DDI-false	@DRUG$: In clinical trials, NSAIDs have produced an elevation of plasma @DRUG$ levels and a reduction in renal lithium clearance.
506	DDI-false	@DRUG$: In clinical trials, NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal @DRUG$ clearance.
507	DDI-mechanism	Lithium: In clinical trials, @DRUG$ have produced an elevation of plasma @DRUG$ levels and a reduction in renal lithium clearance.
508	DDI-false	Lithium: In clinical trials, @DRUG$ have produced an elevation of plasma lithium levels and a reduction in renal @DRUG$ clearance.
509	DDI-false	Lithium: In clinical trials, NSAIDs have produced an elevation of plasma @DRUG$ levels and a reduction in renal @DRUG$ clearance.
510	DDI-false	@DRUG$: Concomitant administration of @DRUG$ (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of meloxicam.
511	DDI-false	@DRUG$: Concomitant administration of aspirin (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of @DRUG$.
512	DDI-mechanism	Aspirin: Concomitant administration of @DRUG$ (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of @DRUG$.
513	DDI-false	In a study conducted in healthy subjects, mean pre-dose @DRUG$ concentration and AUC were increased by 21% in subjects receiving @DRUG$ doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone.
514	DDI-false	In a study conducted in healthy subjects, mean pre-dose @DRUG$ concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with @DRUG$ 15 mg QD as compared to subjects receiving lithium alone.
515	DDI-false	In a study conducted in healthy subjects, mean pre-dose @DRUG$ concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving @DRUG$ alone.
516	DDI-mechanism	In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving @DRUG$ doses ranging from 804 to 1072 mg BID with @DRUG$ 15 mg QD as compared to subjects receiving lithium alone.
517	DDI-false	In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving @DRUG$ doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving @DRUG$ alone.
518	DDI-false	In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with @DRUG$ 15 mg QD as compared to subjects receiving @DRUG$ alone.
519	DDI-advise	Patients on @DRUG$ treatment should be closely monitored when @DRUG$ is introduced or withdrawn.
520	DDI-false	@DRUG$: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of @DRUG$ on the pharmacokinetics of methotrexate taken once weekly.
521	DDI-false	@DRUG$: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of meloxicam on the pharmacokinetics of @DRUG$ taken once weekly.
522	DDI-false	Methotrexate: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of @DRUG$ on the pharmacokinetics of @DRUG$ taken once weekly.
523	DDI-false	@DRUG$ did not have a significant effect on the pharmacokinetics of single doses of @DRUG$.
524	DDI-false	In vitro, @DRUG$ did not displace @DRUG$ from its human serum binding sites.
525	DDI-false	@DRUG$: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing @DRUG$ therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding.
526	DDI-false	@DRUG$: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing MOBIC therapy in patients receiving @DRUG$ or similar agents, since these patients are at an increased risk of bleeding.
527	DDI-advise	Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing @DRUG$ therapy in patients receiving @DRUG$ or similar agents, since these patients are at an increased risk of bleeding.
528	DDI-false	The effect of @DRUG$ on the anticoagulant effect of @DRUG$ was studied in a group of healthy subjects receiving daily doses of warfarin that produced an INR (International Normalized Ratio) between 1.2 and 1.8.
529	DDI-false	The effect of @DRUG$ on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of @DRUG$ that produced an INR (International Normalized Ratio) between 1.2 and 1.8.
530	DDI-false	The effect of meloxicam on the anticoagulant effect of @DRUG$ was studied in a group of healthy subjects receiving daily doses of @DRUG$ that produced an INR (International Normalized Ratio) between 1.2 and 1.8.
531	DDI-false	In these subjects, @DRUG$ did not alter @DRUG$ pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time.
532	DDI-false	In these subjects, @DRUG$ did not alter warfarin pharmacokinetics and the average anticoagulant effect of @DRUG$ as determined by prothrombin time.
533	DDI-false	In these subjects, meloxicam did not alter @DRUG$ pharmacokinetics and the average anticoagulant effect of @DRUG$ as determined by prothrombin time.
534	DDI-advise	Caution should be used when administering @DRUG$ with @DRUG$ since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.
535	DDI-false	Caution should be used when administering @DRUG$ with warfarin since patients on @DRUG$ may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.
536	DDI-false	Caution should be used when administering MOBIC with @DRUG$ since patients on @DRUG$ may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.
537	DDI-false	however, as with other @DRUG$, concomitant administration of @DRUG$ and aspirin is not generally recommended because of the potential for increased adverse effects.
538	DDI-advise	however, as with other @DRUG$, concomitant administration of meloxicam and @DRUG$ is not generally recommended because of the potential for increased adverse effects.
539	DDI-advise	however, as with other NSAIDs, concomitant administration of @DRUG$ and @DRUG$ is not generally recommended because of the potential for increased adverse effects.
540	DDI-effect	Concomitant administration of low-dose @DRUG$ with @DRUG$ may result in an increased rate of GI ulceration or other complications, compared to use of MOBIC alone.
541	DDI-false	Concomitant administration of low-dose @DRUG$ with MOBIC may result in an increased rate of GI ulceration or other complications, compared to use of @DRUG$ alone.
542	DDI-false	Concomitant administration of low-dose aspirin with @DRUG$ may result in an increased rate of GI ulceration or other complications, compared to use of @DRUG$ alone.
543	DDI-false	@DRUG$ is not a substitute for @DRUG$ for cardiovascular prophylaxis.
544	DDI-false	@DRUG$: Pretreatment for four days with @DRUG$ significantly increased the clearance of meloxicam by 50%.
545	DDI-false	@DRUG$: Pretreatment for four days with cholestyramine significantly increased the clearance of @DRUG$ by 50%.
546	DDI-mechanism	Cholestyramine: Pretreatment for four days with @DRUG$ significantly increased the clearance of @DRUG$ by 50%.
547	DDI-mechanism	@DRUG$ may inhibit the hepatic metabolism of @DRUG$.
548	DDI-mechanism	@DRUG$, given at a common clinical dosage, increased the @DRUG$ half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%.
549	DDI-mechanism	@DRUG$, given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the @DRUG$ metabolic clearance rate by 30%.
550	DDI-false	Trimethoprim, given at a common clinical dosage, increased the @DRUG$ half-life by 51% and decreased the @DRUG$ metabolic clearance rate by 30%.
551	DDI-false	If @DRUG$ replacement is required, the @DRUG$ dose should be carefully adjusted.
552	DDI-mechanism	Limited published data indicate that @DRUG$ treatment increases cytochrome P450 (CP450) mediated @DRUG$ clearance in man.
553	DDI-mechanism	These data suggest that @DRUG$ administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., @DRUG$, sex steroids, anticonvulsants, cyclosporin).
554	DDI-mechanism	These data suggest that @DRUG$ administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, @DRUG$, anticonvulsants, cyclosporin).
555	DDI-mechanism	These data suggest that @DRUG$ administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, @DRUG$, cyclosporin).
556	DDI-mechanism	These data suggest that @DRUG$ administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, @DRUG$).
557	DDI-false	These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., @DRUG$, @DRUG$, anticonvulsants, cyclosporin).
558	DDI-false	These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., @DRUG$, sex steroids, @DRUG$, cyclosporin).
559	DDI-false	These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., @DRUG$, sex steroids, anticonvulsants, @DRUG$).
560	DDI-false	These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, @DRUG$, @DRUG$, cyclosporin).
561	DDI-false	These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, @DRUG$, anticonvulsants, @DRUG$).
562	DDI-false	These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, @DRUG$, @DRUG$).
563	DDI-false	Concurrent use of @DRUG$ and other @DRUG$ may increase the CNS depressant effects of methyprylon or these other medications.
564	DDI-effect	Concurrent use of @DRUG$ and other CNS depression-producing drugs may increase the CNS depressant effects of @DRUG$ or these other medications.
565	DDI-effect	Concurrent use of alcohol and other @DRUG$ may increase the CNS depressant effects of @DRUG$ or these other medications.
566	DDI-int	@DRUG$ may decrease the effectiveness of oral @DRUG$, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.
567	DDI-int	@DRUG$ may decrease the effectiveness of oral contraceptives, certain @DRUG$, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.
568	DDI-int	@DRUG$ may decrease the effectiveness of oral contraceptives, certain antibiotics, @DRUG$, theophylline, corticosteroids, anticoagulants, and beta blockers.
569	DDI-int	@DRUG$ may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, @DRUG$, corticosteroids, anticoagulants, and beta blockers.
570	DDI-int	@DRUG$ may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, @DRUG$, anticoagulants, and beta blockers.
571	DDI-int	@DRUG$ may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, @DRUG$, and beta blockers.
572	DDI-int	@DRUG$ may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and @DRUG$.
573	DDI-false	Barbiturates may decrease the effectiveness of oral @DRUG$, certain @DRUG$, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.
574	DDI-false	Barbiturates may decrease the effectiveness of oral @DRUG$, certain antibiotics, @DRUG$, theophylline, corticosteroids, anticoagulants, and beta blockers.
575	DDI-false	Barbiturates may decrease the effectiveness of oral @DRUG$, certain antibiotics, quinidine, @DRUG$, corticosteroids, anticoagulants, and beta blockers.
576	DDI-false	Barbiturates may decrease the effectiveness of oral @DRUG$, certain antibiotics, quinidine, theophylline, @DRUG$, anticoagulants, and beta blockers.
577	DDI-false	Barbiturates may decrease the effectiveness of oral @DRUG$, certain antibiotics, quinidine, theophylline, corticosteroids, @DRUG$, and beta blockers.
578	DDI-false	Barbiturates may decrease the effectiveness of oral @DRUG$, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and @DRUG$.
579	DDI-false	Barbiturates may decrease the effectiveness of oral contraceptives, certain @DRUG$, @DRUG$, theophylline, corticosteroids, anticoagulants, and beta blockers.
580	DDI-false	Barbiturates may decrease the effectiveness of oral contraceptives, certain @DRUG$, quinidine, @DRUG$, corticosteroids, anticoagulants, and beta blockers.
581	DDI-false	Barbiturates may decrease the effectiveness of oral contraceptives, certain @DRUG$, quinidine, theophylline, @DRUG$, anticoagulants, and beta blockers.
582	DDI-false	Barbiturates may decrease the effectiveness of oral contraceptives, certain @DRUG$, quinidine, theophylline, corticosteroids, @DRUG$, and beta blockers.
583	DDI-false	Barbiturates may decrease the effectiveness of oral contraceptives, certain @DRUG$, quinidine, theophylline, corticosteroids, anticoagulants, and @DRUG$.
584	DDI-false	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, @DRUG$, @DRUG$, corticosteroids, anticoagulants, and beta blockers.
585	DDI-false	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, @DRUG$, theophylline, @DRUG$, anticoagulants, and beta blockers.
586	DDI-false	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, @DRUG$, theophylline, corticosteroids, @DRUG$, and beta blockers.
587	DDI-false	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, @DRUG$, theophylline, corticosteroids, anticoagulants, and @DRUG$.
588	DDI-false	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, @DRUG$, @DRUG$, anticoagulants, and beta blockers.
589	DDI-false	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, @DRUG$, corticosteroids, @DRUG$, and beta blockers.
590	DDI-false	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, @DRUG$, corticosteroids, anticoagulants, and @DRUG$.
591	DDI-false	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, @DRUG$, @DRUG$, and beta blockers.
592	DDI-false	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, @DRUG$, anticoagulants, and @DRUG$.
593	DDI-false	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, @DRUG$, and @DRUG$.
594	DDI-advise	Caution is recommended when administering @DRUG$ with compounds that are metabolized/eliminated predominantly by the UGT1A1 pathway (e.g. @DRUG$).
595	DDI-mechanism	Concomitant treatment with @DRUG$ resulted in a 21% increase in the AUC of @DRUG$.
596	DDI-advise	Caution is recommended when administering @DRUG$ with @DRUG$.
597	DDI-effect	When administered concomitantly with @DRUG$   , @DRUG$ may enhance or precipitate bradycardia, A.V.
598	DDI-false	The use of drugs that stimulate alpha-adrenergic receptors (e.g., @DRUG$, @DRUG$, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.
599	DDI-false	The use of drugs that stimulate alpha-adrenergic receptors (e.g., @DRUG$, pseudoephedrine, @DRUG$, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.
600	DDI-false	The use of drugs that stimulate alpha-adrenergic receptors (e.g., @DRUG$, pseudoephedrine, ephedrine, @DRUG$ or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.
601	DDI-false	The use of drugs that stimulate alpha-adrenergic receptors (e.g., @DRUG$, pseudoephedrine, ephedrine, phenylpropanolamine or @DRUG$) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.
602	DDI-effect	The use of drugs that stimulate alpha-adrenergic receptors (e.g., @DRUG$, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of @DRUG$   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.
603	DDI-false	The use of drugs that stimulate alpha-adrenergic receptors (e.g., @DRUG$, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when @DRUG$    is administered concomitantly with agents that cause vasoconstriction.
604	DDI-false	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, @DRUG$, @DRUG$, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.
605	DDI-false	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, @DRUG$, ephedrine, @DRUG$ or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.
606	DDI-false	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, @DRUG$, ephedrine, phenylpropanolamine or @DRUG$) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.
607	DDI-effect	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, @DRUG$, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of @DRUG$   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.
608	DDI-false	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, @DRUG$, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when @DRUG$    is administered concomitantly with agents that cause vasoconstriction.
609	DDI-false	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, @DRUG$, @DRUG$ or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.
610	DDI-false	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, @DRUG$, phenylpropanolamine or @DRUG$) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.
611	DDI-effect	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, @DRUG$, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of @DRUG$   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.
612	DDI-false	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, @DRUG$, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when @DRUG$    is administered concomitantly with agents that cause vasoconstriction.
613	DDI-false	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, @DRUG$ or @DRUG$) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.
614	DDI-effect	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, @DRUG$ or dihydroergotamine) may enhance or potentiate the pressor effects of @DRUG$   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.
615	DDI-false	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, @DRUG$ or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when @DRUG$    is administered concomitantly with agents that cause vasoconstriction.
616	DDI-effect	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or @DRUG$) may enhance or potentiate the pressor effects of @DRUG$   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.
617	DDI-false	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or @DRUG$) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when @DRUG$    is administered concomitantly with agents that cause vasoconstriction.
618	DDI-false	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of @DRUG$   . Therefore, caution should be used when @DRUG$    is administered concomitantly with agents that cause vasoconstriction.
619	DDI-false	@DRUG$    has been used in patients concomitantly treated with salt-retaining steroid therapy (i.e., @DRUG$), with or without salt supplementation.
620	DDI-false	@DRUG$. @DRUG$, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
621	DDI-false	@DRUG$. Alpha-adrenergic blocking agents, such as @DRUG$, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
622	DDI-false	@DRUG$. Alpha-adrenergic blocking agents, such as prazosin, @DRUG$, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
623	DDI-false	@DRUG$. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and @DRUG$, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
624	DDI-false	@DRUG$. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
625	DDI-false	@DRUG$. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
626	DDI-false	@DRUG$. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
627	DDI-false	@DRUG$. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, @DRUG$, ranitidine, procainamide, triamterene, flecainide, and quinidine.
628	DDI-false	@DRUG$. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, @DRUG$, procainamide, triamterene, flecainide, and quinidine.
629	DDI-false	@DRUG$. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, @DRUG$, triamterene, flecainide, and quinidine.
630	DDI-false	@DRUG$. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, @DRUG$, flecainide, and quinidine.
631	DDI-false	@DRUG$. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, @DRUG$, and quinidine.
632	DDI-false	@DRUG$. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and @DRUG$.
633	DDI-false	ProAmatine. @DRUG$, such as @DRUG$, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
634	DDI-false	ProAmatine. @DRUG$, such as prazosin, @DRUG$, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
635	DDI-false	ProAmatine. @DRUG$, such as prazosin, terazosin, and @DRUG$, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
636	DDI-effect	ProAmatine. @DRUG$, such as prazosin, terazosin, and doxazosin, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
637	DDI-false	ProAmatine. @DRUG$, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
638	DDI-false	ProAmatine. @DRUG$, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
639	DDI-false	ProAmatine. @DRUG$, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, @DRUG$, ranitidine, procainamide, triamterene, flecainide, and quinidine.
640	DDI-false	ProAmatine. @DRUG$, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, @DRUG$, procainamide, triamterene, flecainide, and quinidine.
641	DDI-false	ProAmatine. @DRUG$, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, @DRUG$, triamterene, flecainide, and quinidine.
642	DDI-false	ProAmatine. @DRUG$, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, @DRUG$, flecainide, and quinidine.
643	DDI-false	ProAmatine. @DRUG$, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, @DRUG$, and quinidine.
644	DDI-false	ProAmatine. @DRUG$, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and @DRUG$.
645	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as @DRUG$, @DRUG$, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
646	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as @DRUG$, terazosin, and @DRUG$, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
647	DDI-effect	ProAmatine. Alpha-adrenergic blocking agents, such as @DRUG$, terazosin, and doxazosin, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
648	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as @DRUG$, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
649	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as @DRUG$, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
650	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as @DRUG$, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, @DRUG$, ranitidine, procainamide, triamterene, flecainide, and quinidine.
651	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as @DRUG$, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, @DRUG$, procainamide, triamterene, flecainide, and quinidine.
652	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as @DRUG$, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, @DRUG$, triamterene, flecainide, and quinidine.
653	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as @DRUG$, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, @DRUG$, flecainide, and quinidine.
654	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as @DRUG$, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, @DRUG$, and quinidine.
655	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as @DRUG$, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and @DRUG$.
656	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, @DRUG$, and @DRUG$, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
657	DDI-effect	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, @DRUG$, and doxazosin, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
658	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, @DRUG$, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
659	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, @DRUG$, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
660	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, @DRUG$, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, @DRUG$, ranitidine, procainamide, triamterene, flecainide, and quinidine.
661	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, @DRUG$, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, @DRUG$, procainamide, triamterene, flecainide, and quinidine.
662	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, @DRUG$, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, @DRUG$, triamterene, flecainide, and quinidine.
663	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, @DRUG$, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, @DRUG$, flecainide, and quinidine.
664	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, @DRUG$, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, @DRUG$, and quinidine.
665	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, @DRUG$, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and @DRUG$.
666	DDI-effect	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and @DRUG$, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
667	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and @DRUG$, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
668	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and @DRUG$, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
669	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and @DRUG$, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, @DRUG$, ranitidine, procainamide, triamterene, flecainide, and quinidine.
670	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and @DRUG$, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, @DRUG$, procainamide, triamterene, flecainide, and quinidine.
671	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and @DRUG$, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, @DRUG$, triamterene, flecainide, and quinidine.
672	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and @DRUG$, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, @DRUG$, flecainide, and quinidine.
673	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and @DRUG$, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, @DRUG$, and quinidine.
674	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and @DRUG$, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and @DRUG$.
675	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
676	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
677	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, @DRUG$, ranitidine, procainamide, triamterene, flecainide, and quinidine.
678	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, @DRUG$, procainamide, triamterene, flecainide, and quinidine.
679	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, @DRUG$, triamterene, flecainide, and quinidine.
680	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, @DRUG$, flecainide, and quinidine.
681	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, @DRUG$, and quinidine.
682	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and @DRUG$.
683	DDI-mechanism	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
684	DDI-mechanism	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, @DRUG$, ranitidine, procainamide, triamterene, flecainide, and quinidine.
685	DDI-mechanism	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, @DRUG$, procainamide, triamterene, flecainide, and quinidine.
686	DDI-mechanism	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, @DRUG$, triamterene, flecainide, and quinidine.
687	DDI-mechanism	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, @DRUG$, flecainide, and quinidine.
688	DDI-mechanism	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, @DRUG$, and quinidine.
689	DDI-mechanism	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and @DRUG$.
690	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, @DRUG$, ranitidine, procainamide, triamterene, flecainide, and quinidine.
691	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, cimetidine, @DRUG$, procainamide, triamterene, flecainide, and quinidine.
692	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, cimetidine, ranitidine, @DRUG$, triamterene, flecainide, and quinidine.
693	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, cimetidine, ranitidine, procainamide, @DRUG$, flecainide, and quinidine.
694	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, cimetidine, ranitidine, procainamide, triamterene, @DRUG$, and quinidine.
695	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, cimetidine, ranitidine, procainamide, triamterene, flecainide, and @DRUG$.
696	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, @DRUG$, @DRUG$, procainamide, triamterene, flecainide, and quinidine.
697	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, @DRUG$, ranitidine, @DRUG$, triamterene, flecainide, and quinidine.
698	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, @DRUG$, ranitidine, procainamide, @DRUG$, flecainide, and quinidine.
699	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, @DRUG$, ranitidine, procainamide, triamterene, @DRUG$, and quinidine.
700	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, @DRUG$, ranitidine, procainamide, triamterene, flecainide, and @DRUG$.
701	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, @DRUG$, @DRUG$, triamterene, flecainide, and quinidine.
702	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, @DRUG$, procainamide, @DRUG$, flecainide, and quinidine.
703	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, @DRUG$, procainamide, triamterene, @DRUG$, and quinidine.
704	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, @DRUG$, procainamide, triamterene, flecainide, and @DRUG$.
705	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, @DRUG$, @DRUG$, flecainide, and quinidine.
706	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, @DRUG$, triamterene, @DRUG$, and quinidine.
707	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, @DRUG$, triamterene, flecainide, and @DRUG$.
708	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, @DRUG$, @DRUG$, and quinidine.
709	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, @DRUG$, flecainide, and @DRUG$.
710	DDI-false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, @DRUG$, and @DRUG$.
711	DDI-effect	@DRUG$ has been reported to enhance the sedative activity of @DRUG$, alcohol, chlorpromazine, and reserpine.
712	DDI-false	@DRUG$ has been reported to enhance the sedative activity of barbiturates, @DRUG$, chlorpromazine, and reserpine.
713	DDI-false	@DRUG$ has been reported to enhance the sedative activity of barbiturates, alcohol, @DRUG$, and reserpine.
714	DDI-false	@DRUG$ has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and @DRUG$.
715	DDI-false	Thalidomide has been reported to enhance the sedative activity of @DRUG$, @DRUG$, chlorpromazine, and reserpine.
716	DDI-false	Thalidomide has been reported to enhance the sedative activity of @DRUG$, alcohol, @DRUG$, and reserpine.
717	DDI-false	Thalidomide has been reported to enhance the sedative activity of @DRUG$, alcohol, chlorpromazine, and @DRUG$.
718	DDI-false	Thalidomide has been reported to enhance the sedative activity of barbiturates, @DRUG$, @DRUG$, and reserpine.
719	DDI-false	Thalidomide has been reported to enhance the sedative activity of barbiturates, @DRUG$, chlorpromazine, and @DRUG$.
720	DDI-false	Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, @DRUG$, and @DRUG$.
721	DDI-false	Oral @DRUG$: In 10 healthy women, the pharmacokinetic profiles of @DRUG$ and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied.
722	DDI-false	Oral @DRUG$: In 10 healthy women, the pharmacokinetic profiles of norethindrone and @DRUG$ following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied.
723	DDI-false	Oral @DRUG$: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of @DRUG$ and 75    g of ethinyl estradiol were studied.
724	DDI-false	Oral @DRUG$: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of @DRUG$ were studied.
725	DDI-false	Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of @DRUG$ and @DRUG$ following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied.
726	DDI-false	Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of @DRUG$ and ethinyl estradiol following administration of a single dose containing 1.0 mg of @DRUG$ and 75    g of ethinyl estradiol were studied.
727	DDI-false	Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of @DRUG$ and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of @DRUG$ were studied.
728	DDI-false	Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and @DRUG$ following administration of a single dose containing 1.0 mg of @DRUG$ and 75    g of ethinyl estradiol were studied.
729	DDI-false	Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and @DRUG$ following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of @DRUG$ were studied.
730	DDI-false	Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of @DRUG$ and 75    g of @DRUG$ were studied.
731	DDI-false	Important Non-@DRUG$ Drug Interactions Drugs That Interfere with @DRUG$: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.
732	DDI-false	Important Non-@DRUG$ Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of @DRUG$, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.
733	DDI-false	Important Non-@DRUG$ Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, @DRUG$, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.
734	DDI-false	Important Non-@DRUG$ Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, @DRUG$, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.
735	DDI-false	Important Non-@DRUG$ Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, @DRUG$, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.
736	DDI-false	Important Non-@DRUG$ Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, @DRUG$, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.
737	DDI-false	Important Non-@DRUG$ Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, @DRUG$, phenytoin, carbamazepine, or certain herbal supplements such as St.
738	DDI-false	Important Non-@DRUG$ Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, @DRUG$, carbamazepine, or certain herbal supplements such as St.
739	DDI-false	Important Non-@DRUG$ Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, @DRUG$, or certain herbal supplements such as St.
740	DDI-false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with @DRUG$: Concomitant use of @DRUG$, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.
741	DDI-false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with @DRUG$: Concomitant use of HIV-protease inhibitors, @DRUG$, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.
742	DDI-false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with @DRUG$: Concomitant use of HIV-protease inhibitors, griseofulvin, @DRUG$, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.
743	DDI-false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with @DRUG$: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, @DRUG$, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.
744	DDI-false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with @DRUG$: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, @DRUG$, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.
745	DDI-false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with @DRUG$: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, @DRUG$, phenytoin, carbamazepine, or certain herbal supplements such as St.
746	DDI-false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with @DRUG$: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, @DRUG$, carbamazepine, or certain herbal supplements such as St.
747	DDI-false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with @DRUG$: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, @DRUG$, or certain herbal supplements such as St.
748	DDI-false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of @DRUG$, @DRUG$, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.
749	DDI-false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of @DRUG$, griseofulvin, @DRUG$, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.
750	DDI-false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of @DRUG$, griseofulvin, modafinil, @DRUG$, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.
751	DDI-false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of @DRUG$, griseofulvin, modafinil, penicillins, @DRUG$, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.
752	DDI-false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of @DRUG$, griseofulvin, modafinil, penicillins, rifampin, @DRUG$, phenytoin, carbamazepine, or certain herbal supplements such as St.
753	DDI-false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of @DRUG$, griseofulvin, modafinil, penicillins, rifampin, rifabutin, @DRUG$, carbamazepine, or certain herbal supplements such as St.
754	DDI-false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of @DRUG$, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, @DRUG$, or certain herbal supplements such as St.
755	DDI-false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, @DRUG$, @DRUG$, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.
756	DDI-false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, @DRUG$, modafinil, @DRUG$, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.
757	DDI-false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, @DRUG$, modafinil, penicillins, @DRUG$, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.
758	DDI-false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, @DRUG$, modafinil, penicillins, rifampin, @DRUG$, phenytoin, carbamazepine, or certain herbal supplements such as St.
759	DDI-false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, @DRUG$, modafinil, penicillins, rifampin, rifabutin, @DRUG$, carbamazepine, or certain herbal supplements such as St.
760	DDI-false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, @DRUG$, modafinil, penicillins, rifampin, rifabutin, phenytoin, @DRUG$, or certain herbal supplements such as St.
761	DDI-false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, @DRUG$, @DRUG$, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.
762	DDI-false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, @DRUG$, penicillins, @DRUG$, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.
763	DDI-false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, @DRUG$, penicillins, rifampin, @DRUG$, phenytoin, carbamazepine, or certain herbal supplements such as St.
764	DDI-false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, @DRUG$, penicillins, rifampin, rifabutin, @DRUG$, carbamazepine, or certain herbal supplements such as St.
765	DDI-false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, @DRUG$, penicillins, rifampin, rifabutin, phenytoin, @DRUG$, or certain herbal supplements such as St.
766	DDI-false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, @DRUG$, @DRUG$, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.
767	DDI-false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, @DRUG$, rifampin, @DRUG$, phenytoin, carbamazepine, or certain herbal supplements such as St.
768	DDI-false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, @DRUG$, rifampin, rifabutin, @DRUG$, carbamazepine, or certain herbal supplements such as St.
769	DDI-false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, @DRUG$, rifampin, rifabutin, phenytoin, @DRUG$, or certain herbal supplements such as St.
770	DDI-false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, @DRUG$, @DRUG$, phenytoin, carbamazepine, or certain herbal supplements such as St.
771	DDI-false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, @DRUG$, rifabutin, @DRUG$, carbamazepine, or certain herbal supplements such as St.
772	DDI-false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, @DRUG$, rifabutin, phenytoin, @DRUG$, or certain herbal supplements such as St.
773	DDI-false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, @DRUG$, @DRUG$, carbamazepine, or certain herbal supplements such as St.
774	DDI-false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, @DRUG$, phenytoin, @DRUG$, or certain herbal supplements such as St.
775	DDI-false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, @DRUG$, @DRUG$, or certain herbal supplements such as St.
776	DDI-effect	@DRUG$ with @DRUG$ may reduce the effectiveness of the contraception and up to one month after discontinuation of these concomitant therapies.
777	DDI-effect	@DRUG$ may enhance the effects of @DRUG$, barbiturates and other CNS depressants.
778	DDI-effect	@DRUG$ may enhance the effects of alcohol, @DRUG$ and other CNS depressants.
779	DDI-effect	@DRUG$ may enhance the effects of alcohol, barbiturates and other @DRUG$.
780	DDI-false	SKELAXIN may enhance the effects of @DRUG$, @DRUG$ and other CNS depressants.
781	DDI-false	SKELAXIN may enhance the effects of @DRUG$, barbiturates and other @DRUG$.
782	DDI-false	SKELAXIN may enhance the effects of alcohol, @DRUG$ and other @DRUG$.
783	DDI-false	@DRUG$ and @DRUG$ increase the effects of pseudoephedrine.
784	DDI-effect	@DRUG$ and beta adrenergic blockers increase the effects of @DRUG$.
785	DDI-effect	MAO inhibitors and @DRUG$ increase the effects of @DRUG$.
786	DDI-effect	@DRUG$ may reduce the antihypertensive effects of @DRUG$, mecamylamine, reserpine and veratrum alkaloids.
787	DDI-effect	@DRUG$ may reduce the antihypertensive effects of methyldopa, @DRUG$, reserpine and veratrum alkaloids.
788	DDI-effect	@DRUG$ may reduce the antihypertensive effects of methyldopa, mecamylamine, @DRUG$ and veratrum alkaloids.
789	DDI-effect	@DRUG$ may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and @DRUG$.
790	DDI-false	Sympathomimetics may reduce the antihypertensive effects of @DRUG$, @DRUG$, reserpine and veratrum alkaloids.
791	DDI-false	Sympathomimetics may reduce the antihypertensive effects of @DRUG$, mecamylamine, @DRUG$ and veratrum alkaloids.
792	DDI-false	Sympathomimetics may reduce the antihypertensive effects of @DRUG$, mecamylamine, reserpine and @DRUG$.
793	DDI-false	Sympathomimetics may reduce the antihypertensive effects of methyldopa, @DRUG$, @DRUG$ and veratrum alkaloids.
794	DDI-false	Sympathomimetics may reduce the antihypertensive effects of methyldopa, @DRUG$, reserpine and @DRUG$.
795	DDI-false	Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, @DRUG$ and @DRUG$.
796	DDI-effect	Drugs which may potentiate the myeloproliferative effects of @DRUG$, such as @DRUG$ and corticosteroids, should be used with caution.
797	DDI-effect	Drugs which may potentiate the myeloproliferative effects of @DRUG$, such as lithium and @DRUG$, should be used with caution.
798	DDI-false	Drugs which may potentiate the myeloproliferative effects of Leukine, such as @DRUG$ and @DRUG$, should be used with caution.
799	DDI-false	The in vitro binding of @DRUG$ to human plasma proteins is unaffected by @DRUG$, and tolmetin does not alter the prothrombin time of normal volunteers.
800	DDI-false	The in vitro binding of @DRUG$ to human plasma proteins is unaffected by tolmetin, and @DRUG$ does not alter the prothrombin time of normal volunteers.
801	DDI-false	The in vitro binding of warfarin to human plasma proteins is unaffected by @DRUG$, and @DRUG$ does not alter the prothrombin time of normal volunteers.
802	DDI-effect	However, increased prothrombin time and bleeding have been reported in patients on concomitant @DRUG$ and @DRUG$ therapy.
803	DDI-advise	Therefore, caution should be exercised when administering @DRUG$ to patients on @DRUG$.
804	DDI-false	In adult diabetic patients under treatment with either @DRUG$ or @DRUG$ there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents.
805	DDI-false	In adult diabetic patients under treatment with either @DRUG$ or insulin there is no change in the clinical effects of either @DRUG$ or the hypoglycemic agents.
806	DDI-false	In adult diabetic patients under treatment with either @DRUG$ or insulin there is no change in the clinical effects of either TOLECTIN or the @DRUG$.
807	DDI-false	In adult diabetic patients under treatment with either sulfonylureas or @DRUG$ there is no change in the clinical effects of either @DRUG$ or the hypoglycemic agents.
808	DDI-false	In adult diabetic patients under treatment with either sulfonylureas or @DRUG$ there is no change in the clinical effects of either TOLECTIN or the @DRUG$.
809	DDI-false	In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either @DRUG$ or the @DRUG$.
810	DDI-advise	Caution should be used if @DRUG$ is administered concomitantly with @DRUG$.
811	DDI-false	@DRUG$ and other @DRUG$ have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate.
812	DDI-mechanism	@DRUG$ and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of @DRUG$ in an animal model, possibly enhancing the toxicity of methotrexate.
813	DDI-false	@DRUG$ and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of @DRUG$.
814	DDI-mechanism	TOLECTIN and other @DRUG$ have been reported to reduce the tubular secretion of @DRUG$ in an animal model, possibly enhancing the toxicity of methotrexate.
815	DDI-false	TOLECTIN and other @DRUG$ have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of @DRUG$.
816	DDI-false	TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of @DRUG$ in an animal model, possibly enhancing the toxicity of @DRUG$.
817	DDI-mechanism	An inhibitor of CYP2C8 (such as @DRUG$) may increase the AUC of @DRUG$ and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone.
818	DDI-false	An inhibitor of CYP2C8 (such as @DRUG$) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as @DRUG$) may decrease the AUC of rosiglitazone.
819	DDI-false	An inhibitor of CYP2C8 (such as @DRUG$) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of @DRUG$.
820	DDI-false	An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of @DRUG$ and an inducer of CYP2C8 (such as @DRUG$) may decrease the AUC of rosiglitazone.
821	DDI-false	An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of @DRUG$ and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of @DRUG$.
822	DDI-mechanism	An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as @DRUG$) may decrease the AUC of @DRUG$.
823	DDI-false	Pharmacokinetic properties of @DRUG$ were not altered by the addition of either @DRUG$ or zidovudine or the combination of lamivudine and zidovudine.
824	DDI-false	Pharmacokinetic properties of @DRUG$ were not altered by the addition of either lamivudine or @DRUG$ or the combination of lamivudine and zidovudine.
825	DDI-false	Pharmacokinetic properties of @DRUG$ were not altered by the addition of either lamivudine or zidovudine or the combination of @DRUG$ and zidovudine.
826	DDI-false	Pharmacokinetic properties of @DRUG$ were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and @DRUG$.
827	DDI-false	Pharmacokinetic properties of abacavir were not altered by the addition of either @DRUG$ or @DRUG$ or the combination of lamivudine and zidovudine.
828	DDI-false	Pharmacokinetic properties of abacavir were not altered by the addition of either @DRUG$ or zidovudine or the combination of @DRUG$ and zidovudine.
829	DDI-false	Pharmacokinetic properties of abacavir were not altered by the addition of either @DRUG$ or zidovudine or the combination of lamivudine and @DRUG$.
830	DDI-false	Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or @DRUG$ or the combination of @DRUG$ and zidovudine.
831	DDI-false	Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or @DRUG$ or the combination of lamivudine and @DRUG$.
832	DDI-false	Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of @DRUG$ and @DRUG$.
833	DDI-false	No clinically significant changes to @DRUG$ or @DRUG$ pharmacokinetics were observed following concomitant administration of abacavir.
834	DDI-false	No clinically significant changes to @DRUG$ or zidovudine pharmacokinetics were observed following concomitant administration of @DRUG$.
835	DDI-false	No clinically significant changes to lamivudine or @DRUG$ pharmacokinetics were observed following concomitant administration of @DRUG$.
836	DDI-false	@DRUG$ has no effect on the pharmacokinetic properties of @DRUG$.
837	DDI-mechanism	@DRUG$ decreases the elimination of @DRUG$ causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir.
838	DDI-false	@DRUG$ decreases the elimination of abacavir causing an increase in overall exposure . The addition of @DRUG$ has no clinically significant effect on the pharmacokinetic properties of abacavir.
839	DDI-false	@DRUG$ decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of @DRUG$.
840	DDI-false	Ethanol decreases the elimination of @DRUG$ causing an increase in overall exposure . The addition of @DRUG$ has no clinically significant effect on the pharmacokinetic properties of abacavir.
841	DDI-false	Ethanol decreases the elimination of @DRUG$ causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of @DRUG$.
842	DDI-false	Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of @DRUG$ has no clinically significant effect on the pharmacokinetic properties of @DRUG$.
843	DDI-mechanism	In a study of 11 HIV-infected patients receiving @DRUG$-maintenance therapy (40 mg and 90 mg daily) with 600 mg of @DRUG$ twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI 6% to 42%).
844	DDI-false	In a study of 11 HIV-infected patients receiving @DRUG$-maintenance therapy (40 mg and 90 mg daily) with 600 mg of ZIAGEN twice daily (twice the currently recommended dose), oral @DRUG$ clearance increased 22% (90% CI 6% to 42%).
845	DDI-false	In a study of 11 HIV-infected patients receiving methadone-maintenance therapy (40 mg and 90 mg daily) with 600 mg of @DRUG$ twice daily (twice the currently recommended dose), oral @DRUG$ clearance increased 22% (90% CI 6% to 42%).
846	DDI-advise	Other @DRUG$ should not be used concomitantly with @DRUG$    (metaproterenol sulfate USP) because they may have additive effects.
847	DDI-advise	Other @DRUG$ should not be used concomitantly with Alupent    (@DRUG$ USP) because they may have additive effects.
848	DDI-false	Other beta adrenergic aerosol bronchodilators should not be used concomitantly with @DRUG$    (@DRUG$ USP) because they may have additive effects.
849	DDI-advise	@DRUG$ should be administered with caution to patients being treated with @DRUG$ or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.
850	DDI-advise	@DRUG$ should be administered with caution to patients being treated with monoamine oxidase inhibitors or @DRUG$, since the action of beta adrenergic agonists on the vascular system may be potentiated.
851	DDI-false	@DRUG$ should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of @DRUG$ on the vascular system may be potentiated.
852	DDI-false	Beta adrenergic agonists should be administered with caution to patients being treated with @DRUG$ or @DRUG$, since the action of beta adrenergic agonists on the vascular system may be potentiated.
853	DDI-false	Beta adrenergic agonists should be administered with caution to patients being treated with @DRUG$ or tricyclic antidepressants, since the action of @DRUG$ on the vascular system may be potentiated.
854	DDI-false	Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or @DRUG$, since the action of @DRUG$ on the vascular system may be potentiated.
855	DDI-mechanism	A study published in 2002 found that @DRUG$ causes a statistically significant increase in plasma clearance of @DRUG$.
856	DDI-mechanism	In 1984, Drs Rimmer and Richens at the University of Wales reported that administering @DRUG$ with @DRUG$ lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy.
857	DDI-false	In 1984, Drs Rimmer and Richens at the University of Wales reported that administering @DRUG$ with phenytoin lowered the serum @DRUG$ concentration in patients with treatment-resistant epilepsy.
858	DDI-false	In 1984, Drs Rimmer and Richens at the University of Wales reported that administering vigabatrin with @DRUG$ lowered the serum @DRUG$ concentration in patients with treatment-resistant epilepsy.
859	DDI-effect	@DRUG$ may enhance the sedative effects of @DRUG$ including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.
860	DDI-effect	@DRUG$ may enhance the sedative effects of central nervous system depressants including @DRUG$, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.
861	DDI-effect	@DRUG$ may enhance the sedative effects of central nervous system depressants including alcohol, @DRUG$, hypnotics, narcotic analgesics, sedatives, and tranquillisers.
862	DDI-effect	@DRUG$ may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, @DRUG$, narcotic analgesics, sedatives, and tranquillisers.
863	DDI-effect	@DRUG$ may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, @DRUG$, sedatives, and tranquillisers.
864	DDI-effect	@DRUG$ may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, @DRUG$, and tranquillisers.
865	DDI-effect	@DRUG$ may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and @DRUG$.
866	DDI-false	Triprolidine may enhance the sedative effects of @DRUG$ including @DRUG$, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.
867	DDI-false	Triprolidine may enhance the sedative effects of @DRUG$ including alcohol, @DRUG$, hypnotics, narcotic analgesics, sedatives, and tranquillisers.
868	DDI-false	Triprolidine may enhance the sedative effects of @DRUG$ including alcohol, barbiturates, @DRUG$, narcotic analgesics, sedatives, and tranquillisers.
869	DDI-false	Triprolidine may enhance the sedative effects of @DRUG$ including alcohol, barbiturates, hypnotics, @DRUG$, sedatives, and tranquillisers.
870	DDI-false	Triprolidine may enhance the sedative effects of @DRUG$ including alcohol, barbiturates, hypnotics, narcotic analgesics, @DRUG$, and tranquillisers.
871	DDI-false	Triprolidine may enhance the sedative effects of @DRUG$ including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and @DRUG$.
872	DDI-false	Triprolidine may enhance the sedative effects of central nervous system depressants including @DRUG$, @DRUG$, hypnotics, narcotic analgesics, sedatives, and tranquillisers.
873	DDI-false	Triprolidine may enhance the sedative effects of central nervous system depressants including @DRUG$, barbiturates, @DRUG$, narcotic analgesics, sedatives, and tranquillisers.
874	DDI-false	Triprolidine may enhance the sedative effects of central nervous system depressants including @DRUG$, barbiturates, hypnotics, @DRUG$, sedatives, and tranquillisers.
875	DDI-false	Triprolidine may enhance the sedative effects of central nervous system depressants including @DRUG$, barbiturates, hypnotics, narcotic analgesics, @DRUG$, and tranquillisers.
876	DDI-false	Triprolidine may enhance the sedative effects of central nervous system depressants including @DRUG$, barbiturates, hypnotics, narcotic analgesics, sedatives, and @DRUG$.
877	DDI-false	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, @DRUG$, @DRUG$, narcotic analgesics, sedatives, and tranquillisers.
878	DDI-false	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, @DRUG$, hypnotics, @DRUG$, sedatives, and tranquillisers.
879	DDI-false	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, @DRUG$, hypnotics, narcotic analgesics, @DRUG$, and tranquillisers.
880	DDI-false	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, @DRUG$, hypnotics, narcotic analgesics, sedatives, and @DRUG$.
881	DDI-false	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, @DRUG$, @DRUG$, sedatives, and tranquillisers.
882	DDI-false	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, @DRUG$, narcotic analgesics, @DRUG$, and tranquillisers.
883	DDI-false	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, @DRUG$, narcotic analgesics, sedatives, and @DRUG$.
884	DDI-false	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, @DRUG$, @DRUG$, and tranquillisers.
885	DDI-false	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, @DRUG$, sedatives, and @DRUG$.
886	DDI-false	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, @DRUG$, and @DRUG$.
887	DDI-false	The effects of @DRUG$, such as @DRUG$ and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine.
888	DDI-false	The effects of @DRUG$, such as atropine and @DRUG$ may be enhanced by the concomitant administration of triprolidine.
889	DDI-effect	The effects of @DRUG$, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of @DRUG$.
890	DDI-false	The effects of anticholinergic drugs, such as @DRUG$ and @DRUG$ may be enhanced by the concomitant administration of triprolidine.
891	DDI-effect	The effects of anticholinergic drugs, such as @DRUG$ and tricyclic antidepressants may be enhanced by the concomitant administration of @DRUG$.
892	DDI-effect	The effects of anticholinergic drugs, such as atropine and @DRUG$ may be enhanced by the concomitant administration of @DRUG$.
893	DDI-advise	Caution should be exercised when administering @DRUG$ therapy in combination with other @DRUG$.
894	DDI-false	In addition to bleeding associated with @DRUG$ and @DRUG$, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.
895	DDI-false	In addition to bleeding associated with @DRUG$ and vitamin K antagonists, drugs that alter platelet function (such as @DRUG$, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.
896	DDI-false	In addition to bleeding associated with @DRUG$ and vitamin K antagonists, drugs that alter platelet function (such as aspirin, @DRUG$, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.
897	DDI-false	In addition to bleeding associated with @DRUG$ and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and @DRUG$) may increase the risk of bleeding if administered prior to or after Retavase    therapy.
898	DDI-effect	In addition to bleeding associated with @DRUG$ and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after @DRUG$    therapy.
899	DDI-false	In addition to bleeding associated with heparin and @DRUG$, drugs that alter platelet function (such as @DRUG$, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.
900	DDI-false	In addition to bleeding associated with heparin and @DRUG$, drugs that alter platelet function (such as aspirin, @DRUG$, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.
901	DDI-false	In addition to bleeding associated with heparin and @DRUG$, drugs that alter platelet function (such as aspirin, dipyridamole, and @DRUG$) may increase the risk of bleeding if administered prior to or after Retavase    therapy.
902	DDI-effect	In addition to bleeding associated with heparin and @DRUG$, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after @DRUG$    therapy.
903	DDI-false	In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as @DRUG$, @DRUG$, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.
904	DDI-false	In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as @DRUG$, dipyridamole, and @DRUG$) may increase the risk of bleeding if administered prior to or after Retavase    therapy.
905	DDI-effect	In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as @DRUG$, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after @DRUG$    therapy.
906	DDI-false	In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, @DRUG$, and @DRUG$) may increase the risk of bleeding if administered prior to or after Retavase    therapy.
907	DDI-effect	In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, @DRUG$, and abciximab) may increase the risk of bleeding if administered prior to or after @DRUG$    therapy.
908	DDI-effect	In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and @DRUG$) may increase the risk of bleeding if administered prior to or after @DRUG$    therapy.
909	DDI-effect	The occurrence of stupor, muscular rigidity, severe agitation, and elevated temperature has been reported in some patients receiving the combination of @DRUG$ and @DRUG$.
910	DDI-int	This is typical of the interaction of @DRUG$ and @DRUG$.
911	DDI-effect	Severe toxicity has also been reported in patients receiving the combination of @DRUG$ and @DRUG$ and selective serotonin reuptake inhibitors and ELDEPRYL.
912	DDI-false	Severe toxicity has also been reported in patients receiving the combination of @DRUG$ and ELDEPRYL and @DRUG$ and ELDEPRYL.
913	DDI-false	Severe toxicity has also been reported in patients receiving the combination of @DRUG$ and ELDEPRYL and selective serotonin reuptake inhibitors and @DRUG$.
914	DDI-false	Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and @DRUG$ and @DRUG$ and ELDEPRYL.
915	DDI-false	Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and @DRUG$ and selective serotonin reuptake inhibitors and @DRUG$.
916	DDI-effect	Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and @DRUG$ and @DRUG$.
917	DDI-effect	One case of hypertensive crisis has been reported in a patient taking the recommended doses of @DRUG$ and a @DRUG$ (ephedrine).
918	DDI-effect	One case of hypertensive crisis has been reported in a patient taking the recommended doses of @DRUG$ and a sympathomimetic medication (@DRUG$).
919	DDI-false	One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a @DRUG$ (@DRUG$).
920	DDI-effect	When @DRUG$ and @DRUG$ are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone.
921	DDI-false	When @DRUG$ and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when @DRUG$ is used alone.
922	DDI-false	When atropine and @DRUG$ are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when @DRUG$ is used alone.
923	DDI-false	This is especially true if the total dose of @DRUG$ has been large and the administration of @DRUG$ has been delayed.
924	DDI-false	2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of @DRUG$: since @DRUG$ are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions;
925	DDI-false	2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of @DRUG$: since barbiturates are potentiated by the @DRUG$, they should be used cautiously in the treatment of convulsions;
926	DDI-effect	2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of pralidoxime: since @DRUG$ are potentiated by the @DRUG$, they should be used cautiously in the treatment of convulsions;
927	DDI-false	@DRUG$, @DRUG$, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.
928	DDI-false	@DRUG$, theophylline, @DRUG$, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.
929	DDI-false	@DRUG$, theophylline, aminophylline, @DRUG$, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.
930	DDI-false	@DRUG$, theophylline, aminophylline, succinylcholine, @DRUG$, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.
931	DDI-false	@DRUG$, theophylline, aminophylline, succinylcholine, reserpine, and @DRUG$ should be avoided in patients with organophosphate poisoning.
932	DDI-false	morphine, @DRUG$, @DRUG$, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.
933	DDI-false	morphine, @DRUG$, aminophylline, @DRUG$, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.
934	DDI-false	morphine, @DRUG$, aminophylline, succinylcholine, @DRUG$, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.
935	DDI-false	morphine, @DRUG$, aminophylline, succinylcholine, reserpine, and @DRUG$ should be avoided in patients with organophosphate poisoning.
936	DDI-false	morphine, theophylline, @DRUG$, @DRUG$, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.
937	DDI-false	morphine, theophylline, @DRUG$, succinylcholine, @DRUG$, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.
938	DDI-false	morphine, theophylline, @DRUG$, succinylcholine, reserpine, and @DRUG$ should be avoided in patients with organophosphate poisoning.
939	DDI-false	morphine, theophylline, aminophylline, @DRUG$, @DRUG$, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.
940	DDI-false	morphine, theophylline, aminophylline, @DRUG$, reserpine, and @DRUG$ should be avoided in patients with organophosphate poisoning.
941	DDI-false	morphine, theophylline, aminophylline, succinylcholine, @DRUG$, and @DRUG$ should be avoided in patients with organophosphate poisoning.
942	DDI-mechanism	@DRUG$ administered concomitantly with @DRUG$ may significantly decrease the serum concentrations of MPA.
943	DDI-false	@DRUG$ administered concomitantly with depo-subQ provera 104 may significantly decrease the serum concentrations of @DRUG$.
944	DDI-false	Aminoglutethimide administered concomitantly with @DRUG$ may significantly decrease the serum concentrations of @DRUG$.
945	DDI-false	In clinical studies of @DRUG$, patients taking @DRUG$ concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
946	DDI-false	In clinical studies of @DRUG$, patients taking TOBI concomitantly with @DRUG$ (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
947	DDI-false	In clinical studies of @DRUG$, patients taking TOBI concomitantly with dornase alfa (@DRUG$   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
948	DDI-false	In clinical studies of @DRUG$, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), @DRUG$, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
949	DDI-false	In clinical studies of @DRUG$, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled @DRUG$, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
950	DDI-false	In clinical studies of @DRUG$, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other @DRUG$, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
951	DDI-false	In clinical studies of @DRUG$, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral @DRUG$ demonstrated adverse experience profiles similar to the study population as a whole.
952	DDI-effect	In clinical studies of TOBI, patients taking @DRUG$ concomitantly with @DRUG$ (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
953	DDI-effect	In clinical studies of TOBI, patients taking @DRUG$ concomitantly with dornase alfa (@DRUG$   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
954	DDI-effect	In clinical studies of TOBI, patients taking @DRUG$ concomitantly with dornase alfa (PULMOZYME   , Genentech), @DRUG$, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
955	DDI-effect	In clinical studies of TOBI, patients taking @DRUG$ concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled @DRUG$, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
956	DDI-effect	In clinical studies of TOBI, patients taking @DRUG$ concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other @DRUG$, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
957	DDI-effect	In clinical studies of TOBI, patients taking @DRUG$ concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral @DRUG$ demonstrated adverse experience profiles similar to the study population as a whole.
958	DDI-false	In clinical studies of TOBI, patients taking TOBI concomitantly with @DRUG$ (@DRUG$   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
959	DDI-false	In clinical studies of TOBI, patients taking TOBI concomitantly with @DRUG$ (PULMOZYME   , Genentech), @DRUG$, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
960	DDI-false	In clinical studies of TOBI, patients taking TOBI concomitantly with @DRUG$ (PULMOZYME   , Genentech), (beta)-agonists, inhaled @DRUG$, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
961	DDI-false	In clinical studies of TOBI, patients taking TOBI concomitantly with @DRUG$ (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other @DRUG$, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
962	DDI-false	In clinical studies of TOBI, patients taking TOBI concomitantly with @DRUG$ (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral @DRUG$ demonstrated adverse experience profiles similar to the study population as a whole.
963	DDI-false	In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (@DRUG$   , Genentech), @DRUG$, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
964	DDI-false	In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (@DRUG$   , Genentech), (beta)-agonists, inhaled @DRUG$, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
965	DDI-false	In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (@DRUG$   , Genentech), (beta)-agonists, inhaled corticosteroids, other @DRUG$, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
966	DDI-false	In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (@DRUG$   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral @DRUG$ demonstrated adverse experience profiles similar to the study population as a whole.
967	DDI-false	In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), @DRUG$, inhaled @DRUG$, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
968	DDI-false	In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), @DRUG$, inhaled corticosteroids, other @DRUG$, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
969	DDI-false	In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), @DRUG$, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral @DRUG$ demonstrated adverse experience profiles similar to the study population as a whole.
970	DDI-false	In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled @DRUG$, other @DRUG$, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
971	DDI-false	In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled @DRUG$, other anti-pseudomonal antibiotics, or parenteral @DRUG$ demonstrated adverse experience profiles similar to the study population as a whole.
972	DDI-false	In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other @DRUG$, or parenteral @DRUG$ demonstrated adverse experience profiles similar to the study population as a whole.
973	DDI-effect	Some @DRUG$ can enhance @DRUG$ toxicity by altering antibiotic concentrations in serum and tissue.
974	DDI-false	Some @DRUG$ can enhance aminoglycoside toxicity by altering @DRUG$ concentrations in serum and tissue.
975	DDI-false	Some diuretics can enhance @DRUG$ toxicity by altering @DRUG$ concentrations in serum and tissue.
976	DDI-advise	@DRUG$ should not be administered concomitantly with @DRUG$, furosemide, urea, or mannitol.
977	DDI-advise	@DRUG$ should not be administered concomitantly with ethacrynic acid, @DRUG$, urea, or mannitol.
978	DDI-advise	@DRUG$ should not be administered concomitantly with ethacrynic acid, furosemide, @DRUG$, or mannitol.
979	DDI-advise	@DRUG$ should not be administered concomitantly with ethacrynic acid, furosemide, urea, or @DRUG$.
980	DDI-false	TOBI should not be administered concomitantly with @DRUG$, @DRUG$, urea, or mannitol.
981	DDI-false	TOBI should not be administered concomitantly with @DRUG$, furosemide, @DRUG$, or mannitol.
982	DDI-false	TOBI should not be administered concomitantly with @DRUG$, furosemide, urea, or @DRUG$.
983	DDI-false	TOBI should not be administered concomitantly with ethacrynic acid, @DRUG$, @DRUG$, or mannitol.
984	DDI-false	TOBI should not be administered concomitantly with ethacrynic acid, @DRUG$, urea, or @DRUG$.
985	DDI-false	TOBI should not be administered concomitantly with ethacrynic acid, furosemide, @DRUG$, or @DRUG$.
986	DDI-false	DRUG INTERACTIONS  There are no known drug/drug interactions with oral @DRUG$  Vaccinations with @DRUG$ are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.
987	DDI-false	DRUG INTERACTIONS  There are no known drug/drug interactions with oral @DRUG$  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  @DRUG$ together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.
988	DDI-false	DRUG INTERACTIONS  There are no known drug/drug interactions with oral @DRUG$  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous @DRUG$ has caused deaths in children due to haemorrhagic enterocolitis.
989	DDI-false	DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with @DRUG$ are not recommended in immunocompromised individuals  @DRUG$ together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.
990	DDI-false	DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with @DRUG$ are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous @DRUG$ has caused deaths in children due to haemorrhagic enterocolitis.
991	DDI-effect	DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  @DRUG$ together with high-dose intravenous @DRUG$ has caused deaths in children due to haemorrhagic enterocolitis.
992	DDI-effect	Impaired renal function has been described in bone marrow transplant patients who were conditioned with high-dose intravenous @DRUG$ and who subsequently received @DRUG$ to prevent graft-versus-host disease
993	DDI-advise	@DRUG$ should be administered with caution to patients taking @DRUG$ because of the possibility of conduction disturbances.
994	DDI-false	These effects should be considered when anticholinergic properties may be contributing to the therapeutic effect of concomitant medication (e.g., @DRUG$, inhaled @DRUG$).
995	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: @DRUG$, artificial tears, @DRUG$, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
996	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: @DRUG$, artificial tears, calcium, @DRUG$, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
997	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: @DRUG$, artificial tears, calcium, conjugated estrogens, @DRUG$, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
998	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: @DRUG$, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, @DRUG$, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
999	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: @DRUG$, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, @DRUG$, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
1000	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: @DRUG$, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, @DRUG$, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
1001	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: @DRUG$, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, @DRUG$, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
1002	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: @DRUG$, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, @DRUG$, naproxen, omeprazole, paracetamol, and prednisone.
1003	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: @DRUG$, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, @DRUG$, omeprazole, paracetamol, and prednisone.
1004	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: @DRUG$, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, @DRUG$, paracetamol, and prednisone.
1005	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: @DRUG$, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, @DRUG$, and prednisone.
1006	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: @DRUG$, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and @DRUG$.
1007	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, @DRUG$, @DRUG$, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
1008	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, @DRUG$, conjugated estrogens, @DRUG$, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
1009	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, @DRUG$, conjugated estrogens, hydroxychloroquine sulfate, @DRUG$, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
1010	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, @DRUG$, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, @DRUG$, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
1011	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, @DRUG$, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, @DRUG$, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
1012	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, @DRUG$, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, @DRUG$, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
1013	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, @DRUG$, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, @DRUG$, naproxen, omeprazole, paracetamol, and prednisone.
1014	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, @DRUG$, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, @DRUG$, omeprazole, paracetamol, and prednisone.
1015	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, @DRUG$, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, @DRUG$, paracetamol, and prednisone.
1016	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, @DRUG$, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, @DRUG$, and prednisone.
1017	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, @DRUG$, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and @DRUG$.
1018	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, @DRUG$, @DRUG$, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
1019	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, @DRUG$, hydroxychloroquine sulfate, @DRUG$, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
1020	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, @DRUG$, hydroxychloroquine sulfate, ibuprofen, @DRUG$, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
1021	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, @DRUG$, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, @DRUG$, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
1022	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, @DRUG$, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, @DRUG$, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
1023	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, @DRUG$, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, @DRUG$, naproxen, omeprazole, paracetamol, and prednisone.
1024	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, @DRUG$, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, @DRUG$, omeprazole, paracetamol, and prednisone.
1025	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, @DRUG$, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, @DRUG$, paracetamol, and prednisone.
1026	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, @DRUG$, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, @DRUG$, and prednisone.
1027	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, @DRUG$, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and @DRUG$.
1028	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, @DRUG$, @DRUG$, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
1029	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, @DRUG$, ibuprofen, @DRUG$, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
1030	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, @DRUG$, ibuprofen, levothyroxine sodium, @DRUG$, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
1031	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, @DRUG$, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, @DRUG$, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
1032	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, @DRUG$, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, @DRUG$, naproxen, omeprazole, paracetamol, and prednisone.
1033	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, @DRUG$, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, @DRUG$, omeprazole, paracetamol, and prednisone.
1034	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, @DRUG$, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, @DRUG$, paracetamol, and prednisone.
1035	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, @DRUG$, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, @DRUG$, and prednisone.
1036	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, @DRUG$, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and @DRUG$.
1037	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, @DRUG$, @DRUG$, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
1038	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, @DRUG$, levothyroxine sodium, @DRUG$, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
1039	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, @DRUG$, levothyroxine sodium, medroxyprogesterone acetate, @DRUG$, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
1040	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, @DRUG$, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, @DRUG$, naproxen, omeprazole, paracetamol, and prednisone.
1041	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, @DRUG$, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, @DRUG$, omeprazole, paracetamol, and prednisone.
1042	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, @DRUG$, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, @DRUG$, paracetamol, and prednisone.
1043	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, @DRUG$, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, @DRUG$, and prednisone.
1044	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, @DRUG$, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and @DRUG$.
1045	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, @DRUG$, @DRUG$, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
1046	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, @DRUG$, medroxyprogesterone acetate, @DRUG$, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
1047	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, @DRUG$, medroxyprogesterone acetate, methotrexate, @DRUG$, naproxen, omeprazole, paracetamol, and prednisone.
1048	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, @DRUG$, medroxyprogesterone acetate, methotrexate, multivitamins, @DRUG$, omeprazole, paracetamol, and prednisone.
1049	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, @DRUG$, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, @DRUG$, paracetamol, and prednisone.
1050	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, @DRUG$, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, @DRUG$, and prednisone.
1051	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, @DRUG$, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and @DRUG$.
1052	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, @DRUG$, @DRUG$, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
1053	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, @DRUG$, methotrexate, @DRUG$, naproxen, omeprazole, paracetamol, and prednisone.
1054	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, @DRUG$, methotrexate, multivitamins, @DRUG$, omeprazole, paracetamol, and prednisone.
1055	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, @DRUG$, methotrexate, multivitamins, naproxen, @DRUG$, paracetamol, and prednisone.
1056	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, @DRUG$, methotrexate, multivitamins, naproxen, omeprazole, @DRUG$, and prednisone.
1057	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, @DRUG$, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and @DRUG$.
1058	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, @DRUG$, @DRUG$, naproxen, omeprazole, paracetamol, and prednisone.
1059	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, @DRUG$, multivitamins, @DRUG$, omeprazole, paracetamol, and prednisone.
1060	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, @DRUG$, multivitamins, naproxen, @DRUG$, paracetamol, and prednisone.
1061	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, @DRUG$, multivitamins, naproxen, omeprazole, @DRUG$, and prednisone.
1062	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, @DRUG$, multivitamins, naproxen, omeprazole, paracetamol, and @DRUG$.
1063	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, @DRUG$, @DRUG$, omeprazole, paracetamol, and prednisone.
1064	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, @DRUG$, naproxen, @DRUG$, paracetamol, and prednisone.
1065	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, @DRUG$, naproxen, omeprazole, @DRUG$, and prednisone.
1066	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, @DRUG$, naproxen, omeprazole, paracetamol, and @DRUG$.
1067	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, @DRUG$, @DRUG$, paracetamol, and prednisone.
1068	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, @DRUG$, omeprazole, @DRUG$, and prednisone.
1069	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, @DRUG$, omeprazole, paracetamol, and @DRUG$.
1070	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, @DRUG$, @DRUG$, and prednisone.
1071	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, @DRUG$, paracetamol, and @DRUG$.
1072	DDI-false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, @DRUG$, and @DRUG$.
1073	DDI-effect	The induction dose requirements of @DRUG$ Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with @DRUG$ (eg, morphine, meperidine, and fentanyl, etc.)
1074	DDI-effect	The induction dose requirements of @DRUG$ Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, @DRUG$, meperidine, and fentanyl, etc.)
1075	DDI-effect	The induction dose requirements of @DRUG$ Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, @DRUG$, and fentanyl, etc.)
1076	DDI-effect	The induction dose requirements of @DRUG$ Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and @DRUG$, etc.)
1077	DDI-false	The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with @DRUG$ (eg, @DRUG$, meperidine, and fentanyl, etc.)
1078	DDI-false	The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with @DRUG$ (eg, morphine, @DRUG$, and fentanyl, etc.)
1079	DDI-false	The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with @DRUG$ (eg, morphine, meperidine, and @DRUG$, etc.)
1080	DDI-false	The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, @DRUG$, @DRUG$, and fentanyl, etc.)
1081	DDI-false	The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, @DRUG$, meperidine, and @DRUG$, etc.)
1082	DDI-false	The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, @DRUG$, and @DRUG$, etc.)
1083	DDI-false	and combinations of @DRUG$ and @DRUG$ (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.).
1084	DDI-false	and combinations of @DRUG$ and sedatives (eg, @DRUG$, barbiturates, chloral hydrate, droperidol, etc.).
1085	DDI-false	and combinations of @DRUG$ and sedatives (eg, benzodiazepines, @DRUG$, chloral hydrate, droperidol, etc.).
1086	DDI-false	and combinations of @DRUG$ and sedatives (eg, benzodiazepines, barbiturates, @DRUG$, droperidol, etc.).
1087	DDI-false	and combinations of @DRUG$ and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, @DRUG$, etc.).
1088	DDI-false	and combinations of opioids and @DRUG$ (eg, @DRUG$, barbiturates, chloral hydrate, droperidol, etc.).
1089	DDI-false	and combinations of opioids and @DRUG$ (eg, benzodiazepines, @DRUG$, chloral hydrate, droperidol, etc.).
1090	DDI-false	and combinations of opioids and @DRUG$ (eg, benzodiazepines, barbiturates, @DRUG$, droperidol, etc.).
1091	DDI-false	and combinations of opioids and @DRUG$ (eg, benzodiazepines, barbiturates, chloral hydrate, @DRUG$, etc.).
1092	DDI-false	and combinations of opioids and sedatives (eg, @DRUG$, @DRUG$, chloral hydrate, droperidol, etc.).
1093	DDI-false	and combinations of opioids and sedatives (eg, @DRUG$, barbiturates, @DRUG$, droperidol, etc.).
1094	DDI-false	and combinations of opioids and sedatives (eg, @DRUG$, barbiturates, chloral hydrate, @DRUG$, etc.).
1095	DDI-false	and combinations of opioids and sedatives (eg, benzodiazepines, @DRUG$, @DRUG$, droperidol, etc.).
1096	DDI-false	and combinations of opioids and sedatives (eg, benzodiazepines, @DRUG$, chloral hydrate, @DRUG$, etc.).
1097	DDI-false	and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, @DRUG$, @DRUG$, etc.).
1098	DDI-advise	During maintenance of anesthesia or sedation, the rate of @DRUG$ Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental @DRUG$ (eg, nitrous oxide or opioids).
1099	DDI-advise	During maintenance of anesthesia or sedation, the rate of @DRUG$ Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, @DRUG$ or opioids).
1100	DDI-advise	During maintenance of anesthesia or sedation, the rate of @DRUG$ Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or @DRUG$).
1101	DDI-false	During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental @DRUG$ (eg, @DRUG$ or opioids).
1102	DDI-false	During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental @DRUG$ (eg, nitrous oxide or @DRUG$).
1103	DDI-false	During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, @DRUG$ or @DRUG$).
1104	DDI-false	The concurrent administration of potent inhalational agents (eg, @DRUG$, @DRUG$, and halothane) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated.
1105	DDI-false	The concurrent administration of potent inhalational agents (eg, @DRUG$, enflurane, and @DRUG$) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated.
1106	DDI-false	The concurrent administration of potent inhalational agents (eg, @DRUG$, enflurane, and halothane) during maintenance with @DRUG$ Injectable Emulsion has not been extensively evaluated.
1107	DDI-false	The concurrent administration of potent inhalational agents (eg, isoflurane, @DRUG$, and @DRUG$) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated.
1108	DDI-false	The concurrent administration of potent inhalational agents (eg, isoflurane, @DRUG$, and halothane) during maintenance with @DRUG$ Injectable Emulsion has not been extensively evaluated.
1109	DDI-false	The concurrent administration of potent inhalational agents (eg, isoflurane, enflurane, and @DRUG$) during maintenance with @DRUG$ Injectable Emulsion has not been extensively evaluated.
1110	DDI-false	@DRUG$ Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used @DRUG$ (eg, succinylcholine and nondepolarizing muscle relaxants).
1111	DDI-false	@DRUG$ Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, @DRUG$ and nondepolarizing muscle relaxants).
1112	DDI-false	@DRUG$ Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, succinylcholine and @DRUG$).
1113	DDI-false	DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used @DRUG$ (eg, @DRUG$ and nondepolarizing muscle relaxants).
1114	DDI-false	DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used @DRUG$ (eg, succinylcholine and @DRUG$).
1115	DDI-false	DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, @DRUG$ and @DRUG$).
1116	DDI-false	No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of @DRUG$, inhalational agents, @DRUG$, and local anesthetic agents) have been observed.
1117	DDI-false	No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of @DRUG$, inhalational agents, analgesic agents, and local @DRUG$) have been observed.
1118	DDI-false	No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of muscle relaxants, inhalational agents, @DRUG$, and local @DRUG$) have been observed.
1119	DDI-effect	Oral @DRUG$ has been reported to potentiate the anticoagulant effect of @DRUG$ and warfarin, resulting in a prolongation of prothrombin time.
1120	DDI-effect	Oral @DRUG$ has been reported to potentiate the anticoagulant effect of coumarin and @DRUG$, resulting in a prolongation of prothrombin time.
1121	DDI-false	Oral metronidazole has been reported to potentiate the anticoagulant effect of @DRUG$ and @DRUG$, resulting in a prolongation of prothrombin time.
1122	DDI-false	Drug interactions should be kept in mind when @DRUG$ (@DRUG$ gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical metronidazole administration because of low absorption.
1123	DDI-false	Drug interactions should be kept in mind when @DRUG$ (metronidazole gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical @DRUG$ administration because of low absorption.
1124	DDI-false	Drug interactions should be kept in mind when METROGEL (@DRUG$ gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical @DRUG$ administration because of low absorption.
1125	DDI-advise	Caution is advised for patients receiving high-dose @DRUG$ and @DRUG$ concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.
1126	DDI-false	Caution is advised for patients receiving high-dose @DRUG$ and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose @DRUG$ and carbonic anhydrase inhibitors.
1127	DDI-false	Caution is advised for patients receiving high-dose @DRUG$ and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and @DRUG$.
1128	DDI-false	Caution is advised for patients receiving high-dose aspirin and @DRUG$ concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose @DRUG$ and carbonic anhydrase inhibitors.
1129	DDI-false	Caution is advised for patients receiving high-dose aspirin and @DRUG$ concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and @DRUG$.
1130	DDI-effect	Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose @DRUG$ and @DRUG$.
1131	DDI-false	@DRUG$ may be used with @DRUG$, quinine and other antimalarials, and with other antibiotics.
1132	DDI-false	@DRUG$ may be used with sulfonamides, @DRUG$ and other antimalarials, and with other antibiotics.
1133	DDI-false	@DRUG$ may be used with sulfonamides, quinine and other @DRUG$, and with other antibiotics.
1134	DDI-false	@DRUG$ may be used with sulfonamides, quinine and other antimalarials, and with other @DRUG$.
1135	DDI-false	Pyrimethamine may be used with @DRUG$, @DRUG$ and other antimalarials, and with other antibiotics.
1136	DDI-false	Pyrimethamine may be used with @DRUG$, quinine and other @DRUG$, and with other antibiotics.
1137	DDI-false	Pyrimethamine may be used with @DRUG$, quinine and other antimalarials, and with other @DRUG$.
1138	DDI-false	Pyrimethamine may be used with sulfonamides, @DRUG$ and other @DRUG$, and with other antibiotics.
1139	DDI-false	Pyrimethamine may be used with sulfonamides, @DRUG$ and other antimalarials, and with other @DRUG$.
1140	DDI-false	Pyrimethamine may be used with sulfonamides, quinine and other @DRUG$, and with other @DRUG$.
1141	DDI-false	@DRUG$ (@DRUG$) should be administered until normal hematopoiesis is restored.
1142	DDI-effect	Mild hepatotoxicity has been reported in some patients when @DRUG$ and @DRUG$ were administered concomitantly.
1143	DDI-advise	Due to its effects on gastric emptying, @DRUG$ therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., @DRUG$ such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors).
1144	DDI-advise	Due to its effects on gastric emptying, @DRUG$ therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as @DRUG$) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors).
1145	DDI-advise	Due to its effects on gastric emptying, @DRUG$ therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., @DRUG$).
1146	DDI-false	Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., @DRUG$ such as @DRUG$) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors).
1147	DDI-false	Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., @DRUG$ such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., @DRUG$).
1148	DDI-false	Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as @DRUG$) and agents that slow the intestinal absorption of nutrients (e.g., @DRUG$).
1149	DDI-advise	When the rapid onset of a concomitant orally administered agent is a critical determinant of effectiveness (such as @DRUG$), the agent should be administered at least 1 hour prior to or 2 hours after @DRUG$ injection.
1150	DDI-false	In clinical trials, the concomitant use of @DRUG$ or @DRUG$ did not alter the adverse event profile of SYMLIN.
1151	DDI-false	In clinical trials, the concomitant use of @DRUG$ or biguanides did not alter the adverse event profile of @DRUG$.
1152	DDI-false	In clinical trials, the concomitant use of sulfonylureas or @DRUG$ did not alter the adverse event profile of @DRUG$.
1153	DDI-false	No formal interaction studies have been performed to assess the effect of @DRUG$ on the kinetics of oral @DRUG$.
1154	DDI-false	Mixing @DRUG$ and @DRUG$ The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection.
1155	DDI-false	Mixing @DRUG$ and Insulin The pharmacokinetic parameters of @DRUG$ were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection.
1156	DDI-false	Mixing @DRUG$ and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant @DRUG$ immediately prior to injection.
1157	DDI-false	Mixing SYMLIN and @DRUG$ The pharmacokinetic parameters of @DRUG$ were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection.
1158	DDI-false	Mixing SYMLIN and @DRUG$ The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant @DRUG$ immediately prior to injection.
1159	DDI-mechanism	Mixing SYMLIN and Insulin The pharmacokinetic parameters of @DRUG$ were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant @DRUG$ immediately prior to injection.
1160	DDI-false	Thus, @DRUG$ and @DRUG$ should not be mixed and must be administered separately.
1161	DDI-false	Since @DRUG$ is a substrate for the metabolic pathways involving CYP2D6 and CYP1A2 enzymes, inhibition or induction of either of these enzymes would be expected to alter @DRUG$ plasma concentrations.
1162	DDI-mechanism	In a formal, single-dose interaction study (n = 6 males) the clearance of @DRUG$ was decreased by 38% following the coadministration of @DRUG$, an inhibitor of CYP1A2.
1163	DDI-false	In a formal study, @DRUG$ were shown not to affect @DRUG$    plasma concentrations.
1164	DDI-false	ECG intervals (PR, QRS, and QT) were not affected by concurrent @DRUG$    and @DRUG$, diuretics, or propranolol.
1165	DDI-false	ECG intervals (PR, QRS, and QT) were not affected by concurrent @DRUG$    and digoxin, @DRUG$, or propranolol.
1166	DDI-false	ECG intervals (PR, QRS, and QT) were not affected by concurrent @DRUG$    and digoxin, diuretics, or @DRUG$.
1167	DDI-false	ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and @DRUG$, @DRUG$, or propranolol.
1168	DDI-false	ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and @DRUG$, diuretics, or @DRUG$.
1169	DDI-false	ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and digoxin, @DRUG$, or @DRUG$.
1170	DDI-mechanism	Concurrent administration of @DRUG$ and @DRUG$    has been reported to increase, decrease, or leave unchanged Mexitil    plasma levels;
1171	DDI-false	Concurrent administration of @DRUG$ and Mexitil    has been reported to increase, decrease, or leave unchanged @DRUG$    plasma levels;
1172	DDI-false	Concurrent administration of cimetidine and @DRUG$    has been reported to increase, decrease, or leave unchanged @DRUG$    plasma levels;
1173	DDI-false	@DRUG$    does not alter serum @DRUG$ levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels.
1174	DDI-false	@DRUG$    does not alter serum digoxin levels but @DRUG$, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels.
1175	DDI-false	@DRUG$    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to @DRUG$   , has been reported to lower serum digoxin levels.
1176	DDI-false	@DRUG$    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum @DRUG$ levels.
1177	DDI-false	Mexitil    does not alter serum @DRUG$ levels but @DRUG$, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels.
1178	DDI-false	Mexitil    does not alter serum @DRUG$ levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to @DRUG$   , has been reported to lower serum digoxin levels.
1179	DDI-false	Mexitil    does not alter serum @DRUG$ levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum @DRUG$ levels.
1180	DDI-false	Mexitil    does not alter serum digoxin levels but @DRUG$, when used to treat gastrointestinal symptoms due to @DRUG$   , has been reported to lower serum digoxin levels.
1181	DDI-mechanism	Mexitil    does not alter serum digoxin levels but @DRUG$, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum @DRUG$ levels.
1182	DDI-false	Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to @DRUG$   , has been reported to lower serum @DRUG$ levels.
1183	DDI-mechanism	Concurrent use of @DRUG$    and @DRUG$ may lead to increased plasma theophylline levels.
1184	DDI-false	Concurrent use of @DRUG$    and theophylline may lead to increased plasma @DRUG$ levels.
1185	DDI-false	Concurrent use of Mexitil    and @DRUG$ may lead to increased plasma @DRUG$ levels.
1186	DDI-false	This increase was observed at the first test point which was the second day after starting @DRUG$   . @DRUG$ plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed.
1187	DDI-false	This increase was observed at the first test point which was the second day after starting @DRUG$   . Theophylline plasma levels returned to pre-@DRUG$    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed.
1188	DDI-false	This increase was observed at the first test point which was the second day after starting @DRUG$   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing @DRUG$   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed.
1189	DDI-false	This increase was observed at the first test point which was the second day after starting @DRUG$   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If @DRUG$ and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed.
1190	DDI-false	This increase was observed at the first test point which was the second day after starting @DRUG$   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and @DRUG$ are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed.
1191	DDI-false	This increase was observed at the first test point which was the second day after starting @DRUG$   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, @DRUG$ blood levels should be monitored, particularly when the Mexitil    dose is changed.
1192	DDI-false	This increase was observed at the first test point which was the second day after starting @DRUG$   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the @DRUG$    dose is changed.
1193	DDI-false	This increase was observed at the first test point which was the second day after starting Mexitil   . @DRUG$ plasma levels returned to pre-@DRUG$    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed.
1194	DDI-mechanism	This increase was observed at the first test point which was the second day after starting Mexitil   . @DRUG$ plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing @DRUG$   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed.
1195	DDI-false	This increase was observed at the first test point which was the second day after starting Mexitil   . @DRUG$ plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If @DRUG$ and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed.
1196	DDI-false	This increase was observed at the first test point which was the second day after starting Mexitil   . @DRUG$ plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and @DRUG$ are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed.
1197	DDI-false	This increase was observed at the first test point which was the second day after starting Mexitil   . @DRUG$ plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, @DRUG$ blood levels should be monitored, particularly when the Mexitil    dose is changed.
1198	DDI-false	This increase was observed at the first test point which was the second day after starting Mexitil   . @DRUG$ plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the @DRUG$    dose is changed.
1199	DDI-false	This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-@DRUG$    values within 48 hours after discontinuing @DRUG$   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed.
1200	DDI-false	This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-@DRUG$    values within 48 hours after discontinuing Mexitil   . If @DRUG$ and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed.
1201	DDI-false	This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-@DRUG$    values within 48 hours after discontinuing Mexitil   . If Mexitil and @DRUG$ are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed.
1202	DDI-false	This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-@DRUG$    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, @DRUG$ blood levels should be monitored, particularly when the Mexitil    dose is changed.
1203	DDI-false	This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-@DRUG$    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the @DRUG$    dose is changed.
1204	DDI-false	This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing @DRUG$   . If @DRUG$ and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed.
1205	DDI-false	This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing @DRUG$   . If Mexitil and @DRUG$ are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed.
1206	DDI-false	This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing @DRUG$   . If Mexitil and theophylline are to be used concurrently, @DRUG$ blood levels should be monitored, particularly when the Mexitil    dose is changed.
1207	DDI-false	This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing @DRUG$   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the @DRUG$    dose is changed.
1208	DDI-advise	This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If @DRUG$ and @DRUG$ are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed.
1209	DDI-false	This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If @DRUG$ and theophylline are to be used concurrently, @DRUG$ blood levels should be monitored, particularly when the Mexitil    dose is changed.
1210	DDI-false	This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If @DRUG$ and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the @DRUG$    dose is changed.
1211	DDI-false	This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and @DRUG$ are to be used concurrently, @DRUG$ blood levels should be monitored, particularly when the Mexitil    dose is changed.
1212	DDI-false	This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and @DRUG$ are to be used concurrently, theophylline blood levels should be monitored, particularly when the @DRUG$    dose is changed.
1213	DDI-false	This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, @DRUG$ blood levels should be monitored, particularly when the @DRUG$    dose is changed.
1214	DDI-false	In another formal study (n = 8 extensive and n = 7 poor metabolizers of CYP2D6), coadministration of @DRUG$ did not alter the kinetics of @DRUG$ in the poor CYP2D6 metabolizer group.
1215	DDI-mechanism	Additionally, in one controlled study in five normal subjects and seven patients, the clearance of @DRUG$ was decreased 50% following the administration of @DRUG$   .
1216	DDI-false	In this crossover steady state study, the pharmacokinetics of @DRUG$ were unaffected in either phenotype by the coadministration of @DRUG$.
1217	DDI-false	Addition of @DRUG$ to @DRUG$ did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than propafenone alone.
1218	DDI-false	Addition of @DRUG$ to propafenone did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than @DRUG$ alone.
1219	DDI-false	Addition of mexiletine to @DRUG$ did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than @DRUG$ alone.
1220	DDI-false	When concomitant administration of either of these two drugs with @DRUG$ is initiated, the dose of @DRUG$ should be slowly titrated to desired effect.
1221	DDI-false	In a large compassionate use program @DRUG$    has been used concurrently with commonly employed antianginal, @DRUG$, and anticoagulant drugs without observed interactions.
1222	DDI-false	In a large compassionate use program @DRUG$    has been used concurrently with commonly employed antianginal, antihypertensive, and @DRUG$ without observed interactions.
1223	DDI-false	In a large compassionate use program Mexitil    has been used concurrently with commonly employed antianginal, @DRUG$, and @DRUG$ without observed interactions.
1224	DDI-false	A variety of @DRUG$ such as @DRUG$ or propranolol were also added, sometimes with improved control of ventricular ectopy.
1225	DDI-false	A variety of @DRUG$ such as quinidine or @DRUG$ were also added, sometimes with improved control of ventricular ectopy.
1226	DDI-false	A variety of antiarrhythmics such as @DRUG$ or @DRUG$ were also added, sometimes with improved control of ventricular ectopy.
1227	DDI-false	When @DRUG$ or other hepatic enzyme inducers such as @DRUG$ and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported.
1228	DDI-false	When @DRUG$ or other hepatic enzyme inducers such as rifampin and @DRUG$ have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported.
1229	DDI-mechanism	When @DRUG$ or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with @DRUG$   , lowered Mexitil    plasma levels have been reported.
1230	DDI-false	When @DRUG$ or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered @DRUG$    plasma levels have been reported.
1231	DDI-false	When phenytoin or other hepatic enzyme inducers such as @DRUG$ and @DRUG$ have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported.
1232	DDI-mechanism	When phenytoin or other hepatic enzyme inducers such as @DRUG$ and phenobarbital have been taken concurrently with @DRUG$   , lowered Mexitil    plasma levels have been reported.
1233	DDI-false	When phenytoin or other hepatic enzyme inducers such as @DRUG$ and phenobarbital have been taken concurrently with Mexitil   , lowered @DRUG$    plasma levels have been reported.
1234	DDI-mechanism	When phenytoin or other hepatic enzyme inducers such as rifampin and @DRUG$ have been taken concurrently with @DRUG$   , lowered Mexitil    plasma levels have been reported.
1235	DDI-false	When phenytoin or other hepatic enzyme inducers such as rifampin and @DRUG$ have been taken concurrently with Mexitil   , lowered @DRUG$    plasma levels have been reported.
1236	DDI-false	When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with @DRUG$   , lowered @DRUG$    plasma levels have been reported.
1237	DDI-false	@DRUG$ (oral): The activity of oral @DRUG$ may be potentiated by anti-vitamin-K activity attributed to methimazole.
1238	DDI-false	@DRUG$ (oral): The activity of oral anticoagulants may be potentiated by anti-vitamin-K activity attributed to @DRUG$.
1239	DDI-effect	Anticoagulants (oral): The activity of oral @DRUG$ may be potentiated by anti-vitamin-K activity attributed to @DRUG$.
1240	DDI-false	@DRUG$: Serum digitalis levels may be increased when hyperthyroid patients on a stable @DRUG$ regimen become euthyroid;
1241	DDI-false	@DRUG$: @DRUG$ clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid;
1242	DDI-false	@DRUG$: Theophylline clearance may decrease when hyperthyroid patients on a stable @DRUG$ regimen become euthyroid;
1243	DDI-false	Theophylline: @DRUG$ clearance may decrease when hyperthyroid patients on a stable @DRUG$ regimen become euthyroid;
1244	DDI-advise	Other @DRUG$ should not be used concomitantly with @DRUG$ because they may have additive effects.
1245	DDI-int	Some @DRUG$ may interact with @DRUG$.
1246	DDI-false	Those @DRUG$ include @DRUG$, valproic acid, and phenobarbital.
1247	DDI-false	Those @DRUG$ include divalproex sodium, @DRUG$, and phenobarbital.
1248	DDI-false	Those @DRUG$ include divalproex sodium, valproic acid, and @DRUG$.
1249	DDI-false	Those anticonvulsants include @DRUG$, @DRUG$, and phenobarbital.
1250	DDI-false	Those anticonvulsants include @DRUG$, valproic acid, and @DRUG$.
1251	DDI-false	Those anticonvulsants include divalproex sodium, @DRUG$, and @DRUG$.
1252	DDI-effect	@DRUG$ may also affect the effects of other drugs, which include some @DRUG$, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.
1253	DDI-effect	@DRUG$ may also affect the effects of other drugs, which include some steroid medications, @DRUG$, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.
1254	DDI-effect	@DRUG$ may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, @DRUG$, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.
1255	DDI-effect	@DRUG$ may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, @DRUG$ and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.
1256	DDI-effect	@DRUG$ may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and @DRUG$ Please note that Mephenytoin may interact with other drugs that are not listed here.
1257	DDI-false	@DRUG$ may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that @DRUG$ may interact with other drugs that are not listed here.
1258	DDI-false	Mephenytoin may also affect the effects of other drugs, which include some @DRUG$, @DRUG$, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.
1259	DDI-false	Mephenytoin may also affect the effects of other drugs, which include some @DRUG$, warfarin, certain heart medicines, birth control pills, @DRUG$, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.
1260	DDI-false	Mephenytoin may also affect the effects of other drugs, which include some @DRUG$, warfarin, certain heart medicines, birth control pills, anti-infective medicines, @DRUG$ and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.
1261	DDI-false	Mephenytoin may also affect the effects of other drugs, which include some @DRUG$, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and @DRUG$ Please note that Mephenytoin may interact with other drugs that are not listed here.
1262	DDI-false	Mephenytoin may also affect the effects of other drugs, which include some @DRUG$, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that @DRUG$ may interact with other drugs that are not listed here.
1263	DDI-false	Mephenytoin may also affect the effects of other drugs, which include some steroid medications, @DRUG$, certain heart medicines, birth control pills, @DRUG$, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.
1264	DDI-false	Mephenytoin may also affect the effects of other drugs, which include some steroid medications, @DRUG$, certain heart medicines, birth control pills, anti-infective medicines, @DRUG$ and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.
1265	DDI-false	Mephenytoin may also affect the effects of other drugs, which include some steroid medications, @DRUG$, certain heart medicines, birth control pills, anti-infective medicines, furosemide and @DRUG$ Please note that Mephenytoin may interact with other drugs that are not listed here.
1266	DDI-false	Mephenytoin may also affect the effects of other drugs, which include some steroid medications, @DRUG$, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that @DRUG$ may interact with other drugs that are not listed here.
1267	DDI-false	Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, @DRUG$, @DRUG$ and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.
1268	DDI-false	Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, @DRUG$, furosemide and @DRUG$ Please note that Mephenytoin may interact with other drugs that are not listed here.
1269	DDI-false	Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, @DRUG$, furosemide and theophylline Please note that @DRUG$ may interact with other drugs that are not listed here.
1270	DDI-false	Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, @DRUG$ and @DRUG$ Please note that Mephenytoin may interact with other drugs that are not listed here.
1271	DDI-false	Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, @DRUG$ and theophylline Please note that @DRUG$ may interact with other drugs that are not listed here.
1272	DDI-false	Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and @DRUG$ Please note that @DRUG$ may interact with other drugs that are not listed here.
1273	DDI-false	Use with Other @DRUG$: The depressant effects of @DRUG$ are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs.
1274	DDI-false	Use with Other @DRUG$: The depressant effects of morphine are potentiated by the presence of other @DRUG$ such as alcohol, sedatives, antihistaminics, or psychotropic drugs.
1275	DDI-false	Use with Other @DRUG$: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as @DRUG$, sedatives, antihistaminics, or psychotropic drugs.
1276	DDI-false	Use with Other @DRUG$: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, @DRUG$, antihistaminics, or psychotropic drugs.
1277	DDI-false	Use with Other @DRUG$: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, @DRUG$, or psychotropic drugs.
1278	DDI-false	Use with Other @DRUG$: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or @DRUG$.
1279	DDI-effect	Use with Other Central Nervous System Depressants: The depressant effects of @DRUG$ are potentiated by the presence of other @DRUG$ such as alcohol, sedatives, antihistaminics, or psychotropic drugs.
1280	DDI-effect	Use with Other Central Nervous System Depressants: The depressant effects of @DRUG$ are potentiated by the presence of other CNS depressants such as @DRUG$, sedatives, antihistaminics, or psychotropic drugs.
1281	DDI-effect	Use with Other Central Nervous System Depressants: The depressant effects of @DRUG$ are potentiated by the presence of other CNS depressants such as alcohol, @DRUG$, antihistaminics, or psychotropic drugs.
1282	DDI-effect	Use with Other Central Nervous System Depressants: The depressant effects of @DRUG$ are potentiated by the presence of other CNS depressants such as alcohol, sedatives, @DRUG$, or psychotropic drugs.
1283	DDI-effect	Use with Other Central Nervous System Depressants: The depressant effects of @DRUG$ are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or @DRUG$.
1284	DDI-false	Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other @DRUG$ such as @DRUG$, sedatives, antihistaminics, or psychotropic drugs.
1285	DDI-false	Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other @DRUG$ such as alcohol, @DRUG$, antihistaminics, or psychotropic drugs.
1286	DDI-false	Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other @DRUG$ such as alcohol, sedatives, @DRUG$, or psychotropic drugs.
1287	DDI-false	Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other @DRUG$ such as alcohol, sedatives, antihistaminics, or @DRUG$.
1288	DDI-false	Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as @DRUG$, @DRUG$, antihistaminics, or psychotropic drugs.
1289	DDI-false	Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as @DRUG$, sedatives, @DRUG$, or psychotropic drugs.
1290	DDI-false	Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as @DRUG$, sedatives, antihistaminics, or @DRUG$.
1291	DDI-false	Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, @DRUG$, @DRUG$, or psychotropic drugs.
1292	DDI-false	Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, @DRUG$, antihistaminics, or @DRUG$.
1293	DDI-false	Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, @DRUG$, or @DRUG$.
1294	DDI-effect	Use of @DRUG$ in conjunction with oral @DRUG$ may increase the risk of respiratory depression, hypotension and profound sedation or coma.
1295	DDI-false	Interaction with @DRUG$: @DRUG$ (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.
1296	DDI-false	Interaction with @DRUG$: Agonist/antagonist analgesics (i.e., @DRUG$, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.
1297	DDI-false	Interaction with @DRUG$: Agonist/antagonist analgesics (i.e., pentazocine, @DRUG$, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.
1298	DDI-false	Interaction with @DRUG$: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, @DRUG$, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.
1299	DDI-false	Interaction with @DRUG$: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or @DRUG$) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.
1300	DDI-false	Interaction with @DRUG$: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof @DRUG$.
1301	DDI-false	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: @DRUG$ (i.e., @DRUG$, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.
1302	DDI-false	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: @DRUG$ (i.e., pentazocine, @DRUG$, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.
1303	DDI-false	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: @DRUG$ (i.e., pentazocine, nalbuphine, @DRUG$, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.
1304	DDI-false	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: @DRUG$ (i.e., pentazocine, nalbuphine, butorphanol, or @DRUG$) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.
1305	DDI-advise	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: @DRUG$ (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof @DRUG$.
1306	DDI-false	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., @DRUG$, @DRUG$, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.
1307	DDI-false	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., @DRUG$, nalbuphine, @DRUG$, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.
1308	DDI-false	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., @DRUG$, nalbuphine, butorphanol, or @DRUG$) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.
1309	DDI-advise	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., @DRUG$, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof @DRUG$.
1310	DDI-false	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, @DRUG$, @DRUG$, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.
1311	DDI-false	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, @DRUG$, butorphanol, or @DRUG$) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.
1312	DDI-advise	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, @DRUG$, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof @DRUG$.
1313	DDI-false	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, @DRUG$, or @DRUG$) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.
1314	DDI-advise	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, @DRUG$, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof @DRUG$.
1315	DDI-advise	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or @DRUG$) should NOT be administered to patients who have received or are receiving a course of therapy with a proof @DRUG$.
1316	DDI-effect	@DRUG$ may decrease the hypotensive effect of @DRUG$.
1317	DDI-mechanism	Human pharmacologic studies have shown that @DRUG$ may inhibit the metabolism of @DRUG$, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).
1318	DDI-mechanism	Human pharmacologic studies have shown that @DRUG$ may inhibit the metabolism of coumarin anticoagulants, @DRUG$ (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).
1319	DDI-mechanism	Human pharmacologic studies have shown that @DRUG$ may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (@DRUG$, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).
1320	DDI-mechanism	Human pharmacologic studies have shown that @DRUG$ may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, @DRUG$, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).
1321	DDI-mechanism	Human pharmacologic studies have shown that @DRUG$ may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, @DRUG$), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).
1322	DDI-mechanism	Human pharmacologic studies have shown that @DRUG$ may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), @DRUG$, and tricyclic drugs (imipramine, clomipramine, desipramine).
1323	DDI-mechanism	Human pharmacologic studies have shown that @DRUG$ may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and @DRUG$ (imipramine, clomipramine, desipramine).
1324	DDI-mechanism	Human pharmacologic studies have shown that @DRUG$ may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (@DRUG$, clomipramine, desipramine).
1325	DDI-mechanism	Human pharmacologic studies have shown that @DRUG$ may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, @DRUG$, desipramine).
1326	DDI-mechanism	Human pharmacologic studies have shown that @DRUG$ may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, @DRUG$).
1327	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of @DRUG$, @DRUG$ (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).
1328	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of @DRUG$, anticonvulsants (@DRUG$, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).
1329	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of @DRUG$, anticonvulsants (phenobarbital, @DRUG$, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).
1330	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of @DRUG$, anticonvulsants (phenobarbital, diphenylhydantoin, @DRUG$), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).
1331	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of @DRUG$, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), @DRUG$, and tricyclic drugs (imipramine, clomipramine, desipramine).
1332	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of @DRUG$, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and @DRUG$ (imipramine, clomipramine, desipramine).
1333	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of @DRUG$, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (@DRUG$, clomipramine, desipramine).
1334	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of @DRUG$, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, @DRUG$, desipramine).
1335	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of @DRUG$, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, @DRUG$).
1336	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, @DRUG$ (@DRUG$, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).
1337	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, @DRUG$ (phenobarbital, @DRUG$, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).
1338	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, @DRUG$ (phenobarbital, diphenylhydantoin, @DRUG$), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).
1339	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, @DRUG$ (phenobarbital, diphenylhydantoin, primidone), @DRUG$, and tricyclic drugs (imipramine, clomipramine, desipramine).
1340	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, @DRUG$ (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and @DRUG$ (imipramine, clomipramine, desipramine).
1341	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, @DRUG$ (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (@DRUG$, clomipramine, desipramine).
1342	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, @DRUG$ (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, @DRUG$, desipramine).
1343	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, @DRUG$ (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, @DRUG$).
1344	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (@DRUG$, @DRUG$, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).
1345	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (@DRUG$, diphenylhydantoin, @DRUG$), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).
1346	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (@DRUG$, diphenylhydantoin, primidone), @DRUG$, and tricyclic drugs (imipramine, clomipramine, desipramine).
1347	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (@DRUG$, diphenylhydantoin, primidone), phenylbutazone, and @DRUG$ (imipramine, clomipramine, desipramine).
1348	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (@DRUG$, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (@DRUG$, clomipramine, desipramine).
1349	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (@DRUG$, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, @DRUG$, desipramine).
1350	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (@DRUG$, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, @DRUG$).
1351	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, @DRUG$, @DRUG$), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).
1352	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, @DRUG$, primidone), @DRUG$, and tricyclic drugs (imipramine, clomipramine, desipramine).
1353	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, @DRUG$, primidone), phenylbutazone, and @DRUG$ (imipramine, clomipramine, desipramine).
1354	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, @DRUG$, primidone), phenylbutazone, and tricyclic drugs (@DRUG$, clomipramine, desipramine).
1355	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, @DRUG$, primidone), phenylbutazone, and tricyclic drugs (imipramine, @DRUG$, desipramine).
1356	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, @DRUG$, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, @DRUG$).
1357	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, @DRUG$), @DRUG$, and tricyclic drugs (imipramine, clomipramine, desipramine).
1358	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, @DRUG$), phenylbutazone, and @DRUG$ (imipramine, clomipramine, desipramine).
1359	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, @DRUG$), phenylbutazone, and tricyclic drugs (@DRUG$, clomipramine, desipramine).
1360	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, @DRUG$), phenylbutazone, and tricyclic drugs (imipramine, @DRUG$, desipramine).
1361	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, @DRUG$), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, @DRUG$).
1362	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), @DRUG$, and @DRUG$ (imipramine, clomipramine, desipramine).
1363	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), @DRUG$, and tricyclic drugs (@DRUG$, clomipramine, desipramine).
1364	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), @DRUG$, and tricyclic drugs (imipramine, @DRUG$, desipramine).
1365	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), @DRUG$, and tricyclic drugs (imipramine, clomipramine, @DRUG$).
1366	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and @DRUG$ (@DRUG$, clomipramine, desipramine).
1367	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and @DRUG$ (imipramine, @DRUG$, desipramine).
1368	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and @DRUG$ (imipramine, clomipramine, @DRUG$).
1369	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (@DRUG$, @DRUG$, desipramine).
1370	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (@DRUG$, clomipramine, @DRUG$).
1371	DDI-false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, @DRUG$, @DRUG$).
1372	DDI-false	The safety of using @DRUG$ in combination with @DRUG$ or other centrally acting alpha-2 agonists has not been systemically evaluated.
1373	DDI-false	The safety of using @DRUG$ in combination with clonidine or other centrally acting @DRUG$ has not been systemically evaluated.
1374	DDI-false	The safety of using methylphenidate in combination with @DRUG$ or other centrally acting @DRUG$ has not been systemically evaluated.
1375	DDI-mechanism	Co-administration of @DRUG$ with strong inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
1376	DDI-mechanism	Co-administration of @DRUG$ with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
1377	DDI-mechanism	Co-administration of @DRUG$ with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
1378	DDI-mechanism	Co-administration of @DRUG$ with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, @DRUG$, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
1379	DDI-mechanism	Co-administration of @DRUG$ with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
1380	DDI-mechanism	Co-administration of @DRUG$ with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
1381	DDI-mechanism	Co-administration of @DRUG$ with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
1382	DDI-mechanism	Co-administration of @DRUG$ with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
1383	DDI-mechanism	Co-administration of @DRUG$ with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin, voriconizole) may increases sunitinib concentrations.
1384	DDI-mechanism	Co-administration of @DRUG$ with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$, voriconizole) may increases sunitinib concentrations.
1385	DDI-mechanism	Co-administration of @DRUG$ with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, @DRUG$) may increases sunitinib concentrations.
1386	DDI-false	Co-administration of @DRUG$ with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases @DRUG$ concentrations.
1387	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., @DRUG$, @DRUG$, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
1388	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, @DRUG$, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
1389	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, clarithromycin, @DRUG$, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
1390	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, clarithromycin, atazanavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
1391	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, clarithromycin, atazanavir, indinavir, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
1392	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
1393	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
1394	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin, voriconizole) may increases sunitinib concentrations.
1395	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$, voriconizole) may increases sunitinib concentrations.
1396	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, @DRUG$) may increases sunitinib concentrations.
1397	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases @DRUG$ concentrations.
1398	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, @DRUG$, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
1399	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, clarithromycin, @DRUG$, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
1400	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, clarithromycin, atazanavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
1401	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, clarithromycin, atazanavir, indinavir, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
1402	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, clarithromycin, atazanavir, indinavir, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
1403	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
1404	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin, voriconizole) may increases sunitinib concentrations.
1405	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$, voriconizole) may increases sunitinib concentrations.
1406	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, @DRUG$) may increases sunitinib concentrations.
1407	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases @DRUG$ concentrations.
1408	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, @DRUG$, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
1409	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, atazanavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
1410	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, atazanavir, indinavir, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
1411	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, atazanavir, indinavir, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
1412	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, atazanavir, indinavir, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
1413	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin, voriconizole) may increases sunitinib concentrations.
1414	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$, voriconizole) may increases sunitinib concentrations.
1415	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, @DRUG$) may increases sunitinib concentrations.
1416	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases @DRUG$ concentrations.
1417	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, @DRUG$, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
1418	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, @DRUG$, indinavir, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
1419	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, @DRUG$, indinavir, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
1420	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, @DRUG$, indinavir, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
1421	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, @DRUG$, indinavir, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin, voriconizole) may increases sunitinib concentrations.
1422	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, @DRUG$, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$, voriconizole) may increases sunitinib concentrations.
1423	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, @DRUG$, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, @DRUG$) may increases sunitinib concentrations.
1424	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, @DRUG$, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases @DRUG$ concentrations.
1425	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, @DRUG$, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
1426	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, @DRUG$, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
1427	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, @DRUG$, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
1428	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, @DRUG$, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin, voriconizole) may increases sunitinib concentrations.
1429	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$, voriconizole) may increases sunitinib concentrations.
1430	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, @DRUG$) may increases sunitinib concentrations.
1431	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases @DRUG$ concentrations.
1432	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, @DRUG$, @DRUG$, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
1433	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, @DRUG$, nelfinavir, @DRUG$, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
1434	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, @DRUG$, nelfinavir, ritonavir, @DRUG$, telithromycin, voriconizole) may increases sunitinib concentrations.
1435	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, @DRUG$, nelfinavir, ritonavir, saquinavir, @DRUG$, voriconizole) may increases sunitinib concentrations.
1436	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin, @DRUG$) may increases sunitinib concentrations.
1437	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases @DRUG$ concentrations.
1438	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, @DRUG$, @DRUG$, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
1439	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, @DRUG$, ritonavir, @DRUG$, telithromycin, voriconizole) may increases sunitinib concentrations.
1440	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, @DRUG$, ritonavir, saquinavir, @DRUG$, voriconizole) may increases sunitinib concentrations.
1441	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin, @DRUG$) may increases sunitinib concentrations.
1442	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin, voriconizole) may increases @DRUG$ concentrations.
1443	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, @DRUG$, @DRUG$, telithromycin, voriconizole) may increases sunitinib concentrations.
1444	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, @DRUG$, saquinavir, @DRUG$, voriconizole) may increases sunitinib concentrations.
1445	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin, @DRUG$) may increases sunitinib concentrations.
1446	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin, voriconizole) may increases @DRUG$ concentrations.
1447	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, @DRUG$, @DRUG$, voriconizole) may increases sunitinib concentrations.
1448	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin, @DRUG$) may increases sunitinib concentrations.
1449	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin, voriconizole) may increases @DRUG$ concentrations.
1450	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$, @DRUG$) may increases sunitinib concentrations.
1451	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$, voriconizole) may increases @DRUG$ concentrations.
1452	DDI-false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, @DRUG$) may increases @DRUG$ concentrations.
1453	DDI-mechanism	Co-administration of @DRUG$ with inducers of the CYP3A4 family (e.g., @DRUG$, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.
1454	DDI-mechanism	Co-administration of @DRUG$ with inducers of the CYP3A4 family (e.g., dexamethasone, @DRUG$, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.
1455	DDI-mechanism	Co-administration of @DRUG$ with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, @DRUG$, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.
1456	DDI-mechanism	Co-administration of @DRUG$ with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, @DRUG$, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.
1457	DDI-mechanism	Co-administration of @DRUG$ with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, @DRUG$, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.
1458	DDI-mechanism	Co-administration of @DRUG$ with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, @DRUG$, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.
1459	DDI-mechanism	Co-administration of @DRUG$ with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, @DRUG$, St. Johns Wort) may decrease sunitinib concentrations.
1460	DDI-false	Co-administration of @DRUG$ with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease @DRUG$ concentrations.
1461	DDI-false	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., @DRUG$, @DRUG$, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.
1462	DDI-false	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., @DRUG$, phenytoin, @DRUG$, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.
1463	DDI-false	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., @DRUG$, phenytoin, carbamazepine, @DRUG$, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.
1464	DDI-false	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., @DRUG$, phenytoin, carbamazepine, rifampin, @DRUG$, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.
1465	DDI-false	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., @DRUG$, phenytoin, carbamazepine, rifampin, rifabutin, @DRUG$, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.
1466	DDI-false	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., @DRUG$, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, @DRUG$, St. Johns Wort) may decrease sunitinib concentrations.
1467	DDI-false	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., @DRUG$, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease @DRUG$ concentrations.
1468	DDI-false	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, @DRUG$, @DRUG$, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.
1469	DDI-false	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, @DRUG$, carbamazepine, @DRUG$, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.
1470	DDI-false	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, @DRUG$, carbamazepine, rifampin, @DRUG$, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.
1471	DDI-false	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, @DRUG$, carbamazepine, rifampin, rifabutin, @DRUG$, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.
1472	DDI-false	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, @DRUG$, carbamazepine, rifampin, rifabutin, rifapentin, @DRUG$, St. Johns Wort) may decrease sunitinib concentrations.
1473	DDI-false	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, @DRUG$, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease @DRUG$ concentrations.
1474	DDI-false	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, @DRUG$, @DRUG$, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.
1475	DDI-false	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, @DRUG$, rifampin, @DRUG$, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.
1476	DDI-false	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, @DRUG$, rifampin, rifabutin, @DRUG$, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.
1477	DDI-false	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, @DRUG$, rifampin, rifabutin, rifapentin, @DRUG$, St. Johns Wort) may decrease sunitinib concentrations.
1478	DDI-false	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, @DRUG$, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease @DRUG$ concentrations.
1479	DDI-false	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, @DRUG$, @DRUG$, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.
1480	DDI-false	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, @DRUG$, rifabutin, @DRUG$, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.
1481	DDI-false	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, @DRUG$, rifabutin, rifapentin, @DRUG$, St. Johns Wort) may decrease sunitinib concentrations.
1482	DDI-false	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, @DRUG$, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease @DRUG$ concentrations.
1483	DDI-false	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, @DRUG$, @DRUG$, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.
1484	DDI-false	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, @DRUG$, rifapentin, @DRUG$, St. Johns Wort) may decrease sunitinib concentrations.
1485	DDI-false	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, @DRUG$, rifapentin, phenobarbital, St. Johns Wort) may decrease @DRUG$ concentrations.
1486	DDI-false	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, @DRUG$, @DRUG$, St. Johns Wort) may decrease sunitinib concentrations.
1487	DDI-false	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, @DRUG$, phenobarbital, St. Johns Wort) may decrease @DRUG$ concentrations.
1488	DDI-false	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, @DRUG$, St. Johns Wort) may decrease @DRUG$ concentrations.
1489	DDI-false	@DRUG$: Excessive reductions in blood pressure may occur in patients on diuretic therapy when @DRUG$ are started.
1490	DDI-false	The possibility of hypotensive effects with @DRUG$    can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with @DRUG$   . If this is not possible, the starting dose of moexpril should be reduced..
1491	DDI-false	The possibility of hypotensive effects with @DRUG$    can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with UNIVASC   . If this is not possible, the starting dose of @DRUG$ should be reduced..
1492	DDI-false	The possibility of hypotensive effects with UNIVASC    can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with @DRUG$   . If this is not possible, the starting dose of @DRUG$ should be reduced..
1493	DDI-false	@DRUG$    has been used in clinical trials concomitantly with @DRUG$, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents.
1494	DDI-false	@DRUG$    has been used in clinical trials concomitantly with calcium-channel-blocking agents, @DRUG$, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents.
1495	DDI-false	@DRUG$    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, @DRUG$, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents.
1496	DDI-false	@DRUG$    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, @DRUG$, oral hypoglycemic agents, and cholesterol-lowering agents.
1497	DDI-false	@DRUG$    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral @DRUG$, and cholesterol-lowering agents.
1498	DDI-false	UNIVASC    has been used in clinical trials concomitantly with @DRUG$, @DRUG$, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents.
1499	DDI-false	UNIVASC    has been used in clinical trials concomitantly with @DRUG$, diuretics, @DRUG$, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents.
1500	DDI-false	UNIVASC    has been used in clinical trials concomitantly with @DRUG$, diuretics, H2 blockers, @DRUG$, oral hypoglycemic agents, and cholesterol-lowering agents.
1501	DDI-false	UNIVASC    has been used in clinical trials concomitantly with @DRUG$, diuretics, H2 blockers, digoxin, oral @DRUG$, and cholesterol-lowering agents.
1502	DDI-false	UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, @DRUG$, @DRUG$, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents.
1503	DDI-false	UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, @DRUG$, H2 blockers, @DRUG$, oral hypoglycemic agents, and cholesterol-lowering agents.
1504	DDI-false	UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, @DRUG$, H2 blockers, digoxin, oral @DRUG$, and cholesterol-lowering agents.
1505	DDI-false	UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, @DRUG$, @DRUG$, oral hypoglycemic agents, and cholesterol-lowering agents.
1506	DDI-false	UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, @DRUG$, digoxin, oral @DRUG$, and cholesterol-lowering agents.
1507	DDI-false	UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, @DRUG$, oral @DRUG$, and cholesterol-lowering agents.
1508	DDI-false	@DRUG$ Supplements and @DRUG$: UNIVASC    can increase serum potassium because it decreases aldosterone secretion.
1509	DDI-false	@DRUG$ Supplements and Potassium-Sparing Diuretics: @DRUG$    can increase serum potassium because it decreases aldosterone secretion.
1510	DDI-false	Potassium Supplements and @DRUG$: @DRUG$    can increase serum potassium because it decreases aldosterone secretion.
1511	DDI-false	Use of @DRUG$ (@DRUG$, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.
1512	DDI-false	Use of @DRUG$ (spironolactone, @DRUG$, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.
1513	DDI-false	Use of @DRUG$ (spironolactone, triamterene, @DRUG$) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.
1514	DDI-false	Use of @DRUG$ (spironolactone, triamterene, amiloride) or @DRUG$ supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.
1515	DDI-effect	Use of @DRUG$ (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with @DRUG$ can increase the risk of hyperkalemia.
1516	DDI-false	Use of potassium-sparing diuretics (@DRUG$, @DRUG$, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.
1517	DDI-false	Use of potassium-sparing diuretics (@DRUG$, triamterene, @DRUG$) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.
1518	DDI-false	Use of potassium-sparing diuretics (@DRUG$, triamterene, amiloride) or @DRUG$ supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.
1519	DDI-effect	Use of potassium-sparing diuretics (@DRUG$, triamterene, amiloride) or potassium supplements concomitantly with @DRUG$ can increase the risk of hyperkalemia.
1520	DDI-false	Use of potassium-sparing diuretics (spironolactone, @DRUG$, @DRUG$) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.
1521	DDI-false	Use of potassium-sparing diuretics (spironolactone, @DRUG$, amiloride) or @DRUG$ supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.
1522	DDI-effect	Use of potassium-sparing diuretics (spironolactone, @DRUG$, amiloride) or potassium supplements concomitantly with @DRUG$ can increase the risk of hyperkalemia.
1523	DDI-false	Use of potassium-sparing diuretics (spironolactone, triamterene, @DRUG$) or @DRUG$ supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.
1524	DDI-effect	Use of potassium-sparing diuretics (spironolactone, triamterene, @DRUG$) or potassium supplements concomitantly with @DRUG$ can increase the risk of hyperkalemia.
1525	DDI-effect	Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or @DRUG$ supplements concomitantly with @DRUG$ can increase the risk of hyperkalemia.
1526	DDI-false	Oral @DRUG$: Interaction studies with @DRUG$ failed to identify any clinically important effect on the serum concentrations of the anticoagulant or on its anticoagulant effect.
1527	DDI-false	Oral @DRUG$: Interaction studies with warfarin failed to identify any clinically important effect on the serum concentrations of the @DRUG$ or on its anticoagulant effect.
1528	DDI-false	Oral Anticoagulants: Interaction studies with @DRUG$ failed to identify any clinically important effect on the serum concentrations of the @DRUG$ or on its anticoagulant effect.
1529	DDI-false	@DRUG$: Increased serum @DRUG$ levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.
1530	DDI-false	@DRUG$: Increased serum lithium levels and symptoms of @DRUG$ toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.
1531	DDI-false	@DRUG$: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving @DRUG$ during therapy with lithium.
1532	DDI-false	@DRUG$: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with @DRUG$.
1533	DDI-false	Lithium: Increased serum @DRUG$ levels and symptoms of @DRUG$ toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.
1534	DDI-false	Lithium: Increased serum @DRUG$ levels and symptoms of lithium toxicity have been reported in patients receiving @DRUG$ during therapy with lithium.
1535	DDI-false	Lithium: Increased serum @DRUG$ levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with @DRUG$.
1536	DDI-false	Lithium: Increased serum lithium levels and symptoms of @DRUG$ toxicity have been reported in patients receiving @DRUG$ during therapy with lithium.
1537	DDI-false	Lithium: Increased serum lithium levels and symptoms of @DRUG$ toxicity have been reported in patients receiving ACE inhibitors during therapy with @DRUG$.
1538	DDI-effect	Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving @DRUG$ during therapy with @DRUG$.
1539	DDI-effect	If a @DRUG$ is also used, the risk of @DRUG$ toxicity may be increased.
1540	DDI-false	Other Agents: No clinically important pharmacokinetic interactions occurred when @DRUG$    was administered concomitantly with @DRUG$, digoxin, or cimetidine.
1541	DDI-false	Other Agents: No clinically important pharmacokinetic interactions occurred when @DRUG$    was administered concomitantly with hydrochlorothiazide, @DRUG$, or cimetidine.
1542	DDI-false	Other Agents: No clinically important pharmacokinetic interactions occurred when @DRUG$    was administered concomitantly with hydrochlorothiazide, digoxin, or @DRUG$.
1543	DDI-false	Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC    was administered concomitantly with @DRUG$, @DRUG$, or cimetidine.
1544	DDI-false	Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC    was administered concomitantly with @DRUG$, digoxin, or @DRUG$.
1545	DDI-false	Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC    was administered concomitantly with hydrochlorothiazide, @DRUG$, or @DRUG$.
1546	DDI-mechanism	Concomitant administration of substances that are also tubularly secreted (e.g., @DRUG$) could potentially result in delayed clearance of @DRUG$.
1547	DDI-false	Although @DRUG$ (400 mg qid) can be administered with @DRUG$ in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering ibuprofen concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min).
1548	DDI-false	Although @DRUG$ (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering @DRUG$ concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min).
1549	DDI-false	Although @DRUG$ (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering ibuprofen concurrently with @DRUG$ to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min).
1550	DDI-false	Although ibuprofen (400 mg qid) can be administered with @DRUG$ in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering @DRUG$ concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min).
1551	DDI-false	Although ibuprofen (400 mg qid) can be administered with @DRUG$ in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering ibuprofen concurrently with @DRUG$ to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min).
1552	DDI-advise	Although ibuprofen (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering @DRUG$ concurrently with @DRUG$ to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min).
1553	DDI-advise	Patients with mild to moderate renal insufficiency should avoid taking @DRUG$ with short elimination half-lives for a period of 2 days before, the day of, and 2 days following administration of @DRUG$.
1554	DDI-false	In the absence of data regarding potential interaction between @DRUG$ and @DRUG$ with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following ALIMTA administration.
1555	DDI-false	In the absence of data regarding potential interaction between @DRUG$ and NSAIDs with longer half-lives, all patients taking these @DRUG$ should interrupt dosing for at least 5 days before, the day of, and 2 days following ALIMTA administration.
1556	DDI-false	In the absence of data regarding potential interaction between @DRUG$ and NSAIDs with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following @DRUG$ administration.
1557	DDI-false	In the absence of data regarding potential interaction between ALIMTA and @DRUG$ with longer half-lives, all patients taking these @DRUG$ should interrupt dosing for at least 5 days before, the day of, and 2 days following ALIMTA administration.
1558	DDI-false	In the absence of data regarding potential interaction between ALIMTA and @DRUG$ with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following @DRUG$ administration.
1559	DDI-advise	In the absence of data regarding potential interaction between ALIMTA and NSAIDs with longer half-lives, all patients taking these @DRUG$ should interrupt dosing for at least 5 days before, the day of, and 2 days following @DRUG$ administration.
1560	DDI-advise	Prothrombin time or other suitable anticoagulation test should be monitored if @DRUG$ is administered with @DRUG$.
1561	DDI-effect	Concurrent use of @DRUG$ with oral @DRUG$ may render oral contraceptives less effective.
1562	DDI-false	Concurrent use of @DRUG$ with oral contraceptives may render oral @DRUG$ less effective.
1563	DDI-false	Concurrent use of antibacterial drugs with oral @DRUG$ may render oral @DRUG$ less effective.
1564	DDI-int	@DRUG$ may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1565	DDI-int	@DRUG$ may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1566	DDI-false	@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1567	DDI-int	@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1568	DDI-false	@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1569	DDI-int	@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1570	DDI-false	@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1571	DDI-int	@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1572	DDI-int	@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1573	DDI-false	@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1574	DDI-false	@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1575	DDI-int	@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1576	DDI-int	@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1577	DDI-false	@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids).
1578	DDI-false	@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids).
1579	DDI-false	@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$).
1580	DDI-false	Melatonin may interact with the following drugs: @DRUG$ and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1581	DDI-false	Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1582	DDI-false	Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1583	DDI-false	Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1584	DDI-false	Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1585	DDI-false	Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1586	DDI-false	Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1587	DDI-false	Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1588	DDI-false	Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1589	DDI-false	Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1590	DDI-false	Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1591	DDI-false	Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1592	DDI-false	Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids).
1593	DDI-false	Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids).
1594	DDI-false	Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$).
1595	DDI-false	Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1596	DDI-false	Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1597	DDI-false	Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1598	DDI-false	Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1599	DDI-false	Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1600	DDI-false	Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1601	DDI-false	Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1602	DDI-false	Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1603	DDI-false	Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1604	DDI-false	Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1605	DDI-false	Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1606	DDI-false	Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids).
1607	DDI-false	Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids).
1608	DDI-false	Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$).
1609	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1610	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1611	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1612	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1613	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1614	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1615	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1616	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1617	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1618	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1619	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids).
1620	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids).
1621	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$).
1622	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1623	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1624	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1625	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1626	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1627	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1628	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1629	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1630	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1631	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids).
1632	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids).
1633	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$).
1634	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1635	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1636	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1637	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1638	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1639	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1640	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1641	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1642	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids).
1643	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids).
1644	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$).
1645	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1646	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1647	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1648	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1649	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1650	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1651	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1652	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids).
1653	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids).
1654	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$).
1655	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1656	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1657	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1658	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1659	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1660	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1661	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids).
1662	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids).
1663	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$).
1664	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1665	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1666	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1667	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1668	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1669	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids).
1670	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids).
1671	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$).
1672	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1673	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1674	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1675	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1676	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids).
1677	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids).
1678	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$).
1679	DDI-effect	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1680	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1681	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1682	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids).
1683	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids).
1684	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$).
1685	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1686	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1687	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids).
1688	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids).
1689	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$).
1690	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
1691	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids).
1692	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids).
1693	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$).
1694	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids).
1695	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids).
1696	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$).
1697	DDI-effect	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and @DRUG$ may interfere with the efficacy of the corticosteroids).
1698	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the @DRUG$).
1699	DDI-false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the @DRUG$).
1700	DDI-false	In vitro studies with human liver microsomes showed that @DRUG$ does not inhibit the metabolism of @DRUG$, ethinylestradiol, ethoxycoumarin, and cyclosporine.
1701	DDI-false	In vitro studies with human liver microsomes showed that @DRUG$ does not inhibit the metabolism of tolbutamide, @DRUG$, ethoxycoumarin, and cyclosporine.
1702	DDI-false	In vitro studies with human liver microsomes showed that @DRUG$ does not inhibit the metabolism of tolbutamide, ethinylestradiol, @DRUG$, and cyclosporine.
1703	DDI-false	In vitro studies with human liver microsomes showed that @DRUG$ does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and @DRUG$.
1704	DDI-false	In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of @DRUG$, @DRUG$, ethoxycoumarin, and cyclosporine.
1705	DDI-false	In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of @DRUG$, ethinylestradiol, @DRUG$, and cyclosporine.
1706	DDI-false	In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of @DRUG$, ethinylestradiol, ethoxycoumarin, and @DRUG$.
1707	DDI-false	In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, @DRUG$, @DRUG$, and cyclosporine.
1708	DDI-false	In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, @DRUG$, ethoxycoumarin, and @DRUG$.
1709	DDI-false	In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, @DRUG$, and @DRUG$.
1710	DDI-false	This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as @DRUG$,    -blockers, @DRUG$ (SSRIs), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window.
1711	DDI-false	This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as @DRUG$,    -blockers, selective serotonin reuptake inhibitors (@DRUG$), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window.
1712	DDI-false	This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as @DRUG$,    -blockers, selective serotonin reuptake inhibitors (SSRIs), and @DRUG$, if they have a narrow therapeutic window.
1713	DDI-false	This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, @DRUG$ (@DRUG$), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window.
1714	DDI-false	This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, @DRUG$ (SSRIs), and @DRUG$, if they have a narrow therapeutic window.
1715	DDI-false	This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, selective serotonin reuptake inhibitors (@DRUG$), and @DRUG$, if they have a narrow therapeutic window.
1716	DDI-false	In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that @DRUG$ does not affect the clearance of @DRUG$ or digoxin.
1717	DDI-false	In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that @DRUG$ does not affect the clearance of antipyrine or @DRUG$.
1718	DDI-false	In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that terbinafine does not affect the clearance of @DRUG$ or @DRUG$.
1719	DDI-mechanism	@DRUG$ decreases the clearance of @DRUG$ by 19%.
1720	DDI-mechanism	@DRUG$ increases the clearance of @DRUG$ by 15%.
1721	DDI-effect	There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral @DRUG$ and @DRUG$, however, a causal relationship between LAMISIL    Tablets and these changes has not been established.
1722	DDI-false	There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral @DRUG$ and warfarin, however, a causal relationship between @DRUG$    Tablets and these changes has not been established.
1723	DDI-false	There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and @DRUG$, however, a causal relationship between @DRUG$    Tablets and these changes has not been established.
1724	DDI-mechanism	@DRUG$ clearance is increased 100% by @DRUG$, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor.
1725	DDI-mechanism	@DRUG$ clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by @DRUG$, a CyP450 enzyme inhibitor.
1726	DDI-false	Terbinafine clearance is increased 100% by @DRUG$, a CyP450 enzyme inducer, and decreased 33% by @DRUG$, a CyP450 enzyme inhibitor.
1727	DDI-false	@DRUG$ clearance is unaffected by @DRUG$.
1728	DDI-false	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral @DRUG$, hormone replacement therapies, @DRUG$, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.
1729	DDI-false	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral @DRUG$, hormone replacement therapies, hypoglycemics, @DRUG$, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.
1730	DDI-false	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral @DRUG$, hormone replacement therapies, hypoglycemics, theophyllines, @DRUG$, thiazide diuretics, beta blockers, and calcium channel blockers.
1731	DDI-false	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral @DRUG$, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, @DRUG$, beta blockers, and calcium channel blockers.
1732	DDI-false	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral @DRUG$, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, @DRUG$, and calcium channel blockers.
1733	DDI-false	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral @DRUG$, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and @DRUG$.
1734	DDI-false	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, @DRUG$, @DRUG$, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.
1735	DDI-false	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, @DRUG$, theophyllines, @DRUG$, thiazide diuretics, beta blockers, and calcium channel blockers.
1736	DDI-false	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, @DRUG$, theophyllines, phenytoins, @DRUG$, beta blockers, and calcium channel blockers.
1737	DDI-false	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, @DRUG$, theophyllines, phenytoins, thiazide diuretics, @DRUG$, and calcium channel blockers.
1738	DDI-false	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, @DRUG$, theophyllines, phenytoins, thiazide diuretics, beta blockers, and @DRUG$.
1739	DDI-false	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, @DRUG$, @DRUG$, thiazide diuretics, beta blockers, and calcium channel blockers.
1740	DDI-false	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, @DRUG$, phenytoins, @DRUG$, beta blockers, and calcium channel blockers.
1741	DDI-false	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, @DRUG$, phenytoins, thiazide diuretics, @DRUG$, and calcium channel blockers.
1742	DDI-false	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, @DRUG$, phenytoins, thiazide diuretics, beta blockers, and @DRUG$.
1743	DDI-false	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, @DRUG$, @DRUG$, beta blockers, and calcium channel blockers.
1744	DDI-false	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, @DRUG$, thiazide diuretics, @DRUG$, and calcium channel blockers.
1745	DDI-false	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, @DRUG$, thiazide diuretics, beta blockers, and @DRUG$.
1746	DDI-false	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, @DRUG$, @DRUG$, and calcium channel blockers.
1747	DDI-false	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, @DRUG$, beta blockers, and @DRUG$.
1748	DDI-false	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, @DRUG$, and @DRUG$.
1749	DDI-mechanism	@DRUG$ has been reported to prolong the elimination half-life of @DRUG$ and may lead to severe bone marrow suppression;
1750	DDI-advise	a reduction of the @DRUG$ dosage should be considered in patients receiving @DRUG$ concurrently.
1751	DDI-effect	The concurrent use of @DRUG$ and @DRUG$ has been reported in one case to result in reduced streptozocin cytotoxicity.
1752	DDI-false	The concurrent use of @DRUG$ and phenytoin has been reported in one case to result in reduced @DRUG$ cytotoxicity.
1753	DDI-false	The concurrent use of streptozocin and @DRUG$ has been reported in one case to result in reduced @DRUG$ cytotoxicity.
1754	DDI-false	@DRUG$: @DRUG$ causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA.
1755	DDI-false	@DRUG$: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of @DRUG$ and should not be coadministered with EVISTA.
1756	DDI-false	@DRUG$: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with @DRUG$.
1757	DDI-mechanism	Cholestyramine: @DRUG$ causes a 60% reduction in the absorption and enterohepatic cycling of @DRUG$ and should not be coadministered with EVISTA.
1758	DDI-advise	Cholestyramine: @DRUG$ causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with @DRUG$.
1759	DDI-false	Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of @DRUG$ and should not be coadministered with @DRUG$.
1760	DDI-false	@DRUG$: The coadministration of @DRUG$ and warfarin has not been assessed under chronic conditions.
1761	DDI-false	@DRUG$: The coadministration of EVISTA and @DRUG$ has not been assessed under chronic conditions.
1762	DDI-false	Warfarin: The coadministration of @DRUG$ and @DRUG$ has not been assessed under chronic conditions.
1763	DDI-advise	If @DRUG$ is given concurrently with @DRUG$, prothrombin time should be monitored.
1764	DDI-false	In vitro, @DRUG$ did not affect the binding of @DRUG$, phenytoin, or tamoxifen.
1765	DDI-false	In vitro, @DRUG$ did not affect the binding of warfarin, @DRUG$, or tamoxifen.
1766	DDI-false	In vitro, @DRUG$ did not affect the binding of warfarin, phenytoin, or @DRUG$.
1767	DDI-false	In vitro, raloxifene did not affect the binding of @DRUG$, @DRUG$, or tamoxifen.
1768	DDI-false	In vitro, raloxifene did not affect the binding of @DRUG$, phenytoin, or @DRUG$.
1769	DDI-false	In vitro, raloxifene did not affect the binding of warfarin, @DRUG$, or @DRUG$.
1770	DDI-advise	Caution should be used when @DRUG$ is coadministered with other highly protein-bound drugs, such as @DRUG$, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide.
1771	DDI-advise	Caution should be used when @DRUG$ is coadministered with other highly protein-bound drugs, such as clofibrate, @DRUG$, naproxen, ibuprofen, diazepam, and diazoxide.
1772	DDI-advise	Caution should be used when @DRUG$ is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, @DRUG$, ibuprofen, diazepam, and diazoxide.
1773	DDI-advise	Caution should be used when @DRUG$ is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, @DRUG$, diazepam, and diazoxide.
1774	DDI-advise	Caution should be used when @DRUG$ is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, @DRUG$, and diazoxide.
1775	DDI-advise	Caution should be used when @DRUG$ is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and @DRUG$.
1776	DDI-false	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as @DRUG$, @DRUG$, naproxen, ibuprofen, diazepam, and diazoxide.
1777	DDI-false	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as @DRUG$, indomethacin, @DRUG$, ibuprofen, diazepam, and diazoxide.
1778	DDI-false	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as @DRUG$, indomethacin, naproxen, @DRUG$, diazepam, and diazoxide.
1779	DDI-false	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as @DRUG$, indomethacin, naproxen, ibuprofen, @DRUG$, and diazoxide.
1780	DDI-false	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as @DRUG$, indomethacin, naproxen, ibuprofen, diazepam, and @DRUG$.
1781	DDI-false	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, @DRUG$, @DRUG$, ibuprofen, diazepam, and diazoxide.
1782	DDI-false	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, @DRUG$, naproxen, @DRUG$, diazepam, and diazoxide.
1783	DDI-false	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, @DRUG$, naproxen, ibuprofen, @DRUG$, and diazoxide.
1784	DDI-false	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, @DRUG$, naproxen, ibuprofen, diazepam, and @DRUG$.
1785	DDI-false	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, @DRUG$, @DRUG$, diazepam, and diazoxide.
1786	DDI-false	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, @DRUG$, ibuprofen, @DRUG$, and diazoxide.
1787	DDI-false	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, @DRUG$, ibuprofen, diazepam, and @DRUG$.
1788	DDI-false	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, @DRUG$, @DRUG$, and diazoxide.
1789	DDI-false	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, @DRUG$, diazepam, and @DRUG$.
1790	DDI-false	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, @DRUG$, and @DRUG$.
1791	DDI-effect	@DRUG$ may increase the effects of @DRUG$, tolbutamide, and uricosurics.
1792	DDI-effect	@DRUG$ may increase the effects of barbiturates, @DRUG$, and uricosurics.
1793	DDI-effect	@DRUG$ may increase the effects of barbiturates, tolbutamide, and @DRUG$.
1794	DDI-false	Sulfamethizole may increase the effects of @DRUG$, @DRUG$, and uricosurics.
1795	DDI-false	Sulfamethizole may increase the effects of @DRUG$, tolbutamide, and @DRUG$.
1796	DDI-false	Sulfamethizole may increase the effects of barbiturates, @DRUG$, and @DRUG$.
1797	DDI-false	It may also interact with @DRUG$ (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).
1798	DDI-false	It may also interact with @DRUG$ (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).
1799	DDI-false	It may also interact with @DRUG$ (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).
1800	DDI-false	It may also interact with @DRUG$ (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), @DRUG$ (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).
1801	DDI-false	It may also interact with @DRUG$ (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of @DRUG$), phenytoin (decreased hepatic clearance of phenytoin).
1802	DDI-false	It may also interact with @DRUG$ (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), @DRUG$ (decreased hepatic clearance of phenytoin).
1803	DDI-false	It may also interact with @DRUG$ (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of @DRUG$).
1804	DDI-false	It may also interact with thiazides (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).
1805	DDI-false	It may also interact with thiazides (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).
1806	DDI-false	It may also interact with thiazides (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), @DRUG$ (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).
1807	DDI-false	It may also interact with thiazides (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of @DRUG$), phenytoin (decreased hepatic clearance of phenytoin).
1808	DDI-false	It may also interact with thiazides (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), @DRUG$ (decreased hepatic clearance of phenytoin).
1809	DDI-false	It may also interact with thiazides (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of @DRUG$).
1810	DDI-false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).
1811	DDI-false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), warfarin (increased anticoagulant effect), @DRUG$ (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).
1812	DDI-false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of @DRUG$), phenytoin (decreased hepatic clearance of phenytoin).
1813	DDI-false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), @DRUG$ (decreased hepatic clearance of phenytoin).
1814	DDI-false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of @DRUG$).
1815	DDI-false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), @DRUG$ (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).
1816	DDI-false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), methotrexate (decreased renal excretion of @DRUG$), phenytoin (decreased hepatic clearance of phenytoin).
1817	DDI-false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), @DRUG$ (decreased hepatic clearance of phenytoin).
1818	DDI-false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of @DRUG$).
1819	DDI-false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), @DRUG$ (decreased renal excretion of @DRUG$), phenytoin (decreased hepatic clearance of phenytoin).
1820	DDI-false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), @DRUG$ (decreased renal excretion of methotrexate), @DRUG$ (decreased hepatic clearance of phenytoin).
1821	DDI-false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), @DRUG$ (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of @DRUG$).
1822	DDI-false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of @DRUG$), @DRUG$ (decreased hepatic clearance of phenytoin).
1823	DDI-false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of @DRUG$), phenytoin (decreased hepatic clearance of @DRUG$).
1824	DDI-false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), @DRUG$ (decreased hepatic clearance of @DRUG$).
1825	DDI-false	@DRUG$, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);
1826	DDI-false	@DRUG$, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);
1827	DDI-false	@DRUG$, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);
1828	DDI-false	@DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$ ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);
1829	DDI-false	@DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or @DRUG$, ordinarily should not be administered concurrently with Permax (a dopamine agonist);
1830	DDI-advise	@DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with @DRUG$ (a dopamine agonist);
1831	DDI-false	@DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a @DRUG$);
1832	DDI-false	Dopamine antagonists, such as the @DRUG$ (@DRUG$, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);
1833	DDI-false	Dopamine antagonists, such as the @DRUG$ (phenothiazines, @DRUG$, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);
1834	DDI-false	Dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, @DRUG$ ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);
1835	DDI-false	Dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthines ) or @DRUG$, ordinarily should not be administered concurrently with Permax (a dopamine agonist);
1836	DDI-advise	Dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with @DRUG$ (a dopamine agonist);
1837	DDI-false	Dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a @DRUG$);
1838	DDI-false	Dopamine antagonists, such as the neuroleptics (@DRUG$, @DRUG$, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);
1839	DDI-false	Dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, @DRUG$ ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);
1840	DDI-false	Dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthines ) or @DRUG$, ordinarily should not be administered concurrently with Permax (a dopamine agonist);
1841	DDI-advise	Dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with @DRUG$ (a dopamine agonist);
1842	DDI-false	Dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a @DRUG$);
1843	DDI-false	Dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, @DRUG$ ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);
1844	DDI-false	Dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthines ) or @DRUG$, ordinarily should not be administered concurrently with Permax (a dopamine agonist);
1845	DDI-advise	Dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with @DRUG$ (a dopamine agonist);
1846	DDI-false	Dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a @DRUG$);
1847	DDI-false	Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$ ) or @DRUG$, ordinarily should not be administered concurrently with Permax (a dopamine agonist);
1848	DDI-advise	Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$ ) or metoclopramide, ordinarily should not be administered concurrently with @DRUG$ (a dopamine agonist);
1849	DDI-false	Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$ ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a @DRUG$);
1850	DDI-advise	Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or @DRUG$, ordinarily should not be administered concurrently with @DRUG$ (a dopamine agonist);
1851	DDI-false	Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or @DRUG$, ordinarily should not be administered concurrently with Permax (a @DRUG$);
1852	DDI-false	Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with @DRUG$ (a @DRUG$);
1853	DDI-false	Because @DRUG$ is approximately 90% bound to plasma proteins, caution should be exercised if @DRUG$ is coadministered with other drugs known to affect protein binding.
1854	DDI-mechanism	Drug Interactions: Women on oral @DRUG$ have shown a significant increase in plasma @DRUG$ levels.
1855	DDI-effect	The effects of @DRUG$ on gastrointestinal motility are antagonized by @DRUG$ and narcotic analgesics.
1856	DDI-effect	The effects of @DRUG$ on gastrointestinal motility are antagonized by anticholinergic drugs and @DRUG$.
1857	DDI-false	The effects of metoclopramide on gastrointestinal motility are antagonized by @DRUG$ and @DRUG$.
1858	DDI-effect	Additive sedative effects can occur when @DRUG$ is given with @DRUG$, sedatives, hypnotics, narcotics, or tranquilizers.
1859	DDI-effect	Additive sedative effects can occur when @DRUG$ is given with alcohol, @DRUG$, hypnotics, narcotics, or tranquilizers.
1860	DDI-effect	Additive sedative effects can occur when @DRUG$ is given with alcohol, sedatives, @DRUG$, narcotics, or tranquilizers.
1861	DDI-effect	Additive sedative effects can occur when @DRUG$ is given with alcohol, sedatives, hypnotics, @DRUG$, or tranquilizers.
1862	DDI-effect	Additive sedative effects can occur when @DRUG$ is given with alcohol, sedatives, hypnotics, narcotics, or @DRUG$.
1863	DDI-false	Additive sedative effects can occur when metoclopramide is given with @DRUG$, @DRUG$, hypnotics, narcotics, or tranquilizers.
1864	DDI-false	Additive sedative effects can occur when metoclopramide is given with @DRUG$, sedatives, @DRUG$, narcotics, or tranquilizers.
1865	DDI-false	Additive sedative effects can occur when metoclopramide is given with @DRUG$, sedatives, hypnotics, @DRUG$, or tranquilizers.
1866	DDI-false	Additive sedative effects can occur when metoclopramide is given with @DRUG$, sedatives, hypnotics, narcotics, or @DRUG$.
1867	DDI-false	Additive sedative effects can occur when metoclopramide is given with alcohol, @DRUG$, @DRUG$, narcotics, or tranquilizers.
1868	DDI-false	Additive sedative effects can occur when metoclopramide is given with alcohol, @DRUG$, hypnotics, @DRUG$, or tranquilizers.
1869	DDI-false	Additive sedative effects can occur when metoclopramide is given with alcohol, @DRUG$, hypnotics, narcotics, or @DRUG$.
1870	DDI-false	Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, @DRUG$, @DRUG$, or tranquilizers.
1871	DDI-false	Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, @DRUG$, narcotics, or @DRUG$.
1872	DDI-false	Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, @DRUG$, or @DRUG$.
1873	DDI-advise	The finding that @DRUG$ releases catecholamines in patients with essential hypertension suggests that it should be used cautiously, if at all, in patients receiving @DRUG$.
1874	DDI-mechanism	Absorption of drugs from the stomach may be diminished (e.g., @DRUG$) by @DRUG$, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).
1875	DDI-false	Absorption of drugs from the stomach may be diminished (e.g., @DRUG$) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., @DRUG$, tetracycline, levodopa, ethanol, cyclosporine).
1876	DDI-false	Absorption of drugs from the stomach may be diminished (e.g., @DRUG$) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, @DRUG$, levodopa, ethanol, cyclosporine).
1877	DDI-false	Absorption of drugs from the stomach may be diminished (e.g., @DRUG$) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, @DRUG$, ethanol, cyclosporine).
1878	DDI-false	Absorption of drugs from the stomach may be diminished (e.g., @DRUG$) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, @DRUG$, cyclosporine).
1879	DDI-false	Absorption of drugs from the stomach may be diminished (e.g., @DRUG$) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, @DRUG$).
1880	DDI-mechanism	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by @DRUG$, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., @DRUG$, tetracycline, levodopa, ethanol, cyclosporine).
1881	DDI-false	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by @DRUG$, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, @DRUG$, levodopa, ethanol, cyclosporine).
1882	DDI-false	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by @DRUG$, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, @DRUG$, ethanol, cyclosporine).
1883	DDI-false	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by @DRUG$, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, @DRUG$, cyclosporine).
1884	DDI-false	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by @DRUG$, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, @DRUG$).
1885	DDI-false	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., @DRUG$, @DRUG$, levodopa, ethanol, cyclosporine).
1886	DDI-false	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., @DRUG$, tetracycline, @DRUG$, ethanol, cyclosporine).
1887	DDI-false	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., @DRUG$, tetracycline, levodopa, @DRUG$, cyclosporine).
1888	DDI-false	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., @DRUG$, tetracycline, levodopa, ethanol, @DRUG$).
1889	DDI-false	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, @DRUG$, @DRUG$, ethanol, cyclosporine).
1890	DDI-false	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, @DRUG$, levodopa, @DRUG$, cyclosporine).
1891	DDI-false	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, @DRUG$, levodopa, ethanol, @DRUG$).
1892	DDI-false	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, @DRUG$, @DRUG$, cyclosporine).
1893	DDI-false	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, @DRUG$, ethanol, @DRUG$).
1894	DDI-false	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, @DRUG$, @DRUG$).
1895	DDI-advise	Because the action of @DRUG$ will influence the delivery of food to the intestines and thus the rate of absorption, @DRUG$ dosage or timing of dosage may require adjustment.
1896	DDI-false	Drugs that induce hepatic enzymes such as @DRUG$, @DRUG$ and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.
1897	DDI-false	Drugs that induce hepatic enzymes such as @DRUG$, phenytoin and @DRUG$ may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.
1898	DDI-mechanism	Drugs that induce hepatic enzymes such as @DRUG$, phenytoin and rifampin may increase the clearance of @DRUG$ and may require increases in corticosteroid dose to achieve the desired response.
1899	DDI-mechanism	Drugs that induce hepatic enzymes such as @DRUG$, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in @DRUG$ dose to achieve the desired response.
1900	DDI-false	Drugs that induce hepatic enzymes such as phenobarbital, @DRUG$ and @DRUG$ may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.
1901	DDI-mechanism	Drugs that induce hepatic enzymes such as phenobarbital, @DRUG$ and rifampin may increase the clearance of @DRUG$ and may require increases in corticosteroid dose to achieve the desired response.
1902	DDI-mechanism	Drugs that induce hepatic enzymes such as phenobarbital, @DRUG$ and rifampin may increase the clearance of corticosteroids and may require increases in @DRUG$ dose to achieve the desired response.
1903	DDI-mechanism	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and @DRUG$ may increase the clearance of @DRUG$ and may require increases in corticosteroid dose to achieve the desired response.
1904	DDI-mechanism	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and @DRUG$ may increase the clearance of corticosteroids and may require increases in @DRUG$ dose to achieve the desired response.
1905	DDI-false	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of @DRUG$ and may require increases in @DRUG$ dose to achieve the desired response.
1906	DDI-false	Drugs such as @DRUG$ and @DRUG$ may inhibit the metabolism of corticosteroids and thus decrease their clearance.
1907	DDI-mechanism	Drugs such as @DRUG$ and ketoconazole may inhibit the metabolism of @DRUG$ and thus decrease their clearance.
1908	DDI-mechanism	Drugs such as troleandomycin and @DRUG$ may inhibit the metabolism of @DRUG$ and thus decrease their clearance.
1909	DDI-mechanism	@DRUG$ may increase the clearance of chronic high dose @DRUG$.
1910	DDI-false	This could lead to decreased @DRUG$ serum levels or increase the risk of @DRUG$ toxicity when corticosteroid is withdrawn.
1911	DDI-false	This could lead to decreased @DRUG$ serum levels or increase the risk of salicylate toxicity when @DRUG$ is withdrawn.
1912	DDI-effect	This could lead to decreased salicylate serum levels or increase the risk of @DRUG$ toxicity when @DRUG$ is withdrawn.
1913	DDI-advise	@DRUG$ should be used cautiously in conjunction with @DRUG$ in patients suffering from hypoprothrombinemia.
1914	DDI-effect	The effect of @DRUG$ on oral @DRUG$ is variable.
1915	DDI-effect	There are reports of enhanced as well as diminished effects of @DRUG$ when given concurrently with @DRUG$.
1916	DDI-false	Co-administration of oral @DRUG$ 200 mg twice daily increased @DRUG$ geometric mean AUC(0-24) and Cmax by 81% after topical application of retapamulin ointment, 1% on the abraded skin of healthy adult males.
1917	DDI-mechanism	Co-administration of oral @DRUG$ 200 mg twice daily increased retapamulin geometric mean AUC(0-24) and Cmax by 81% after topical application of @DRUG$ ointment, 1% on the abraded skin of healthy adult males.
1918	DDI-false	Co-administration of oral ketoconazole 200 mg twice daily increased @DRUG$ geometric mean AUC(0-24) and Cmax by 81% after topical application of @DRUG$ ointment, 1% on the abraded skin of healthy adult males.
1919	DDI-false	Due to low systemic exposure to @DRUG$ following topical application in patients, dosage adjustments for @DRUG$ are unnecessary when co-administered with CYP3A4 inhibitors, such as ketoconazole.
1920	DDI-false	Due to low systemic exposure to @DRUG$ following topical application in patients, dosage adjustments for retapamulin are unnecessary when co-administered with CYP3A4 inhibitors, such as @DRUG$.
1921	DDI-false	Due to low systemic exposure to retapamulin following topical application in patients, dosage adjustments for @DRUG$ are unnecessary when co-administered with CYP3A4 inhibitors, such as @DRUG$.
1922	DDI-false	Based on in vitro P450 inhibition studies and the low systemic exposure observed following topical application of @DRUG$, @DRUG$ is unlikely to affect the metabolism of other P450 substrates.
1923	DDI-false	@DRUG$ may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1924	DDI-int	@DRUG$ may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1925	DDI-int	@DRUG$ may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1926	DDI-int	@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1927	DDI-int	@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1928	DDI-int	@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1929	DDI-int	@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1930	DDI-int	@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1931	DDI-int	@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1932	DDI-int	@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1933	DDI-int	@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1934	DDI-int	@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1935	DDI-int	@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1936	DDI-int	@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1937	DDI-int	@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1938	DDI-int	@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1939	DDI-int	@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1940	DDI-int	@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1941	DDI-int	@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine).
1942	DDI-int	@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine).
1943	DDI-int	@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine).
1944	DDI-int	@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$).
1945	DDI-false	Methscopolamine may interact with @DRUG$ (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1946	DDI-false	Methscopolamine may interact with @DRUG$ (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1947	DDI-false	Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1948	DDI-false	Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1949	DDI-false	Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1950	DDI-false	Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1951	DDI-false	Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1952	DDI-false	Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1953	DDI-false	Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1954	DDI-false	Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1955	DDI-false	Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1956	DDI-false	Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1957	DDI-false	Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1958	DDI-false	Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1959	DDI-false	Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1960	DDI-false	Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1961	DDI-false	Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1962	DDI-false	Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine).
1963	DDI-false	Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine).
1964	DDI-false	Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine).
1965	DDI-false	Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$).
1966	DDI-false	Methscopolamine may interact with antidepressants (@DRUG$ type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1967	DDI-false	Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1968	DDI-false	Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1969	DDI-false	Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1970	DDI-false	Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1971	DDI-false	Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1972	DDI-false	Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1973	DDI-false	Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1974	DDI-false	Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1975	DDI-false	Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1976	DDI-false	Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1977	DDI-false	Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1978	DDI-false	Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1979	DDI-false	Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1980	DDI-false	Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1981	DDI-false	Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1982	DDI-false	Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine).
1983	DDI-false	Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine).
1984	DDI-false	Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine).
1985	DDI-false	Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$).
1986	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1987	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1988	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1989	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1990	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1991	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1992	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1993	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1994	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1995	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1996	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1997	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1998	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
1999	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2000	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2001	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine).
2002	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine).
2003	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine).
2004	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$).
2005	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2006	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2007	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2008	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2009	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2010	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2011	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2012	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2013	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2014	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2015	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2016	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2017	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2018	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2019	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine).
2020	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine).
2021	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine).
2022	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$).
2023	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2024	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2025	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2026	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2027	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2028	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2029	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2030	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2031	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2032	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2033	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2034	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2035	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2036	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine).
2037	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine).
2038	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine).
2039	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$).
2040	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2041	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2042	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2043	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2044	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2045	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2046	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2047	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2048	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2049	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2050	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2051	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2052	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine).
2053	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine).
2054	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine).
2055	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$).
2056	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2057	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2058	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2059	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2060	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2061	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2062	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2063	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2064	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2065	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2066	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2067	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine).
2068	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine).
2069	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine).
2070	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$).
2071	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2072	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2073	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2074	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2075	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2076	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2077	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2078	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2079	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2080	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2081	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine).
2082	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine).
2083	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine).
2084	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$).
2085	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2086	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2087	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2088	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2089	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2090	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2091	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2092	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2093	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2094	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine).
2095	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine).
2096	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine).
2097	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$).
2098	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2099	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2100	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2101	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2102	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2103	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2104	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2105	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2106	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine).
2107	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine).
2108	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine).
2109	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$).
2110	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2111	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2112	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2113	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2114	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2115	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2116	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2117	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine).
2118	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine).
2119	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine).
2120	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$).
2121	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2122	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2123	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2124	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2125	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2126	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2127	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine).
2128	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine).
2129	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine).
2130	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$).
2131	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2132	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2133	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2134	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2135	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2136	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine).
2137	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine).
2138	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine).
2139	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$).
2140	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2141	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2142	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2143	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2144	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine).
2145	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine).
2146	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine).
2147	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$).
2148	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2149	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2150	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2151	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine).
2152	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine).
2153	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine).
2154	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$).
2155	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2156	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2157	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine).
2158	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine).
2159	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine).
2160	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$).
2161	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
2162	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine).
2163	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine).
2164	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine).
2165	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$).
2166	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine).
2167	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), @DRUG$ (e.g., chlorpromazine, promethazine).
2168	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., @DRUG$, promethazine).
2169	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$).
2170	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), @DRUG$ (e.g., chlorpromazine, promethazine).
2171	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., @DRUG$, promethazine).
2172	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, @DRUG$).
2173	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., @DRUG$, promethazine).
2174	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, @DRUG$).
2175	DDI-false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, @DRUG$).
2176	DDI-false	Although this has not occurred in in vitro studies with @DRUG$, interactions with @DRUG$ have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs.
2177	DDI-false	Although this has not occurred in in vitro studies with @DRUG$, interactions with coumarin-type anticoagulants have been reported with @DRUG$ since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs.
2178	DDI-false	Although this has not occurred in in vitro studies with @DRUG$, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering @DRUG$ to patients on coumarin-type anticoagulants and other highly protein-bound drugs.
2179	DDI-false	Although this has not occurred in in vitro studies with @DRUG$, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on @DRUG$ and other highly protein-bound drugs.
2180	DDI-int	Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with @DRUG$ have been reported with @DRUG$ since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs.
2181	DDI-false	Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with @DRUG$ have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering @DRUG$ to patients on coumarin-type anticoagulants and other highly protein-bound drugs.
2182	DDI-false	Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with @DRUG$ have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on @DRUG$ and other highly protein-bound drugs.
2183	DDI-false	Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with @DRUG$ since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering @DRUG$ to patients on coumarin-type anticoagulants and other highly protein-bound drugs.
2184	DDI-false	Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with @DRUG$ since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on @DRUG$ and other highly protein-bound drugs.
2185	DDI-advise	Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering @DRUG$ to patients on @DRUG$ and other highly protein-bound drugs.
2186	DDI-false	Plasma levels of @DRUG$ are depressed to approximately 80% of their normal values when @DRUG$ is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels.
2187	DDI-false	Plasma levels of @DRUG$ are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with @DRUG$ (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels.
2188	DDI-false	Plasma levels of @DRUG$ are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of @DRUG$ has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels.
2189	DDI-false	Plasma levels of @DRUG$ are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on @DRUG$ plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels.
2190	DDI-false	Plasma levels of @DRUG$ are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . @DRUG$, including FELDENE, have been reported to increase steady state plasma lithium levels.
2191	DDI-false	Plasma levels of @DRUG$ are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including @DRUG$, have been reported to increase steady state plasma lithium levels.
2192	DDI-false	Plasma levels of @DRUG$ are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma @DRUG$ levels.
2193	DDI-mechanism	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when @DRUG$ is administered in conjunction with @DRUG$ (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels.
2194	DDI-false	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when @DRUG$ is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of @DRUG$ has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels.
2195	DDI-false	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when @DRUG$ is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on @DRUG$ plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels.
2196	DDI-false	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when @DRUG$ is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . @DRUG$, including FELDENE, have been reported to increase steady state plasma lithium levels.
2197	DDI-false	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when @DRUG$ is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including @DRUG$, have been reported to increase steady state plasma lithium levels.
2198	DDI-false	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when @DRUG$ is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma @DRUG$ levels.
2199	DDI-false	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with @DRUG$ (3900 mg/day), but concomitant administration of @DRUG$ has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels.
2200	DDI-false	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with @DRUG$ (3900 mg/day), but concomitant administration of antacids has no effect on @DRUG$ plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels.
2201	DDI-false	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with @DRUG$ (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . @DRUG$, including FELDENE, have been reported to increase steady state plasma lithium levels.
2202	DDI-false	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with @DRUG$ (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including @DRUG$, have been reported to increase steady state plasma lithium levels.
2203	DDI-false	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with @DRUG$ (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma @DRUG$ levels.
2204	DDI-false	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of @DRUG$ has no effect on @DRUG$ plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels.
2205	DDI-false	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of @DRUG$ has no effect on piroxicam plasma levels . @DRUG$, including FELDENE, have been reported to increase steady state plasma lithium levels.
2206	DDI-false	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of @DRUG$ has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including @DRUG$, have been reported to increase steady state plasma lithium levels.
2207	DDI-false	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of @DRUG$ has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma @DRUG$ levels.
2208	DDI-false	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on @DRUG$ plasma levels . @DRUG$, including FELDENE, have been reported to increase steady state plasma lithium levels.
2209	DDI-false	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on @DRUG$ plasma levels . Nonsteroidal anti-inflammatory agents, including @DRUG$, have been reported to increase steady state plasma lithium levels.
2210	DDI-false	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on @DRUG$ plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma @DRUG$ levels.
2211	DDI-false	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . @DRUG$, including @DRUG$, have been reported to increase steady state plasma lithium levels.
2212	DDI-mechanism	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . @DRUG$, including FELDENE, have been reported to increase steady state plasma @DRUG$ levels.
2213	DDI-mechanism	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including @DRUG$, have been reported to increase steady state plasma @DRUG$ levels.
2214	DDI-advise	It is recommended that plasma @DRUG$ levels be monitored when initiating, adjusting and discontinuing @DRUG$.
2215	DDI-effect	When administered concurrently, @DRUG$ may increase the effects of oral @DRUG$;
2216	DDI-effect	Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with @DRUG$ with and without @DRUG$ or platelet aggregation inhibitors.
2217	DDI-effect	Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with @DRUG$ with and without anticoagulants or @DRUG$.
2218	DDI-false	Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without @DRUG$ or @DRUG$.
2219	DDI-mechanism	Concomitant administration of @DRUG$ and @DRUG$-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals.
2220	DDI-false	Concomitant administration of @DRUG$ and theophylline-containing drugs leads to increased @DRUG$ levels and theophylline toxicity in some individuals.
2221	DDI-false	Concomitant administration of @DRUG$ and theophylline-containing drugs leads to increased theophylline levels and @DRUG$ toxicity in some individuals.
2222	DDI-false	Concomitant administration of TRENTAL and @DRUG$-containing drugs leads to increased @DRUG$ levels and theophylline toxicity in some individuals.
2223	DDI-false	Concomitant administration of TRENTAL and @DRUG$-containing drugs leads to increased theophylline levels and @DRUG$ toxicity in some individuals.
2224	DDI-false	Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased @DRUG$ levels and @DRUG$ toxicity in some individuals.
2225	DDI-false	@DRUG$ has been used concurrently with @DRUG$, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.
2226	DDI-false	@DRUG$ has been used concurrently with antihypertensive drugs, @DRUG$, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.
2227	DDI-false	@DRUG$ has been used concurrently with antihypertensive drugs, beta blockers, @DRUG$, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.
2228	DDI-false	@DRUG$ has been used concurrently with antihypertensive drugs, beta blockers, digitalis, @DRUG$, antidiabetic agents, and antiarrhythmics, without observed problems.
2229	DDI-false	@DRUG$ has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, @DRUG$, and antiarrhythmics, without observed problems.
2230	DDI-false	@DRUG$ has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and @DRUG$, without observed problems.
2231	DDI-false	TRENTAL has been used concurrently with @DRUG$, @DRUG$, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.
2232	DDI-false	TRENTAL has been used concurrently with @DRUG$, beta blockers, @DRUG$, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.
2233	DDI-false	TRENTAL has been used concurrently with @DRUG$, beta blockers, digitalis, @DRUG$, antidiabetic agents, and antiarrhythmics, without observed problems.
2234	DDI-false	TRENTAL has been used concurrently with @DRUG$, beta blockers, digitalis, diuretics, @DRUG$, and antiarrhythmics, without observed problems.
2235	DDI-false	TRENTAL has been used concurrently with @DRUG$, beta blockers, digitalis, diuretics, antidiabetic agents, and @DRUG$, without observed problems.
2236	DDI-false	TRENTAL has been used concurrently with antihypertensive drugs, @DRUG$, @DRUG$, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.
2237	DDI-false	TRENTAL has been used concurrently with antihypertensive drugs, @DRUG$, digitalis, @DRUG$, antidiabetic agents, and antiarrhythmics, without observed problems.
2238	DDI-false	TRENTAL has been used concurrently with antihypertensive drugs, @DRUG$, digitalis, diuretics, @DRUG$, and antiarrhythmics, without observed problems.
2239	DDI-false	TRENTAL has been used concurrently with antihypertensive drugs, @DRUG$, digitalis, diuretics, antidiabetic agents, and @DRUG$, without observed problems.
2240	DDI-false	TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, @DRUG$, @DRUG$, antidiabetic agents, and antiarrhythmics, without observed problems.
2241	DDI-false	TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, @DRUG$, diuretics, @DRUG$, and antiarrhythmics, without observed problems.
2242	DDI-false	TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, @DRUG$, diuretics, antidiabetic agents, and @DRUG$, without observed problems.
2243	DDI-false	TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, @DRUG$, @DRUG$, and antiarrhythmics, without observed problems.
2244	DDI-false	TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, @DRUG$, antidiabetic agents, and @DRUG$, without observed problems.
2245	DDI-false	TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, @DRUG$, and @DRUG$, without observed problems.
2246	DDI-false	Drug Interactions: The use of @DRUG$    (@DRUG$) Injection before succinylcholine, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied.
2247	DDI-false	Drug Interactions: The use of @DRUG$    (rocuronium bromide) Injection before @DRUG$, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied.
2248	DDI-false	Drug Interactions: The use of @DRUG$    (rocuronium bromide) Injection before succinylcholine, for the purpose of attenuating some of the side effects of @DRUG$, has not been studied.
2249	DDI-false	Drug Interactions: The use of ZEMURON    (@DRUG$) Injection before @DRUG$, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied.
2250	DDI-false	Drug Interactions: The use of ZEMURON    (@DRUG$) Injection before succinylcholine, for the purpose of attenuating some of the side effects of @DRUG$, has not been studied.
2251	DDI-false	Drug Interactions: The use of ZEMURON    (rocuronium bromide) Injection before @DRUG$, for the purpose of attenuating some of the side effects of @DRUG$, has not been studied.
2252	DDI-advise	If @DRUG$    is administered following administration of @DRUG$, it should not be given until recovery from succinylcholine has been observed.
2253	DDI-false	If @DRUG$    is administered following administration of succinylcholine, it should not be given until recovery from @DRUG$ has been observed.
2254	DDI-false	If ZEMURON    is administered following administration of @DRUG$, it should not be given until recovery from @DRUG$ has been observed.
2255	DDI-false	The median duration of action of @DRUG$    0.6 mg/kg administered after a 1 mg/kg dose of @DRUG$ when T 1 returned to 75% of control was 36 minutes (range 14-57, n=12) vs.
2256	DDI-false	There are no controlled studies documenting the use of @DRUG$    before or after other @DRUG$.
2257	DDI-false	Concurrent administration of @DRUG$ (e.g., @DRUG$, tetracycline) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth.
2258	DDI-false	Concurrent administration of @DRUG$ (e.g., erythromycin, @DRUG$) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth.
2259	DDI-effect	Concurrent administration of @DRUG$ (e.g., erythromycin, tetracycline) may diminish the bactericidal effects of @DRUG$ by slowing the rate of bacterial growth.
2260	DDI-false	Concurrent administration of bacteriostatic antibiotics (e.g., @DRUG$, @DRUG$) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth.
2261	DDI-effect	Concurrent administration of bacteriostatic antibiotics (e.g., @DRUG$, tetracycline) may diminish the bactericidal effects of @DRUG$ by slowing the rate of bacterial growth.
2262	DDI-effect	Concurrent administration of bacteriostatic antibiotics (e.g., erythromycin, @DRUG$) may diminish the bactericidal effects of @DRUG$ by slowing the rate of bacterial growth.
2263	DDI-mechanism	@DRUG$ blood levels may be prolonged by concurrent administration of @DRUG$ which blocks the renal tubular secretion of penicillins.
2264	DDI-false	@DRUG$ blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of @DRUG$.
2265	DDI-false	Penicillin blood levels may be prolonged by concurrent administration of @DRUG$ which blocks the renal tubular secretion of @DRUG$.
2266	DDI-false	Displacement of @DRUG$ from plasma protein binding sites will elevate the level of free @DRUG$ in the serum.
2267	DDI-effect	Catecholamine-depleting drugs (e.g., @DRUG$) may have an additive effect when given with @DRUG$.
2268	DDI-false	@DRUG$ has been used with a variety of @DRUG$, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions.
2269	DDI-false	@DRUG$ has been used with a variety of antihypertensive agents, including @DRUG$, hydralazine, and guanethidine without unexpected adverse interactions.
2270	DDI-false	@DRUG$ has been used with a variety of antihypertensive agents, including hydrochlorothiazide, @DRUG$, and guanethidine without unexpected adverse interactions.
2271	DDI-false	@DRUG$ has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and @DRUG$ without unexpected adverse interactions.
2272	DDI-false	Pindolol has been used with a variety of @DRUG$, including @DRUG$, hydralazine, and guanethidine without unexpected adverse interactions.
2273	DDI-false	Pindolol has been used with a variety of @DRUG$, including hydrochlorothiazide, @DRUG$, and guanethidine without unexpected adverse interactions.
2274	DDI-false	Pindolol has been used with a variety of @DRUG$, including hydrochlorothiazide, hydralazine, and @DRUG$ without unexpected adverse interactions.
2275	DDI-false	Pindolol has been used with a variety of antihypertensive agents, including @DRUG$, @DRUG$, and guanethidine without unexpected adverse interactions.
2276	DDI-false	Pindolol has been used with a variety of antihypertensive agents, including @DRUG$, hydralazine, and @DRUG$ without unexpected adverse interactions.
2277	DDI-false	Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, @DRUG$, and @DRUG$ without unexpected adverse interactions.
2278	DDI-mechanism	@DRUG$ has been shown to increase serum @DRUG$ levels when both drugs are co-administered.
2279	DDI-false	Although specific drug or food interactions with @DRUG$ have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that @DRUG$, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).
2280	DDI-false	Although specific drug or food interactions with @DRUG$ have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, @DRUG$, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).
2281	DDI-false	Although specific drug or food interactions with @DRUG$ have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, @DRUG$, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).
2282	DDI-false	Although specific drug or food interactions with @DRUG$ have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of @DRUG$).
2283	DDI-false	Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that @DRUG$, @DRUG$, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).
2284	DDI-false	Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that @DRUG$, itraconazole, @DRUG$, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).
2285	DDI-mechanism	Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that @DRUG$, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of @DRUG$).
2286	DDI-false	Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, @DRUG$, @DRUG$, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).
2287	DDI-mechanism	Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, @DRUG$, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of @DRUG$).
2288	DDI-mechanism	Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, @DRUG$, and grapefruit juice may inhibit its metabolism (increasing serum levels of @DRUG$).
2289	DDI-false	Furthermore, @DRUG$, @DRUG$, St.
2290	DDI-false	John   s Wort, and certain @DRUG$ (@DRUG$, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone).
2291	DDI-false	John   s Wort, and certain @DRUG$ (phenytoin, @DRUG$, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone).
2292	DDI-false	John   s Wort, and certain @DRUG$ (phenytoin, phenobarbital, @DRUG$) may induce mifepristone metabolism (lowering serum levels of mifepristone).
2293	DDI-mechanism	John   s Wort, and certain @DRUG$ (phenytoin, phenobarbital, carbamazepine) may induce @DRUG$ metabolism (lowering serum levels of mifepristone).
2294	DDI-false	John   s Wort, and certain @DRUG$ (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of @DRUG$).
2295	DDI-false	John   s Wort, and certain anticonvulsants (@DRUG$, @DRUG$, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone).
2296	DDI-false	John   s Wort, and certain anticonvulsants (@DRUG$, phenobarbital, @DRUG$) may induce mifepristone metabolism (lowering serum levels of mifepristone).
2297	DDI-mechanism	John   s Wort, and certain anticonvulsants (@DRUG$, phenobarbital, carbamazepine) may induce @DRUG$ metabolism (lowering serum levels of mifepristone).
2298	DDI-false	John   s Wort, and certain anticonvulsants (@DRUG$, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of @DRUG$).
2299	DDI-false	John   s Wort, and certain anticonvulsants (phenytoin, @DRUG$, @DRUG$) may induce mifepristone metabolism (lowering serum levels of mifepristone).
2300	DDI-mechanism	John   s Wort, and certain anticonvulsants (phenytoin, @DRUG$, carbamazepine) may induce @DRUG$ metabolism (lowering serum levels of mifepristone).
2301	DDI-false	John   s Wort, and certain anticonvulsants (phenytoin, @DRUG$, carbamazepine) may induce mifepristone metabolism (lowering serum levels of @DRUG$).
2302	DDI-mechanism	John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, @DRUG$) may induce @DRUG$ metabolism (lowering serum levels of mifepristone).
2303	DDI-false	John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, @DRUG$) may induce mifepristone metabolism (lowering serum levels of @DRUG$).
2304	DDI-false	John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce @DRUG$ metabolism (lowering serum levels of @DRUG$).
2305	DDI-effect	Concomitant administration of @DRUG$ and @DRUG$ has been associated with erythema and histamine-like flushing and anaphylactoid reactions.
2306	DDI-false	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as @DRUG$, @DRUG$, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.
2307	DDI-false	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as @DRUG$, aminoglycosides, @DRUG$, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.
2308	DDI-false	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as @DRUG$, aminoglycosides, bacitracin, @DRUG$, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.
2309	DDI-false	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as @DRUG$, aminoglycosides, bacitracin, polymyxin B, @DRUG$, viomycin, or cisplatin, when indicated, requires careful monitoring.
2310	DDI-false	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as @DRUG$, aminoglycosides, bacitracin, polymyxin B, colistin, @DRUG$, or cisplatin, when indicated, requires careful monitoring.
2311	DDI-false	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as @DRUG$, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or @DRUG$, when indicated, requires careful monitoring.
2312	DDI-false	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, @DRUG$, @DRUG$, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.
2313	DDI-false	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, @DRUG$, bacitracin, @DRUG$, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.
2314	DDI-false	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, @DRUG$, bacitracin, polymyxin B, @DRUG$, viomycin, or cisplatin, when indicated, requires careful monitoring.
2315	DDI-false	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, @DRUG$, bacitracin, polymyxin B, colistin, @DRUG$, or cisplatin, when indicated, requires careful monitoring.
2316	DDI-false	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, @DRUG$, bacitracin, polymyxin B, colistin, viomycin, or @DRUG$, when indicated, requires careful monitoring.
2317	DDI-false	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, @DRUG$, @DRUG$, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.
2318	DDI-false	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, @DRUG$, polymyxin B, @DRUG$, viomycin, or cisplatin, when indicated, requires careful monitoring.
2319	DDI-false	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, @DRUG$, polymyxin B, colistin, @DRUG$, or cisplatin, when indicated, requires careful monitoring.
2320	DDI-false	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, @DRUG$, polymyxin B, colistin, viomycin, or @DRUG$, when indicated, requires careful monitoring.
2321	DDI-false	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, @DRUG$, @DRUG$, viomycin, or cisplatin, when indicated, requires careful monitoring.
2322	DDI-false	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, @DRUG$, colistin, @DRUG$, or cisplatin, when indicated, requires careful monitoring.
2323	DDI-false	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, @DRUG$, colistin, viomycin, or @DRUG$, when indicated, requires careful monitoring.
2324	DDI-false	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, @DRUG$, @DRUG$, or cisplatin, when indicated, requires careful monitoring.
2325	DDI-false	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, @DRUG$, viomycin, or @DRUG$, when indicated, requires careful monitoring.
2326	DDI-false	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, @DRUG$, or @DRUG$, when indicated, requires careful monitoring.
2327	DDI-false	Potential for @DRUG$    to Affect Other Drugs @DRUG$ is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes.
2328	DDI-false	Given the primary CNS effects of @DRUG$, @DRUG$    should be used with caution in combination with other centrally acting drugs and alcohol.
2329	DDI-advise	Given the primary CNS effects of @DRUG$, INVEGA    should be used with caution in combination with other @DRUG$ and alcohol.
2330	DDI-advise	Given the primary CNS effects of @DRUG$, INVEGA    should be used with caution in combination with other centrally acting drugs and @DRUG$.
2331	DDI-advise	Given the primary CNS effects of paliperidone, @DRUG$    should be used with caution in combination with other @DRUG$ and alcohol.
2332	DDI-advise	Given the primary CNS effects of paliperidone, @DRUG$    should be used with caution in combination with other centrally acting drugs and @DRUG$.
2333	DDI-false	Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other @DRUG$ and @DRUG$.
2334	DDI-effect	@DRUG$ may antagonize the effect of @DRUG$ and other dopamine agonists.
2335	DDI-effect	@DRUG$ may antagonize the effect of levodopa and other @DRUG$.
2336	DDI-false	Paliperidone may antagonize the effect of @DRUG$ and other @DRUG$.
2337	DDI-false	Potential for Other Drugs to Affect @DRUG$    @DRUG$ is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely.
2338	DDI-false	The interaction of @DRUG$ (@DRUG$) with other drugs has not been studied in humans.
2339	DDI-effect	Decreased seizure threshold has been reported in patients receiving @DRUG$ concomitantly with @DRUG$.
2340	DDI-false	CYP 3A4 Inhibitors (e.g. @DRUG$ and @DRUG$) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.
2341	DDI-false	CYP 3A4 Inhibitors (e.g. @DRUG$ and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain @DRUG$ (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.
2342	DDI-false	CYP 3A4 Inhibitors (e.g. @DRUG$ and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. @DRUG$ and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.
2343	DDI-false	CYP 3A4 Inhibitors (e.g. @DRUG$ and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and @DRUG$) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.
2344	DDI-false	CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and @DRUG$) There have been rare reports of serious adverse events in connection with the coadministration of certain @DRUG$ (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.
2345	DDI-false	CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and @DRUG$) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. @DRUG$ and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.
2346	DDI-false	CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and @DRUG$) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and @DRUG$) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.
2347	DDI-false	CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain @DRUG$ (e.g. @DRUG$ and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.
2348	DDI-false	CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain @DRUG$ (e.g. dihydroergotamine and @DRUG$) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.
2349	DDI-false	CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. @DRUG$ and @DRUG$) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.
2350	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2351	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2352	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2353	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2354	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2355	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2356	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2357	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2358	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2359	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole).
2360	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole).
2361	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole).
2362	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$).
2363	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2364	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2365	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2366	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2367	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2368	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2369	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2370	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2371	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole).
2372	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole).
2373	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole).
2374	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$).
2375	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2376	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2377	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2378	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2379	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2380	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2381	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2382	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole).
2383	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole).
2384	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole).
2385	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$).
2386	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2387	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2388	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2389	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2390	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2391	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2392	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole).
2393	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole).
2394	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole).
2395	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$).
2396	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG-DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2397	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2398	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2399	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2400	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2401	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole).
2402	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole).
2403	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole).
2404	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$).
2405	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2406	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2407	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2408	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2409	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole).
2410	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole).
2411	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole).
2412	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$).
2413	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2414	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2415	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2416	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole).
2417	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole).
2418	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole).
2419	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$).
2420	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2421	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2422	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole).
2423	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole).
2424	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole).
2425	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$).
2426	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
2427	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole).
2428	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole).
2429	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole).
2430	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$).
2431	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole).
2432	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole).
2433	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole).
2434	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$).
2435	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., @DRUG$, itraconazole, voriconazole).
2436	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, @DRUG$, voriconazole).
2437	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, @DRUG$).
2438	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, @DRUG$, voriconazole).
2439	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, @DRUG$).
2440	DDI-false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, @DRUG$).
2441	DDI-false	Less potent inhibitors include @DRUG$, @DRUG$, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.
2442	DDI-false	Less potent inhibitors include @DRUG$, nefazodone, @DRUG$, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.
2443	DDI-false	Less potent inhibitors include @DRUG$, nefazodone, fluconazole, grapefruit juice, @DRUG$, fluvoxamine, zileuton, and clotrimazole.
2444	DDI-false	Less potent inhibitors include @DRUG$, nefazodone, fluconazole, grapefruit juice, fluoxetine, @DRUG$, zileuton, and clotrimazole.
2445	DDI-false	Less potent inhibitors include @DRUG$, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, @DRUG$, and clotrimazole.
2446	DDI-false	Less potent inhibitors include @DRUG$, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and @DRUG$.
2447	DDI-false	Less potent inhibitors include saquinavir, @DRUG$, @DRUG$, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.
2448	DDI-false	Less potent inhibitors include saquinavir, @DRUG$, fluconazole, grapefruit juice, @DRUG$, fluvoxamine, zileuton, and clotrimazole.
2449	DDI-false	Less potent inhibitors include saquinavir, @DRUG$, fluconazole, grapefruit juice, fluoxetine, @DRUG$, zileuton, and clotrimazole.
2450	DDI-false	Less potent inhibitors include saquinavir, @DRUG$, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, @DRUG$, and clotrimazole.
2451	DDI-false	Less potent inhibitors include saquinavir, @DRUG$, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and @DRUG$.
2452	DDI-false	Less potent inhibitors include saquinavir, nefazodone, @DRUG$, grapefruit juice, @DRUG$, fluvoxamine, zileuton, and clotrimazole.
2453	DDI-false	Less potent inhibitors include saquinavir, nefazodone, @DRUG$, grapefruit juice, fluoxetine, @DRUG$, zileuton, and clotrimazole.
2454	DDI-false	Less potent inhibitors include saquinavir, nefazodone, @DRUG$, grapefruit juice, fluoxetine, fluvoxamine, @DRUG$, and clotrimazole.
2455	DDI-false	Less potent inhibitors include saquinavir, nefazodone, @DRUG$, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and @DRUG$.
2456	DDI-false	Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, @DRUG$, @DRUG$, zileuton, and clotrimazole.
2457	DDI-false	Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, @DRUG$, fluvoxamine, @DRUG$, and clotrimazole.
2458	DDI-false	Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, @DRUG$, fluvoxamine, zileuton, and @DRUG$.
2459	DDI-false	Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, @DRUG$, @DRUG$, and clotrimazole.
2460	DDI-false	Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, @DRUG$, zileuton, and @DRUG$.
2461	DDI-false	Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, @DRUG$, and @DRUG$.
2462	DDI-false	Caution should be exercised when @DRUG$    (@DRUG$) is used concurrently with other vasoconstrictors or ergot alkaloids.
2463	DDI-advise	Caution should be exercised when @DRUG$    (methylergonovine maleate) is used concurrently with other @DRUG$ or ergot alkaloids.
2464	DDI-advise	Caution should be exercised when @DRUG$    (methylergonovine maleate) is used concurrently with other vasoconstrictors or @DRUG$.
2465	DDI-advise	Caution should be exercised when Methergine    (@DRUG$) is used concurrently with other @DRUG$ or ergot alkaloids.
2466	DDI-false	Caution should be exercised when Methergine    (@DRUG$) is used concurrently with other vasoconstrictors or @DRUG$.
2467	DDI-false	Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other @DRUG$ or @DRUG$.
2468	DDI-false	To minimize CNS depression and possible potentiation, @DRUG$, @DRUG$, narcotics, hypotensive agents or phenothiazines should be used with caution.
2469	DDI-false	To minimize CNS depression and possible potentiation, @DRUG$, antihistamines, @DRUG$, hypotensive agents or phenothiazines should be used with caution.
2470	DDI-false	To minimize CNS depression and possible potentiation, @DRUG$, antihistamines, narcotics, @DRUG$ or phenothiazines should be used with caution.
2471	DDI-false	To minimize CNS depression and possible potentiation, @DRUG$, antihistamines, narcotics, hypotensive agents or @DRUG$ should be used with caution.
2472	DDI-false	To minimize CNS depression and possible potentiation, barbiturates, @DRUG$, @DRUG$, hypotensive agents or phenothiazines should be used with caution.
2473	DDI-false	To minimize CNS depression and possible potentiation, barbiturates, @DRUG$, narcotics, @DRUG$ or phenothiazines should be used with caution.
2474	DDI-false	To minimize CNS depression and possible potentiation, barbiturates, @DRUG$, narcotics, hypotensive agents or @DRUG$ should be used with caution.
2475	DDI-false	To minimize CNS depression and possible potentiation, barbiturates, antihistamines, @DRUG$, @DRUG$ or phenothiazines should be used with caution.
2476	DDI-false	To minimize CNS depression and possible potentiation, barbiturates, antihistamines, @DRUG$, hypotensive agents or @DRUG$ should be used with caution.
2477	DDI-false	To minimize CNS depression and possible potentiation, barbiturates, antihistamines, narcotics, @DRUG$ or @DRUG$ should be used with caution.
2478	DDI-advise	Because @DRUG$ exhibits some monoamine oxidase inhibitory activity, @DRUG$, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
2479	DDI-advise	Because @DRUG$ exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, @DRUG$ drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
2480	DDI-advise	Because @DRUG$ exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., @DRUG$, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
2481	DDI-advise	Because @DRUG$ exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, @DRUG$) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
2482	DDI-advise	Because @DRUG$ exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high @DRUG$ content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
2483	DDI-false	Because Matulane exhibits some monoamine oxidase inhibitory activity, @DRUG$, @DRUG$ drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
2484	DDI-false	Because Matulane exhibits some monoamine oxidase inhibitory activity, @DRUG$, tricyclic antidepressant drugs (e.g., @DRUG$, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
2485	DDI-false	Because Matulane exhibits some monoamine oxidase inhibitory activity, @DRUG$, tricyclic antidepressant drugs (e.g., amitriptyline HCl, @DRUG$) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
2486	DDI-false	Because Matulane exhibits some monoamine oxidase inhibitory activity, @DRUG$, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high @DRUG$ content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
2487	DDI-false	Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, @DRUG$ drugs (e.g., @DRUG$, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
2488	DDI-false	Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, @DRUG$ drugs (e.g., amitriptyline HCl, @DRUG$) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
2489	DDI-false	Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, @DRUG$ drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high @DRUG$ content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
2490	DDI-false	Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., @DRUG$, @DRUG$) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
2491	DDI-false	Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., @DRUG$, imipramine HCl) and other drugs and foods with known high @DRUG$ content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
2492	DDI-false	Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, @DRUG$) and other drugs and foods with known high @DRUG$ content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
2493	DDI-false	No cross-resistance with other @DRUG$, radiotherapy or @DRUG$ has been demonstrated.
2494	DDI-effect	@DRUG$ are capable of potentiating @DRUG$ (e.g., barbiturates, anesthetics, opiates, alcohol, etc.)
2495	DDI-effect	@DRUG$ are capable of potentiating CNS depressants (e.g., @DRUG$, anesthetics, opiates, alcohol, etc.)
2496	DDI-effect	@DRUG$ are capable of potentiating CNS depressants (e.g., barbiturates, @DRUG$, opiates, alcohol, etc.)
2497	DDI-effect	@DRUG$ are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, @DRUG$, alcohol, etc.)
2498	DDI-effect	@DRUG$ are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, @DRUG$, etc.)
2499	DDI-false	Phenothiazines are capable of potentiating @DRUG$ (e.g., @DRUG$, anesthetics, opiates, alcohol, etc.)
2500	DDI-false	Phenothiazines are capable of potentiating @DRUG$ (e.g., barbiturates, @DRUG$, opiates, alcohol, etc.)
2501	DDI-false	Phenothiazines are capable of potentiating @DRUG$ (e.g., barbiturates, anesthetics, @DRUG$, alcohol, etc.)
2502	DDI-false	Phenothiazines are capable of potentiating @DRUG$ (e.g., barbiturates, anesthetics, opiates, @DRUG$, etc.)
2503	DDI-false	Phenothiazines are capable of potentiating CNS depressants (e.g., @DRUG$, @DRUG$, opiates, alcohol, etc.)
2504	DDI-false	Phenothiazines are capable of potentiating CNS depressants (e.g., @DRUG$, anesthetics, @DRUG$, alcohol, etc.)
2505	DDI-false	Phenothiazines are capable of potentiating CNS depressants (e.g., @DRUG$, anesthetics, opiates, @DRUG$, etc.)
2506	DDI-false	Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, @DRUG$, @DRUG$, alcohol, etc.)
2507	DDI-false	Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, @DRUG$, opiates, @DRUG$, etc.)
2508	DDI-false	Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, @DRUG$, @DRUG$, etc.)
2509	DDI-false	as well as @DRUG$ and @DRUG$.
2510	DDI-mechanism	The metabolism of @DRUG$ is accelerated by @DRUG$;
2511	DDI-mechanism	@DRUG$ inhibits the glucuronidation of @DRUG$ and could possibly potentiate acetaminophen toxicity.
2512	DDI-effect	@DRUG$ inhibits the glucuronidation of acetaminophen and could possibly potentiate @DRUG$ toxicity.
2513	DDI-false	Metopirone inhibits the glucuronidation of @DRUG$ and could possibly potentiate @DRUG$ toxicity.
2514	DDI-mechanism	Preliminary evidence suggests that @DRUG$ inhibits @DRUG$ metabolism and may result in an increase in plasma concentrations of mebendazole.
2515	DDI-false	Preliminary evidence suggests that @DRUG$ inhibits mebendazole metabolism and may result in an increase in plasma concentrations of @DRUG$.
2516	DDI-false	Preliminary evidence suggests that cimetidine inhibits @DRUG$ metabolism and may result in an increase in plasma concentrations of @DRUG$.
2517	DDI-false	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2518	DDI-false	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2519	DDI-false	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2520	DDI-false	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2521	DDI-false	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2522	DDI-false	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2523	DDI-false	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2524	DDI-false	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2525	DDI-false	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2526	DDI-false	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2527	DDI-false	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2528	DDI-false	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2529	DDI-false	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2530	DDI-false	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2531	DDI-false	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2532	DDI-false	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2533	DDI-false	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2534	DDI-false	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2535	DDI-false	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2536	DDI-false	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.
2537	DDI-false	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.
2538	DDI-false	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.
2539	DDI-false	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.
2540	DDI-false	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.
2541	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2542	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2543	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2544	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2545	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2546	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2547	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2548	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2549	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2550	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2551	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2552	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2553	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2554	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2555	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2556	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2557	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2558	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2559	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.
2560	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.
2561	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.
2562	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.
2563	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.
2564	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2565	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2566	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2567	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2568	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2569	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2570	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2571	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2572	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2573	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2574	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2575	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2576	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2577	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2578	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2579	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2580	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2581	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.
2582	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.
2583	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.
2584	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.
2585	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.
2586	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2587	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2588	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2589	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2590	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2591	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2592	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2593	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2594	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2595	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2596	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2597	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2598	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2599	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2600	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2601	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2602	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.
2603	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.
2604	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.
2605	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.
2606	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.
2607	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2608	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2609	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2610	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2611	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2612	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2613	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2614	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2615	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2616	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2617	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2618	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2619	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2620	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2621	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2622	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.
2623	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.
2624	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.
2625	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.
2626	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.
2627	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2628	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2629	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2630	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2631	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2632	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2633	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2634	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2635	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2636	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2637	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2638	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2639	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2640	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2641	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.
2642	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.
2643	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.
2644	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.
2645	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.
2646	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2647	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2648	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2649	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2650	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2651	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2652	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2653	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2654	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2655	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2656	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2657	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2658	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2659	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.
2660	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.
2661	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.
2662	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.
2663	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.
2664	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2665	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2666	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2667	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2668	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2669	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2670	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2671	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2672	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2673	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2674	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2675	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2676	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.
2677	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.
2678	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.
2679	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.
2680	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.
2681	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2682	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2683	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2684	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2685	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2686	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2687	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2688	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2689	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2690	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2691	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2692	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.
2693	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.
2694	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.
2695	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.
2696	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.
2697	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2698	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2699	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2700	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2701	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2702	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2703	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2704	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2705	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2706	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2707	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.
2708	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.
2709	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.
2710	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.
2711	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.
2712	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2713	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2714	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2715	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2716	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2717	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2718	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2719	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2720	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2721	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.
2722	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.
2723	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.
2724	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.
2725	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.
2726	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2727	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2728	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2729	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2730	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2731	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2732	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2733	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2734	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.
2735	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.
2736	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.
2737	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.
2738	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.
2739	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2740	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2741	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2742	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2743	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2744	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2745	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2746	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.
2747	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.
2748	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.
2749	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.
2750	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.
2751	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2752	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2753	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2754	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2755	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2756	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2757	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.
2758	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.
2759	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.
2760	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.
2761	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.
2762	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2763	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2764	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2765	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2766	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2767	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.
2768	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.
2769	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.
2770	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.
2771	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.
2772	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2773	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2774	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2775	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2776	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.
2777	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.
2778	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.
2779	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.
2780	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.
2781	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2782	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2783	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2784	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.
2785	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.
2786	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.
2787	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.
2788	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.
2789	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2790	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2791	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.
2792	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.
2793	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.
2794	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.
2795	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.
2796	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
2797	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.
2798	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.
2799	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.
2800	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.
2801	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.
2802	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.
2803	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.
2804	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.
2805	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.
2806	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.
2807	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, @DRUG$, clarithromycin, metronidazole, or amoxicillin.
2808	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, @DRUG$, metronidazole, or amoxicillin.
2809	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, @DRUG$, or amoxicillin.
2810	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or @DRUG$.
2811	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, @DRUG$, metronidazole, or amoxicillin.
2812	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, @DRUG$, or amoxicillin.
2813	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or @DRUG$.
2814	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, @DRUG$, or amoxicillin.
2815	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or @DRUG$.
2816	DDI-false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or @DRUG$.
2817	DDI-false	Therefore, when coadministered with @DRUG$, adjustment of the dosage of @DRUG$ or of such drugs may not be necessary.
2818	DDI-false	There have been postmarketing reports of increased INR and prothrombin time in patients receiving @DRUG$, including @DRUG$, and warfarin concomitantly.
2819	DDI-effect	There have been postmarketing reports of increased INR and prothrombin time in patients receiving @DRUG$, including pantoprazole, and @DRUG$ concomitantly.
2820	DDI-effect	There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including @DRUG$, and @DRUG$ concomitantly.
2821	DDI-advise	Patients treated with @DRUG$ and @DRUG$ concomitantly should be monitored for increases in INR and prothrombin time.
2822	DDI-mechanism	Because of profound and long lasting inhibition of gastric acid secretion, @DRUG$ may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, @DRUG$, ampicillin esters, and iron salts).
2823	DDI-mechanism	Because of profound and long lasting inhibition of gastric acid secretion, @DRUG$ may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, @DRUG$ esters, and iron salts).
2824	DDI-mechanism	Because of profound and long lasting inhibition of gastric acid secretion, @DRUG$ may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and @DRUG$ salts).
2825	DDI-false	Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, @DRUG$, @DRUG$ esters, and iron salts).
2826	DDI-false	Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, @DRUG$, ampicillin esters, and @DRUG$ salts).
2827	DDI-false	Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, @DRUG$ esters, and @DRUG$ salts).
2828	DDI-false	Laboratory Tests There have been reports of false-positive urine screening tests for @DRUG$ (@DRUG$) in patients receiving most proton pump inhibitors, including pantoprazole.
2829	DDI-false	Laboratory Tests There have been reports of false-positive urine screening tests for @DRUG$ (THC) in patients receiving most @DRUG$, including pantoprazole.
2830	DDI-false	Laboratory Tests There have been reports of false-positive urine screening tests for @DRUG$ (THC) in patients receiving most proton pump inhibitors, including @DRUG$.
2831	DDI-false	Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (@DRUG$) in patients receiving most @DRUG$, including pantoprazole.
2832	DDI-false	Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (@DRUG$) in patients receiving most proton pump inhibitors, including @DRUG$.
2833	DDI-false	Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving most @DRUG$, including @DRUG$.
2834	DDI-effect	@DRUG$ may increase the effects of @DRUG$, tolbutamide, and uricosurics.
2835	DDI-effect	@DRUG$ may increase the effects of barbiturates, @DRUG$, and uricosurics.
2836	DDI-effect	@DRUG$ may increase the effects of barbiturates, tolbutamide, and @DRUG$.
2837	DDI-false	Sulfoxone may increase the effects of @DRUG$, @DRUG$, and uricosurics.
2838	DDI-false	Sulfoxone may increase the effects of @DRUG$, tolbutamide, and @DRUG$.
2839	DDI-false	Sulfoxone may increase the effects of barbiturates, @DRUG$, and @DRUG$.
2840	DDI-false	It may also interact with @DRUG$ (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).
2841	DDI-false	It may also interact with @DRUG$ (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).
2842	DDI-false	It may also interact with @DRUG$ (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).
2843	DDI-false	It may also interact with @DRUG$ (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), @DRUG$ (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).
2844	DDI-false	It may also interact with @DRUG$ (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of @DRUG$), phenytoin (decreased hepatic clearance of phenytoin).
2845	DDI-false	It may also interact with @DRUG$ (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), @DRUG$ (decreased hepatic clearance of phenytoin).
2846	DDI-false	It may also interact with @DRUG$ (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of @DRUG$).
2847	DDI-false	It may also interact with thiazides (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).
2848	DDI-false	It may also interact with thiazides (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).
2849	DDI-false	It may also interact with thiazides (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), @DRUG$ (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).
2850	DDI-false	It may also interact with thiazides (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of @DRUG$), phenytoin (decreased hepatic clearance of phenytoin).
2851	DDI-false	It may also interact with thiazides (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), @DRUG$ (decreased hepatic clearance of phenytoin).
2852	DDI-false	It may also interact with thiazides (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of @DRUG$).
2853	DDI-false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).
2854	DDI-false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), warfarin (increased anticoagulant effect), @DRUG$ (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).
2855	DDI-false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of @DRUG$), phenytoin (decreased hepatic clearance of phenytoin).
2856	DDI-false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), @DRUG$ (decreased hepatic clearance of phenytoin).
2857	DDI-false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of @DRUG$).
2858	DDI-false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), @DRUG$ (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).
2859	DDI-false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), methotrexate (decreased renal excretion of @DRUG$), phenytoin (decreased hepatic clearance of phenytoin).
2860	DDI-false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), @DRUG$ (decreased hepatic clearance of phenytoin).
2861	DDI-false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of @DRUG$).
2862	DDI-false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), @DRUG$ (decreased renal excretion of @DRUG$), phenytoin (decreased hepatic clearance of phenytoin).
2863	DDI-false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), @DRUG$ (decreased renal excretion of methotrexate), @DRUG$ (decreased hepatic clearance of phenytoin).
2864	DDI-false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), @DRUG$ (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of @DRUG$).
2865	DDI-false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of @DRUG$), @DRUG$ (decreased hepatic clearance of phenytoin).
2866	DDI-false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of @DRUG$), phenytoin (decreased hepatic clearance of @DRUG$).
2867	DDI-false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), @DRUG$ (decreased hepatic clearance of @DRUG$).
2868	DDI-mechanism	@DRUG$ may compete with other drugs, such as @DRUG$, for sites of metabolism in the liver, thus elevating the serum levels of such compounds to potentially toxic levels.
2869	DDI-advise	Therefore, when concomitant use of @DRUG$ and @DRUG$ is anticipated, it may be necessary to monitor blood levels and/or reduce the dosage of such compounds.
2870	DDI-mechanism	Administration of @DRUG$ decreases oral clearance of @DRUG$ by about 5%.
2871	DDI-false	Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of @DRUG$ or @DRUG$ to warrant dosage adjustment when megestrol acetate is administered with these drugs.
2872	DDI-false	Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of @DRUG$ or rifabutin to warrant dosage adjustment when @DRUG$ is administered with these drugs.
2873	DDI-false	Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or @DRUG$ to warrant dosage adjustment when @DRUG$ is administered with these drugs.
2874	DDI-mechanism	A pharmacokinetic study demonstrated that coadministration of @DRUG$ and @DRUG$ results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of indinavir.
2875	DDI-false	A pharmacokinetic study demonstrated that coadministration of @DRUG$ and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of @DRUG$.
2876	DDI-false	A pharmacokinetic study demonstrated that coadministration of megestrol acetate and @DRUG$ results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of @DRUG$.
2877	DDI-advise	Administration of a higher dose of @DRUG$ should be considered when coadministering with @DRUG$.
2878	DDI-false	The effects of @DRUG$, @DRUG$ or rifabutin on the pharmacokinetics of megestrol acetate were not studied.
2879	DDI-false	The effects of @DRUG$, zidovudine or @DRUG$ on the pharmacokinetics of megestrol acetate were not studied.
2880	DDI-false	The effects of @DRUG$, zidovudine or rifabutin on the pharmacokinetics of @DRUG$ were not studied.
2881	DDI-false	The effects of indinavir, @DRUG$ or @DRUG$ on the pharmacokinetics of megestrol acetate were not studied.
2882	DDI-false	The effects of indinavir, @DRUG$ or rifabutin on the pharmacokinetics of @DRUG$ were not studied.
2883	DDI-false	The effects of indinavir, zidovudine or @DRUG$ on the pharmacokinetics of @DRUG$ were not studied.
2884	DDI-false	@DRUG$, particularly @DRUG$, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all.
2885	DDI-effect	@DRUG$, particularly metaraminol, may cause serious cardiac arrhythmias during @DRUG$ anesthesia and therefore should be used only with great caution or not at all.
2886	DDI-effect	Vasopressors, particularly @DRUG$, may cause serious cardiac arrhythmias during @DRUG$ anesthesia and therefore should be used only with great caution or not at all.
2887	DDI-false	@DRUG$ - The pressor effect of @DRUG$ is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI).
2888	DDI-false	@DRUG$ - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving @DRUG$ (MAOI).
2889	DDI-false	@DRUG$ - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (@DRUG$).
2890	DDI-effect	MAO Inhibitors - The pressor effect of @DRUG$ is markedly potentiated in patients receiving @DRUG$ (MAOI).
2891	DDI-effect	MAO Inhibitors - The pressor effect of @DRUG$ is markedly potentiated in patients receiving monoamine oxidase inhibitors (@DRUG$).
2892	DDI-false	MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving @DRUG$ (@DRUG$).
2893	DDI-effect	The pressor response of @DRUG$ may also be potentiated by @DRUG$.
2894	DDI-effect	The CNS-depressant effect of @DRUG$ is additive with that of other @DRUG$, including alcohol.
2895	DDI-effect	The CNS-depressant effect of @DRUG$ is additive with that of other CNS depressants, including @DRUG$.
2896	DDI-false	The CNS-depressant effect of propoxyphene is additive with that of other @DRUG$, including @DRUG$.
2897	DDI-false	Such occurrences have been reported when @DRUG$ was administered to patients on @DRUG$, anticonvulsants, or warfarin-like drugs.
2898	DDI-false	Such occurrences have been reported when @DRUG$ was administered to patients on antidepressants, @DRUG$, or warfarin-like drugs.
2899	DDI-false	Such occurrences have been reported when @DRUG$ was administered to patients on antidepressants, anticonvulsants, or @DRUG$-like drugs.
2900	DDI-false	Such occurrences have been reported when propoxyphene was administered to patients on @DRUG$, @DRUG$, or warfarin-like drugs.
2901	DDI-false	Such occurrences have been reported when propoxyphene was administered to patients on @DRUG$, anticonvulsants, or @DRUG$-like drugs.
2902	DDI-false	Such occurrences have been reported when propoxyphene was administered to patients on antidepressants, @DRUG$, or @DRUG$-like drugs.
2903	DDI-false	Reduced absorption of @DRUG$ and @DRUG$ have been reported when those agents were administered concomitantly with sulfasalazine.
2904	DDI-mechanism	Reduced absorption of @DRUG$ and digoxin have been reported when those agents were administered concomitantly with @DRUG$.
2905	DDI-mechanism	Reduced absorption of folic acid and @DRUG$ have been reported when those agents were administered concomitantly with @DRUG$.
2906	DDI-false	When daily doses of @DRUG$ 2 g and weekly doses of @DRUG$ 7.5 mg were coadministered to 15 rheumatoid arthritis patients in a drug-drug interaction study, the pharmacokinetic disposition of the drugs was not altered.
2907	DDI-false	Daily doses of @DRUG$ 2 g (maximum 3 g) and weekly doses of @DRUG$ 7.5 mg (maximum 15 mg) were administered alone or in combination to 310 rheumatoid arthritis patients in two controlled 52-week clinical studies.
2908	DDI-false	@DRUG$: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of @DRUG$ with the co-administration of 100 mg sitagliptin for 10 days.
2909	DDI-false	@DRUG$: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg @DRUG$ for 10 days.
2910	DDI-mechanism	Digoxin: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of @DRUG$ with the co-administration of 100 mg @DRUG$ for 10 days.
2911	DDI-false	No dosage adjustment of @DRUG$ or @DRUG$ is recommended.
2912	DDI-mechanism	While co-administration of @DRUG$    appeared to increase the clearance of @DRUG$ by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme.
2913	DDI-false	While co-administration of @DRUG$    appeared to increase the clearance of Cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of @DRUG$.
2914	DDI-false	While co-administration of ZAVESCA    appeared to increase the clearance of @DRUG$ by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of @DRUG$.
2915	DDI-false	Combination therapy with @DRUG$    (@DRUG$) and ZAVESCA    is not indicated.
2916	DDI-advise	Combination therapy with @DRUG$    (imiglucerase) and @DRUG$    is not indicated.
2917	DDI-advise	Combination therapy with Cerezyme    (@DRUG$) and @DRUG$    is not indicated.
2918	DDI-effect	@DRUG$ may reverse the analgesic activity of @DRUG$.
2919	DDI-false	Concurrent use with @DRUG$ including @DRUG$, sumatriptan, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.
2920	DDI-false	Concurrent use with @DRUG$ including ergot alkaloids, @DRUG$, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.
2921	DDI-false	Concurrent use with @DRUG$ including ergot alkaloids, sumatriptan, and @DRUG$ (e.g. smoking) may result in enhanced vasoconstriction.
2922	DDI-false	Concurrent use with vasoconstrictor agents including @DRUG$, @DRUG$, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.
2923	DDI-false	Concurrent use with vasoconstrictor agents including @DRUG$, sumatriptan, and @DRUG$ (e.g. smoking) may result in enhanced vasoconstriction.
2924	DDI-false	Concurrent use with vasoconstrictor agents including ergot alkaloids, @DRUG$, and @DRUG$ (e.g. smoking) may result in enhanced vasoconstriction.
2925	DDI-false	Interactions for @DRUG$ (@DRUG$):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants
2926	DDI-int	Interactions for @DRUG$ (Thiamine):  @DRUG$, Oral Contraceptives, Stavudine, Tricyclic Antidepressants
2927	DDI-int	Interactions for @DRUG$ (Thiamine):  Loop Diuretics, Oral @DRUG$, Stavudine, Tricyclic Antidepressants
2928	DDI-int	Interactions for @DRUG$ (Thiamine):  Loop Diuretics, Oral Contraceptives, @DRUG$, Tricyclic Antidepressants
2929	DDI-int	Interactions for @DRUG$ (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, @DRUG$
2930	DDI-int	Interactions for Vitamin B1 (@DRUG$):  @DRUG$, Oral Contraceptives, Stavudine, Tricyclic Antidepressants
2931	DDI-int	Interactions for Vitamin B1 (@DRUG$):  Loop Diuretics, Oral @DRUG$, Stavudine, Tricyclic Antidepressants
2932	DDI-int	Interactions for Vitamin B1 (@DRUG$):  Loop Diuretics, Oral Contraceptives, @DRUG$, Tricyclic Antidepressants
2933	DDI-int	Interactions for Vitamin B1 (@DRUG$):  Loop Diuretics, Oral Contraceptives, Stavudine, @DRUG$
2934	DDI-false	Interactions for Vitamin B1 (Thiamine):  @DRUG$, Oral @DRUG$, Stavudine, Tricyclic Antidepressants
2935	DDI-false	Interactions for Vitamin B1 (Thiamine):  @DRUG$, Oral Contraceptives, @DRUG$, Tricyclic Antidepressants
2936	DDI-false	Interactions for Vitamin B1 (Thiamine):  @DRUG$, Oral Contraceptives, Stavudine, @DRUG$
2937	DDI-false	Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral @DRUG$, @DRUG$, Tricyclic Antidepressants
2938	DDI-false	Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral @DRUG$, Stavudine, @DRUG$
2939	DDI-false	Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, @DRUG$, @DRUG$
2940	DDI-false	Interactions for @DRUG$ (@DRUG$):  Alcohol - impairs the intestinal absorption of riboflavin
2941	DDI-false	Interactions for @DRUG$ (Riboflavin):  @DRUG$ - impairs the intestinal absorption of riboflavin
2942	DDI-false	Interactions for @DRUG$ (Riboflavin):  Alcohol - impairs the intestinal absorption of @DRUG$
2943	DDI-false	Interactions for Vitamin B2 (@DRUG$):  @DRUG$ - impairs the intestinal absorption of riboflavin
2944	DDI-false	Interactions for Vitamin B2 (@DRUG$):  Alcohol - impairs the intestinal absorption of @DRUG$
2945	DDI-mechanism	Interactions for Vitamin B2 (Riboflavin):  @DRUG$ - impairs the intestinal absorption of @DRUG$
2946	DDI-mechanism	@DRUG$ - concurrent use decreases gastrointestinal absorption of @DRUG$;
2947	DDI-effect	requirements for @DRUG$ may be increased in patients receiving @DRUG$.
2948	DDI-int	@DRUG$ can interact with @DRUG$, antichlolinergic, TCA, MAOIs, and alcohol.
2949	DDI-int	@DRUG$ can interact with CNS depressant, @DRUG$, TCA, MAOIs, and alcohol.
2950	DDI-int	@DRUG$ can interact with CNS depressant, antichlolinergic, @DRUG$, MAOIs, and alcohol.
2951	DDI-int	@DRUG$ can interact with CNS depressant, antichlolinergic, TCA, @DRUG$, and alcohol.
2952	DDI-int	@DRUG$ can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and @DRUG$.
2953	DDI-false	Mequitazine can interact with @DRUG$, @DRUG$, TCA, MAOIs, and alcohol.
2954	DDI-false	Mequitazine can interact with @DRUG$, antichlolinergic, @DRUG$, MAOIs, and alcohol.
2955	DDI-false	Mequitazine can interact with @DRUG$, antichlolinergic, TCA, @DRUG$, and alcohol.
2956	DDI-false	Mequitazine can interact with @DRUG$, antichlolinergic, TCA, MAOIs, and @DRUG$.
2957	DDI-false	Mequitazine can interact with CNS depressant, @DRUG$, @DRUG$, MAOIs, and alcohol.
2958	DDI-false	Mequitazine can interact with CNS depressant, @DRUG$, TCA, @DRUG$, and alcohol.
2959	DDI-false	Mequitazine can interact with CNS depressant, @DRUG$, TCA, MAOIs, and @DRUG$.
2960	DDI-false	Mequitazine can interact with CNS depressant, antichlolinergic, @DRUG$, @DRUG$, and alcohol.
2961	DDI-false	Mequitazine can interact with CNS depressant, antichlolinergic, @DRUG$, MAOIs, and @DRUG$.
2962	DDI-false	Mequitazine can interact with CNS depressant, antichlolinergic, TCA, @DRUG$, and @DRUG$.
2963	DDI-false	@DRUG$: Absorption of a single dose of @DRUG$ was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.
2964	DDI-false	@DRUG$: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking @DRUG$-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.
2965	DDI-false	@DRUG$: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-@DRUG$ containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.
2966	DDI-false	@DRUG$: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing @DRUG$ (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.
2967	DDI-false	@DRUG$: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when @DRUG$ was administered alone under fasting conditions.
2968	DDI-mechanism	Antacids: Absorption of a single dose of @DRUG$ was decreased when administered to 12 stable renal transplant patients also taking @DRUG$-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.
2969	DDI-mechanism	Antacids: Absorption of a single dose of @DRUG$ was decreased when administered to 12 stable renal transplant patients also taking magnesium-@DRUG$ containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.
2970	DDI-false	Antacids: Absorption of a single dose of @DRUG$ was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing @DRUG$ (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.
2971	DDI-false	Antacids: Absorption of a single dose of @DRUG$ was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when @DRUG$ was administered alone under fasting conditions.
2972	DDI-false	Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking @DRUG$-@DRUG$ containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.
2973	DDI-false	Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking @DRUG$-aluminum containing @DRUG$ (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.
2974	DDI-false	Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking @DRUG$-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when @DRUG$ was administered alone under fasting conditions.
2975	DDI-false	Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-@DRUG$ containing @DRUG$ (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.
2976	DDI-false	Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-@DRUG$ containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when @DRUG$ was administered alone under fasting conditions.
2977	DDI-false	Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing @DRUG$ (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when @DRUG$ was administered alone under fasting conditions.
2978	DDI-advise	It is recommended that @DRUG$ and @DRUG$ not be administered simultaneously.
2979	DDI-mechanism	However, in a drug-drug interaction study, mean @DRUG$ AUC was decreased by 15% when coadministered with @DRUG$.
2980	DDI-advise	Therefore, it is recommended that oral @DRUG$ are co- administered with @DRUG$ with caution and additional birth control methods be considered.
2981	DDI-false	@DRUG$: During treatment with @DRUG$, the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective.
2982	DDI-false	@DRUG$: During treatment with Myfortic, the use of @DRUG$ should be avoided and patients should be advised that vaccinations may be less effective.
2983	DDI-advise	Live Vaccines: During treatment with @DRUG$, the use of @DRUG$ should be avoided and patients should be advised that vaccinations may be less effective.
2984	DDI-false	Interference of @DRUG$ hydrolysis may lead to less @DRUG$ available for absorption.
2985	DDI-false	@DRUG$: When studied in stable renal transplant patients, @DRUG$, USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of Myfortic.
2986	DDI-false	@DRUG$: When studied in stable renal transplant patients, cyclosporine, USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of @DRUG$.
2987	DDI-false	Cyclosporine: When studied in stable renal transplant patients, @DRUG$, USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of @DRUG$.
2988	DDI-false	@DRUG$/@DRUG$: may be taken with Myfortic;
2989	DDI-false	@DRUG$/Ganciclovir: may be taken with @DRUG$;
2990	DDI-false	Acyclovir/@DRUG$: may be taken with @DRUG$;
2991	DDI-false	Both @DRUG$/@DRUG$ and MPAG concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two.
2992	DDI-false	Both @DRUG$/ganciclovir and @DRUG$ concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two.
2993	DDI-false	Both acyclovir/@DRUG$ and @DRUG$ concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two.
2994	DDI-false	@DRUG$/@DRUG$: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.
2995	DDI-false	@DRUG$/Mycophenolate Mofetil: Given that @DRUG$ and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.
2996	DDI-false	@DRUG$/Mycophenolate Mofetil: Given that azathioprine and @DRUG$ inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.
2997	DDI-false	@DRUG$/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that @DRUG$ not be administered concomitantly with azathioprine or mycophenolate mofetil.
2998	DDI-false	@DRUG$/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with @DRUG$ or mycophenolate mofetil.
2999	DDI-false	@DRUG$/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or @DRUG$.
3000	DDI-false	Azathioprine/@DRUG$: Given that @DRUG$ and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.
3001	DDI-false	Azathioprine/@DRUG$: Given that azathioprine and @DRUG$ inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.
3002	DDI-false	Azathioprine/@DRUG$: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that @DRUG$ not be administered concomitantly with azathioprine or mycophenolate mofetil.
3003	DDI-false	Azathioprine/@DRUG$: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with @DRUG$ or mycophenolate mofetil.
3004	DDI-false	Azathioprine/@DRUG$: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or @DRUG$.
3005	DDI-false	Azathioprine/Mycophenolate Mofetil: Given that @DRUG$ and @DRUG$ inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.
3006	DDI-false	Azathioprine/Mycophenolate Mofetil: Given that @DRUG$ and mycophenolate mofetil inhibit purine metabolism, it is recommended that @DRUG$ not be administered concomitantly with azathioprine or mycophenolate mofetil.
3007	DDI-false	Azathioprine/Mycophenolate Mofetil: Given that @DRUG$ and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with @DRUG$ or mycophenolate mofetil.
3008	DDI-false	Azathioprine/Mycophenolate Mofetil: Given that @DRUG$ and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or @DRUG$.
3009	DDI-false	Azathioprine/Mycophenolate Mofetil: Given that azathioprine and @DRUG$ inhibit purine metabolism, it is recommended that @DRUG$ not be administered concomitantly with azathioprine or mycophenolate mofetil.
3010	DDI-false	Azathioprine/Mycophenolate Mofetil: Given that azathioprine and @DRUG$ inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with @DRUG$ or mycophenolate mofetil.
3011	DDI-false	Azathioprine/Mycophenolate Mofetil: Given that azathioprine and @DRUG$ inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or @DRUG$.
3012	DDI-advise	Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that @DRUG$ not be administered concomitantly with @DRUG$ or mycophenolate mofetil.
3013	DDI-advise	Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that @DRUG$ not be administered concomitantly with azathioprine or @DRUG$.
3014	DDI-false	Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with @DRUG$ or @DRUG$.
3015	DDI-false	@DRUG$ and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce @DRUG$ exposure when coadministered with mycophenolate mofetil.
3016	DDI-false	@DRUG$ and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce MPA exposure when coadministered with @DRUG$.
3017	DDI-false	Cholestyramine and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce @DRUG$ exposure when coadministered with @DRUG$.
3018	DDI-advise	Therefore, do not administer @DRUG$ with @DRUG$ or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic.
3019	DDI-advise	Therefore, do not administer @DRUG$ with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral @DRUG$, because of the potential to reduce the efficacy of Myfortic.
3020	DDI-false	Therefore, do not administer @DRUG$ with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of @DRUG$.
3021	DDI-false	Therefore, do not administer Myfortic with @DRUG$ or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral @DRUG$, because of the potential to reduce the efficacy of Myfortic.
3022	DDI-false	Therefore, do not administer Myfortic with @DRUG$ or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of @DRUG$.
3023	DDI-false	Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral @DRUG$, because of the potential to reduce the efficacy of @DRUG$.
3024	DDI-false	Oral @DRUG$: Given the different metabolism of @DRUG$ and oral contraceptives, no drug interaction between these two classes of drug is expected.
3025	DDI-false	Oral @DRUG$: Given the different metabolism of Myfortic and oral @DRUG$, no drug interaction between these two classes of drug is expected.
3026	DDI-false	Oral Contraceptives: Given the different metabolism of @DRUG$ and oral @DRUG$, no drug interaction between these two classes of drug is expected.
3027	DDI-false	These include @DRUG$, @DRUG$, and oral and inhaled steroids.
3028	DDI-false	These include @DRUG$, methylxanthines, and oral and inhaled @DRUG$.
3029	DDI-false	These include sympathomimetic bronchodilators, @DRUG$, and oral and inhaled @DRUG$.
3030	DDI-advise	However, the co   administration of @DRUG$ with other @DRUG$   containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.
3031	DDI-advise	However, the co   administration of @DRUG$ with other anticholinergic   containing drugs (e.g., @DRUG$) has not been studied and is therefore not recommended.
3032	DDI-false	However, the co   administration of SPIRIVA with other @DRUG$   containing drugs (e.g., @DRUG$) has not been studied and is therefore not recommended.
3033	DDI-false	Interaction with Other @DRUG$: @DRUG$ SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
3034	DDI-false	Interaction with Other @DRUG$: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER @DRUG$, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
3035	DDI-false	Interaction with Other @DRUG$: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL @DRUG$, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
3036	DDI-false	Interaction with Other @DRUG$: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, @DRUG$, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
3037	DDI-false	Interaction with Other @DRUG$: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER @DRUG$, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
3038	DDI-false	Interaction with Other @DRUG$: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, @DRUG$ (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
3039	DDI-false	Interaction with Other @DRUG$: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING @DRUG$), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
3040	DDI-false	Interaction with Other @DRUG$: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), @DRUG$ AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
3041	DDI-false	Interaction with Other @DRUG$: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER @DRUG$ (INCLUDING ALCOHOL).
3042	DDI-false	Interaction with Other @DRUG$: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING @DRUG$).
3043	DDI-advise	Interaction with Other Central Nervous System Depressants: @DRUG$ SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER @DRUG$, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
3044	DDI-advise	Interaction with Other Central Nervous System Depressants: @DRUG$ SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL @DRUG$, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
3045	DDI-advise	Interaction with Other Central Nervous System Depressants: @DRUG$ SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, @DRUG$, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
3046	DDI-advise	Interaction with Other Central Nervous System Depressants: @DRUG$ SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER @DRUG$, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
3047	DDI-advise	Interaction with Other Central Nervous System Depressants: @DRUG$ SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, @DRUG$ (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
3048	DDI-advise	Interaction with Other Central Nervous System Depressants: @DRUG$ SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING @DRUG$), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
3049	DDI-advise	Interaction with Other Central Nervous System Depressants: @DRUG$ SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), @DRUG$ AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
3050	DDI-advise	Interaction with Other Central Nervous System Depressants: @DRUG$ SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER @DRUG$ (INCLUDING ALCOHOL).
3051	DDI-advise	Interaction with Other Central Nervous System Depressants: @DRUG$ SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING @DRUG$).
3052	DDI-false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER @DRUG$, GENERAL @DRUG$, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
3053	DDI-false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER @DRUG$, GENERAL ANESTHETICS, @DRUG$, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
3054	DDI-false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER @DRUG$, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER @DRUG$, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
3055	DDI-false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER @DRUG$, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, @DRUG$ (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
3056	DDI-false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER @DRUG$, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING @DRUG$), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
3057	DDI-false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER @DRUG$, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), @DRUG$ AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
3058	DDI-false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER @DRUG$, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER @DRUG$ (INCLUDING ALCOHOL).
3059	DDI-false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER @DRUG$, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING @DRUG$).
3060	DDI-false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL @DRUG$, @DRUG$, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
3061	DDI-false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL @DRUG$, PHENOTHIAZINES, OTHER @DRUG$, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
3062	DDI-false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL @DRUG$, PHENOTHIAZINES, OTHER TRANQUILIZERS, @DRUG$ (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
3063	DDI-false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL @DRUG$, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING @DRUG$), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
3064	DDI-false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL @DRUG$, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), @DRUG$ AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
3065	DDI-false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL @DRUG$, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER @DRUG$ (INCLUDING ALCOHOL).
3066	DDI-false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL @DRUG$, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING @DRUG$).
3067	DDI-false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, @DRUG$, OTHER @DRUG$, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
3068	DDI-false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, @DRUG$, OTHER TRANQUILIZERS, @DRUG$ (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
3069	DDI-false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, @DRUG$, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING @DRUG$), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
3070	DDI-false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, @DRUG$, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), @DRUG$ AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
3071	DDI-false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, @DRUG$, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER @DRUG$ (INCLUDING ALCOHOL).
3072	DDI-false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, @DRUG$, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING @DRUG$).
3073	DDI-false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER @DRUG$, @DRUG$ (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
3074	DDI-false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER @DRUG$, SEDATIVE-HYPNOTICS (INCLUDING @DRUG$), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
3075	DDI-false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER @DRUG$, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), @DRUG$ AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
3076	DDI-false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER @DRUG$, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER @DRUG$ (INCLUDING ALCOHOL).
3077	DDI-false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER @DRUG$, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING @DRUG$).
3078	DDI-false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, @DRUG$ (INCLUDING @DRUG$), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
3079	DDI-false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, @DRUG$ (INCLUDING BARBITURATES), @DRUG$ AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
3080	DDI-false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, @DRUG$ (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER @DRUG$ (INCLUDING ALCOHOL).
3081	DDI-false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, @DRUG$ (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING @DRUG$).
3082	DDI-false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING @DRUG$), @DRUG$ AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
3083	DDI-false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING @DRUG$), TRICYCLIC ANTIDEPRESSANTS AND OTHER @DRUG$ (INCLUDING ALCOHOL).
3084	DDI-false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING @DRUG$), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING @DRUG$).
3085	DDI-false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), @DRUG$ AND OTHER @DRUG$ (INCLUDING ALCOHOL).
3086	DDI-false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), @DRUG$ AND OTHER CNS DEPRESSANTS (INCLUDING @DRUG$).
3087	DDI-false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER @DRUG$ (INCLUDING @DRUG$).
3088	DDI-false	Drug-Drug Interactions: The pharmacokinetic and pharmacodynamic interactions between @DRUG$ capsules and other @DRUG$ have not been determined.
3089	DDI-advise	However, interactions may be expected and @DRUG$ capsules should NOT be used in combination with other @DRUG$.
3090	DDI-false	The pharmacokinetic interaction between @DRUG$ and @DRUG$ capsules was investigated.
3091	DDI-advise	Therefore, @DRUG$ capsules should be used with caution in combination with @DRUG$, particularly at doses higher than 0.4 mg.
3092	DDI-false	Results from limited in vitro and in vivo drug-drug interaction studies between @DRUG$ and @DRUG$ are inconclusive.
3093	DDI-advise	Therefore, caution should be exercised with concomitant administration of @DRUG$ and @DRUG$ capsules.
3094	DDI-effect	Catecholamine-depleting drugs (e.g., @DRUG$) may have an additive effect when given with @DRUG$.
3095	DDI-false	Concomitant administrations not recommended:  - @DRUG$ and @DRUG$: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter.
3096	DDI-false	Concomitant administrations not recommended:  - @DRUG$ and astemizole: Certain @DRUG$ interact with terfenadine and astemizole leading to increased serum concentrations of the latter.
3097	DDI-false	Concomitant administrations not recommended:  - @DRUG$ and astemizole: Certain macrolides interact with @DRUG$ and astemizole leading to increased serum concentrations of the latter.
3098	DDI-false	Concomitant administrations not recommended:  - @DRUG$ and astemizole: Certain macrolides interact with terfenadine and @DRUG$ leading to increased serum concentrations of the latter.
3099	DDI-false	Concomitant administrations not recommended:  - Terfenadine and @DRUG$: Certain @DRUG$ interact with terfenadine and astemizole leading to increased serum concentrations of the latter.
3100	DDI-false	Concomitant administrations not recommended:  - Terfenadine and @DRUG$: Certain macrolides interact with @DRUG$ and astemizole leading to increased serum concentrations of the latter.
3101	DDI-false	Concomitant administrations not recommended:  - Terfenadine and @DRUG$: Certain macrolides interact with terfenadine and @DRUG$ leading to increased serum concentrations of the latter.
3102	DDI-int	Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain @DRUG$ interact with @DRUG$ and astemizole leading to increased serum concentrations of the latter.
3103	DDI-int	Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain @DRUG$ interact with terfenadine and @DRUG$ leading to increased serum concentrations of the latter.
3104	DDI-false	Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with @DRUG$ and @DRUG$ leading to increased serum concentrations of the latter.
3105	DDI-false	Although such a reaction has not been demonstrated with @DRUG$, concomitant administration of @DRUG$ with terfenadine or astemizole is not recommended.
3106	DDI-false	Although such a reaction has not been demonstrated with @DRUG$, concomitant administration of roxithromycin with @DRUG$ or astemizole is not recommended.
3107	DDI-false	Although such a reaction has not been demonstrated with @DRUG$, concomitant administration of roxithromycin with terfenadine or @DRUG$ is not recommended.
3108	DDI-advise	Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of @DRUG$ with @DRUG$ or astemizole is not recommended.
3109	DDI-advise	Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of @DRUG$ with terfenadine or @DRUG$ is not recommended.
3110	DDI-false	Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with @DRUG$ or @DRUG$ is not recommended.
3111	DDI-false	- @DRUG$, @DRUG$: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials.
3112	DDI-false	- @DRUG$, pimozide: Other drugs such as @DRUG$ or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials.
3113	DDI-false	- @DRUG$, pimozide: Other drugs such as cisapride or @DRUG$, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials.
3114	DDI-false	- @DRUG$, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some @DRUG$.
3115	DDI-false	- Cisapride, @DRUG$: Other drugs such as @DRUG$ or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials.
3116	DDI-false	- Cisapride, @DRUG$: Other drugs such as cisapride or @DRUG$, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials.
3117	DDI-mechanism	- Cisapride, @DRUG$: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some @DRUG$.
3118	DDI-false	- Cisapride, pimozide: Other drugs such as @DRUG$ or @DRUG$, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials.
3119	DDI-mechanism	- Cisapride, pimozide: Other drugs such as @DRUG$ or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some @DRUG$.
3120	DDI-false	- Cisapride, pimozide: Other drugs such as cisapride or @DRUG$, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some @DRUG$.
3121	DDI-false	Although such a risk is not verified for @DRUG$, combination of @DRUG$ with such drugs is not recommended.
3122	DDI-false	@DRUG$: The effects of chronic @DRUG$ use on the metabolism of rimantadine are not known.
3123	DDI-false	@DRUG$: The effects of chronic cimetidine use on the metabolism of @DRUG$ are not known.
3124	DDI-false	Cimetidine: The effects of chronic @DRUG$ use on the metabolism of @DRUG$ are not known.
3125	DDI-mechanism	When a single 100 mg dose of @DRUG$ was administered one hour after the initiation of @DRUG$ (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine).
3126	DDI-false	When a single 100 mg dose of @DRUG$ was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total @DRUG$ clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine).
3127	DDI-false	When a single 100 mg dose of @DRUG$ was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total @DRUG$ clearance in the same subjects in the absence of cimetidine).
3128	DDI-false	When a single 100 mg dose of @DRUG$ was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of @DRUG$).
3129	DDI-false	When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of @DRUG$ (300 mg four times a day), the apparent total @DRUG$ clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine).
3130	DDI-false	When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of @DRUG$ (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total @DRUG$ clearance in the same subjects in the absence of cimetidine).
3131	DDI-false	When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of @DRUG$ (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of @DRUG$).
3132	DDI-false	When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total @DRUG$ clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total @DRUG$ clearance in the same subjects in the absence of cimetidine).
3133	DDI-false	When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total @DRUG$ clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of @DRUG$).
3134	DDI-false	When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total @DRUG$ clearance in the same subjects in the absence of @DRUG$).
3135	DDI-false	@DRUG$: @DRUG$, 100 mg, was given twice daily for 13 days to 12 healthy volunteers.
3136	DDI-mechanism	Coadministration with @DRUG$ reduced the peak concentration and AUC values for @DRUG$ by approximately 11%.
3137	DDI-false	@DRUG$: @DRUG$, 100 mg, was given twice daily fro 13 days to 12 healthy volunteers.
3138	DDI-mechanism	Peak plasma concentrations and AUC of @DRUG$ were reduced approximately 10% in the presence of @DRUG$.
3139	DDI-advise	Because @DRUG$ have been shown to depress plasma prothrombin activity, patients who are on @DRUG$ therapy may require downward adjustment of their anticoagulant dosage.
3140	DDI-false	Because @DRUG$ have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their @DRUG$ dosage.
3141	DDI-false	Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on @DRUG$ therapy may require downward adjustment of their @DRUG$ dosage.
3142	DDI-false	Since bacteriostatic drugs may interfere with the bactericidal action of @DRUG$, it is advisable to avoid giving @DRUG$ in conjunction with penicillin.
3143	DDI-false	Since bacteriostatic drugs may interfere with the bactericidal action of @DRUG$, it is advisable to avoid giving tetracycline class drugs in conjunction with @DRUG$.
3144	DDI-advise	Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving @DRUG$ in conjunction with @DRUG$.
3145	DDI-false	Absorption of @DRUG$ is impaired by @DRUG$ containing aluminum, calcium or magnesium, and iron-containing preparations.
3146	DDI-mechanism	Absorption of @DRUG$ is impaired by antacids containing @DRUG$, calcium or magnesium, and iron-containing preparations.
3147	DDI-mechanism	Absorption of @DRUG$ is impaired by antacids containing aluminum, @DRUG$ or magnesium, and iron-containing preparations.
3148	DDI-mechanism	Absorption of @DRUG$ is impaired by antacids containing aluminum, calcium or @DRUG$, and iron-containing preparations.
3149	DDI-mechanism	Absorption of @DRUG$ is impaired by antacids containing aluminum, calcium or magnesium, and @DRUG$-containing preparations.
3150	DDI-false	Absorption of tetracyclines is impaired by @DRUG$ containing @DRUG$, calcium or magnesium, and iron-containing preparations.
3151	DDI-false	Absorption of tetracyclines is impaired by @DRUG$ containing aluminum, @DRUG$ or magnesium, and iron-containing preparations.
3152	DDI-false	Absorption of tetracyclines is impaired by @DRUG$ containing aluminum, calcium or @DRUG$, and iron-containing preparations.
3153	DDI-false	Absorption of tetracyclines is impaired by @DRUG$ containing aluminum, calcium or magnesium, and @DRUG$-containing preparations.
3154	DDI-false	Absorption of tetracyclines is impaired by antacids containing @DRUG$, @DRUG$ or magnesium, and iron-containing preparations.
3155	DDI-false	Absorption of tetracyclines is impaired by antacids containing @DRUG$, calcium or @DRUG$, and iron-containing preparations.
3156	DDI-false	Absorption of tetracyclines is impaired by antacids containing @DRUG$, calcium or magnesium, and @DRUG$-containing preparations.
3157	DDI-false	Absorption of tetracyclines is impaired by antacids containing aluminum, @DRUG$ or @DRUG$, and iron-containing preparations.
3158	DDI-false	Absorption of tetracyclines is impaired by antacids containing aluminum, @DRUG$ or magnesium, and @DRUG$-containing preparations.
3159	DDI-false	Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or @DRUG$, and @DRUG$-containing preparations.
3160	DDI-effect	The concurrent use of @DRUG$ and @DRUG$ has been reported to result in fatal renal toxicity.
3161	DDI-effect	Concurrent use of @DRUG$ with oral @DRUG$ may render oral contraceptives less effective.
3162	DDI-false	Concurrent use of @DRUG$ with oral contraceptives may render oral @DRUG$ less effective.
3163	DDI-false	Concurrent use of tetracyclines with oral @DRUG$ may render oral @DRUG$ less effective.
3164	DDI-mechanism	Administration of @DRUG$ in combination with @DRUG$ resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.
3165	DDI-false	Administration of @DRUG$ in combination with HERCEPTIN resulted in a two-fold decrease in @DRUG$ clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.
3166	DDI-false	Administration of @DRUG$ in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in @DRUG$ serum levels in clinical studies.
3167	DDI-false	Administration of paclitaxel in combination with @DRUG$ resulted in a two-fold decrease in @DRUG$ clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.
3168	DDI-false	Administration of paclitaxel in combination with @DRUG$ resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in @DRUG$ serum levels in clinical studies.
3169	DDI-false	Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in @DRUG$ clearance in a non-human primate study and in a 1.5-fold increase in @DRUG$ serum levels in clinical studies.
3170	DDI-effect	The concomitant use of @DRUG$ with other @DRUG$ that produce dry mouth, constipation, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects.
3171	DDI-false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with @DRUG$ have not been conducted, @DRUG$ has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).
3172	DDI-false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with @DRUG$ have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. @DRUG$, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).
3173	DDI-false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with @DRUG$ have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, @DRUG$, pancuronium, morphine, vancomycin, metformin and tenofovir).
3174	DDI-false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with @DRUG$ have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, @DRUG$, morphine, vancomycin, metformin and tenofovir).
3175	DDI-false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with @DRUG$ have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, @DRUG$, vancomycin, metformin and tenofovir).
3176	DDI-false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with @DRUG$ have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, @DRUG$, metformin and tenofovir).
3177	DDI-false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with @DRUG$ have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, @DRUG$ and tenofovir).
3178	DDI-false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with @DRUG$ have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and @DRUG$).
3179	DDI-mechanism	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, @DRUG$ has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. @DRUG$, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).
3180	DDI-mechanism	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, @DRUG$ has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, @DRUG$, pancuronium, morphine, vancomycin, metformin and tenofovir).
3181	DDI-mechanism	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, @DRUG$ has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, @DRUG$, morphine, vancomycin, metformin and tenofovir).
3182	DDI-mechanism	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, @DRUG$ has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, @DRUG$, vancomycin, metformin and tenofovir).
3183	DDI-mechanism	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, @DRUG$ has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, @DRUG$, metformin and tenofovir).
3184	DDI-mechanism	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, @DRUG$ has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, @DRUG$ and tenofovir).
3185	DDI-mechanism	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, @DRUG$ has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and @DRUG$).
3186	DDI-false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. @DRUG$, @DRUG$, pancuronium, morphine, vancomycin, metformin and tenofovir).
3187	DDI-false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. @DRUG$, procainamide, @DRUG$, morphine, vancomycin, metformin and tenofovir).
3188	DDI-false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. @DRUG$, procainamide, pancuronium, @DRUG$, vancomycin, metformin and tenofovir).
3189	DDI-false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. @DRUG$, procainamide, pancuronium, morphine, @DRUG$, metformin and tenofovir).
3190	DDI-false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. @DRUG$, procainamide, pancuronium, morphine, vancomycin, @DRUG$ and tenofovir).
3191	DDI-false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. @DRUG$, procainamide, pancuronium, morphine, vancomycin, metformin and @DRUG$).
3192	DDI-false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, @DRUG$, @DRUG$, morphine, vancomycin, metformin and tenofovir).
3193	DDI-false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, @DRUG$, pancuronium, @DRUG$, vancomycin, metformin and tenofovir).
3194	DDI-false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, @DRUG$, pancuronium, morphine, @DRUG$, metformin and tenofovir).
3195	DDI-false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, @DRUG$, pancuronium, morphine, vancomycin, @DRUG$ and tenofovir).
3196	DDI-false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, @DRUG$, pancuronium, morphine, vancomycin, metformin and @DRUG$).
3197	DDI-false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, @DRUG$, @DRUG$, vancomycin, metformin and tenofovir).
3198	DDI-false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, @DRUG$, morphine, @DRUG$, metformin and tenofovir).
3199	DDI-false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, @DRUG$, morphine, vancomycin, @DRUG$ and tenofovir).
3200	DDI-false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, @DRUG$, morphine, vancomycin, metformin and @DRUG$).
3201	DDI-false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, @DRUG$, @DRUG$, metformin and tenofovir).
3202	DDI-false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, @DRUG$, vancomycin, @DRUG$ and tenofovir).
3203	DDI-false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, @DRUG$, vancomycin, metformin and @DRUG$).
3204	DDI-false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, @DRUG$, @DRUG$ and tenofovir).
3205	DDI-false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, @DRUG$, metformin and @DRUG$).
3206	DDI-false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, @DRUG$ and @DRUG$).
3207	DDI-false	Coadministration of @DRUG$ with drugs that are eliminated by active renal tubular secretion may increase the serum concentration of @DRUG$ and/or the coadministered drug due to competition for this elimination pathway.
3208	DDI-advise	Caution should be observed in administering @DRUG$ to patients receiving @DRUG$ or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis.
3209	DDI-advise	Caution should be observed in administering @DRUG$ to patients receiving phenothiazines or @DRUG$ because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis.
3210	DDI-false	Caution should be observed in administering DEMSER to patients receiving @DRUG$ or @DRUG$ because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis.
3211	DDI-effect	Concurrent use of @DRUG$ with @DRUG$ or other CNS depressants can increase their sedative effects.
3212	DDI-effect	Concurrent use of @DRUG$ with alcohol or other @DRUG$ can increase their sedative effects.
3213	DDI-false	Concurrent use of DEMSER with @DRUG$ or other @DRUG$ can increase their sedative effects.
3214	DDI-advise	You cannot take @DRUG$ if you have taken a @DRUG$ (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.
3215	DDI-advise	You cannot take @DRUG$ if you have taken a monoamine oxidase inhibitor (@DRUG$) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.
3216	DDI-advise	You cannot take @DRUG$ if you have taken a monoamine oxidase inhibitor (MAOI) such as @DRUG$ (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.
3217	DDI-advise	You cannot take @DRUG$ if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (@DRUG$), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.
3218	DDI-advise	You cannot take @DRUG$ if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), @DRUG$ (Parnate), or phenelzine (Nardil) in the last 14 days.
3219	DDI-advise	You cannot take @DRUG$ if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (@DRUG$), or phenelzine (Nardil) in the last 14 days.
3220	DDI-advise	You cannot take @DRUG$ if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or @DRUG$ (Nardil) in the last 14 days.
3221	DDI-advise	You cannot take @DRUG$ if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (@DRUG$) in the last 14 days.
3222	DDI-false	You cannot take mazindol if you have taken a @DRUG$ (@DRUG$) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.
3223	DDI-false	You cannot take mazindol if you have taken a @DRUG$ (MAOI) such as @DRUG$ (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.
3224	DDI-false	You cannot take mazindol if you have taken a @DRUG$ (MAOI) such as isocarboxazid (@DRUG$), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.
3225	DDI-false	You cannot take mazindol if you have taken a @DRUG$ (MAOI) such as isocarboxazid (Marplan), @DRUG$ (Parnate), or phenelzine (Nardil) in the last 14 days.
3226	DDI-false	You cannot take mazindol if you have taken a @DRUG$ (MAOI) such as isocarboxazid (Marplan), tranylcypromine (@DRUG$), or phenelzine (Nardil) in the last 14 days.
3227	DDI-false	You cannot take mazindol if you have taken a @DRUG$ (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or @DRUG$ (Nardil) in the last 14 days.
3228	DDI-false	You cannot take mazindol if you have taken a @DRUG$ (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (@DRUG$) in the last 14 days.
3229	DDI-false	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (@DRUG$) such as @DRUG$ (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.
3230	DDI-false	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (@DRUG$) such as isocarboxazid (@DRUG$), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.
3231	DDI-false	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (@DRUG$) such as isocarboxazid (Marplan), @DRUG$ (Parnate), or phenelzine (Nardil) in the last 14 days.
3232	DDI-false	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (@DRUG$) such as isocarboxazid (Marplan), tranylcypromine (@DRUG$), or phenelzine (Nardil) in the last 14 days.
3233	DDI-false	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (@DRUG$) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or @DRUG$ (Nardil) in the last 14 days.
3234	DDI-false	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (@DRUG$) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (@DRUG$) in the last 14 days.
3235	DDI-false	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as @DRUG$ (@DRUG$), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.
3236	DDI-false	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as @DRUG$ (Marplan), @DRUG$ (Parnate), or phenelzine (Nardil) in the last 14 days.
3237	DDI-false	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as @DRUG$ (Marplan), tranylcypromine (@DRUG$), or phenelzine (Nardil) in the last 14 days.
3238	DDI-false	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as @DRUG$ (Marplan), tranylcypromine (Parnate), or @DRUG$ (Nardil) in the last 14 days.
3239	DDI-false	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as @DRUG$ (Marplan), tranylcypromine (Parnate), or phenelzine (@DRUG$) in the last 14 days.
3240	DDI-false	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (@DRUG$), @DRUG$ (Parnate), or phenelzine (Nardil) in the last 14 days.
3241	DDI-false	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (@DRUG$), tranylcypromine (@DRUG$), or phenelzine (Nardil) in the last 14 days.
3242	DDI-false	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (@DRUG$), tranylcypromine (Parnate), or @DRUG$ (Nardil) in the last 14 days.
3243	DDI-false	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (@DRUG$), tranylcypromine (Parnate), or phenelzine (@DRUG$) in the last 14 days.
3244	DDI-false	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), @DRUG$ (@DRUG$), or phenelzine (Nardil) in the last 14 days.
3245	DDI-false	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), @DRUG$ (Parnate), or @DRUG$ (Nardil) in the last 14 days.
3246	DDI-false	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), @DRUG$ (Parnate), or phenelzine (@DRUG$) in the last 14 days.
3247	DDI-false	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (@DRUG$), or @DRUG$ (Nardil) in the last 14 days.
3248	DDI-false	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (@DRUG$), or phenelzine (@DRUG$) in the last 14 days.
3249	DDI-false	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or @DRUG$ (@DRUG$) in the last 14 days.
3250	DDI-advise	Changes in @DRUG$ and other diabetes drug therapies may be necessary during treatment with @DRUG$.
3251	DDI-effect	@DRUG$ may reduce the effects of @DRUG$ (Ismelin).
3252	DDI-effect	@DRUG$ may reduce the effects of guanethidine (@DRUG$).
3253	DDI-false	Mazindol may reduce the effects of @DRUG$ (@DRUG$).
3254	DDI-false	Before taking this medication, tell your doctor if you are taking a @DRUG$ such as @DRUG$ (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3255	DDI-false	Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (@DRUG$), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3256	DDI-false	Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), @DRUG$ (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3257	DDI-false	Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (@DRUG$), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3258	DDI-false	Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (Asendin), @DRUG$ (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3259	DDI-false	Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (@DRUG$), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3260	DDI-false	Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), @DRUG$ (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3261	DDI-false	Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (@DRUG$), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3262	DDI-false	Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), @DRUG$ (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3263	DDI-false	Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (@DRUG$), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3264	DDI-false	Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), @DRUG$ (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3265	DDI-false	Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (@DRUG$), protriptyline (Vivactil), or desipramine (Norpramin).
3266	DDI-false	Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), @DRUG$ (Vivactil), or desipramine (Norpramin).
3267	DDI-false	Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (@DRUG$), or desipramine (Norpramin).
3268	DDI-false	Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or @DRUG$ (Norpramin).
3269	DDI-false	Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (@DRUG$).
3270	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (@DRUG$), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3271	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), @DRUG$ (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3272	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (@DRUG$), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3273	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (Asendin), @DRUG$ (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3274	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (Asendin), doxepin (@DRUG$), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3275	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (Asendin), doxepin (Sinequan), @DRUG$ (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3276	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (@DRUG$), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3277	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), @DRUG$ (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3278	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (@DRUG$), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3279	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), @DRUG$ (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3280	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (@DRUG$), protriptyline (Vivactil), or desipramine (Norpramin).
3281	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), @DRUG$ (Vivactil), or desipramine (Norpramin).
3282	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (@DRUG$), or desipramine (Norpramin).
3283	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or @DRUG$ (Norpramin).
3284	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (@DRUG$).
3285	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), @DRUG$ (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3286	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (@DRUG$), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3287	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (Asendin), @DRUG$ (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3288	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (Asendin), doxepin (@DRUG$), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3289	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (Asendin), doxepin (Sinequan), @DRUG$ (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3290	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (@DRUG$), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3291	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), @DRUG$ (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3292	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (@DRUG$), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3293	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), @DRUG$ (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3294	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (@DRUG$), protriptyline (Vivactil), or desipramine (Norpramin).
3295	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), @DRUG$ (Vivactil), or desipramine (Norpramin).
3296	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (@DRUG$), or desipramine (Norpramin).
3297	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or @DRUG$ (Norpramin).
3298	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (@DRUG$).
3299	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (@DRUG$), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3300	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (Asendin), @DRUG$ (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3301	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (Asendin), doxepin (@DRUG$), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3302	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (Asendin), doxepin (Sinequan), @DRUG$ (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3303	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (Asendin), doxepin (Sinequan), nortriptyline (@DRUG$), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3304	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), @DRUG$ (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3305	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (@DRUG$), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3306	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), @DRUG$ (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3307	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (@DRUG$), protriptyline (Vivactil), or desipramine (Norpramin).
3308	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), @DRUG$ (Vivactil), or desipramine (Norpramin).
3309	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (@DRUG$), or desipramine (Norpramin).
3310	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or @DRUG$ (Norpramin).
3311	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (@DRUG$).
3312	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (@DRUG$), @DRUG$ (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3313	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (@DRUG$), doxepin (@DRUG$), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3314	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (@DRUG$), doxepin (Sinequan), @DRUG$ (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3315	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (@DRUG$), doxepin (Sinequan), nortriptyline (@DRUG$), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3316	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (@DRUG$), doxepin (Sinequan), nortriptyline (Pamelor), @DRUG$ (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3317	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (@DRUG$), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (@DRUG$), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3318	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (@DRUG$), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), @DRUG$ (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3319	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (@DRUG$), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (@DRUG$), protriptyline (Vivactil), or desipramine (Norpramin).
3320	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (@DRUG$), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), @DRUG$ (Vivactil), or desipramine (Norpramin).
3321	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (@DRUG$), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (@DRUG$), or desipramine (Norpramin).
3322	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (@DRUG$), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or @DRUG$ (Norpramin).
3323	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (@DRUG$), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (@DRUG$).
3324	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), @DRUG$ (@DRUG$), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3325	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), @DRUG$ (Sinequan), @DRUG$ (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3326	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), @DRUG$ (Sinequan), nortriptyline (@DRUG$), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3327	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), @DRUG$ (Sinequan), nortriptyline (Pamelor), @DRUG$ (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3328	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), @DRUG$ (Sinequan), nortriptyline (Pamelor), imipramine (@DRUG$), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3329	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), @DRUG$ (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), @DRUG$ (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3330	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), @DRUG$ (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (@DRUG$), protriptyline (Vivactil), or desipramine (Norpramin).
3331	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), @DRUG$ (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), @DRUG$ (Vivactil), or desipramine (Norpramin).
3332	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), @DRUG$ (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (@DRUG$), or desipramine (Norpramin).
3333	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), @DRUG$ (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or @DRUG$ (Norpramin).
3334	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), @DRUG$ (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (@DRUG$).
3335	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (@DRUG$), @DRUG$ (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3336	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (@DRUG$), nortriptyline (@DRUG$), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3337	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (@DRUG$), nortriptyline (Pamelor), @DRUG$ (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3338	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (@DRUG$), nortriptyline (Pamelor), imipramine (@DRUG$), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3339	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (@DRUG$), nortriptyline (Pamelor), imipramine (Tofranil), @DRUG$ (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3340	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (@DRUG$), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (@DRUG$), protriptyline (Vivactil), or desipramine (Norpramin).
3341	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (@DRUG$), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), @DRUG$ (Vivactil), or desipramine (Norpramin).
3342	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (@DRUG$), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (@DRUG$), or desipramine (Norpramin).
3343	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (@DRUG$), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or @DRUG$ (Norpramin).
3344	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (@DRUG$), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (@DRUG$).
3345	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), @DRUG$ (@DRUG$), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3346	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), @DRUG$ (Pamelor), @DRUG$ (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3347	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), @DRUG$ (Pamelor), imipramine (@DRUG$), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3348	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), @DRUG$ (Pamelor), imipramine (Tofranil), @DRUG$ (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3349	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), @DRUG$ (Pamelor), imipramine (Tofranil), clomipramine (@DRUG$), protriptyline (Vivactil), or desipramine (Norpramin).
3350	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), @DRUG$ (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), @DRUG$ (Vivactil), or desipramine (Norpramin).
3351	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), @DRUG$ (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (@DRUG$), or desipramine (Norpramin).
3352	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), @DRUG$ (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or @DRUG$ (Norpramin).
3353	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), @DRUG$ (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (@DRUG$).
3354	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (@DRUG$), @DRUG$ (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3355	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (@DRUG$), imipramine (@DRUG$), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3356	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (@DRUG$), imipramine (Tofranil), @DRUG$ (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3357	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (@DRUG$), imipramine (Tofranil), clomipramine (@DRUG$), protriptyline (Vivactil), or desipramine (Norpramin).
3358	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (@DRUG$), imipramine (Tofranil), clomipramine (Anafranil), @DRUG$ (Vivactil), or desipramine (Norpramin).
3359	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (@DRUG$), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (@DRUG$), or desipramine (Norpramin).
3360	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (@DRUG$), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or @DRUG$ (Norpramin).
3361	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (@DRUG$), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (@DRUG$).
3362	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), @DRUG$ (@DRUG$), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3363	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), @DRUG$ (Tofranil), @DRUG$ (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3364	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), @DRUG$ (Tofranil), clomipramine (@DRUG$), protriptyline (Vivactil), or desipramine (Norpramin).
3365	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), @DRUG$ (Tofranil), clomipramine (Anafranil), @DRUG$ (Vivactil), or desipramine (Norpramin).
3366	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), @DRUG$ (Tofranil), clomipramine (Anafranil), protriptyline (@DRUG$), or desipramine (Norpramin).
3367	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), @DRUG$ (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or @DRUG$ (Norpramin).
3368	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), @DRUG$ (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (@DRUG$).
3369	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (@DRUG$), @DRUG$ (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
3370	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (@DRUG$), clomipramine (@DRUG$), protriptyline (Vivactil), or desipramine (Norpramin).
3371	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (@DRUG$), clomipramine (Anafranil), @DRUG$ (Vivactil), or desipramine (Norpramin).
3372	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (@DRUG$), clomipramine (Anafranil), protriptyline (@DRUG$), or desipramine (Norpramin).
3373	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (@DRUG$), clomipramine (Anafranil), protriptyline (Vivactil), or @DRUG$ (Norpramin).
3374	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (@DRUG$), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (@DRUG$).
3375	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), @DRUG$ (@DRUG$), protriptyline (Vivactil), or desipramine (Norpramin).
3376	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), @DRUG$ (Anafranil), @DRUG$ (Vivactil), or desipramine (Norpramin).
3377	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), @DRUG$ (Anafranil), protriptyline (@DRUG$), or desipramine (Norpramin).
3378	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), @DRUG$ (Anafranil), protriptyline (Vivactil), or @DRUG$ (Norpramin).
3379	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), @DRUG$ (Anafranil), protriptyline (Vivactil), or desipramine (@DRUG$).
3380	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (@DRUG$), @DRUG$ (Vivactil), or desipramine (Norpramin).
3381	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (@DRUG$), protriptyline (@DRUG$), or desipramine (Norpramin).
3382	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (@DRUG$), protriptyline (Vivactil), or @DRUG$ (Norpramin).
3383	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (@DRUG$), protriptyline (Vivactil), or desipramine (@DRUG$).
3384	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), @DRUG$ (@DRUG$), or desipramine (Norpramin).
3385	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), @DRUG$ (Vivactil), or @DRUG$ (Norpramin).
3386	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), @DRUG$ (Vivactil), or desipramine (@DRUG$).
3387	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (@DRUG$), or @DRUG$ (Norpramin).
3388	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (@DRUG$), or desipramine (@DRUG$).
3389	DDI-false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or @DRUG$ (@DRUG$).
3390	DDI-mechanism	@DRUG$ has been reported to accelerate the metabolism of @DRUG$ by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin.
3391	DDI-false	@DRUG$ has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for @DRUG$.
3392	DDI-false	Mitotane has been reported to accelerate the metabolism of @DRUG$ by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for @DRUG$.
3393	DDI-false	Therefore, physicians should closely monitor patients for a change in @DRUG$ dosage requirements when administering @DRUG$ to patients on coumarin-type anticoagulants.
3394	DDI-false	Therefore, physicians should closely monitor patients for a change in @DRUG$ dosage requirements when administering Mitotane to patients on @DRUG$.
3395	DDI-advise	Therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering @DRUG$ to patients on @DRUG$.
3396	DDI-false	Because there is a theoretical basis that these effects may be additive, use of @DRUG$-containing or @DRUG$ (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided.
3397	DDI-false	Because there is a theoretical basis that these effects may be additive, use of @DRUG$-containing or ergot-type medications (like @DRUG$ or methysergide) and sumatriptan within 24 hours of each other should be avoided.
3398	DDI-false	Because there is a theoretical basis that these effects may be additive, use of @DRUG$-containing or ergot-type medications (like dihydroergotamine or @DRUG$) and sumatriptan within 24 hours of each other should be avoided.
3399	DDI-advise	Because there is a theoretical basis that these effects may be additive, use of @DRUG$-containing or ergot-type medications (like dihydroergotamine or methysergide) and @DRUG$ within 24 hours of each other should be avoided.
3400	DDI-false	Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or @DRUG$ (like @DRUG$ or methysergide) and sumatriptan within 24 hours of each other should be avoided.
3401	DDI-false	Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or @DRUG$ (like dihydroergotamine or @DRUG$) and sumatriptan within 24 hours of each other should be avoided.
3402	DDI-advise	Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or @DRUG$ (like dihydroergotamine or methysergide) and @DRUG$ within 24 hours of each other should be avoided.
3403	DDI-false	Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like @DRUG$ or @DRUG$) and sumatriptan within 24 hours of each other should be avoided.
3404	DDI-advise	Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like @DRUG$ or methysergide) and @DRUG$ within 24 hours of each other should be avoided.
3405	DDI-advise	Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or @DRUG$) and @DRUG$ within 24 hours of each other should be avoided.
3406	DDI-mechanism	@DRUG$ reduce @DRUG$ clearance, significantly increasing systemic exposure.
3407	DDI-advise	Therefore, the use of @DRUG$ tablets in patients receiving @DRUG$ is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.
3408	DDI-false	Therefore, the use of @DRUG$ tablets in patients receiving MAO-A inhibitors is contraindicated . @DRUG$ (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.
3409	DDI-false	Therefore, the use of @DRUG$ tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (@DRUG$) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.
3410	DDI-false	Therefore, the use of @DRUG$ tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., @DRUG$, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.
3411	DDI-false	Therefore, the use of @DRUG$ tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, @DRUG$, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.
3412	DDI-false	Therefore, the use of @DRUG$ tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, @DRUG$, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.
3413	DDI-false	Therefore, the use of @DRUG$ tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.
3414	DDI-false	Therefore, the use of @DRUG$ tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.
3415	DDI-false	Therefore, the use of sumatriptan succinate tablets in patients receiving @DRUG$ is contraindicated . @DRUG$ (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.
3416	DDI-false	Therefore, the use of sumatriptan succinate tablets in patients receiving @DRUG$ is contraindicated . Selective serotonin reuptake inhibitors (@DRUG$) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.
3417	DDI-false	Therefore, the use of sumatriptan succinate tablets in patients receiving @DRUG$ is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., @DRUG$, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.
3418	DDI-false	Therefore, the use of sumatriptan succinate tablets in patients receiving @DRUG$ is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, @DRUG$, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.
3419	DDI-false	Therefore, the use of sumatriptan succinate tablets in patients receiving @DRUG$ is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, @DRUG$, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.
3420	DDI-false	Therefore, the use of sumatriptan succinate tablets in patients receiving @DRUG$ is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.
3421	DDI-false	Therefore, the use of sumatriptan succinate tablets in patients receiving @DRUG$ is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.
3422	DDI-false	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . @DRUG$ (@DRUG$) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.
3423	DDI-false	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . @DRUG$ (SSRIs) (e.g., @DRUG$, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.
3424	DDI-false	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . @DRUG$ (SSRIs) (e.g., fluoxetine, @DRUG$, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.
3425	DDI-false	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . @DRUG$ (SSRIs) (e.g., fluoxetine, fluvoxamine, @DRUG$, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.
3426	DDI-false	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . @DRUG$ (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.
3427	DDI-effect	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . @DRUG$ (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.
3428	DDI-false	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (@DRUG$) (e.g., @DRUG$, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.
3429	DDI-false	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (@DRUG$) (e.g., fluoxetine, @DRUG$, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.
3430	DDI-false	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (@DRUG$) (e.g., fluoxetine, fluvoxamine, @DRUG$, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.
3431	DDI-false	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (@DRUG$) (e.g., fluoxetine, fluvoxamine, paroxetine, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.
3432	DDI-effect	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (@DRUG$) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.
3433	DDI-false	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., @DRUG$, @DRUG$, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.
3434	DDI-false	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., @DRUG$, fluvoxamine, @DRUG$, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.
3435	DDI-false	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., @DRUG$, fluvoxamine, paroxetine, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.
3436	DDI-effect	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., @DRUG$, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.
3437	DDI-false	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, @DRUG$, @DRUG$, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.
3438	DDI-false	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, @DRUG$, paroxetine, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.
3439	DDI-effect	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, @DRUG$, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.
3440	DDI-false	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, @DRUG$, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.
3441	DDI-effect	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, @DRUG$, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.
3442	DDI-effect	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.
3443	DDI-advise	If concomitant treatment with @DRUG$ and an @DRUG$ is clinically warranted, appropriate observation of the patient is advised.
3444	DDI-mechanism	The bioavailability of @DRUG$ is decreased 80% by @DRUG$, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID.
3445	DDI-false	The bioavailability of @DRUG$ is decreased 80% by calcium, when @DRUG$ and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID.
3446	DDI-false	The bioavailability of @DRUG$ is decreased 80% by calcium, when calcium and @DRUG$ are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID.
3447	DDI-false	The bioavailability of @DRUG$ is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some @DRUG$- or magnesium-containing antacids, when administered 1 hour before SKELID.
3448	DDI-false	The bioavailability of @DRUG$ is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or @DRUG$-containing antacids, when administered 1 hour before SKELID.
3449	DDI-false	The bioavailability of @DRUG$ is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing @DRUG$, when administered 1 hour before SKELID.
3450	DDI-false	The bioavailability of @DRUG$ is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before @DRUG$.
3451	DDI-false	The bioavailability of SKELID is decreased 80% by @DRUG$, when @DRUG$ and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID.
3452	DDI-false	The bioavailability of SKELID is decreased 80% by @DRUG$, when calcium and @DRUG$ are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID.
3453	DDI-false	The bioavailability of SKELID is decreased 80% by @DRUG$, when calcium and SKELID are administered at the same time, and 60% by some @DRUG$- or magnesium-containing antacids, when administered 1 hour before SKELID.
3454	DDI-false	The bioavailability of SKELID is decreased 80% by @DRUG$, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or @DRUG$-containing antacids, when administered 1 hour before SKELID.
3455	DDI-false	The bioavailability of SKELID is decreased 80% by @DRUG$, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing @DRUG$, when administered 1 hour before SKELID.
3456	DDI-false	The bioavailability of SKELID is decreased 80% by @DRUG$, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before @DRUG$.
3457	DDI-false	The bioavailability of SKELID is decreased 80% by calcium, when @DRUG$ and @DRUG$ are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID.
3458	DDI-false	The bioavailability of SKELID is decreased 80% by calcium, when @DRUG$ and SKELID are administered at the same time, and 60% by some @DRUG$- or magnesium-containing antacids, when administered 1 hour before SKELID.
3459	DDI-false	The bioavailability of SKELID is decreased 80% by calcium, when @DRUG$ and SKELID are administered at the same time, and 60% by some aluminum- or @DRUG$-containing antacids, when administered 1 hour before SKELID.
3460	DDI-false	The bioavailability of SKELID is decreased 80% by calcium, when @DRUG$ and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing @DRUG$, when administered 1 hour before SKELID.
3461	DDI-false	The bioavailability of SKELID is decreased 80% by calcium, when @DRUG$ and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before @DRUG$.
3462	DDI-false	The bioavailability of SKELID is decreased 80% by calcium, when calcium and @DRUG$ are administered at the same time, and 60% by some @DRUG$- or magnesium-containing antacids, when administered 1 hour before SKELID.
3463	DDI-false	The bioavailability of SKELID is decreased 80% by calcium, when calcium and @DRUG$ are administered at the same time, and 60% by some aluminum- or @DRUG$-containing antacids, when administered 1 hour before SKELID.
3464	DDI-false	The bioavailability of SKELID is decreased 80% by calcium, when calcium and @DRUG$ are administered at the same time, and 60% by some aluminum- or magnesium-containing @DRUG$, when administered 1 hour before SKELID.
3465	DDI-false	The bioavailability of SKELID is decreased 80% by calcium, when calcium and @DRUG$ are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before @DRUG$.
3466	DDI-false	The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some @DRUG$- or @DRUG$-containing antacids, when administered 1 hour before SKELID.
3467	DDI-false	The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some @DRUG$- or magnesium-containing @DRUG$, when administered 1 hour before SKELID.
3468	DDI-mechanism	The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some @DRUG$- or magnesium-containing antacids, when administered 1 hour before @DRUG$.
3469	DDI-false	The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or @DRUG$-containing @DRUG$, when administered 1 hour before SKELID.
3470	DDI-mechanism	The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or @DRUG$-containing antacids, when administered 1 hour before @DRUG$.
3471	DDI-false	The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing @DRUG$, when administered 1 hour before @DRUG$.
3472	DDI-mechanism	@DRUG$ may decrease bioavailability of @DRUG$ by up to 50% when taken 2 hours after SKELID.
3473	DDI-false	@DRUG$ may decrease bioavailability of SKELID by up to 50% when taken 2 hours after @DRUG$.
3474	DDI-false	Aspirin may decrease bioavailability of @DRUG$ by up to 50% when taken 2 hours after @DRUG$.
3475	DDI-mechanism	The bioavailability of @DRUG$ is increased 2-4 fold by @DRUG$ but is not significantly altered by coadministration of diclofenac.
3476	DDI-false	The bioavailability of @DRUG$ is increased 2-4 fold by indomethacin but is not significantly altered by coadministration of @DRUG$.
3477	DDI-false	The bioavailability of SKELID is increased 2-4 fold by @DRUG$ but is not significantly altered by coadministration of @DRUG$.
3478	DDI-false	The pharmacokinetic parameters of @DRUG$ are not significantly modified by @DRUG$ coadministration.
3479	DDI-false	In vitro studies show that @DRUG$ does not displace @DRUG$ from its binding site on protein.
3480	DDI-false	There is usually complete cross-resistance between @DRUG$ (@DRUG$) and TABLOID brand Thioguanine.
3481	DDI-effect	There is usually complete cross-resistance between @DRUG$ (mercaptopurine) and @DRUG$ brand Thioguanine.
3482	DDI-effect	There is usually complete cross-resistance between @DRUG$ (mercaptopurine) and TABLOID brand @DRUG$.
3483	DDI-effect	There is usually complete cross-resistance between PURINETHOL (@DRUG$) and @DRUG$ brand Thioguanine.
3484	DDI-effect	There is usually complete cross-resistance between PURINETHOL (@DRUG$) and TABLOID brand @DRUG$.
3485	DDI-false	There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and @DRUG$ brand @DRUG$.
3486	DDI-false	As there is in vitro evidence that @DRUG$ (e.g., @DRUG$, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.
3487	DDI-false	As there is in vitro evidence that @DRUG$ (e.g., olsalazine, @DRUG$, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.
3488	DDI-false	As there is in vitro evidence that @DRUG$ (e.g., olsalazine, mesalazine, or @DRUG$) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.
3489	DDI-mechanism	As there is in vitro evidence that @DRUG$ (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent @DRUG$ therapy.
3490	DDI-false	As there is in vitro evidence that aminosalicylate derivatives (e.g., @DRUG$, @DRUG$, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.
3491	DDI-false	As there is in vitro evidence that aminosalicylate derivatives (e.g., @DRUG$, mesalazine, or @DRUG$) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.
3492	DDI-mechanism	As there is in vitro evidence that aminosalicylate derivatives (e.g., @DRUG$, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent @DRUG$ therapy.
3493	DDI-false	As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, @DRUG$, or @DRUG$) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.
3494	DDI-mechanism	As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, @DRUG$, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent @DRUG$ therapy.
3495	DDI-mechanism	As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or @DRUG$) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent @DRUG$ therapy.
3496	DDI-false	Other eye drops or medications such as @DRUG$ (@DRUG$) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.
3497	DDI-false	Other eye drops or medications such as @DRUG$ (Miochol) and @DRUG$ (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.
3498	DDI-false	Other eye drops or medications such as @DRUG$ (Miochol) and carbachol (@DRUG$, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.
3499	DDI-false	Other eye drops or medications such as @DRUG$ (Miochol) and carbachol (Carboptic, @DRUG$) may decrease the effects of suprofen ophthalmic.
3500	DDI-effect	Other eye drops or medications such as @DRUG$ (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of @DRUG$ ophthalmic.
3501	DDI-false	Other eye drops or medications such as acetylcholine chloride (@DRUG$) and @DRUG$ (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.
3502	DDI-false	Other eye drops or medications such as acetylcholine chloride (@DRUG$) and carbachol (@DRUG$, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.
3503	DDI-false	Other eye drops or medications such as acetylcholine chloride (@DRUG$) and carbachol (Carboptic, @DRUG$) may decrease the effects of suprofen ophthalmic.
3504	DDI-effect	Other eye drops or medications such as acetylcholine chloride (@DRUG$) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of @DRUG$ ophthalmic.
3505	DDI-false	Other eye drops or medications such as acetylcholine chloride (Miochol) and @DRUG$ (@DRUG$, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.
3506	DDI-false	Other eye drops or medications such as acetylcholine chloride (Miochol) and @DRUG$ (Carboptic, @DRUG$) may decrease the effects of suprofen ophthalmic.
3507	DDI-effect	Other eye drops or medications such as acetylcholine chloride (Miochol) and @DRUG$ (Carboptic, Isopto Carbachol) may decrease the effects of @DRUG$ ophthalmic.
3508	DDI-false	Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (@DRUG$, @DRUG$) may decrease the effects of suprofen ophthalmic.
3509	DDI-effect	Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (@DRUG$, Isopto Carbachol) may decrease the effects of @DRUG$ ophthalmic.
3510	DDI-effect	Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, @DRUG$) may decrease the effects of @DRUG$ ophthalmic.
3511	DDI-false	@DRUG$, particularly @DRUG$, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all.
3512	DDI-effect	@DRUG$, particularly metaraminol, may cause serious cardiac arrhythmias during @DRUG$ anesthesia and therefore should be used only with great caution or not at all.
3513	DDI-effect	Vasopressors, particularly @DRUG$, may cause serious cardiac arrhythmias during @DRUG$ anesthesia and therefore should be used only with great caution or not at all.
3514	DDI-false	@DRUG$: The pressor effect of @DRUG$ is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI).
3515	DDI-false	@DRUG$: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving @DRUG$ (MAOI).
3516	DDI-false	@DRUG$: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (@DRUG$).
3517	DDI-effect	MAO Inhibitors: The pressor effect of @DRUG$ is markedly potentiated in patients receiving @DRUG$ (MAOI).
3518	DDI-effect	MAO Inhibitors: The pressor effect of @DRUG$ is markedly potentiated in patients receiving monoamine oxidase inhibitors (@DRUG$).
3519	DDI-false	MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving @DRUG$ (@DRUG$).
3520	DDI-effect	The pressor response of @DRUG$ may also be potentiated by @DRUG$.
3521	DDI-mechanism	A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3522	DDI-false	A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3523	DDI-false	A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3524	DDI-false	A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3525	DDI-false	A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3526	DDI-false	A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3527	DDI-false	A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3528	DDI-false	A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3529	DDI-false	A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3530	DDI-false	A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3531	DDI-false	A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin or voriconazole.
3532	DDI-false	A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin or voriconazole.
3533	DDI-false	A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin or voriconazole.
3534	DDI-false	A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$ or voriconazole.
3535	DDI-false	A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or @DRUG$.
3536	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3537	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3538	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3539	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3540	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3541	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3542	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3543	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3544	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3545	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin or voriconazole.
3546	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin or voriconazole.
3547	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin or voriconazole.
3548	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$ or voriconazole.
3549	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or @DRUG$.
3550	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3551	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3552	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3553	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3554	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3555	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3556	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3557	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3558	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin or voriconazole.
3559	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin or voriconazole.
3560	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin or voriconazole.
3561	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$ or voriconazole.
3562	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or @DRUG$.
3563	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3564	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3565	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3566	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3567	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3568	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3569	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3570	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin or voriconazole.
3571	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin or voriconazole.
3572	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin or voriconazole.
3573	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$ or voriconazole.
3574	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or @DRUG$.
3575	DDI-advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3576	DDI-advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3577	DDI-advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3578	DDI-advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3579	DDI-advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3580	DDI-advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3581	DDI-advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin or voriconazole.
3582	DDI-advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin or voriconazole.
3583	DDI-advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin or voriconazole.
3584	DDI-advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$ or voriconazole.
3585	DDI-advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or @DRUG$.
3586	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3587	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3588	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3589	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3590	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3591	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin or voriconazole.
3592	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin or voriconazole.
3593	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin or voriconazole.
3594	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$ or voriconazole.
3595	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or @DRUG$.
3596	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, @DRUG$, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3597	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, @DRUG$, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3598	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3599	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, itraconazole, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3600	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, itraconazole, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin or voriconazole.
3601	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin or voriconazole.
3602	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin or voriconazole.
3603	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$ or voriconazole.
3604	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or @DRUG$.
3605	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, @DRUG$, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3606	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3607	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, itraconazole, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3608	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, itraconazole, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin or voriconazole.
3609	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, itraconazole, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin or voriconazole.
3610	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin or voriconazole.
3611	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$ or voriconazole.
3612	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or @DRUG$.
3613	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3614	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, itraconazole, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3615	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, itraconazole, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin or voriconazole.
3616	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, itraconazole, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin or voriconazole.
3617	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, itraconazole, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin or voriconazole.
3618	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$ or voriconazole.
3619	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or @DRUG$.
3620	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, @DRUG$, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
3621	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, @DRUG$, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin or voriconazole.
3622	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, @DRUG$, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin or voriconazole.
3623	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, @DRUG$, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin or voriconazole.
3624	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$ or voriconazole.
3625	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or @DRUG$.
3626	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, @DRUG$, @DRUG$, ritonavir, saquinavir, telithromycin or voriconazole.
3627	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, @DRUG$, nelfinavir, @DRUG$, saquinavir, telithromycin or voriconazole.
3628	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, @DRUG$, nelfinavir, ritonavir, @DRUG$, telithromycin or voriconazole.
3629	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, @DRUG$, nelfinavir, ritonavir, saquinavir, @DRUG$ or voriconazole.
3630	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin or @DRUG$.
3631	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, @DRUG$, @DRUG$, saquinavir, telithromycin or voriconazole.
3632	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, @DRUG$, ritonavir, @DRUG$, telithromycin or voriconazole.
3633	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, @DRUG$, ritonavir, saquinavir, @DRUG$ or voriconazole.
3634	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin or @DRUG$.
3635	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, @DRUG$, @DRUG$, telithromycin or voriconazole.
3636	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, @DRUG$, saquinavir, @DRUG$ or voriconazole.
3637	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin or @DRUG$.
3638	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, @DRUG$, @DRUG$ or voriconazole.
3639	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin or @DRUG$.
3640	DDI-false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$ or @DRUG$.
3641	DDI-advise	Dose adjustment of @DRUG$ Capsules may be required, and iPTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor such as @DRUG$.
3642	DDI-mechanism	Drugs that impair intestinal absorption of @DRUG$, such as @DRUG$, may interfere with the absorption of Zemplar Capsules.
3643	DDI-false	Drugs that impair intestinal absorption of @DRUG$, such as cholestyramine, may interfere with the absorption of @DRUG$ Capsules.
3644	DDI-mechanism	Drugs that impair intestinal absorption of fat-soluble vitamins, such as @DRUG$, may interfere with the absorption of @DRUG$ Capsules.
3645	DDI-effect	@DRUG$ competitively inhibits the intracellular phosphorylation of @DRUG$.
3646	DDI-advise	Therefore, use of @DRUG$ in combination with @DRUG$ should be avoided.
3647	DDI-effect	In vitro data indicate that the phosphorylation of @DRUG$ is also inhibited at relevant concentrations by @DRUG$ and ribavirin.
3648	DDI-effect	In vitro data indicate that the phosphorylation of @DRUG$ is also inhibited at relevant concentrations by doxorubicin and @DRUG$.
3649	DDI-false	In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by @DRUG$ and @DRUG$.
3650	DDI-false	No pharmacokinetic interaction between 85 mg/m2 @DRUG$ and infusional @DRUG$ has been observed in patients treated every 2 weeks.
3651	DDI-mechanism	Increases of @DRUG$ plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2 @DRUG$ dosed every 3 weeks.
3652	DDI-false	@DRUG$ is not known to interact with other drugs including @DRUG$ supplements;
3653	DDI-advise	Concomitant administration of @DRUG$ with other chelation therapy, such as @DRUG$ is not recommended.
3654	DDI-effect	@DRUG$ may accentuate the orthostatic hypotension that may occur with @DRUG$.
3655	DDI-effect	Antihypertensive effects of @DRUG$ and related compounds may be counteracted when @DRUG$ are used concomitantly.
3656	DDI-mechanism	Concomitant administration of @DRUG$ with @DRUG$ results in increased plasma levels of both drugs.
3657	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between @DRUG$ and @DRUG$, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.
3658	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between @DRUG$ and mycophenolate mofetil, @DRUG$, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.
3659	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between @DRUG$ and mycophenolate mofetil, cyclosporine, @DRUG$, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.
3660	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between @DRUG$ and mycophenolate mofetil, cyclosporine, tacrolimus, @DRUG$, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.
3661	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between @DRUG$ and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, @DRUG$, nifedipine, fluconazole, ritonavir, and rifampin.
3662	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between @DRUG$ and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, @DRUG$, fluconazole, ritonavir, and rifampin.
3663	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between @DRUG$ and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, @DRUG$, ritonavir, and rifampin.
3664	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between @DRUG$ and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, @DRUG$, and rifampin.
3665	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between @DRUG$ and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and @DRUG$.
3666	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and @DRUG$, @DRUG$, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.
3667	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and @DRUG$, cyclosporine, @DRUG$, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.
3668	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and @DRUG$, cyclosporine, tacrolimus, @DRUG$, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.
3669	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and @DRUG$, cyclosporine, tacrolimus, prednisolone, @DRUG$, nifedipine, fluconazole, ritonavir, and rifampin.
3670	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and @DRUG$, cyclosporine, tacrolimus, prednisolone, sirolimus, @DRUG$, fluconazole, ritonavir, and rifampin.
3671	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and @DRUG$, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, @DRUG$, ritonavir, and rifampin.
3672	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and @DRUG$, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, @DRUG$, and rifampin.
3673	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and @DRUG$, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and @DRUG$.
3674	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, @DRUG$, @DRUG$, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.
3675	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, @DRUG$, tacrolimus, @DRUG$, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.
3676	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, @DRUG$, tacrolimus, prednisolone, @DRUG$, nifedipine, fluconazole, ritonavir, and rifampin.
3677	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, @DRUG$, tacrolimus, prednisolone, sirolimus, @DRUG$, fluconazole, ritonavir, and rifampin.
3678	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, @DRUG$, tacrolimus, prednisolone, sirolimus, nifedipine, @DRUG$, ritonavir, and rifampin.
3679	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, @DRUG$, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, @DRUG$, and rifampin.
3680	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, @DRUG$, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and @DRUG$.
3681	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, @DRUG$, @DRUG$, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.
3682	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, @DRUG$, prednisolone, @DRUG$, nifedipine, fluconazole, ritonavir, and rifampin.
3683	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, @DRUG$, prednisolone, sirolimus, @DRUG$, fluconazole, ritonavir, and rifampin.
3684	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, @DRUG$, prednisolone, sirolimus, nifedipine, @DRUG$, ritonavir, and rifampin.
3685	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, @DRUG$, prednisolone, sirolimus, nifedipine, fluconazole, @DRUG$, and rifampin.
3686	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, @DRUG$, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and @DRUG$.
3687	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, @DRUG$, @DRUG$, nifedipine, fluconazole, ritonavir, and rifampin.
3688	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, @DRUG$, sirolimus, @DRUG$, fluconazole, ritonavir, and rifampin.
3689	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, @DRUG$, sirolimus, nifedipine, @DRUG$, ritonavir, and rifampin.
3690	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, @DRUG$, sirolimus, nifedipine, fluconazole, @DRUG$, and rifampin.
3691	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, @DRUG$, sirolimus, nifedipine, fluconazole, ritonavir, and @DRUG$.
3692	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, @DRUG$, @DRUG$, fluconazole, ritonavir, and rifampin.
3693	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, @DRUG$, nifedipine, @DRUG$, ritonavir, and rifampin.
3694	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, @DRUG$, nifedipine, fluconazole, @DRUG$, and rifampin.
3695	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, @DRUG$, nifedipine, fluconazole, ritonavir, and @DRUG$.
3696	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, @DRUG$, @DRUG$, ritonavir, and rifampin.
3697	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, @DRUG$, fluconazole, @DRUG$, and rifampin.
3698	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, @DRUG$, fluconazole, ritonavir, and @DRUG$.
3699	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, @DRUG$, @DRUG$, and rifampin.
3700	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, @DRUG$, ritonavir, and @DRUG$.
3701	DDI-false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, @DRUG$, and @DRUG$.
3702	DDI-false	There was no effect of a single dose or multiple doses of @DRUG$ on @DRUG$, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics.
3703	DDI-false	There was no effect of a single dose or multiple doses of @DRUG$ on mycophenolate mofetil, @DRUG$, tacrolimus, prednisolone, and fluconazole pharmacokinetics.
3704	DDI-false	There was no effect of a single dose or multiple doses of @DRUG$ on mycophenolate mofetil, cyclosporine, @DRUG$, prednisolone, and fluconazole pharmacokinetics.
3705	DDI-false	There was no effect of a single dose or multiple doses of @DRUG$ on mycophenolate mofetil, cyclosporine, tacrolimus, @DRUG$, and fluconazole pharmacokinetics.
3706	DDI-false	There was no effect of a single dose or multiple doses of @DRUG$ on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and @DRUG$ pharmacokinetics.
3707	DDI-false	There was no effect of a single dose or multiple doses of MYCAMINE on @DRUG$, @DRUG$, tacrolimus, prednisolone, and fluconazole pharmacokinetics.
3708	DDI-false	There was no effect of a single dose or multiple doses of MYCAMINE on @DRUG$, cyclosporine, @DRUG$, prednisolone, and fluconazole pharmacokinetics.
3709	DDI-false	There was no effect of a single dose or multiple doses of MYCAMINE on @DRUG$, cyclosporine, tacrolimus, @DRUG$, and fluconazole pharmacokinetics.
3710	DDI-false	There was no effect of a single dose or multiple doses of MYCAMINE on @DRUG$, cyclosporine, tacrolimus, prednisolone, and @DRUG$ pharmacokinetics.
3711	DDI-false	There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, @DRUG$, @DRUG$, prednisolone, and fluconazole pharmacokinetics.
3712	DDI-false	There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, @DRUG$, tacrolimus, @DRUG$, and fluconazole pharmacokinetics.
3713	DDI-false	There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, @DRUG$, tacrolimus, prednisolone, and @DRUG$ pharmacokinetics.
3714	DDI-false	There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, @DRUG$, @DRUG$, and fluconazole pharmacokinetics.
3715	DDI-false	There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, @DRUG$, prednisolone, and @DRUG$ pharmacokinetics.
3716	DDI-false	There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, @DRUG$, and @DRUG$ pharmacokinetics.
3717	DDI-mechanism	@DRUG$ AUC was increased by 21% with no effect on Cmax in the presence of steady-state @DRUG$ compared with sirolimus alone.
3718	DDI-false	@DRUG$ AUC was increased by 21% with no effect on Cmax in the presence of steady-state MYCAMINE compared with @DRUG$ alone.
3719	DDI-false	Sirolimus AUC was increased by 21% with no effect on Cmax in the presence of steady-state @DRUG$ compared with @DRUG$ alone.
3720	DDI-mechanism	@DRUG$ AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state @DRUG$ compared with nifedipine alone.
3721	DDI-false	@DRUG$ AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state MYCAMINE compared with @DRUG$ alone.
3722	DDI-false	Nifedipine AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state @DRUG$ compared with @DRUG$ alone.
3723	DDI-false	Patients receiving @DRUG$ or @DRUG$ in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.
3724	DDI-advise	Patients receiving @DRUG$ or nifedipine in combination with @DRUG$ should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.
3725	DDI-false	Patients receiving @DRUG$ or nifedipine in combination with MYCAMINE should be monitored for @DRUG$ or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.
3726	DDI-false	Patients receiving @DRUG$ or nifedipine in combination with MYCAMINE should be monitored for sirolimus or @DRUG$ toxicity and sirolimus or nifedipine dosage should be reduced if necessary.
3727	DDI-false	Patients receiving @DRUG$ or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and @DRUG$ or nifedipine dosage should be reduced if necessary.
3728	DDI-false	Patients receiving @DRUG$ or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or @DRUG$ dosage should be reduced if necessary.
3729	DDI-advise	Patients receiving sirolimus or @DRUG$ in combination with @DRUG$ should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.
3730	DDI-false	Patients receiving sirolimus or @DRUG$ in combination with MYCAMINE should be monitored for @DRUG$ or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.
3731	DDI-false	Patients receiving sirolimus or @DRUG$ in combination with MYCAMINE should be monitored for sirolimus or @DRUG$ toxicity and sirolimus or nifedipine dosage should be reduced if necessary.
3732	DDI-false	Patients receiving sirolimus or @DRUG$ in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and @DRUG$ or nifedipine dosage should be reduced if necessary.
3733	DDI-false	Patients receiving sirolimus or @DRUG$ in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or @DRUG$ dosage should be reduced if necessary.
3734	DDI-false	Patients receiving sirolimus or nifedipine in combination with @DRUG$ should be monitored for @DRUG$ or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.
3735	DDI-false	Patients receiving sirolimus or nifedipine in combination with @DRUG$ should be monitored for sirolimus or @DRUG$ toxicity and sirolimus or nifedipine dosage should be reduced if necessary.
3736	DDI-false	Patients receiving sirolimus or nifedipine in combination with @DRUG$ should be monitored for sirolimus or nifedipine toxicity and @DRUG$ or nifedipine dosage should be reduced if necessary.
3737	DDI-false	Patients receiving sirolimus or nifedipine in combination with @DRUG$ should be monitored for sirolimus or nifedipine toxicity and sirolimus or @DRUG$ dosage should be reduced if necessary.
3738	DDI-false	Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for @DRUG$ or @DRUG$ toxicity and sirolimus or nifedipine dosage should be reduced if necessary.
3739	DDI-false	Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for @DRUG$ or nifedipine toxicity and @DRUG$ or nifedipine dosage should be reduced if necessary.
3740	DDI-false	Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for @DRUG$ or nifedipine toxicity and sirolimus or @DRUG$ dosage should be reduced if necessary.
3741	DDI-false	Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or @DRUG$ toxicity and @DRUG$ or nifedipine dosage should be reduced if necessary.
3742	DDI-false	Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or @DRUG$ toxicity and sirolimus or @DRUG$ dosage should be reduced if necessary.
3743	DDI-false	Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and @DRUG$ or @DRUG$ dosage should be reduced if necessary.
3744	DDI-false	Hypokalemia may develop during concomitant use of @DRUG$ or @DRUG$.
3745	DDI-effect	@DRUG$ may decrease arterial responsiveness to @DRUG$.
3746	DDI-effect	@DRUG$ may increase the responsiveness of @DRUG$.
3747	DDI-mechanism	@DRUG$ renal clearance is reduced by @DRUG$, increasing the risk of lithium toxicity.
3748	DDI-false	@DRUG$ renal clearance is reduced by thiazides, increasing the risk of @DRUG$ toxicity.
3749	DDI-false	Lithium renal clearance is reduced by @DRUG$, increasing the risk of @DRUG$ toxicity.
3750	DDI-effect	@DRUG$ may add to or potentiate the action of other @DRUG$.
3751	DDI-false	Potentiation occurs with @DRUG-DRUG$.
3752	DDI-false	@DRUG$/@DRUG$: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10).
3753	DDI-false	@DRUG$/Levodopa: @DRUG$/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10).
3754	DDI-false	@DRUG$/Levodopa: Carbidopa/@DRUG$ does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10).
3755	DDI-false	@DRUG$/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of @DRUG$ in healthy volunteers (N= 10).
3756	DDI-false	Carbidopa/@DRUG$: @DRUG$/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10).
3757	DDI-false	Carbidopa/@DRUG$: Carbidopa/@DRUG$ does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10).
3758	DDI-false	Carbidopa/@DRUG$: Carbidopa/Levodopa does not influence the pharmacokinetics of @DRUG$ in healthy volunteers (N= 10).
3759	DDI-false	Carbidopa/Levodopa: @DRUG$/@DRUG$ does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10).
3760	DDI-false	Carbidopa/Levodopa: @DRUG$/Levodopa does not influence the pharmacokinetics of @DRUG$ in healthy volunteers (N= 10).
3761	DDI-false	Carbidopa/Levodopa: Carbidopa/@DRUG$ does not influence the pharmacokinetics of @DRUG$ in healthy volunteers (N= 10).
3762	DDI-false	@DRUG$: Since @DRUG$ is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.
3763	DDI-false	@DRUG$: Since pramipexole is a @DRUG$, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.
3764	DDI-false	@DRUG$: Since pramipexole is a dopamine agonist, it is possible that @DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.
3765	DDI-false	@DRUG$: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.
3766	DDI-false	@DRUG$: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.
3767	DDI-false	@DRUG$: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.
3768	DDI-false	@DRUG$: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$) or metoclopramide, may diminish the effectiveness of MIRAPEX.
3769	DDI-false	@DRUG$: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or @DRUG$, may diminish the effectiveness of MIRAPEX.
3770	DDI-false	@DRUG$: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of @DRUG$.
3771	DDI-false	Dopamine antagonists: Since @DRUG$ is a @DRUG$, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.
3772	DDI-false	Dopamine antagonists: Since @DRUG$ is a dopamine agonist, it is possible that @DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.
3773	DDI-false	Dopamine antagonists: Since @DRUG$ is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.
3774	DDI-false	Dopamine antagonists: Since @DRUG$ is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.
3775	DDI-false	Dopamine antagonists: Since @DRUG$ is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.
3776	DDI-false	Dopamine antagonists: Since @DRUG$ is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$) or metoclopramide, may diminish the effectiveness of MIRAPEX.
3777	DDI-false	Dopamine antagonists: Since @DRUG$ is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or @DRUG$, may diminish the effectiveness of MIRAPEX.
3778	DDI-false	Dopamine antagonists: Since @DRUG$ is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of @DRUG$.
3779	DDI-false	Dopamine antagonists: Since pramipexole is a @DRUG$, it is possible that @DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.
3780	DDI-false	Dopamine antagonists: Since pramipexole is a @DRUG$, it is possible that dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.
3781	DDI-false	Dopamine antagonists: Since pramipexole is a @DRUG$, it is possible that dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.
3782	DDI-false	Dopamine antagonists: Since pramipexole is a @DRUG$, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.
3783	DDI-false	Dopamine antagonists: Since pramipexole is a @DRUG$, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$) or metoclopramide, may diminish the effectiveness of MIRAPEX.
3784	DDI-false	Dopamine antagonists: Since pramipexole is a @DRUG$, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or @DRUG$, may diminish the effectiveness of MIRAPEX.
3785	DDI-false	Dopamine antagonists: Since pramipexole is a @DRUG$, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of @DRUG$.
3786	DDI-false	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that @DRUG$, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.
3787	DDI-false	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that @DRUG$, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.
3788	DDI-false	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that @DRUG$, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.
3789	DDI-false	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that @DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$) or metoclopramide, may diminish the effectiveness of MIRAPEX.
3790	DDI-false	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that @DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or @DRUG$, may diminish the effectiveness of MIRAPEX.
3791	DDI-effect	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that @DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of @DRUG$.
3792	DDI-false	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ (@DRUG$, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.
3793	DDI-false	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ (phenothiazines, @DRUG$, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.
3794	DDI-false	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, @DRUG$) or metoclopramide, may diminish the effectiveness of MIRAPEX.
3795	DDI-false	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthenes) or @DRUG$, may diminish the effectiveness of MIRAPEX.
3796	DDI-effect	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of @DRUG$.
3797	DDI-false	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (@DRUG$, @DRUG$, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.
3798	DDI-false	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, @DRUG$) or metoclopramide, may diminish the effectiveness of MIRAPEX.
3799	DDI-false	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthenes) or @DRUG$, may diminish the effectiveness of MIRAPEX.
3800	DDI-effect	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of @DRUG$.
3801	DDI-false	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, @DRUG$) or metoclopramide, may diminish the effectiveness of MIRAPEX.
3802	DDI-false	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthenes) or @DRUG$, may diminish the effectiveness of MIRAPEX.
3803	DDI-effect	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthenes) or metoclopramide, may diminish the effectiveness of @DRUG$.
3804	DDI-false	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$) or @DRUG$, may diminish the effectiveness of MIRAPEX.
3805	DDI-effect	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$) or metoclopramide, may diminish the effectiveness of @DRUG$.
3806	DDI-effect	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or @DRUG$, may diminish the effectiveness of @DRUG$.
3807	DDI-false	@DRUG$: In healthy volunteers (N= 11), @DRUG$ did not influence the pharmacokinetics of pramipexole.
3808	DDI-false	@DRUG$: In healthy volunteers (N= 11), selegiline did not influence the pharmacokinetics of @DRUG$.
3809	DDI-false	Selegiline: In healthy volunteers (N= 11), @DRUG$ did not influence the pharmacokinetics of @DRUG$.
3810	DDI-false	@DRUG$: Population pharmacokinetic analysis suggests that @DRUG$ is unlikely to alter the oral clearance of pramipexole (N= 54).
3811	DDI-false	@DRUG$: Population pharmacokinetic analysis suggests that amantadine is unlikely to alter the oral clearance of @DRUG$ (N= 54).
3812	DDI-false	Amantadine: Population pharmacokinetic analysis suggests that @DRUG$ is unlikely to alter the oral clearance of @DRUG$ (N= 54).
3813	DDI-false	@DRUG$: @DRUG$, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in pramipexole AUC and a 40% increase in half-life (N= 12).
3814	DDI-false	@DRUG$: Cimetidine, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in @DRUG$ AUC and a 40% increase in half-life (N= 12).
3815	DDI-mechanism	Cimetidine: @DRUG$, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in @DRUG$ AUC and a 40% increase in half-life (N= 12).
3816	DDI-false	@DRUG$: @DRUG$, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence pramipexole pharmacokinetics (N= 12).
3817	DDI-false	@DRUG$: Probenecid, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence @DRUG$ pharmacokinetics (N= 12).
3818	DDI-false	Probenecid: @DRUG$, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence @DRUG$ pharmacokinetics (N= 12).
3819	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, @DRUG$, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3820	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, ranitidine, @DRUG$, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3821	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, ranitidine, diltiazem, @DRUG$, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3822	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, ranitidine, diltiazem, triamterene, @DRUG$, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3823	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, ranitidine, diltiazem, triamterene, verapamil, @DRUG$, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3824	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, ranitidine, diltiazem, triamterene, verapamil, quinidine, and @DRUG$) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3825	DDI-mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3826	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3827	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, @DRUG$, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3828	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, @DRUG$, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3829	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, @DRUG$, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3830	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and @DRUG$) are likely to have little effect on the oral clearance of pramipexole.
3831	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of @DRUG$.
3832	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, @DRUG$, @DRUG$, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3833	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, @DRUG$, diltiazem, @DRUG$, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3834	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, @DRUG$, diltiazem, triamterene, @DRUG$, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3835	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, @DRUG$, diltiazem, triamterene, verapamil, @DRUG$, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3836	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, @DRUG$, diltiazem, triamterene, verapamil, quinidine, and @DRUG$) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3837	DDI-mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, @DRUG$, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3838	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, @DRUG$, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3839	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, @DRUG$, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, @DRUG$, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3840	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, @DRUG$, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, @DRUG$, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3841	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, @DRUG$, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, @DRUG$, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3842	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, @DRUG$, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and @DRUG$) are likely to have little effect on the oral clearance of pramipexole.
3843	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, @DRUG$, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of @DRUG$.
3844	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, @DRUG$, @DRUG$, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3845	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, @DRUG$, triamterene, @DRUG$, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3846	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, @DRUG$, triamterene, verapamil, @DRUG$, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3847	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, @DRUG$, triamterene, verapamil, quinidine, and @DRUG$) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3848	DDI-mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, @DRUG$, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3849	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, @DRUG$, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3850	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, @DRUG$, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, @DRUG$, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3851	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, @DRUG$, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, @DRUG$, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3852	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, @DRUG$, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, @DRUG$, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3853	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, @DRUG$, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and @DRUG$) are likely to have little effect on the oral clearance of pramipexole.
3854	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, @DRUG$, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of @DRUG$.
3855	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, @DRUG$, @DRUG$, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3856	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, @DRUG$, verapamil, @DRUG$, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3857	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, @DRUG$, verapamil, quinidine, and @DRUG$) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3858	DDI-mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, @DRUG$, verapamil, quinidine, and quinine) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3859	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, @DRUG$, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3860	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, @DRUG$, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, @DRUG$, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3861	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, @DRUG$, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, @DRUG$, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3862	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, @DRUG$, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, @DRUG$, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3863	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, @DRUG$, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and @DRUG$) are likely to have little effect on the oral clearance of pramipexole.
3864	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, @DRUG$, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of @DRUG$.
3865	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, @DRUG$, @DRUG$, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3866	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, @DRUG$, quinidine, and @DRUG$) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3867	DDI-mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, @DRUG$, quinidine, and quinine) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3868	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, @DRUG$, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3869	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, @DRUG$, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, @DRUG$, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3870	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, @DRUG$, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, @DRUG$, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3871	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, @DRUG$, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, @DRUG$, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3872	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, @DRUG$, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and @DRUG$) are likely to have little effect on the oral clearance of pramipexole.
3873	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, @DRUG$, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of @DRUG$.
3874	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, @DRUG$, and @DRUG$) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3875	DDI-mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, @DRUG$, and quinine) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3876	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, @DRUG$, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3877	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, @DRUG$, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, @DRUG$, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3878	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, @DRUG$, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, @DRUG$, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3879	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, @DRUG$, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, @DRUG$, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3880	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, @DRUG$, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and @DRUG$) are likely to have little effect on the oral clearance of pramipexole.
3881	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, @DRUG$, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of @DRUG$.
3882	DDI-mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and @DRUG$) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3883	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and @DRUG$) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3884	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and @DRUG$) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, @DRUG$, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3885	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and @DRUG$) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, @DRUG$, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3886	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and @DRUG$) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, @DRUG$, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3887	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and @DRUG$) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and @DRUG$) are likely to have little effect on the oral clearance of pramipexole.
3888	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and @DRUG$) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of @DRUG$.
3889	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3890	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, @DRUG$, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3891	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, @DRUG$, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3892	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, @DRUG$, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3893	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and @DRUG$) are likely to have little effect on the oral clearance of pramipexole.
3894	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of @DRUG$.
3895	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, @DRUG$, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3896	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, penicillins, @DRUG$, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3897	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, penicillins, indomethacin, @DRUG$, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3898	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, penicillins, indomethacin, hydrochlorothiazide, and @DRUG$) are likely to have little effect on the oral clearance of pramipexole.
3899	DDI-mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of @DRUG$.
3900	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, @DRUG$, @DRUG$, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3901	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, @DRUG$, indomethacin, @DRUG$, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3902	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, @DRUG$, indomethacin, hydrochlorothiazide, and @DRUG$) are likely to have little effect on the oral clearance of pramipexole.
3903	DDI-mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, @DRUG$, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of @DRUG$.
3904	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, @DRUG$, @DRUG$, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
3905	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, @DRUG$, hydrochlorothiazide, and @DRUG$) are likely to have little effect on the oral clearance of pramipexole.
3906	DDI-mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, @DRUG$, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of @DRUG$.
3907	DDI-false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, @DRUG$, and @DRUG$) are likely to have little effect on the oral clearance of pramipexole.
3908	DDI-mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, @DRUG$, and chlorpropamide) are likely to have little effect on the oral clearance of @DRUG$.
3909	DDI-mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and @DRUG$) are likely to have little effect on the oral clearance of @DRUG$.
3910	DDI-false	CYP interactions: Inhibitors of cytochrome P450 enzymes would not be expected to affect @DRUG$ elimination because @DRUG$ is not appreciably metabolized by these enzymes in vivo or in vitro.
3911	DDI-advise	Do not exceed a 5 mg daily dose of @DRUG$ when administered with therapeutic doses of @DRUG$ or other potent CYP3A4 inhibitors.
3912	DDI-false	Patients with Congenital or Acquired QT Prolongation In a study of the effect of @DRUG$ on the QT interval in 76 healthy women, the QT prolonging effect appeared less with @DRUG$ 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose.
3913	DDI-false	Patients with Congenital or Acquired QT Prolongation In a study of the effect of @DRUG$ on the QT interval in 76 healthy women, the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of @DRUG$ 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose.
3914	DDI-false	Patients with Congenital or Acquired QT Prolongation In a study of the effect of @DRUG$ on the QT interval in 76 healthy women, the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control @DRUG$ at its therapeutic dose.
3915	DDI-false	Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women, the QT prolonging effect appeared less with @DRUG$ 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of @DRUG$ 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose.
3916	DDI-false	Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women, the QT prolonging effect appeared less with @DRUG$ 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control @DRUG$ at its therapeutic dose.
3917	DDI-false	Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women, the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of @DRUG$ 30 mg did not appear as large as that of the positive control @DRUG$ at its therapeutic dose.
3918	DDI-false	@DRUG$ at a Dose of 10 mg Once Daily Dosed to Pharmacokinetic Steady State  - did not cause clinically significant changes in the kinetics of a single intravenous dose of @DRUG$ (predominantly a cytochrome P450 1A2 substrate).
3919	DDI-false	- did not change the pharmacokinetic profile of @DRUG$ (a substrate of cytochromes P450 2A6 and 2C9) or influence the effect of a single 30-mg oral dose of @DRUG$ on prothrombin time or the INR (International Normalized Ratio).
3920	DDI-false	In drug-interaction studies, the recommended clinical dose of @DRUG$ did not have clinically important effects on the pharmacokinetics of the following drugs: @DRUG$, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.
3921	DDI-false	In drug-interaction studies, the recommended clinical dose of @DRUG$ did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, @DRUG$, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.
3922	DDI-false	In drug-interaction studies, the recommended clinical dose of @DRUG$ did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, @DRUG$, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.
3923	DDI-false	In drug-interaction studies, the recommended clinical dose of @DRUG$ did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral @DRUG$ (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.
3924	DDI-false	In drug-interaction studies, the recommended clinical dose of @DRUG$ did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (@DRUG$ 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.
3925	DDI-false	In drug-interaction studies, the recommended clinical dose of @DRUG$ did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/@DRUG$ 35 mcg), terfenadine, digoxin, and warfarin.
3926	DDI-false	In drug-interaction studies, the recommended clinical dose of @DRUG$ did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), @DRUG$, digoxin, and warfarin.
3927	DDI-false	In drug-interaction studies, the recommended clinical dose of @DRUG$ did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, @DRUG$, and warfarin.
3928	DDI-false	In drug-interaction studies, the recommended clinical dose of @DRUG$ did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and @DRUG$.
3929	DDI-false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: @DRUG$, @DRUG$, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.
3930	DDI-false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: @DRUG$, prednisone, @DRUG$, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.
3931	DDI-false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: @DRUG$, prednisone, prednisolone, oral @DRUG$ (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.
3932	DDI-false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: @DRUG$, prednisone, prednisolone, oral contraceptives (@DRUG$ 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.
3933	DDI-false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: @DRUG$, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/@DRUG$ 35 mcg), terfenadine, digoxin, and warfarin.
3934	DDI-false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: @DRUG$, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), @DRUG$, digoxin, and warfarin.
3935	DDI-false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: @DRUG$, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, @DRUG$, and warfarin.
3936	DDI-false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: @DRUG$, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and @DRUG$.
3937	DDI-false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, @DRUG$, @DRUG$, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.
3938	DDI-false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, @DRUG$, prednisolone, oral @DRUG$ (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.
3939	DDI-false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, @DRUG$, prednisolone, oral contraceptives (@DRUG$ 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.
3940	DDI-false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, @DRUG$, prednisolone, oral contraceptives (norethindrone 1 mg/@DRUG$ 35 mcg), terfenadine, digoxin, and warfarin.
3941	DDI-false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, @DRUG$, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), @DRUG$, digoxin, and warfarin.
3942	DDI-false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, @DRUG$, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, @DRUG$, and warfarin.
3943	DDI-false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, @DRUG$, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and @DRUG$.
3944	DDI-false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, @DRUG$, oral @DRUG$ (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.
3945	DDI-false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, @DRUG$, oral contraceptives (@DRUG$ 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.
3946	DDI-false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, @DRUG$, oral contraceptives (norethindrone 1 mg/@DRUG$ 35 mcg), terfenadine, digoxin, and warfarin.
3947	DDI-false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, @DRUG$, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), @DRUG$, digoxin, and warfarin.
3948	DDI-false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, @DRUG$, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, @DRUG$, and warfarin.
3949	DDI-false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, @DRUG$, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and @DRUG$.
3950	DDI-false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral @DRUG$ (@DRUG$ 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.
3951	DDI-false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral @DRUG$ (norethindrone 1 mg/@DRUG$ 35 mcg), terfenadine, digoxin, and warfarin.
3952	DDI-false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral @DRUG$ (norethindrone 1 mg/ethinyl estradiol 35 mcg), @DRUG$, digoxin, and warfarin.
3953	DDI-false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral @DRUG$ (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, @DRUG$, and warfarin.
3954	DDI-false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral @DRUG$ (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and @DRUG$.
3955	DDI-false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (@DRUG$ 1 mg/@DRUG$ 35 mcg), terfenadine, digoxin, and warfarin.
3956	DDI-false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (@DRUG$ 1 mg/ethinyl estradiol 35 mcg), @DRUG$, digoxin, and warfarin.
3957	DDI-false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (@DRUG$ 1 mg/ethinyl estradiol 35 mcg), terfenadine, @DRUG$, and warfarin.
3958	DDI-false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (@DRUG$ 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and @DRUG$.
3959	DDI-false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/@DRUG$ 35 mcg), @DRUG$, digoxin, and warfarin.
3960	DDI-false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/@DRUG$ 35 mcg), terfenadine, @DRUG$, and warfarin.
3961	DDI-false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/@DRUG$ 35 mcg), terfenadine, digoxin, and @DRUG$.
3962	DDI-false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), @DRUG$, @DRUG$, and warfarin.
3963	DDI-false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), @DRUG$, digoxin, and @DRUG$.
3964	DDI-false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, @DRUG$, and @DRUG$.
3965	DDI-false	These medications included @DRUG$, @DRUG$, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants.
3966	DDI-false	These medications included @DRUG$, sedative hypnotics, @DRUG$, benzodiazepines, and decongestants.
3967	DDI-false	These medications included @DRUG$, sedative hypnotics, non-steroidal anti-inflammatory agents, @DRUG$, and decongestants.
3968	DDI-false	These medications included @DRUG$, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and @DRUG$.
3969	DDI-false	These medications included thyroid hormones, @DRUG$, @DRUG$, benzodiazepines, and decongestants.
3970	DDI-false	These medications included thyroid hormones, @DRUG$, non-steroidal anti-inflammatory agents, @DRUG$, and decongestants.
3971	DDI-false	These medications included thyroid hormones, @DRUG$, non-steroidal anti-inflammatory agents, benzodiazepines, and @DRUG$.
3972	DDI-false	These medications included thyroid hormones, sedative hypnotics, @DRUG$, @DRUG$, and decongestants.
3973	DDI-false	These medications included thyroid hormones, sedative hypnotics, @DRUG$, benzodiazepines, and @DRUG$.
3974	DDI-false	These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, @DRUG$, and @DRUG$.
3975	DDI-false	@DRUG$, which induces hepatic metabolism, decreased the AUC of @DRUG$ approximately 40% following a single 10-mg dose of montelukast.
3976	DDI-false	@DRUG$, which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of @DRUG$.
3977	DDI-false	Phenobarbital, which induces hepatic metabolism, decreased the AUC of @DRUG$ approximately 40% following a single 10-mg dose of @DRUG$.
3978	DDI-false	It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as @DRUG$ or @DRUG$, are co-administered with montelukast.
3979	DDI-advise	It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as @DRUG$ or rifampin, are co-administered with @DRUG$.
3980	DDI-advise	It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or @DRUG$, are co-administered with @DRUG$.
3981	DDI-false	- did not change the plasma concentration profile of @DRUG$ (a substrate of cytochrome P450 3A4) or @DRUG$, its carboxylated metabolite, and did not prolong the QTc interval following co-administration with terfenadine 60 mg twice daily.
3982	DDI-false	- did not change the plasma concentration profile of @DRUG$ (a substrate of cytochrome P450 3A4) or fexofenadine, its carboxylated metabolite, and did not prolong the QTc interval following co-administration with @DRUG$ 60 mg twice daily.
3983	DDI-false	- did not change the plasma concentration profile of terfenadine (a substrate of cytochrome P450 3A4) or @DRUG$, its carboxylated metabolite, and did not prolong the QTc interval following co-administration with @DRUG$ 60 mg twice daily.
3984	DDI-false	@DRUG$ at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral @DRUG$ containing norethindrone 1 mg/ethinyl estradiol 35 mcg.
3985	DDI-false	@DRUG$ at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing @DRUG$ 1 mg/ethinyl estradiol 35 mcg.
3986	DDI-false	@DRUG$ at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl @DRUG$ 35 mcg.
3987	DDI-false	Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral @DRUG$ containing @DRUG$ 1 mg/ethinyl estradiol 35 mcg.
3988	DDI-false	Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral @DRUG$ containing norethindrone 1 mg/ethinyl @DRUG$ 35 mcg.
3989	DDI-false	Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing @DRUG$ 1 mg/ethinyl @DRUG$ 35 mcg.
3990	DDI-false	- did not cause any clinically significant change in plasma profiles of @DRUG$ or @DRUG$ following administration of either oral prednisone or intravenous prednisolone.
3991	DDI-false	- did not cause any clinically significant change in plasma profiles of @DRUG$ or prednisolone following administration of either oral @DRUG$ or intravenous prednisolone.
3992	DDI-false	- did not cause any clinically significant change in plasma profiles of @DRUG$ or prednisolone following administration of either oral prednisone or intravenous @DRUG$.
3993	DDI-false	- did not cause any clinically significant change in plasma profiles of prednisone or @DRUG$ following administration of either oral @DRUG$ or intravenous prednisolone.
3994	DDI-false	- did not cause any clinically significant change in plasma profiles of prednisone or @DRUG$ following administration of either oral prednisone or intravenous @DRUG$.
3995	DDI-false	- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral @DRUG$ or intravenous @DRUG$.
3996	DDI-false	@DRUG$, which induces hepatic metabolism, decreased the AUC of @DRUG$ approximately 40% following a single 10-mg dose of montelukast.
3997	DDI-false	@DRUG$, which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of @DRUG$.
3998	DDI-false	Phenobarbital, which induces hepatic metabolism, decreased the AUC of @DRUG$ approximately 40% following a single 10-mg dose of @DRUG$.
3999	DDI-false	It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as @DRUG$ or @DRUG$, are co-administered with montelukast.
4000	DDI-advise	It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as @DRUG$ or rifampin, are co-administered with @DRUG$.
4001	DDI-advise	It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or @DRUG$, are co-administered with @DRUG$.
4002	DDI-mechanism	In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving @DRUG$, treatment with @DRUG$ once weekly for 4 weeks was associated with a mean increase of 16% in methadone AUC;
4003	DDI-false	In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving @DRUG$, treatment with PEG-Intron once weekly for 4 weeks was associated with a mean increase of 16% in @DRUG$ AUC;
4004	DDI-false	In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving methadone, treatment with @DRUG$ once weekly for 4 weeks was associated with a mean increase of 16% in @DRUG$ AUC;
4005	DDI-effect	However, the impairment of motor skills produced by @DRUG$ has been shown to be additive with those caused by @DRUG$.
4006	DDI-advise	Accordingly, patients should be advised to avoid @DRUG$ and other similar drugs while taking @DRUG$.
4007	DDI-false	Drugs Affecting Hepatic Metabolism The metabolism and pharmacokinetics of @DRUG$    (@DRUG$) Orally Disintegrating Tablets may be affected by the induction or inhibition of drug-metab-olizing enzymes.
4008	DDI-false	While in vitro studies have shown that @DRUG$ is not a potent inhibitor of any of these enzymes, an indication that @DRUG$ is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of REMERON SolTab with most other drugs metabolized by these enzymes has not been formally studied.
4009	DDI-false	While in vitro studies have shown that @DRUG$ is not a potent inhibitor of any of these enzymes, an indication that mirtazapine is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of @DRUG$ with most other drugs metabolized by these enzymes has not been formally studied.
4010	DDI-false	While in vitro studies have shown that mirtazapine is not a potent inhibitor of any of these enzymes, an indication that @DRUG$ is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of @DRUG$ with most other drugs metabolized by these enzymes has not been formally studied.
4011	DDI-false	@DRUG$: Concomitant administration of @DRUG$ (equivalent to 60 g) had a minimal effect on plasma levels of mirtazapine (15 mg) in 6 healthy male subjects.
4012	DDI-false	@DRUG$: Concomitant administration of alcohol (equivalent to 60 g) had a minimal effect on plasma levels of @DRUG$ (15 mg) in 6 healthy male subjects.
4013	DDI-mechanism	Alcohol: Concomitant administration of @DRUG$ (equivalent to 60 g) had a minimal effect on plasma levels of @DRUG$ (15 mg) in 6 healthy male subjects.
4014	DDI-effect	However, the impairment of cognitive and motor skills produced by @DRUG$    were shown to be additive with those produced by @DRUG$.
4015	DDI-advise	Accordingly, patients should be advised to avoid @DRUG$ while taking @DRUG$. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects.
4016	DDI-false	Accordingly, patients should be advised to avoid @DRUG$ while taking REMERON SolTab. @DRUG$: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects.
4017	DDI-false	Accordingly, patients should be advised to avoid @DRUG$ while taking REMERON SolTab. Diazepam: Concomitant administration of @DRUG$ (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects.
4018	DDI-false	Accordingly, patients should be advised to avoid @DRUG$ while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of @DRUG$ (15 mg) in 12 healthy subjects.
4019	DDI-false	Accordingly, patients should be advised to avoid alcohol while taking @DRUG$. @DRUG$: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects.
4020	DDI-false	Accordingly, patients should be advised to avoid alcohol while taking @DRUG$. Diazepam: Concomitant administration of @DRUG$ (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects.
4021	DDI-false	Accordingly, patients should be advised to avoid alcohol while taking @DRUG$. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of @DRUG$ (15 mg) in 12 healthy subjects.
4022	DDI-false	Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. @DRUG$: Concomitant administration of @DRUG$ (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects.
4023	DDI-false	Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. @DRUG$: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of @DRUG$ (15 mg) in 12 healthy subjects.
4024	DDI-mechanism	Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of @DRUG$ (15 mg) had a minimal effect on plasma levels of @DRUG$ (15 mg) in 12 healthy subjects.
4025	DDI-false	@DRUG$: Spontaneous adverse reaction reports of patients taking concomitant @DRUG$ with recommended doses of terfenadine demonstrate QT interval prolongation and rare serious cardiac events, e.g.
4026	DDI-false	@DRUG$: Spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of @DRUG$ demonstrate QT interval prolongation and rare serious cardiac events, e.g.
4027	DDI-effect	Ketoconazole: Spontaneous adverse reaction reports of patients taking concomitant @DRUG$ with recommended doses of @DRUG$ demonstrate QT interval prolongation and rare serious cardiac events, e.g.
4028	DDI-false	A few spontaneous accounts of QT interval prolongation with ventricular arrhythmia including torsades de pointes, have been reported in patients receiving @DRUG$ or @DRUG$.
4029	DDI-advise	Concomitant administration of @DRUG$ with @DRUG$, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.
4030	DDI-advise	Concomitant administration of @DRUG$ with clarithromycin, @DRUG$, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.
4031	DDI-advise	Concomitant administration of @DRUG$ with clarithromycin, erythromycin, or @DRUG$ is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.
4032	DDI-false	Concomitant administration of @DRUG$ with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of @DRUG$ with other macrolide antibiotics, including azithromycin, is not recommended.
4033	DDI-false	Concomitant administration of @DRUG$ with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other @DRUG$, including azithromycin, is not recommended.
4034	DDI-false	Concomitant administration of @DRUG$ with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including @DRUG$, is not recommended.
4035	DDI-false	Concomitant administration of terfenadine with @DRUG$, @DRUG$, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.
4036	DDI-false	Concomitant administration of terfenadine with @DRUG$, erythromycin, or @DRUG$ is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.
4037	DDI-false	Concomitant administration of terfenadine with @DRUG$, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of @DRUG$ with other macrolide antibiotics, including azithromycin, is not recommended.
4038	DDI-false	Concomitant administration of terfenadine with @DRUG$, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other @DRUG$, including azithromycin, is not recommended.
4039	DDI-false	Concomitant administration of terfenadine with @DRUG$, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including @DRUG$, is not recommended.
4040	DDI-false	Concomitant administration of terfenadine with clarithromycin, @DRUG$, or @DRUG$ is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.
4041	DDI-false	Concomitant administration of terfenadine with clarithromycin, @DRUG$, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of @DRUG$ with other macrolide antibiotics, including azithromycin, is not recommended.
4042	DDI-false	Concomitant administration of terfenadine with clarithromycin, @DRUG$, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other @DRUG$, including azithromycin, is not recommended.
4043	DDI-false	Concomitant administration of terfenadine with clarithromycin, @DRUG$, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including @DRUG$, is not recommended.
4044	DDI-false	Concomitant administration of terfenadine with clarithromycin, erythromycin, or @DRUG$ is contraindicated: Pending full characterization of potential interactions, concomitant administration of @DRUG$ with other macrolide antibiotics, including azithromycin, is not recommended.
4045	DDI-false	Concomitant administration of terfenadine with clarithromycin, erythromycin, or @DRUG$ is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other @DRUG$, including azithromycin, is not recommended.
4046	DDI-false	Concomitant administration of terfenadine with clarithromycin, erythromycin, or @DRUG$ is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including @DRUG$, is not recommended.
4047	DDI-advise	Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of @DRUG$ with other @DRUG$, including azithromycin, is not recommended.
4048	DDI-advise	Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of @DRUG$ with other macrolide antibiotics, including @DRUG$, is not recommended.
4049	DDI-false	Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other @DRUG$, including @DRUG$, is not recommended.
4050	DDI-false	Studies to evaluate potential interactions of @DRUG$ with @DRUG$ are in progress.
4051	DDI-mechanism	Pharmacokinetic data indicate that @DRUG$ markedly inhibits the metabolism of @DRUG$, resulting in elevated plasma terfenadine levels.
4052	DDI-false	Pharmacokinetic data indicate that @DRUG$ markedly inhibits the metabolism of terfenadine, resulting in elevated plasma @DRUG$ levels.
4053	DDI-false	Pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of @DRUG$, resulting in elevated plasma @DRUG$ levels.
4054	DDI-advise	Concomitant administration of @DRUG$ and @DRUG$ is contraindicated.
4055	DDI-false	@DRUG$: Torsades de pointes and elevated parent @DRUG$ levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources.
4056	DDI-false	@DRUG$: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of @DRUG$ and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources.
4057	DDI-false	@DRUG$: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and @DRUG$ in clinical trials of itraconazole and from foreign post-marketing sources.
4058	DDI-false	@DRUG$: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of @DRUG$ and from foreign post-marketing sources.
4059	DDI-false	Itraconazole: Torsades de pointes and elevated parent @DRUG$ levels have been reported during concomitant use of @DRUG$ and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources.
4060	DDI-false	Itraconazole: Torsades de pointes and elevated parent @DRUG$ levels have been reported during concomitant use of terfenadine and @DRUG$ in clinical trials of itraconazole and from foreign post-marketing sources.
4061	DDI-false	Itraconazole: Torsades de pointes and elevated parent @DRUG$ levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of @DRUG$ and from foreign post-marketing sources.
4062	DDI-mechanism	Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of @DRUG$ and @DRUG$ in clinical trials of itraconazole and from foreign post-marketing sources.
4063	DDI-false	Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of @DRUG$ and itraconazole in clinical trials of @DRUG$ and from foreign post-marketing sources.
4064	DDI-false	Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and @DRUG$ in clinical trials of @DRUG$ and from foreign post-marketing sources.
4065	DDI-advise	Concomitant administration of @DRUG$ and @DRUG$ is contraindicated.
4066	DDI-false	Due to the chemical similarity of other @DRUG$ (including @DRUG$, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.
4067	DDI-false	Due to the chemical similarity of other @DRUG$ (including fluconazole, @DRUG$, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.
4068	DDI-false	Due to the chemical similarity of other @DRUG$ (including fluconazole, metronidazole, and @DRUG$) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.
4069	DDI-false	Due to the chemical similarity of other @DRUG$ (including fluconazole, metronidazole, and miconazole) to @DRUG$, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.
4070	DDI-false	Due to the chemical similarity of other @DRUG$ (including fluconazole, metronidazole, and miconazole) to ketoconazole, and @DRUG$, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.
4071	DDI-advise	Due to the chemical similarity of other @DRUG$ (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with @DRUG$ is not recommended pending full examination of potential interactions.
4072	DDI-false	Due to the chemical similarity of other azole-type antifungal agents (including @DRUG$, @DRUG$, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.
4073	DDI-false	Due to the chemical similarity of other azole-type antifungal agents (including @DRUG$, metronidazole, and @DRUG$) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.
4074	DDI-false	Due to the chemical similarity of other azole-type antifungal agents (including @DRUG$, metronidazole, and miconazole) to @DRUG$, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.
4075	DDI-false	Due to the chemical similarity of other azole-type antifungal agents (including @DRUG$, metronidazole, and miconazole) to ketoconazole, and @DRUG$, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.
4076	DDI-advise	Due to the chemical similarity of other azole-type antifungal agents (including @DRUG$, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with @DRUG$ is not recommended pending full examination of potential interactions.
4077	DDI-false	Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, @DRUG$, and @DRUG$) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.
4078	DDI-false	Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, @DRUG$, and miconazole) to @DRUG$, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.
4079	DDI-false	Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, @DRUG$, and miconazole) to ketoconazole, and @DRUG$, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.
4080	DDI-advise	Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, @DRUG$, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with @DRUG$ is not recommended pending full examination of potential interactions.
4081	DDI-false	Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and @DRUG$) to @DRUG$, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.
4082	DDI-false	Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and @DRUG$) to ketoconazole, and @DRUG$, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.
4083	DDI-advise	Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and @DRUG$) to ketoconazole, and itraconazole, concomitant use of these products with @DRUG$ is not recommended pending full examination of potential interactions.
4084	DDI-false	Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to @DRUG$, and @DRUG$, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.
4085	DDI-false	Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to @DRUG$, and itraconazole, concomitant use of these products with @DRUG$ is not recommended pending full examination of potential interactions.
4086	DDI-false	Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and @DRUG$, concomitant use of these products with @DRUG$ is not recommended pending full examination of potential interactions.
4087	DDI-false	@DRUG$: Clinical drug interaction studies indicate that @DRUG$ and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent.
4088	DDI-false	@DRUG$: Clinical drug interaction studies indicate that erythromycin and @DRUG$ can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent.
4089	DDI-false	@DRUG$: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on @DRUG$ metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent.
4090	DDI-false	@DRUG$: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of @DRUG$, but to a lesser extent.
4091	DDI-false	Macrolides: Clinical drug interaction studies indicate that @DRUG$ and @DRUG$ can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent.
4092	DDI-mechanism	Macrolides: Clinical drug interaction studies indicate that @DRUG$ and clarithromycin can exert an effect on @DRUG$ metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent.
4093	DDI-false	Macrolides: Clinical drug interaction studies indicate that @DRUG$ and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of @DRUG$, but to a lesser extent.
4094	DDI-mechanism	Macrolides: Clinical drug interaction studies indicate that erythromycin and @DRUG$ can exert an effect on @DRUG$ metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent.
4095	DDI-false	Macrolides: Clinical drug interaction studies indicate that erythromycin and @DRUG$ can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of @DRUG$, but to a lesser extent.
4096	DDI-false	Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on @DRUG$ metabolism by a mechanism which may be similar to that of @DRUG$, but to a lesser extent.
4097	DDI-false	Acromegalic patients with diabetes mellitus being treated with @DRUG$ and/or oral @DRUG$ agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT.
4098	DDI-advise	Acromegalic patients with diabetes mellitus being treated with @DRUG$ and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with @DRUG$.
4099	DDI-advise	Acromegalic patients with diabetes mellitus being treated with insulin and/or oral @DRUG$ agents may require dose reductions of these therapeutic agents after the initiation of therapy with @DRUG$.
4100	DDI-mechanism	In clinical studies, patients on @DRUG$ often needed higher serum @DRUG$ concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids.
4101	DDI-false	In clinical studies, patients on @DRUG$ often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving @DRUG$.
4102	DDI-false	In clinical studies, patients on opioids often needed higher serum @DRUG$ concentrations to achieve appropriate IGF-I suppression compared with patients not receiving @DRUG$.
4103	DDI-false	@DRUG$ should be used with caution in digitalized patients, since the combination of @DRUG$ and sympathomimetic amines may cause ectopic arrhythmias.
4104	DDI-false	@DRUG$ should be used with caution in digitalized patients, since the combination of digitalis and @DRUG$ may cause ectopic arrhythmias.
4105	DDI-effect	ARAMINE should be used with caution in digitalized patients, since the combination of @DRUG$ and @DRUG$ may cause ectopic arrhythmias.
4106	DDI-false	@DRUG$ or @DRUG$ may potentiate the action of sympathomimetic amines.
4107	DDI-effect	@DRUG$ or tricyclic antidepressants may potentiate the action of @DRUG$.
4108	DDI-effect	Monoamine oxidase inhibitors or @DRUG$ may potentiate the action of @DRUG$.
4109	DDI-false	@DRUG$, a bacteriostatic @DRUG$, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.
4110	DDI-effect	@DRUG$, a bacteriostatic antibiotic, may antagonize the bactericidal effect of @DRUG$ and concurrent use of these drugs should be avoided.
4111	DDI-false	Tetracycline, a bacteriostatic @DRUG$, may antagonize the bactericidal effect of @DRUG$ and concurrent use of these drugs should be avoided.
4112	DDI-int	Concomitant use of @DRUG$ with @DRUG$ may result in an adverse drug interaction.
4113	DDI-false	@DRUG$ has been studied on a background of @DRUG$ and heparin.
4114	DDI-false	@DRUG$ has been studied on a background of aspirin and @DRUG$.
4115	DDI-false	AGGRASTAT has been studied on a background of @DRUG$ and @DRUG$.
4116	DDI-effect	The use of @DRUG$, in combination with @DRUG$ and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see
4117	DDI-effect	The use of @DRUG$, in combination with heparin and @DRUG$, has been associated with an increase in bleeding compared to heparin and aspirin alone (see
4118	DDI-false	The use of @DRUG$, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to @DRUG$ and aspirin alone (see
4119	DDI-false	The use of @DRUG$, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and @DRUG$ alone (see
4120	DDI-false	The use of AGGRASTAT, in combination with @DRUG$ and @DRUG$, has been associated with an increase in bleeding compared to heparin and aspirin alone (see
4121	DDI-false	The use of AGGRASTAT, in combination with @DRUG$ and aspirin, has been associated with an increase in bleeding compared to @DRUG$ and aspirin alone (see
4122	DDI-false	The use of AGGRASTAT, in combination with @DRUG$ and aspirin, has been associated with an increase in bleeding compared to heparin and @DRUG$ alone (see
4123	DDI-false	The use of AGGRASTAT, in combination with heparin and @DRUG$, has been associated with an increase in bleeding compared to @DRUG$ and aspirin alone (see
4124	DDI-false	The use of AGGRASTAT, in combination with heparin and @DRUG$, has been associated with an increase in bleeding compared to heparin and @DRUG$ alone (see
4125	DDI-false	The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to @DRUG$ and @DRUG$ alone (see
4126	DDI-advise	Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when @DRUG$ is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of @DRUG$, protease inhibitors, calcium channel antagonists, and macrolide antibiotics).
4127	DDI-advise	Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when @DRUG$ is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, @DRUG$, calcium channel antagonists, and macrolide antibiotics).
4128	DDI-advise	Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when @DRUG$ is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, @DRUG$, and macrolide antibiotics).
4129	DDI-advise	Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when @DRUG$ is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and @DRUG$).
4130	DDI-false	Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of @DRUG$, @DRUG$, calcium channel antagonists, and macrolide antibiotics).
4131	DDI-false	Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of @DRUG$, protease inhibitors, @DRUG$, and macrolide antibiotics).
4132	DDI-false	Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of @DRUG$, protease inhibitors, calcium channel antagonists, and @DRUG$).
4133	DDI-false	Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, @DRUG$, @DRUG$, and macrolide antibiotics).
4134	DDI-false	Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, @DRUG$, calcium channel antagonists, and @DRUG$).
4135	DDI-false	Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, @DRUG$, and @DRUG$).
4136	DDI-false	Drugs such as @DRUG$, @DRUG$, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.
4137	DDI-false	Drugs such as @DRUG$, diltiazem, @DRUG$, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.
4138	DDI-false	Drugs such as @DRUG$, diltiazem, verapamil, @DRUG$, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.
4139	DDI-false	Drugs such as @DRUG$, diltiazem, verapamil, ketoconazole, @DRUG$ and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.
4140	DDI-false	Drugs such as @DRUG$, diltiazem, verapamil, ketoconazole, fluconazole and @DRUG$ were shown to significantly increase the C max and AUC of orally administered midazolam.
4141	DDI-mechanism	Drugs such as @DRUG$, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered @DRUG$.
4142	DDI-false	Drugs such as erythromycin, @DRUG$, @DRUG$, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.
4143	DDI-false	Drugs such as erythromycin, @DRUG$, verapamil, @DRUG$, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.
4144	DDI-false	Drugs such as erythromycin, @DRUG$, verapamil, ketoconazole, @DRUG$ and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.
4145	DDI-false	Drugs such as erythromycin, @DRUG$, verapamil, ketoconazole, fluconazole and @DRUG$ were shown to significantly increase the C max and AUC of orally administered midazolam.
4146	DDI-mechanism	Drugs such as erythromycin, @DRUG$, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered @DRUG$.
4147	DDI-false	Drugs such as erythromycin, diltiazem, @DRUG$, @DRUG$, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.
4148	DDI-false	Drugs such as erythromycin, diltiazem, @DRUG$, ketoconazole, @DRUG$ and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.
4149	DDI-false	Drugs such as erythromycin, diltiazem, @DRUG$, ketoconazole, fluconazole and @DRUG$ were shown to significantly increase the C max and AUC of orally administered midazolam.
4150	DDI-mechanism	Drugs such as erythromycin, diltiazem, @DRUG$, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered @DRUG$.
4151	DDI-false	Drugs such as erythromycin, diltiazem, verapamil, @DRUG$, @DRUG$ and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.
4152	DDI-false	Drugs such as erythromycin, diltiazem, verapamil, @DRUG$, fluconazole and @DRUG$ were shown to significantly increase the C max and AUC of orally administered midazolam.
4153	DDI-mechanism	Drugs such as erythromycin, diltiazem, verapamil, @DRUG$, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered @DRUG$.
4154	DDI-false	Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, @DRUG$ and @DRUG$ were shown to significantly increase the C max and AUC of orally administered midazolam.
4155	DDI-mechanism	Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, @DRUG$ and itraconazole were shown to significantly increase the C max and AUC of orally administered @DRUG$.
4156	DDI-mechanism	Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and @DRUG$ were shown to significantly increase the C max and AUC of orally administered @DRUG$.
4157	DDI-effect	The sedative effect of @DRUG$ is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly @DRUG$ (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.
4158	DDI-effect	The sedative effect of @DRUG$ is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, @DRUG$, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.
4159	DDI-effect	The sedative effect of @DRUG$ is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, @DRUG$ and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.
4160	DDI-effect	The sedative effect of @DRUG$ is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and @DRUG$), propofol, ketamine, nitrous oxide, secobarbital and droperidol.
4161	DDI-effect	The sedative effect of @DRUG$ is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), @DRUG$, ketamine, nitrous oxide, secobarbital and droperidol.
4162	DDI-effect	The sedative effect of @DRUG$ is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, @DRUG$, nitrous oxide, secobarbital and droperidol.
4163	DDI-effect	The sedative effect of @DRUG$ is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, @DRUG$, secobarbital and droperidol.
4164	DDI-effect	The sedative effect of @DRUG$ is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, @DRUG$ and droperidol.
4165	DDI-effect	The sedative effect of @DRUG$ is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and @DRUG$.
4166	DDI-false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly @DRUG$ (eg, @DRUG$, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.
4167	DDI-false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly @DRUG$ (eg, morphine, @DRUG$ and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.
4168	DDI-false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly @DRUG$ (eg, morphine, meperidine and @DRUG$), propofol, ketamine, nitrous oxide, secobarbital and droperidol.
4169	DDI-false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly @DRUG$ (eg, morphine, meperidine and fentanyl), @DRUG$, ketamine, nitrous oxide, secobarbital and droperidol.
4170	DDI-false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly @DRUG$ (eg, morphine, meperidine and fentanyl), propofol, @DRUG$, nitrous oxide, secobarbital and droperidol.
4171	DDI-false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly @DRUG$ (eg, morphine, meperidine and fentanyl), propofol, ketamine, @DRUG$, secobarbital and droperidol.
4172	DDI-false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly @DRUG$ (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, @DRUG$ and droperidol.
4173	DDI-false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly @DRUG$ (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and @DRUG$.
4174	DDI-false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, @DRUG$, @DRUG$ and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.
4175	DDI-false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, @DRUG$, meperidine and @DRUG$), propofol, ketamine, nitrous oxide, secobarbital and droperidol.
4176	DDI-false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, @DRUG$, meperidine and fentanyl), @DRUG$, ketamine, nitrous oxide, secobarbital and droperidol.
4177	DDI-false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, @DRUG$, meperidine and fentanyl), propofol, @DRUG$, nitrous oxide, secobarbital and droperidol.
4178	DDI-false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, @DRUG$, meperidine and fentanyl), propofol, ketamine, @DRUG$, secobarbital and droperidol.
4179	DDI-false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, @DRUG$, meperidine and fentanyl), propofol, ketamine, nitrous oxide, @DRUG$ and droperidol.
4180	DDI-false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, @DRUG$, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and @DRUG$.
4181	DDI-false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, @DRUG$ and @DRUG$), propofol, ketamine, nitrous oxide, secobarbital and droperidol.
4182	DDI-false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, @DRUG$ and fentanyl), @DRUG$, ketamine, nitrous oxide, secobarbital and droperidol.
4183	DDI-false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, @DRUG$ and fentanyl), propofol, @DRUG$, nitrous oxide, secobarbital and droperidol.
4184	DDI-false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, @DRUG$ and fentanyl), propofol, ketamine, @DRUG$, secobarbital and droperidol.
4185	DDI-false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, @DRUG$ and fentanyl), propofol, ketamine, nitrous oxide, @DRUG$ and droperidol.
4186	DDI-false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, @DRUG$ and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and @DRUG$.
4187	DDI-false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and @DRUG$), @DRUG$, ketamine, nitrous oxide, secobarbital and droperidol.
4188	DDI-false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and @DRUG$), propofol, @DRUG$, nitrous oxide, secobarbital and droperidol.
4189	DDI-false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and @DRUG$), propofol, ketamine, @DRUG$, secobarbital and droperidol.
4190	DDI-false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and @DRUG$), propofol, ketamine, nitrous oxide, @DRUG$ and droperidol.
4191	DDI-false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and @DRUG$), propofol, ketamine, nitrous oxide, secobarbital and @DRUG$.
4192	DDI-false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), @DRUG$, @DRUG$, nitrous oxide, secobarbital and droperidol.
4193	DDI-false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), @DRUG$, ketamine, @DRUG$, secobarbital and droperidol.
4194	DDI-false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), @DRUG$, ketamine, nitrous oxide, @DRUG$ and droperidol.
4195	DDI-false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), @DRUG$, ketamine, nitrous oxide, secobarbital and @DRUG$.
4196	DDI-false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, @DRUG$, @DRUG$, secobarbital and droperidol.
4197	DDI-false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, @DRUG$, nitrous oxide, @DRUG$ and droperidol.
4198	DDI-false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, @DRUG$, nitrous oxide, secobarbital and @DRUG$.
4199	DDI-false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, @DRUG$, @DRUG$ and droperidol.
4200	DDI-false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, @DRUG$, secobarbital and @DRUG$.
4201	DDI-false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, @DRUG$ and @DRUG$.
4202	DDI-false	No significant adverse interactions with common premedications (such as @DRUG$, @DRUG$, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.
4203	DDI-false	No significant adverse interactions with common premedications (such as @DRUG$, scopolamine, @DRUG$, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.
4204	DDI-false	No significant adverse interactions with common premedications (such as @DRUG$, scopolamine, glycopyrrolate, @DRUG$, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.
4205	DDI-false	No significant adverse interactions with common premedications (such as @DRUG$, scopolamine, glycopyrrolate, diazepam, @DRUG$, and other muscle relaxants) or local anesthetics have been observed.
4206	DDI-false	No significant adverse interactions with common premedications (such as @DRUG$, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other @DRUG$) or local anesthetics have been observed.
4207	DDI-false	No significant adverse interactions with common premedications (such as @DRUG$, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local @DRUG$ have been observed.
4208	DDI-false	No significant adverse interactions with common premedications (such as atropine, @DRUG$, @DRUG$, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.
4209	DDI-false	No significant adverse interactions with common premedications (such as atropine, @DRUG$, glycopyrrolate, @DRUG$, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.
4210	DDI-false	No significant adverse interactions with common premedications (such as atropine, @DRUG$, glycopyrrolate, diazepam, @DRUG$, and other muscle relaxants) or local anesthetics have been observed.
4211	DDI-false	No significant adverse interactions with common premedications (such as atropine, @DRUG$, glycopyrrolate, diazepam, hydroxyzine, and other @DRUG$) or local anesthetics have been observed.
4212	DDI-false	No significant adverse interactions with common premedications (such as atropine, @DRUG$, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local @DRUG$ have been observed.
4213	DDI-false	No significant adverse interactions with common premedications (such as atropine, scopolamine, @DRUG$, @DRUG$, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.
4214	DDI-false	No significant adverse interactions with common premedications (such as atropine, scopolamine, @DRUG$, diazepam, @DRUG$, and other muscle relaxants) or local anesthetics have been observed.
4215	DDI-false	No significant adverse interactions with common premedications (such as atropine, scopolamine, @DRUG$, diazepam, hydroxyzine, and other @DRUG$) or local anesthetics have been observed.
4216	DDI-false	No significant adverse interactions with common premedications (such as atropine, scopolamine, @DRUG$, diazepam, hydroxyzine, and other muscle relaxants) or local @DRUG$ have been observed.
4217	DDI-false	No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, @DRUG$, @DRUG$, and other muscle relaxants) or local anesthetics have been observed.
4218	DDI-false	No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, @DRUG$, hydroxyzine, and other @DRUG$) or local anesthetics have been observed.
4219	DDI-false	No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, @DRUG$, hydroxyzine, and other muscle relaxants) or local @DRUG$ have been observed.
4220	DDI-false	No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, @DRUG$, and other @DRUG$) or local anesthetics have been observed.
4221	DDI-false	No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, @DRUG$, and other muscle relaxants) or local @DRUG$ have been observed.
4222	DDI-false	No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other @DRUG$) or local @DRUG$ have been observed.
4223	DDI-false	Although not studied, the potent cytochrome P450 3A4 inhibitors @DRUG$ and @DRUG$ may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam.
4224	DDI-mechanism	Although not studied, the potent cytochrome P450 3A4 inhibitors @DRUG$ and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of @DRUG$.
4225	DDI-mechanism	Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and @DRUG$ may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of @DRUG$.
4226	DDI-false	Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as @DRUG$, @DRUG$, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies.
4227	DDI-false	Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as @DRUG$, carbamazepine, and @DRUG$, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies.
4228	DDI-mechanism	Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as @DRUG$, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral @DRUG$ in adult studies.
4229	DDI-false	Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, @DRUG$, and @DRUG$, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies.
4230	DDI-mechanism	Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, @DRUG$, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral @DRUG$ in adult studies.
4231	DDI-mechanism	Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and @DRUG$, induce metabolism and caused a markedly decreased C max and AUC of oral @DRUG$ in adult studies.
4232	DDI-false	The difficulty in achieving adequate sedation may have been the result of decreased absorption of the @DRUG$ due to both the gastrointestinal effects and stimulant effects of @DRUG$.
4233	DDI-false	The concomitant use of other @DRUG$ including @DRUG$, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.
4234	DDI-false	The concomitant use of other @DRUG$ including sedatives, @DRUG$, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.
4235	DDI-false	The concomitant use of other @DRUG$ including sedatives, hypnotics, @DRUG$, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.
4236	DDI-false	The concomitant use of other @DRUG$ including sedatives, hypnotics, tranquilizers, general @DRUG$, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.
4237	DDI-false	The concomitant use of other @DRUG$ including sedatives, hypnotics, tranquilizers, general anesthetics, @DRUG$, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.
4238	DDI-false	The concomitant use of other @DRUG$ including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other @DRUG$, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.
4239	DDI-false	The concomitant use of other @DRUG$ including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, @DRUG$, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.
4240	DDI-false	The concomitant use of other @DRUG$ including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, @DRUG$, and alcohol may produce additive CNS depressant effects.
4241	DDI-false	The concomitant use of other @DRUG$ including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and @DRUG$ may produce additive CNS depressant effects.
4242	DDI-false	The concomitant use of other CNS depressants including @DRUG$, @DRUG$, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.
4243	DDI-false	The concomitant use of other CNS depressants including @DRUG$, hypnotics, @DRUG$, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.
4244	DDI-false	The concomitant use of other CNS depressants including @DRUG$, hypnotics, tranquilizers, general @DRUG$, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.
4245	DDI-false	The concomitant use of other CNS depressants including @DRUG$, hypnotics, tranquilizers, general anesthetics, @DRUG$, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.
4246	DDI-false	The concomitant use of other CNS depressants including @DRUG$, hypnotics, tranquilizers, general anesthetics, phenothiazines, other @DRUG$, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.
4247	DDI-false	The concomitant use of other CNS depressants including @DRUG$, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, @DRUG$, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.
4248	DDI-false	The concomitant use of other CNS depressants including @DRUG$, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, @DRUG$, and alcohol may produce additive CNS depressant effects.
4249	DDI-false	The concomitant use of other CNS depressants including @DRUG$, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and @DRUG$ may produce additive CNS depressant effects.
4250	DDI-false	The concomitant use of other CNS depressants including sedatives, @DRUG$, @DRUG$, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.
4251	DDI-false	The concomitant use of other CNS depressants including sedatives, @DRUG$, tranquilizers, general @DRUG$, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.
4252	DDI-false	The concomitant use of other CNS depressants including sedatives, @DRUG$, tranquilizers, general anesthetics, @DRUG$, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.
4253	DDI-false	The concomitant use of other CNS depressants including sedatives, @DRUG$, tranquilizers, general anesthetics, phenothiazines, other @DRUG$, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.
4254	DDI-false	The concomitant use of other CNS depressants including sedatives, @DRUG$, tranquilizers, general anesthetics, phenothiazines, other opioids, @DRUG$, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.
4255	DDI-false	The concomitant use of other CNS depressants including sedatives, @DRUG$, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, @DRUG$, and alcohol may produce additive CNS depressant effects.
4256	DDI-false	The concomitant use of other CNS depressants including sedatives, @DRUG$, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and @DRUG$ may produce additive CNS depressant effects.
4257	DDI-false	The concomitant use of other CNS depressants including sedatives, hypnotics, @DRUG$, general @DRUG$, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.
4258	DDI-false	The concomitant use of other CNS depressants including sedatives, hypnotics, @DRUG$, general anesthetics, @DRUG$, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.
4259	DDI-false	The concomitant use of other CNS depressants including sedatives, hypnotics, @DRUG$, general anesthetics, phenothiazines, other @DRUG$, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.
4260	DDI-false	The concomitant use of other CNS depressants including sedatives, hypnotics, @DRUG$, general anesthetics, phenothiazines, other opioids, @DRUG$, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.
4261	DDI-false	The concomitant use of other CNS depressants including sedatives, hypnotics, @DRUG$, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, @DRUG$, and alcohol may produce additive CNS depressant effects.
4262	DDI-false	The concomitant use of other CNS depressants including sedatives, hypnotics, @DRUG$, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and @DRUG$ may produce additive CNS depressant effects.
4263	DDI-false	The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general @DRUG$, @DRUG$, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.
4264	DDI-false	The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general @DRUG$, phenothiazines, other @DRUG$, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.
4265	DDI-false	The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general @DRUG$, phenothiazines, other opioids, @DRUG$, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.
4266	DDI-false	The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general @DRUG$, phenothiazines, other opioids, tricyclic antidepressants, @DRUG$, and alcohol may produce additive CNS depressant effects.
4267	DDI-false	The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general @DRUG$, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and @DRUG$ may produce additive CNS depressant effects.
4268	DDI-false	The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, @DRUG$, other @DRUG$, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.
4269	DDI-false	The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, @DRUG$, other opioids, @DRUG$, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.
4270	DDI-false	The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, @DRUG$, other opioids, tricyclic antidepressants, @DRUG$, and alcohol may produce additive CNS depressant effects.
4271	DDI-false	The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, @DRUG$, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and @DRUG$ may produce additive CNS depressant effects.
4272	DDI-false	The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other @DRUG$, @DRUG$, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.
4273	DDI-false	The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other @DRUG$, tricyclic antidepressants, @DRUG$, and alcohol may produce additive CNS depressant effects.
4274	DDI-false	The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other @DRUG$, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and @DRUG$ may produce additive CNS depressant effects.
4275	DDI-false	The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, @DRUG$, @DRUG$, and alcohol may produce additive CNS depressant effects.
4276	DDI-false	The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, @DRUG$, monoamine oxidase (MAO) inhibitors, and @DRUG$ may produce additive CNS depressant effects.
4277	DDI-false	The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, @DRUG$, and @DRUG$ may produce additive CNS depressant effects.
4278	DDI-effect	@DRUG$ or other medications with anticholinergic activity when used concurrently with @DRUG$ may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.
4279	DDI-effect	It has been reported that the incidence of bradycardia was increased when @DRUG$ was combined with @DRUG$ for induction of anesthesia.
4280	DDI-effect	In addition, CNS toxicity has been reported (confusion, disorientation, respiratory depression, apnea, seizures) following coadministration of @DRUG$ with @DRUG$;
4281	DDI-effect	Dosages of concomitantly administered @DRUG$ should be reduced by approximately half, because @DRUG$ amplifies the therapeutic actions and side-effects of opioids.
4282	DDI-false	Dosages of concomitantly administered @DRUG$ should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of @DRUG$.
4283	DDI-effect	Dosages of concomitantly administered opioids should be reduced by approximately half, because @DRUG$ amplifies the therapeutic actions and side-effects of @DRUG$.
4284	DDI-false	Combination with @DRUG$ (@DRUG$) is associated with increased risk of seizures.
4285	DDI-effect	Additive sedative effects and confusional states may emerge if @DRUG$ is given with @DRUG$ or barbiturates.
4286	DDI-effect	Additive sedative effects and confusional states may emerge if @DRUG$ is given with benzodiazepines or @DRUG$.
4287	DDI-false	Additive sedative effects and confusional states may emerge if levomepromazine is given with @DRUG$ or @DRUG$.
4288	DDI-advise	Exert particular caution in combining @DRUG$ with other @DRUG$ (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.
4289	DDI-advise	Exert particular caution in combining @DRUG$ with other anticholinergic drugs (@DRUG$ and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.
4290	DDI-advise	Exert particular caution in combining @DRUG$ with other anticholinergic drugs (tricyclic antidepressants and @DRUG$): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.
4291	DDI-false	Exert particular caution in combining levomepromazine with other @DRUG$ (@DRUG$ and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.
4292	DDI-false	Exert particular caution in combining levomepromazine with other @DRUG$ (tricyclic antidepressants and @DRUG$): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.
4293	DDI-false	Exert particular caution in combining levomepromazine with other anticholinergic drugs (@DRUG$ and @DRUG$): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.
4294	DDI-false	@DRUG$ and/or stimulantes of the @DRUG$/amphetamine type may counteract the specific actions of levomepromazine.
4295	DDI-false	@DRUG$ and/or stimulantes of the ephedrine/@DRUG$ type may counteract the specific actions of levomepromazine.
4296	DDI-effect	@DRUG$ and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of @DRUG$.
4297	DDI-false	Caffeine and/or stimulantes of the @DRUG$/@DRUG$ type may counteract the specific actions of levomepromazine.
4298	DDI-effect	Caffeine and/or stimulantes of the @DRUG$/amphetamine type may counteract the specific actions of @DRUG$.
4299	DDI-effect	Caffeine and/or stimulantes of the ephedrine/@DRUG$ type may counteract the specific actions of @DRUG$.
4300	DDI-false	Usage with @DRUG$: Due to the potential for increased CNS depressants effects, @DRUG$ should be used with caution in patients who are currently receiving pentazocine.
4301	DDI-false	Usage with @DRUG$: Due to the potential for increased CNS depressants effects, alcohol should be used with caution in patients who are currently receiving @DRUG$.
4302	DDI-advise	Usage with Alcohol: Due to the potential for increased CNS depressants effects, @DRUG$ should be used with caution in patients who are currently receiving @DRUG$.
4303	DDI-effect	The CNS depressant effects of @DRUG$ may be additive with that of other @DRUG$..
4304	DDI-mechanism	Limited evidence suggests that @DRUG$ may influence the intensity and duration of action of @DRUG$.
4305	DDI-false	@DRUG$: In a multiple-dose study in 30 normal weight subjects, coadministration of @DRUG$ and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.
4306	DDI-false	@DRUG$: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of @DRUG$ (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.
4307	DDI-false	@DRUG$: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of @DRUG$ pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.
4308	DDI-false	@DRUG$: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, @DRUG$ pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.
4309	DDI-false	@DRUG$: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to @DRUG$.
4310	DDI-false	Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of @DRUG$ and 40 grams of @DRUG$ (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.
4311	DDI-false	Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of @DRUG$ and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of @DRUG$ pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.
4312	DDI-false	Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of @DRUG$ and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, @DRUG$ pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.
4313	DDI-false	Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of @DRUG$ and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to @DRUG$.
4314	DDI-false	Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of @DRUG$ (e.g., approximately 3 glasses of wine) did not result in alteration of @DRUG$ pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.
4315	DDI-false	Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of @DRUG$ (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, @DRUG$ pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.
4316	DDI-false	Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of @DRUG$ (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to @DRUG$.
4317	DDI-false	Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of @DRUG$ pharmacokinetics, @DRUG$ pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.
4318	DDI-false	Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of @DRUG$ pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to @DRUG$.
4319	DDI-false	Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, @DRUG$ pharmacodynamics (fecal fat excretion), or systemic exposure to @DRUG$.
4320	DDI-false	@DRUG$: Preliminary data from a @DRUG$ and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine.
4321	DDI-false	@DRUG$: Preliminary data from a XENICAL and @DRUG$ drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine.
4322	DDI-false	@DRUG$: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in @DRUG$ plasma levels when XENICAL was coadministered with cyclosporine.
4323	DDI-false	@DRUG$: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when @DRUG$ was coadministered with cyclosporine.
4324	DDI-false	@DRUG$: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with @DRUG$.
4325	DDI-false	Cyclosporine: Preliminary data from a @DRUG$ and @DRUG$ drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine.
4326	DDI-false	Cyclosporine: Preliminary data from a @DRUG$ and cyclosporine drug interaction study indicate a reduction in @DRUG$ plasma levels when XENICAL was coadministered with cyclosporine.
4327	DDI-false	Cyclosporine: Preliminary data from a @DRUG$ and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when @DRUG$ was coadministered with cyclosporine.
4328	DDI-false	Cyclosporine: Preliminary data from a @DRUG$ and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with @DRUG$.
4329	DDI-false	Cyclosporine: Preliminary data from a XENICAL and @DRUG$ drug interaction study indicate a reduction in @DRUG$ plasma levels when XENICAL was coadministered with cyclosporine.
4330	DDI-false	Cyclosporine: Preliminary data from a XENICAL and @DRUG$ drug interaction study indicate a reduction in cyclosporine plasma levels when @DRUG$ was coadministered with cyclosporine.
4331	DDI-false	Cyclosporine: Preliminary data from a XENICAL and @DRUG$ drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with @DRUG$.
4332	DDI-false	Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in @DRUG$ plasma levels when @DRUG$ was coadministered with cyclosporine.
4333	DDI-false	Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in @DRUG$ plasma levels when XENICAL was coadministered with @DRUG$.
4334	DDI-mechanism	Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when @DRUG$ was coadministered with @DRUG$.
4335	DDI-false	@DRUG$: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving @DRUG$ 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of pravastatin.
4336	DDI-false	@DRUG$: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, @DRUG$ did not affect the pharmacokinetics of pravastatin.
4337	DDI-false	@DRUG$: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of @DRUG$.
4338	DDI-false	Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving @DRUG$ 120 mg three times a day for 6 days, @DRUG$ did not affect the pharmacokinetics of pravastatin.
4339	DDI-false	Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving @DRUG$ 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of @DRUG$.
4340	DDI-false	Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, @DRUG$ did not affect the pharmacokinetics of @DRUG$.
4341	DDI-false	@DRUG$: In 12 normal-weight subjects, administration of @DRUG$ 120 mg three times a day for 16 days did not result in any change in either warfarin pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII).
4342	DDI-false	@DRUG$: In 12 normal-weight subjects, administration of XENICAL 120 mg three times a day for 16 days did not result in any change in either @DRUG$ pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII).
4343	DDI-false	Warfarin: In 12 normal-weight subjects, administration of @DRUG$ 120 mg three times a day for 16 days did not result in any change in either @DRUG$ pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII).
4344	DDI-false	Although undercarboxylated osteocalcin, a marker of vitamin K nutritional status, was unaltered with @DRUG$ administration, vitamin K levels tended to decline in subjects taking @DRUG$.
4345	DDI-mechanism	Therefore, as @DRUG$ absorption may be decreased with @DRUG$, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.
4346	DDI-false	Therefore, as @DRUG$ absorption may be decreased with XENICAL, patients on chronic stable doses of @DRUG$ who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.
4347	DDI-false	Therefore, as @DRUG$ absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed @DRUG$ should be monitored closely for changes in coagulation parameters.
4348	DDI-false	Therefore, as vitamin K absorption may be decreased with @DRUG$, patients on chronic stable doses of @DRUG$ who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.
4349	DDI-false	Therefore, as vitamin K absorption may be decreased with @DRUG$, patients on chronic stable doses of warfarin who are prescribed @DRUG$ should be monitored closely for changes in coagulation parameters.
4350	DDI-advise	Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of @DRUG$ who are prescribed @DRUG$ should be monitored closely for changes in coagulation parameters.
4351	DDI-false	@DRUG$: In 12 normal-weight subjects receiving @DRUG$ 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of digoxin.
4352	DDI-false	@DRUG$: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, @DRUG$ did not alter the pharmacokinetics of a single dose of digoxin.
4353	DDI-false	@DRUG$: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of @DRUG$.
4354	DDI-false	Digoxin: In 12 normal-weight subjects receiving @DRUG$ 120 mg three times a day for 6 days, @DRUG$ did not alter the pharmacokinetics of a single dose of digoxin.
4355	DDI-false	Digoxin: In 12 normal-weight subjects receiving @DRUG$ 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of @DRUG$.
4356	DDI-false	Digoxin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, @DRUG$ did not alter the pharmacokinetics of a single dose of @DRUG$.
4357	DDI-false	@DRUG$ and Analogues: A pharmacokinetic interaction study showed a 30% reduction in @DRUG$ supplement absorption when concomitantly administered with XENICAL.
4358	DDI-false	@DRUG$ and Analogues: A pharmacokinetic interaction study showed a 30% reduction in beta-carotene supplement absorption when concomitantly administered with @DRUG$.
4359	DDI-mechanism	Fat-soluble Vitamin Supplements and Analogues: A pharmacokinetic interaction study showed a 30% reduction in @DRUG$ supplement absorption when concomitantly administered with @DRUG$.
4360	DDI-mechanism	@DRUG$ inhibited absorption of a @DRUG$ supplement by approximately 60%.
4361	DDI-false	The effect of @DRUG$ on the absorption of supplemental @DRUG$, vitamin A, and nutritionally-derived vitamin K is not known at this time.
4362	DDI-false	The effect of @DRUG$ on the absorption of supplemental vitamin D, @DRUG$, and nutritionally-derived vitamin K is not known at this time.
4363	DDI-false	The effect of @DRUG$ on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived @DRUG$ is not known at this time.
4364	DDI-false	The effect of orlistat on the absorption of supplemental @DRUG$, @DRUG$, and nutritionally-derived vitamin K is not known at this time.
4365	DDI-false	The effect of orlistat on the absorption of supplemental @DRUG$, vitamin A, and nutritionally-derived @DRUG$ is not known at this time.
4366	DDI-false	The effect of orlistat on the absorption of supplemental vitamin D, @DRUG$, and nutritionally-derived @DRUG$ is not known at this time.
4367	DDI-false	@DRUG$: In 12 normal-weight subjects receiving @DRUG$ 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide.
4368	DDI-false	@DRUG$: In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, @DRUG$ did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide.
4369	DDI-false	@DRUG$: In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of @DRUG$.
4370	DDI-false	Glyburide: In 12 normal-weight subjects receiving @DRUG$ 80 mg three times a day for 5 days, @DRUG$ did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide.
4371	DDI-false	Glyburide: In 12 normal-weight subjects receiving @DRUG$ 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of @DRUG$.
4372	DDI-false	Glyburide: In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, @DRUG$ did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of @DRUG$.
4373	DDI-false	@DRUG$ (extended-release tablets): In 17 normal-weight subjects receiving @DRUG$ 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of nifedipine (extended-release tablets).
4374	DDI-false	@DRUG$ (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, @DRUG$ did not alter the bioavailability of nifedipine (extended-release tablets).
4375	DDI-false	@DRUG$ (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of @DRUG$ (extended-release tablets).
4376	DDI-false	Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving @DRUG$ 120 mg three times a day for 6 days, @DRUG$ did not alter the bioavailability of nifedipine (extended-release tablets).
4377	DDI-false	Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving @DRUG$ 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of @DRUG$ (extended-release tablets).
4378	DDI-false	Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, @DRUG$ did not alter the bioavailability of @DRUG$ (extended-release tablets).
4379	DDI-false	Oral @DRUG$: In 20 normal-weight female subjects, the treatment of @DRUG$ 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral contraceptives.
4380	DDI-false	Oral @DRUG$: In 20 normal-weight female subjects, the treatment of XENICAL 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral @DRUG$.
4381	DDI-false	Oral Contraceptives: In 20 normal-weight female subjects, the treatment of @DRUG$ 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral @DRUG$.
4382	DDI-false	@DRUG$: In 12 normal-weight subjects receiving @DRUG$ 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of phenytoin.
4383	DDI-false	@DRUG$: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, @DRUG$ did not alter the pharmacokinetics of a single 300-mg dose of phenytoin.
4384	DDI-false	@DRUG$: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of @DRUG$.
4385	DDI-false	Phenytoin: In 12 normal-weight subjects receiving @DRUG$ 120 mg three times a day for 7 days, @DRUG$ did not alter the pharmacokinetics of a single 300-mg dose of phenytoin.
4386	DDI-false	Phenytoin: In 12 normal-weight subjects receiving @DRUG$ 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of @DRUG$.
4387	DDI-false	Phenytoin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, @DRUG$ did not alter the pharmacokinetics of a single 300-mg dose of @DRUG$.
4388	DDI-mechanism	@DRUG$ competes with @DRUG$ for active tubular secretion and thus inhibits the renal excretion of meropenem.
4389	DDI-false	@DRUG$ competes with meropenem for active tubular secretion and thus inhibits the renal excretion of @DRUG$.
4390	DDI-false	Probenecid competes with @DRUG$ for active tubular secretion and thus inhibits the renal excretion of @DRUG$.
4391	DDI-advise	Therefore, the coadministration of @DRUG$ with @DRUG$ is not recommended.
4392	DDI-mechanism	There is evidence that @DRUG$ may reduce serum levels of @DRUG$ to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total valproate).
4393	DDI-false	There is evidence that @DRUG$ may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total @DRUG$).
4394	DDI-false	There is evidence that meropenem may reduce serum levels of @DRUG$ to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total @DRUG$).
4395	DDI-false	Because @DRUG$ is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes (CYP3A4, CYP2D6, CYP1A2), inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of @DRUG$.
4396	DDI-false	@DRUG$, @DRUG$, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.
4397	DDI-false	@DRUG$, Carbamazepine, and @DRUG$: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.
4398	DDI-false	@DRUG$, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., @DRUG$, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.
4399	DDI-false	@DRUG$, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, @DRUG$, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.
4400	DDI-false	@DRUG$, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and @DRUG$), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.
4401	DDI-false	@DRUG$, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of @DRUG$ was significantly increased and ondansetron blood concentrations were decreased.
4402	DDI-false	@DRUG$, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and @DRUG$ blood concentrations were decreased.
4403	DDI-false	Phenytoin, @DRUG$, and @DRUG$: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.
4404	DDI-false	Phenytoin, @DRUG$, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., @DRUG$, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.
4405	DDI-false	Phenytoin, @DRUG$, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, @DRUG$, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.
4406	DDI-false	Phenytoin, @DRUG$, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and @DRUG$), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.
4407	DDI-false	Phenytoin, @DRUG$, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of @DRUG$ was significantly increased and ondansetron blood concentrations were decreased.
4408	DDI-false	Phenytoin, @DRUG$, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and @DRUG$ blood concentrations were decreased.
4409	DDI-false	Phenytoin, Carbamazepine, and @DRUG$: In patients treated with potent inducers of CYP3A4 (i.e., @DRUG$, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.
4410	DDI-false	Phenytoin, Carbamazepine, and @DRUG$: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, @DRUG$, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.
4411	DDI-false	Phenytoin, Carbamazepine, and @DRUG$: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and @DRUG$), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.
4412	DDI-false	Phenytoin, Carbamazepine, and @DRUG$: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of @DRUG$ was significantly increased and ondansetron blood concentrations were decreased.
4413	DDI-false	Phenytoin, Carbamazepine, and @DRUG$: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and @DRUG$ blood concentrations were decreased.
4414	DDI-false	Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., @DRUG$, @DRUG$, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.
4415	DDI-false	Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., @DRUG$, carbamazepine, and @DRUG$), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.
4416	DDI-mechanism	Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., @DRUG$, carbamazepine, and rifampicin), the clearance of @DRUG$ was significantly increased and ondansetron blood concentrations were decreased.
4417	DDI-mechanism	Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., @DRUG$, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and @DRUG$ blood concentrations were decreased.
4418	DDI-false	Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, @DRUG$, and @DRUG$), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.
4419	DDI-mechanism	Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, @DRUG$, and rifampicin), the clearance of @DRUG$ was significantly increased and ondansetron blood concentrations were decreased.
4420	DDI-mechanism	Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, @DRUG$, and rifampicin), the clearance of ondansetron was significantly increased and @DRUG$ blood concentrations were decreased.
4421	DDI-mechanism	Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and @DRUG$), the clearance of @DRUG$ was significantly increased and ondansetron blood concentrations were decreased.
4422	DDI-mechanism	Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and @DRUG$), the clearance of ondansetron was significantly increased and @DRUG$ blood concentrations were decreased.
4423	DDI-false	Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of @DRUG$ was significantly increased and @DRUG$ blood concentrations were decreased.
4424	DDI-false	However, on the basis of available data, no dosage adjustment for @DRUG$ is recommended for patients on these drugs.1,3  @DRUG$: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.
4425	DDI-false	However, on the basis of available data, no dosage adjustment for @DRUG$ is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between @DRUG$ and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.
4426	DDI-false	However, on the basis of available data, no dosage adjustment for @DRUG$ is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and @DRUG$ has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.
4427	DDI-false	However, on the basis of available data, no dosage adjustment for @DRUG$ is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that @DRUG$ may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.
4428	DDI-false	However, on the basis of available data, no dosage adjustment for @DRUG$ is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of @DRUG$.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.
4429	DDI-false	However, on the basis of available data, no dosage adjustment for @DRUG$ is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by @DRUG$.
4430	DDI-false	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  @DRUG$: Although no pharmacokinetic drug interaction between @DRUG$ and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.
4431	DDI-false	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  @DRUG$: Although no pharmacokinetic drug interaction between ondansetron and @DRUG$ has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.
4432	DDI-false	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  @DRUG$: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that @DRUG$ may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.
4433	DDI-false	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  @DRUG$: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of @DRUG$.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.
4434	DDI-false	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  @DRUG$: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by @DRUG$.
4435	DDI-false	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between @DRUG$ and @DRUG$ has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.
4436	DDI-false	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between @DRUG$ and tramadol has been observed, data from 2 small studies indicate that @DRUG$ may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.
4437	DDI-false	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between @DRUG$ and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of @DRUG$.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.
4438	DDI-false	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between @DRUG$ and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by @DRUG$.
4439	DDI-false	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and @DRUG$ has been observed, data from 2 small studies indicate that @DRUG$ may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.
4440	DDI-false	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and @DRUG$ has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of @DRUG$.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.
4441	DDI-false	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and @DRUG$ has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by @DRUG$.
4442	DDI-effect	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that @DRUG$ may be associated with an increase in patient controlled administration of @DRUG$.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.
4443	DDI-false	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that @DRUG$ may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by @DRUG$.
4444	DDI-false	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of @DRUG$.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by @DRUG$.
4445	DDI-false	In humans, @DRUG$, @DRUG$, and cisplatin do not affect the pharmacokinetics of ondansetron.
4446	DDI-false	In humans, @DRUG$, etoposide, and @DRUG$ do not affect the pharmacokinetics of ondansetron.
4447	DDI-false	In humans, @DRUG$, etoposide, and cisplatin do not affect the pharmacokinetics of @DRUG$.
4448	DDI-false	In humans, carmustine, @DRUG$, and @DRUG$ do not affect the pharmacokinetics of ondansetron.
4449	DDI-false	In humans, carmustine, @DRUG$, and cisplatin do not affect the pharmacokinetics of @DRUG$.
4450	DDI-false	In humans, carmustine, etoposide, and @DRUG$ do not affect the pharmacokinetics of @DRUG$.
4451	DDI-false	@DRUG$ did not increase blood levels of high-dose @DRUG$.
4452	DDI-mechanism	CYP3A4 Inhibitors: @DRUG$, an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of @DRUG$ when coadministered to subjects who were poor metabolizers (see CLINICAL PHARMACOLOGY, Variability in Metabolism and Drug-Drug Interactions).
4453	DDI-false	For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
4454	DDI-false	For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other azole antifungals (eg, @DRUG$, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
4455	DDI-false	For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, @DRUG$) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
4456	DDI-false	For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or @DRUG$ (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
4457	DDI-false	For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, @DRUG$, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
4458	DDI-false	For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, @DRUG$) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
4459	DDI-false	For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
4460	DDI-false	For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or @DRUG$, the recommended dose of DETROL LA is 2 mg daily.
4461	DDI-advise	For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of @DRUG$ is 2 mg daily.
4462	DDI-false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, @DRUG$, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
4463	DDI-false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, @DRUG$) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
4464	DDI-false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, miconazole) or @DRUG$ (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
4465	DDI-false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, miconazole) or macrolide antibiotics (eg, @DRUG$, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
4466	DDI-false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, @DRUG$) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
4467	DDI-false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
4468	DDI-false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or @DRUG$, the recommended dose of DETROL LA is 2 mg daily.
4469	DDI-advise	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of @DRUG$ is 2 mg daily.
4470	DDI-false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, @DRUG$, @DRUG$) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
4471	DDI-false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, @DRUG$, miconazole) or @DRUG$ (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
4472	DDI-false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, @DRUG$, miconazole) or macrolide antibiotics (eg, @DRUG$, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
4473	DDI-false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, @DRUG$, miconazole) or macrolide antibiotics (eg, erythromycin, @DRUG$) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
4474	DDI-false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, @DRUG$, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
4475	DDI-false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, @DRUG$, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or @DRUG$, the recommended dose of DETROL LA is 2 mg daily.
4476	DDI-advise	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, @DRUG$, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of @DRUG$ is 2 mg daily.
4477	DDI-false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, @DRUG$) or @DRUG$ (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
4478	DDI-false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, @DRUG$) or macrolide antibiotics (eg, @DRUG$, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
4479	DDI-false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, @DRUG$) or macrolide antibiotics (eg, erythromycin, @DRUG$) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
4480	DDI-false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, @DRUG$) or macrolide antibiotics (eg, erythromycin, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
4481	DDI-false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, @DRUG$) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or @DRUG$, the recommended dose of DETROL LA is 2 mg daily.
4482	DDI-advise	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, @DRUG$) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of @DRUG$ is 2 mg daily.
4483	DDI-false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or @DRUG$ (eg, @DRUG$, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
4484	DDI-false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or @DRUG$ (eg, erythromycin, @DRUG$) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
4485	DDI-false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or @DRUG$ (eg, erythromycin, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
4486	DDI-false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or @DRUG$ (eg, erythromycin, clarithromycin) or cyclosporine or @DRUG$, the recommended dose of DETROL LA is 2 mg daily.
4487	DDI-advise	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or @DRUG$ (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of @DRUG$ is 2 mg daily.
4488	DDI-false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, @DRUG$, @DRUG$) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
4489	DDI-false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, @DRUG$, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
4490	DDI-false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, @DRUG$, clarithromycin) or cyclosporine or @DRUG$, the recommended dose of DETROL LA is 2 mg daily.
4491	DDI-advise	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, @DRUG$, clarithromycin) or cyclosporine or vinblastine, the recommended dose of @DRUG$ is 2 mg daily.
4492	DDI-false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, @DRUG$) or @DRUG$ or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
4493	DDI-false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, @DRUG$) or cyclosporine or @DRUG$, the recommended dose of DETROL LA is 2 mg daily.
4494	DDI-advise	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, @DRUG$) or cyclosporine or vinblastine, the recommended dose of @DRUG$ is 2 mg daily.
4495	DDI-false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or @DRUG$ or @DRUG$, the recommended dose of DETROL LA is 2 mg daily.
4496	DDI-advise	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of @DRUG$ is 2 mg daily.
4497	DDI-advise	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or @DRUG$, the recommended dose of @DRUG$ is 2 mg daily.
4498	DDI-false	Since @DRUG$ is metabolized by a P450 enzyme system, drugs that induce or inhibit this drug metabolizing enzyme system may elicit important drug-drug interactions that may alter @DRUG$ plasma concentrations.
4499	DDI-effect	Agents that might be coadministered with @DRUG$ in AIDS patients for other indications that could elicit this activity include @DRUG$, rifampin, rifabutin, ketoconazole, and fluconazole.
4500	DDI-effect	Agents that might be coadministered with @DRUG$ in AIDS patients for other indications that could elicit this activity include erythromycin, @DRUG$, rifabutin, ketoconazole, and fluconazole.
4501	DDI-effect	Agents that might be coadministered with @DRUG$ in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, @DRUG$, ketoconazole, and fluconazole.
4502	DDI-effect	Agents that might be coadministered with @DRUG$ in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, @DRUG$, and fluconazole.
4503	DDI-effect	Agents that might be coadministered with @DRUG$ in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and @DRUG$.
4504	DDI-false	Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include @DRUG$, @DRUG$, rifabutin, ketoconazole, and fluconazole.
4505	DDI-false	Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include @DRUG$, rifampin, @DRUG$, ketoconazole, and fluconazole.
4506	DDI-false	Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include @DRUG$, rifampin, rifabutin, @DRUG$, and fluconazole.
4507	DDI-false	Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include @DRUG$, rifampin, rifabutin, ketoconazole, and @DRUG$.
4508	DDI-false	Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, @DRUG$, @DRUG$, ketoconazole, and fluconazole.
4509	DDI-false	Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, @DRUG$, rifabutin, @DRUG$, and fluconazole.
4510	DDI-false	Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, @DRUG$, rifabutin, ketoconazole, and @DRUG$.
4511	DDI-false	Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, @DRUG$, @DRUG$, and fluconazole.
4512	DDI-false	Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, @DRUG$, ketoconazole, and @DRUG$.
4513	DDI-false	Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, @DRUG$, and @DRUG$.
4514	DDI-mechanism	In vitro perfusion of isolated rat liver has shown that @DRUG$ caused a significant reduction in @DRUG$ metabolism and that acetaminophen altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites.
4515	DDI-false	In vitro perfusion of isolated rat liver has shown that @DRUG$ caused a significant reduction in trimetrexate metabolism and that @DRUG$ altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites.
4516	DDI-false	In vitro perfusion of isolated rat liver has shown that cimetidine caused a significant reduction in @DRUG$ metabolism and that @DRUG$ altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites.
4517	DDI-false	Based on an in vitro rat liver model, nitrogen substituted @DRUG$ (@DRUG$, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism.
4518	DDI-false	Based on an in vitro rat liver model, nitrogen substituted @DRUG$ (clotrimazole, @DRUG$, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism.
4519	DDI-false	Based on an in vitro rat liver model, nitrogen substituted @DRUG$ (clotrimazole, ketoconazole, @DRUG$) were potent, non-competitive inhibitors of trimetrexate metabolism.
4520	DDI-mechanism	Based on an in vitro rat liver model, nitrogen substituted @DRUG$ (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of @DRUG$ metabolism.
4521	DDI-false	Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (@DRUG$, @DRUG$, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism.
4522	DDI-false	Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (@DRUG$, ketoconazole, @DRUG$) were potent, non-competitive inhibitors of trimetrexate metabolism.
4523	DDI-mechanism	Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (@DRUG$, ketoconazole, miconazole) were potent, non-competitive inhibitors of @DRUG$ metabolism.
4524	DDI-false	Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, @DRUG$, @DRUG$) were potent, non-competitive inhibitors of trimetrexate metabolism.
4525	DDI-mechanism	Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, @DRUG$, miconazole) were potent, non-competitive inhibitors of @DRUG$ metabolism.
4526	DDI-mechanism	Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, @DRUG$) were potent, non-competitive inhibitors of @DRUG$ metabolism.
4527	DDI-false	@DRUG$: Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving @DRUG$ concomitantly with coumarin-derivative anticoagulants.
4528	DDI-false	@DRUG$: Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving ZOLINZA concomitantly with @DRUG$.
4529	DDI-effect	Coumarin-Derivative Anticoagulants: Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving @DRUG$ concomitantly with @DRUG$.
4530	DDI-advise	Physicians should carefully monitor PT and INR in patients concurrently administered @DRUG$ and @DRUG$.
4531	DDI-false	Other @DRUG$ Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of @DRUG$ and other HDAC inhibitors (e.g., valproic acid).
4532	DDI-false	Other @DRUG$ Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other @DRUG$ (e.g., valproic acid).
4533	DDI-false	Other @DRUG$ Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., @DRUG$).
4534	DDI-effect	Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of @DRUG$ and other @DRUG$ (e.g., valproic acid).
4535	DDI-effect	Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of @DRUG$ and other HDAC inhibitors (e.g., @DRUG$).
4536	DDI-false	Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other @DRUG$ (e.g., @DRUG$).
4537	DDI-effect	however, in patients with Paget's Disease prior @DRUG$ use appears to reduce the anti-resorptive response to @DRUG$ nasal spray.
4538	DDI-advise	@DRUG$ should be used with care in patients taking other drugs that are capable of causing CNS effects such as @DRUG$, tranquilizers, or alcohol.
4539	DDI-advise	@DRUG$ should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, @DRUG$, or alcohol.
4540	DDI-advise	@DRUG$ should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or @DRUG$.
4541	DDI-false	Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as @DRUG$, @DRUG$, or alcohol.
4542	DDI-false	Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as @DRUG$, tranquilizers, or @DRUG$.
4543	DDI-false	Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, @DRUG$, or @DRUG$.
4544	DDI-false	e.g., other @DRUG$, @DRUG$ (including meclizine), tricyclic antidepressants, and muscle relaxants.
4545	DDI-false	e.g., other @DRUG$, antihistamines (including @DRUG$), tricyclic antidepressants, and muscle relaxants.
4546	DDI-false	e.g., other @DRUG$, antihistamines (including meclizine), @DRUG$, and muscle relaxants.
4547	DDI-false	e.g., other @DRUG$, antihistamines (including meclizine), tricyclic antidepressants, and @DRUG$.
4548	DDI-false	e.g., other belladonna alkaloids, @DRUG$ (including @DRUG$), tricyclic antidepressants, and muscle relaxants.
4549	DDI-false	e.g., other belladonna alkaloids, @DRUG$ (including meclizine), @DRUG$, and muscle relaxants.
4550	DDI-false	e.g., other belladonna alkaloids, @DRUG$ (including meclizine), tricyclic antidepressants, and @DRUG$.
4551	DDI-false	e.g., other belladonna alkaloids, antihistamines (including @DRUG$), @DRUG$, and muscle relaxants.
4552	DDI-false	e.g., other belladonna alkaloids, antihistamines (including @DRUG$), tricyclic antidepressants, and @DRUG$.
4553	DDI-false	e.g., other belladonna alkaloids, antihistamines (including meclizine), @DRUG$, and @DRUG$.
4554	DDI-false	Patients studied in clinical trials of @DRUG$ were routinely treated with @DRUG$ and aspirin.
4555	DDI-false	Patients studied in clinical trials of @DRUG$ were routinely treated with heparin and @DRUG$.
4556	DDI-false	Patients studied in clinical trials of TNKase were routinely treated with @DRUG$ and @DRUG$.
4557	DDI-false	@DRUG$ (such as @DRUG$ and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.
4558	DDI-false	@DRUG$ (such as heparin and @DRUG$) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.
4559	DDI-false	@DRUG$ (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as @DRUG$, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.
4560	DDI-false	@DRUG$ (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, @DRUG$, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.
4561	DDI-effect	@DRUG$ (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after @DRUG$ therapy.
4562	DDI-false	Anticoagulants (such as @DRUG$ and @DRUG$) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.
4563	DDI-false	Anticoagulants (such as @DRUG$ and vitamin K antagonists) and drugs that alter platelet function (such as @DRUG$, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.
4564	DDI-false	Anticoagulants (such as @DRUG$ and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, @DRUG$, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.
4565	DDI-effect	Anticoagulants (such as @DRUG$ and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after @DRUG$ therapy.
4566	DDI-false	Anticoagulants (such as heparin and @DRUG$) and drugs that alter platelet function (such as @DRUG$, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.
4567	DDI-false	Anticoagulants (such as heparin and @DRUG$) and drugs that alter platelet function (such as acetylsalicylic acid, @DRUG$, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.
4568	DDI-effect	Anticoagulants (such as heparin and @DRUG$) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after @DRUG$ therapy.
4569	DDI-false	Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as @DRUG$, @DRUG$, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.
4570	DDI-effect	Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as @DRUG$, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after @DRUG$ therapy.
4571	DDI-effect	Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, @DRUG$, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after @DRUG$ therapy.
4572	DDI-int	@DRUG$ may interact with @DRUG$ or mitotane (causing too great a decrease in adrenal function).
4573	DDI-int	@DRUG$ may interact with aminoglutethimide or @DRUG$ (causing too great a decrease in adrenal function).
4574	DDI-false	Trilostane may interact with @DRUG$ or @DRUG$ (causing too great a decrease in adrenal function).
4575	DDI-false	Although @DRUG$ (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between @DRUG$ and succinylcholine has not been systematically studied.
4576	DDI-false	Although @DRUG$ (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between MIVACRON and @DRUG$ has not been systematically studied.
4577	DDI-false	Although MIVACRON (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between @DRUG$ and @DRUG$ has not been systematically studied.
4578	DDI-effect	Prior administration of @DRUG$ can potentiate the neuromuscular blocking effects of @DRUG$.
4579	DDI-false	Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4580	DDI-int	Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4581	DDI-int	Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4582	DDI-int	Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4583	DDI-int	Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4584	DDI-int	Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4585	DDI-int	Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4586	DDI-int	Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4587	DDI-int	Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4588	DDI-int	Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4589	DDI-int	Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.
4590	DDI-int	Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.
4591	DDI-int	Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.
4592	DDI-int	Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.
4593	DDI-int	Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.
4594	DDI-int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4595	DDI-int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4596	DDI-int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4597	DDI-int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4598	DDI-int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4599	DDI-int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4600	DDI-int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4601	DDI-int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4602	DDI-int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4603	DDI-int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.
4604	DDI-int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.
4605	DDI-int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.
4606	DDI-int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.
4607	DDI-int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.
4608	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4609	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4610	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4611	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4612	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4613	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4614	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4615	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4616	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.
4617	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.
4618	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.
4619	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.
4620	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.
4621	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., @DRUG$, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4622	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., @DRUG$, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4623	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., @DRUG$, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4624	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., @DRUG$, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4625	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4626	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4627	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4628	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.
4629	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.
4630	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.
4631	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.
4632	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.
4633	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, @DRUG$, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4634	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, @DRUG$, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4635	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, @DRUG$, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4636	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4637	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4638	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4639	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.
4640	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.
4641	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.
4642	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.
4643	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.
4644	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, @DRUG$, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4645	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4646	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4647	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4648	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4649	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.
4650	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.
4651	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.
4652	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.
4653	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.
4654	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4655	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4656	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4657	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4658	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.
4659	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.
4660	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.
4661	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.
4662	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.
4663	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4664	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4665	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4666	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.
4667	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.
4668	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.
4669	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.
4670	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.
4671	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4672	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4673	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.
4674	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.
4675	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.
4676	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.
4677	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.
4678	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
4679	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.
4680	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.
4681	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.
4682	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.
4683	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.
4684	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.
4685	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.
4686	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.
4687	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.
4688	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.
4689	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, @DRUG$, local anesthetics, procainamide, and quinidine.
4690	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local @DRUG$, procainamide, and quinidine.
4691	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, @DRUG$, and quinidine.
4692	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and @DRUG$.
4693	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local @DRUG$, procainamide, and quinidine.
4694	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, @DRUG$, and quinidine.
4695	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and @DRUG$.
4696	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, @DRUG$, and quinidine.
4697	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and @DRUG$.
4698	DDI-false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and @DRUG$.
4699	DDI-effect	The neuromuscular blocking effect of @DRUG$ may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral @DRUG$, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.
4700	DDI-effect	The neuromuscular blocking effect of @DRUG$ may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, @DRUG$, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.
4701	DDI-effect	The neuromuscular blocking effect of @DRUG$ may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain @DRUG$) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.
4702	DDI-false	The neuromuscular blocking effect of @DRUG$ may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing @DRUG$ has been demonstrated in patients chronically administered phenytoin or carbamazepine.
4703	DDI-false	The neuromuscular blocking effect of @DRUG$ may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered @DRUG$ or carbamazepine.
4704	DDI-false	The neuromuscular blocking effect of @DRUG$ may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or @DRUG$.
4705	DDI-false	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral @DRUG$, @DRUG$, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.
4706	DDI-false	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral @DRUG$, glucocorticoids, or certain @DRUG$) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.
4707	DDI-false	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral @DRUG$, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing @DRUG$ has been demonstrated in patients chronically administered phenytoin or carbamazepine.
4708	DDI-false	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral @DRUG$, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered @DRUG$ or carbamazepine.
4709	DDI-false	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral @DRUG$, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or @DRUG$.
4710	DDI-false	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, @DRUG$, or certain @DRUG$) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.
4711	DDI-false	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, @DRUG$, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing @DRUG$ has been demonstrated in patients chronically administered phenytoin or carbamazepine.
4712	DDI-false	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, @DRUG$, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered @DRUG$ or carbamazepine.
4713	DDI-false	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, @DRUG$, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or @DRUG$.
4714	DDI-false	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain @DRUG$) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing @DRUG$ has been demonstrated in patients chronically administered phenytoin or carbamazepine.
4715	DDI-false	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain @DRUG$) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered @DRUG$ or carbamazepine.
4716	DDI-false	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain @DRUG$) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or @DRUG$.
4717	DDI-effect	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing @DRUG$ has been demonstrated in patients chronically administered @DRUG$ or carbamazepine.
4718	DDI-effect	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing @DRUG$ has been demonstrated in patients chronically administered phenytoin or @DRUG$.
4719	DDI-false	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered @DRUG$ or @DRUG$.
4720	DDI-false	While the effects of chronic @DRUG$ or @DRUG$ therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.
4721	DDI-effect	While the effects of chronic @DRUG$ or carbamazepine therapy on the action of @DRUG$ are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.
4722	DDI-effect	While the effects of chronic phenytoin or @DRUG$ therapy on the action of @DRUG$ are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.
4723	DDI-false	Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4724	DDI-false	Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or @DRUG$ - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4725	DDI-false	Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain @DRUG$ given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4726	DDI-false	Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - @DRUG$ - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4727	DDI-false	Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - @DRUG$ - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4728	DDI-false	Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - @DRUG$ - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4729	DDI-false	Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - @DRUG$ or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4730	DDI-false	Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or @DRUG$ - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4731	DDI-false	Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local @DRUG$ such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4732	DDI-false	Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as @DRUG$ - general anesthetics - succinylcholine or other muscle relaxants
4733	DDI-false	Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general @DRUG$ - succinylcholine or other muscle relaxants
4734	DDI-false	Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - @DRUG$ or other muscle relaxants
4735	DDI-false	Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other @DRUG$
4736	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or @DRUG$ - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4737	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or carbamazepine - certain @DRUG$ given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4738	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or carbamazepine - certain antibiotics given by injection - @DRUG$ - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4739	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or carbamazepine - certain antibiotics given by injection - cisplatin - @DRUG$ - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4740	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - @DRUG$ - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4741	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - @DRUG$ or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4742	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or @DRUG$ - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4743	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local @DRUG$ such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4744	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as @DRUG$ - general anesthetics - succinylcholine or other muscle relaxants
4745	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general @DRUG$ - succinylcholine or other muscle relaxants
4746	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - @DRUG$ or other muscle relaxants
4747	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other @DRUG$
4748	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or @DRUG$ - certain @DRUG$ given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4749	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or @DRUG$ - certain antibiotics given by injection - @DRUG$ - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4750	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or @DRUG$ - certain antibiotics given by injection - cisplatin - @DRUG$ - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4751	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or @DRUG$ - certain antibiotics given by injection - cisplatin - edrophonium - @DRUG$ - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4752	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or @DRUG$ - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - @DRUG$ or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4753	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or @DRUG$ - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or @DRUG$ - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4754	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or @DRUG$ - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local @DRUG$ such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4755	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or @DRUG$ - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as @DRUG$ - general anesthetics - succinylcholine or other muscle relaxants
4756	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or @DRUG$ - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general @DRUG$ - succinylcholine or other muscle relaxants
4757	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or @DRUG$ - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - @DRUG$ or other muscle relaxants
4758	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or @DRUG$ - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other @DRUG$
4759	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain @DRUG$ given by injection - @DRUG$ - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4760	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain @DRUG$ given by injection - cisplatin - @DRUG$ - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4761	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain @DRUG$ given by injection - cisplatin - edrophonium - @DRUG$ - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4762	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain @DRUG$ given by injection - cisplatin - edrophonium - neostigmine - @DRUG$ or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4763	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain @DRUG$ given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or @DRUG$ - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4764	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain @DRUG$ given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local @DRUG$ such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4765	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain @DRUG$ given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as @DRUG$ - general anesthetics - succinylcholine or other muscle relaxants
4766	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain @DRUG$ given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general @DRUG$ - succinylcholine or other muscle relaxants
4767	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain @DRUG$ given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - @DRUG$ or other muscle relaxants
4768	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain @DRUG$ given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other @DRUG$
4769	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - @DRUG$ - @DRUG$ - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4770	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - @DRUG$ - edrophonium - @DRUG$ - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4771	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - @DRUG$ - edrophonium - neostigmine - @DRUG$ or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4772	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - @DRUG$ - edrophonium - neostigmine - polymyxin B or @DRUG$ - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4773	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - @DRUG$ - edrophonium - neostigmine - polymyxin B or bacitracin - local @DRUG$ such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4774	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - @DRUG$ - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as @DRUG$ - general anesthetics - succinylcholine or other muscle relaxants
4775	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - @DRUG$ - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general @DRUG$ - succinylcholine or other muscle relaxants
4776	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - @DRUG$ - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - @DRUG$ or other muscle relaxants
4777	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - @DRUG$ - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other @DRUG$
4778	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - @DRUG$ - @DRUG$ - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4779	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - @DRUG$ - neostigmine - @DRUG$ or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4780	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - @DRUG$ - neostigmine - polymyxin B or @DRUG$ - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4781	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - @DRUG$ - neostigmine - polymyxin B or bacitracin - local @DRUG$ such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4782	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - @DRUG$ - neostigmine - polymyxin B or bacitracin - local anesthetics such as @DRUG$ - general anesthetics - succinylcholine or other muscle relaxants
4783	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - @DRUG$ - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general @DRUG$ - succinylcholine or other muscle relaxants
4784	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - @DRUG$ - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - @DRUG$ or other muscle relaxants
4785	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - @DRUG$ - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other @DRUG$
4786	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - @DRUG$ - @DRUG$ or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4787	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - @DRUG$ - polymyxin B or @DRUG$ - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4788	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - @DRUG$ - polymyxin B or bacitracin - local @DRUG$ such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4789	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - @DRUG$ - polymyxin B or bacitracin - local anesthetics such as @DRUG$ - general anesthetics - succinylcholine or other muscle relaxants
4790	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - @DRUG$ - polymyxin B or bacitracin - local anesthetics such as procaine - general @DRUG$ - succinylcholine or other muscle relaxants
4791	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - @DRUG$ - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - @DRUG$ or other muscle relaxants
4792	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - @DRUG$ - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other @DRUG$
4793	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - @DRUG$ or @DRUG$ - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4794	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - @DRUG$ or bacitracin - local @DRUG$ such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4795	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - @DRUG$ or bacitracin - local anesthetics such as @DRUG$ - general anesthetics - succinylcholine or other muscle relaxants
4796	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - @DRUG$ or bacitracin - local anesthetics such as procaine - general @DRUG$ - succinylcholine or other muscle relaxants
4797	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - @DRUG$ or bacitracin - local anesthetics such as procaine - general anesthetics - @DRUG$ or other muscle relaxants
4798	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - @DRUG$ or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other @DRUG$
4799	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or @DRUG$ - local @DRUG$ such as procaine - general anesthetics - succinylcholine or other muscle relaxants
4800	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or @DRUG$ - local anesthetics such as @DRUG$ - general anesthetics - succinylcholine or other muscle relaxants
4801	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or @DRUG$ - local anesthetics such as procaine - general @DRUG$ - succinylcholine or other muscle relaxants
4802	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or @DRUG$ - local anesthetics such as procaine - general anesthetics - @DRUG$ or other muscle relaxants
4803	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or @DRUG$ - local anesthetics such as procaine - general anesthetics - succinylcholine or other @DRUG$
4804	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local @DRUG$ such as @DRUG$ - general anesthetics - succinylcholine or other muscle relaxants
4805	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local @DRUG$ such as procaine - general @DRUG$ - succinylcholine or other muscle relaxants
4806	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local @DRUG$ such as procaine - general anesthetics - @DRUG$ or other muscle relaxants
4807	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local @DRUG$ such as procaine - general anesthetics - succinylcholine or other @DRUG$
4808	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as @DRUG$ - general @DRUG$ - succinylcholine or other muscle relaxants
4809	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as @DRUG$ - general anesthetics - @DRUG$ or other muscle relaxants
4810	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as @DRUG$ - general anesthetics - succinylcholine or other @DRUG$
4811	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general @DRUG$ - @DRUG$ or other muscle relaxants
4812	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general @DRUG$ - succinylcholine or other @DRUG$
4813	DDI-false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - @DRUG$ or other @DRUG$
4814	DDI-advise	Evidence of spontaneous recovery from @DRUG$ should be observed before the administration of @DRUG$.
4815	DDI-false	The use of @DRUG$ before @DRUG$ to attenuate some of the side effects of succinylcholine has not been studied.
4816	DDI-false	The use of @DRUG$ before succinylcholine to attenuate some of the side effects of @DRUG$ has not been studied.
4817	DDI-false	The use of MIVACRON before @DRUG$ to attenuate some of the side effects of @DRUG$ has not been studied.
4818	DDI-false	There are no clinical data on the use of @DRUG$ with other @DRUG$.
4819	DDI-false	@DRUG$ and @DRUG$ (administered with nitrous oxide/oxygen to achieve 1.25 M.C.
4820	DDI-false	@DRUG$ and enflurane (administered with @DRUG$/oxygen to achieve 1.25 M.C.
4821	DDI-false	@DRUG$ and enflurane (administered with nitrous oxide/@DRUG$ to achieve 1.25 M.C.
4822	DDI-false	Isoflurane and @DRUG$ (administered with @DRUG$/oxygen to achieve 1.25 M.C.
4823	DDI-false	Isoflurane and @DRUG$ (administered with nitrous oxide/@DRUG$ to achieve 1.25 M.C.
4824	DDI-false	Isoflurane and enflurane (administered with @DRUG$/@DRUG$ to achieve 1.25 M.C.
4825	DDI-false	A greater potentiation of the neuromuscular blocking effects of @DRUG$ may be expected with higher concentrations of @DRUG$ or isoflurane.
4826	DDI-false	A greater potentiation of the neuromuscular blocking effects of @DRUG$ may be expected with higher concentrations of enflurane or @DRUG$.
4827	DDI-false	A greater potentiation of the neuromuscular blocking effects of MIVACRON may be expected with higher concentrations of @DRUG$ or @DRUG$.
4828	DDI-false	@DRUG$: @DRUG$ increases the plasma concentrations of phenytoin.
4829	DDI-false	@DRUG$: DIFLUCAN increases the plasma concentrations of @DRUG$.
4830	DDI-mechanism	Phenytoin: @DRUG$ increases the plasma concentrations of @DRUG$.
4831	DDI-false	Careful monitoring of @DRUG$ concentrations in patients receiving @DRUG$ and phenytoin is recommended.
4832	DDI-false	Careful monitoring of @DRUG$ concentrations in patients receiving DIFLUCAN and @DRUG$ is recommended.
4833	DDI-advise	Careful monitoring of phenytoin concentrations in patients receiving @DRUG$ and @DRUG$ is recommended.
4834	DDI-false	@DRUG$: @DRUG$ may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment.
4835	DDI-false	@DRUG$: DIFLUCAN may significantly increase @DRUG$ levels in renal transplant patients with or without renal impairment.
4836	DDI-mechanism	Cyclosporine: @DRUG$ may significantly increase @DRUG$ levels in renal transplant patients with or without renal impairment.
4837	DDI-false	Careful monitoring of @DRUG$ concentrations and serum creatinine is recommended in patients receiving @DRUG$ and cyclosporine.
4838	DDI-false	Careful monitoring of @DRUG$ concentrations and serum creatinine is recommended in patients receiving DIFLUCAN and @DRUG$.
4839	DDI-advise	Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving @DRUG$ and @DRUG$.
4840	DDI-false	@DRUG$: @DRUG$ enhances the metabolism of concurrently administered DIFLUCAN.
4841	DDI-false	@DRUG$: Rifampin enhances the metabolism of concurrently administered @DRUG$.
4842	DDI-mechanism	Rifampin: @DRUG$ enhances the metabolism of concurrently administered @DRUG$.
4843	DDI-advise	Depending on clinical circumstances, consideration should be given to increasing the dose of @DRUG$ when it is administered with @DRUG$.
4844	DDI-false	@DRUG$: @DRUG$ increases the serum concentrations of theophylline.
4845	DDI-false	@DRUG$: DIFLUCAN increases the serum concentrations of @DRUG$.
4846	DDI-mechanism	Theophylline: @DRUG$ increases the serum concentrations of @DRUG$.
4847	DDI-false	Careful monitoring of serum @DRUG$ concentrations in patients receiving @DRUG$ and theophylline is recommended.
4848	DDI-false	Careful monitoring of serum @DRUG$ concentrations in patients receiving DIFLUCAN and @DRUG$ is recommended.
4849	DDI-advise	Careful monitoring of serum theophylline concentrations in patients receiving @DRUG$ and @DRUG$ is recommended.
4850	DDI-false	These are described in greater detail below:  Oral @DRUG$, @DRUG$, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4851	DDI-false	These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, @DRUG$, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4852	DDI-false	These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, Phenytoin, @DRUG$, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4853	DDI-false	These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, @DRUG$, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4854	DDI-false	These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, @DRUG$, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4855	DDI-false	These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, @DRUG$, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4856	DDI-false	These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, @DRUG$, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4857	DDI-false	These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, @DRUG$, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4858	DDI-false	These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, @DRUG$, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4859	DDI-false	These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, @DRUG$, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4860	DDI-false	These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4861	DDI-false	These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4862	DDI-false	These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents;
4863	DDI-false	These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$;
4864	DDI-false	These are described in greater detail below:  Oral hypoglycemics, @DRUG$, @DRUG$, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4865	DDI-false	These are described in greater detail below:  Oral hypoglycemics, @DRUG$, Phenytoin, @DRUG$, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4866	DDI-false	These are described in greater detail below:  Oral hypoglycemics, @DRUG$, Phenytoin, Cyclosporine, @DRUG$, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4867	DDI-false	These are described in greater detail below:  Oral hypoglycemics, @DRUG$, Phenytoin, Cyclosporine, Rifampin, @DRUG$, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4868	DDI-false	These are described in greater detail below:  Oral hypoglycemics, @DRUG$, Phenytoin, Cyclosporine, Rifampin, Theophylline, @DRUG$, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4869	DDI-false	These are described in greater detail below:  Oral hypoglycemics, @DRUG$, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, @DRUG$, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4870	DDI-false	These are described in greater detail below:  Oral hypoglycemics, @DRUG$, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, @DRUG$, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4871	DDI-false	These are described in greater detail below:  Oral hypoglycemics, @DRUG$, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, @DRUG$, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4872	DDI-false	These are described in greater detail below:  Oral hypoglycemics, @DRUG$, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, @DRUG$, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4873	DDI-false	These are described in greater detail below:  Oral hypoglycemics, @DRUG$, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4874	DDI-false	These are described in greater detail below:  Oral hypoglycemics, @DRUG$, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4875	DDI-false	These are described in greater detail below:  Oral hypoglycemics, @DRUG$, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents;
4876	DDI-false	These are described in greater detail below:  Oral hypoglycemics, @DRUG$, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$;
4877	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, @DRUG$, @DRUG$, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4878	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, @DRUG$, Cyclosporine, @DRUG$, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4879	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, @DRUG$, Cyclosporine, Rifampin, @DRUG$, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4880	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, @DRUG$, Cyclosporine, Rifampin, Theophylline, @DRUG$, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4881	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, @DRUG$, Cyclosporine, Rifampin, Theophylline, Terfenadine, @DRUG$, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4882	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, @DRUG$, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, @DRUG$, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4883	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, @DRUG$, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, @DRUG$, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4884	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, @DRUG$, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, @DRUG$, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4885	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, @DRUG$, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4886	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, @DRUG$, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4887	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, @DRUG$, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents;
4888	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, @DRUG$, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$;
4889	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, @DRUG$, @DRUG$, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4890	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, @DRUG$, Rifampin, @DRUG$, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4891	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, @DRUG$, Rifampin, Theophylline, @DRUG$, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4892	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, @DRUG$, Rifampin, Theophylline, Terfenadine, @DRUG$, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4893	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, @DRUG$, Rifampin, Theophylline, Terfenadine, Cisapride, @DRUG$, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4894	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, @DRUG$, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, @DRUG$, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4895	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, @DRUG$, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, @DRUG$, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4896	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, @DRUG$, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4897	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, @DRUG$, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4898	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, @DRUG$, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents;
4899	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, @DRUG$, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$;
4900	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, @DRUG$, @DRUG$, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4901	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, @DRUG$, Theophylline, @DRUG$, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4902	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, @DRUG$, Theophylline, Terfenadine, @DRUG$, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4903	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, @DRUG$, Theophylline, Terfenadine, Cisapride, @DRUG$, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4904	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, @DRUG$, Theophylline, Terfenadine, Cisapride, Astemizole, @DRUG$, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4905	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, @DRUG$, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, @DRUG$, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4906	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, @DRUG$, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4907	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, @DRUG$, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4908	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, @DRUG$, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents;
4909	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, @DRUG$, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$;
4910	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, @DRUG$, @DRUG$, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4911	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, @DRUG$, Terfenadine, @DRUG$, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4912	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, @DRUG$, Terfenadine, Cisapride, @DRUG$, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4913	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, @DRUG$, Terfenadine, Cisapride, Astemizole, @DRUG$, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4914	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, @DRUG$, Terfenadine, Cisapride, Astemizole, Rifabutin, @DRUG$, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4915	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, @DRUG$, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4916	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, @DRUG$, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4917	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, @DRUG$, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents;
4918	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, @DRUG$, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$;
4919	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, @DRUG$, @DRUG$, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4920	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, @DRUG$, Cisapride, @DRUG$, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4921	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, @DRUG$, Cisapride, Astemizole, @DRUG$, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4922	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, @DRUG$, Cisapride, Astemizole, Rifabutin, @DRUG$, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4923	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, @DRUG$, Cisapride, Astemizole, Rifabutin, Tacrolimus, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4924	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, @DRUG$, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4925	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, @DRUG$, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents;
4926	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, @DRUG$, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$;
4927	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, @DRUG$, @DRUG$, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4928	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, @DRUG$, Astemizole, @DRUG$, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4929	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, @DRUG$, Astemizole, Rifabutin, @DRUG$, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4930	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, @DRUG$, Astemizole, Rifabutin, Tacrolimus, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4931	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, @DRUG$, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4932	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, @DRUG$, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents;
4933	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, @DRUG$, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$;
4934	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, @DRUG$, @DRUG$, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4935	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, @DRUG$, Rifabutin, @DRUG$, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4936	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, @DRUG$, Rifabutin, Tacrolimus, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4937	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, @DRUG$, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4938	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, @DRUG$, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents;
4939	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, @DRUG$, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$;
4940	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, @DRUG$, @DRUG$, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4941	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, @DRUG$, Tacrolimus, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4942	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, @DRUG$, Tacrolimus, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4943	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, @DRUG$, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents;
4944	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, @DRUG$, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$;
4945	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, @DRUG$, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4946	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, @DRUG$, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4947	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, @DRUG$, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents;
4948	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, @DRUG$, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$;
4949	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, @DRUG$,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
4950	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents;
4951	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$;
4952	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents;
4953	DDI-false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$;
4954	DDI-effect	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral @DRUG$;
4955	DDI-false	@DRUG$: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving @DRUG$ in conjunction with terfenadine, interaction studies have been performed.
4956	DDI-false	@DRUG$: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving azole antifungals in conjunction with @DRUG$, interaction studies have been performed.
4957	DDI-effect	Terfenadine: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving @DRUG$ in conjunction with @DRUG$, interaction studies have been performed.
4958	DDI-false	Another study at a 400-mg and 800-mg daily dose of @DRUG$ demonstrated that @DRUG$ taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly.
4959	DDI-false	Another study at a 400-mg and 800-mg daily dose of @DRUG$ demonstrated that DIFLUCAN taken in doses of 400 mg per day or greater significantly increases plasma levels of @DRUG$ when taken concomitantly.
4960	DDI-mechanism	Another study at a 400-mg and 800-mg daily dose of fluconazole demonstrated that @DRUG$ taken in doses of 400 mg per day or greater significantly increases plasma levels of @DRUG$ when taken concomitantly.
4961	DDI-advise	The combined use of @DRUG$ at doses of 400 mg or greater with @DRUG$ is contraindicated.
4962	DDI-advise	The coadministration of @DRUG$ at doses lower than 400 mg/day with @DRUG$ should be carefully monitored.
4963	DDI-false	@DRUG$: There have been reports of cardiac events, including torsade de pointes in patients to whom @DRUG$ and cisapride were coadministered.
4964	DDI-false	@DRUG$: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and @DRUG$ were coadministered.
4965	DDI-effect	Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom @DRUG$ and @DRUG$ were coadministered.
4966	DDI-mechanism	A controlled study found that concomitant @DRUG$ 200 mg once daily and @DRUG$ 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.
4967	DDI-false	A controlled study found that concomitant @DRUG$ 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in @DRUG$ plasma levels and prolongation of QTc interval.
4968	DDI-false	A controlled study found that concomitant fluconazole 200 mg once daily and @DRUG$ 20 mg four times a day yielded a significant increase in @DRUG$ plasma levels and prolongation of QTc interval.
4969	DDI-advise	The combined use of @DRUG$ with @DRUG$ is contraindicated.
4970	DDI-false	@DRUG$: The use of @DRUG$ in patients concurrently taking astemizole or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs.
4971	DDI-false	@DRUG$: The use of fluconazole in patients concurrently taking @DRUG$ or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs.
4972	DDI-mechanism	Astemizole: The use of @DRUG$ in patients concurrently taking @DRUG$ or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs.
4973	DDI-effect	one fatality has been reported from hypoglycemia in association with combined @DRUG$ and @DRUG$ use.
4974	DDI-false	@DRUG$: There have been reports of uveitis in patients to whom @DRUG$ and rifabutin were coadministered.
4975	DDI-false	@DRUG$: There have been reports of uveitis in patients to whom fluconazole and @DRUG$ were coadministered.
4976	DDI-effect	Rifabutin: There have been reports of uveitis in patients to whom @DRUG$ and @DRUG$ were coadministered.
4977	DDI-advise	Patients receiving @DRUG$ and @DRUG$ concomitantly should be carefully monitored.
4978	DDI-false	@DRUG$: There have been reports of nephrotoxicity in patients to whom @DRUG$ and tacrolimus were coadministered.
4979	DDI-false	@DRUG$: There have been reports of nephrotoxicity in patients to whom fluconazole and @DRUG$ were coadministered.
4980	DDI-effect	Tacrolimus: There have been reports of nephrotoxicity in patients to whom @DRUG$ and @DRUG$ were coadministered.
4981	DDI-advise	Patients receiving @DRUG$ and @DRUG$ concomitantly should be carefully monitored.
4982	DDI-false	@DRUG$: Following oral administration of @DRUG$, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects.
4983	DDI-false	@DRUG$: Following oral administration of midazolam, @DRUG$ resulted in substantial increases in midazolam concentrations and psychomotor effects.
4984	DDI-false	@DRUG$: Following oral administration of midazolam, fluconazole resulted in substantial increases in @DRUG$ concentrations and psychomotor effects.
4985	DDI-mechanism	Short-acting Benzodiazepines: Following oral administration of @DRUG$, @DRUG$ resulted in substantial increases in midazolam concentrations and psychomotor effects.
4986	DDI-false	Short-acting Benzodiazepines: Following oral administration of @DRUG$, fluconazole resulted in substantial increases in @DRUG$ concentrations and psychomotor effects.
4987	DDI-false	Short-acting Benzodiazepines: Following oral administration of midazolam, @DRUG$ resulted in substantial increases in @DRUG$ concentrations and psychomotor effects.
4988	DDI-effect	This effect on @DRUG$ appears to be more pronounced following oral administration of @DRUG$ than with fluconazole administered intravenously.
4989	DDI-false	This effect on @DRUG$ appears to be more pronounced following oral administration of fluconazole than with @DRUG$ administered intravenously.
4990	DDI-false	This effect on midazolam appears to be more pronounced following oral administration of @DRUG$ than with @DRUG$ administered intravenously.
4991	DDI-advise	If @DRUG$, which are metabolized by the cytochrome P450 system, are concomitantly administered with @DRUG$, consideration should be given to decreasing the benzodiazepine dosage, and the patients should be appropriately monitored.
4992	DDI-false	If @DRUG$, which are metabolized by the cytochrome P450 system, are concomitantly administered with fluconazole, consideration should be given to decreasing the @DRUG$ dosage, and the patients should be appropriately monitored.
4993	DDI-false	If short-acting benzodiazepines, which are metabolized by the cytochrome P450 system, are concomitantly administered with @DRUG$, consideration should be given to decreasing the @DRUG$ dosage, and the patients should be appropriately monitored.
4994	DDI-mechanism	@DRUG$ tablets coadministered with @DRUG$- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;
4995	DDI-mechanism	@DRUG$ tablets coadministered with ethinyl estradiol- and @DRUG$-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;
4996	DDI-false	@DRUG$ tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral @DRUG$ produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;
4997	DDI-false	@DRUG$ tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in @DRUG$ and levonorgestrel levels;
4998	DDI-false	@DRUG$ tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and @DRUG$ levels;
4999	DDI-false	Fluconazole tablets coadministered with @DRUG$- and @DRUG$-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;
5000	DDI-false	Fluconazole tablets coadministered with @DRUG$- and levonorgestrel-containing oral @DRUG$ produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;
5001	DDI-false	Fluconazole tablets coadministered with @DRUG$- and levonorgestrel-containing oral contraceptives produced an overall mean increase in @DRUG$ and levonorgestrel levels;
5002	DDI-false	Fluconazole tablets coadministered with @DRUG$- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and @DRUG$ levels;
5003	DDI-false	Fluconazole tablets coadministered with ethinyl estradiol- and @DRUG$-containing oral @DRUG$ produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;
5004	DDI-false	Fluconazole tablets coadministered with ethinyl estradiol- and @DRUG$-containing oral contraceptives produced an overall mean increase in @DRUG$ and levonorgestrel levels;
5005	DDI-false	Fluconazole tablets coadministered with ethinyl estradiol- and @DRUG$-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and @DRUG$ levels;
5006	DDI-false	Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral @DRUG$ produced an overall mean increase in @DRUG$ and levonorgestrel levels;
5007	DDI-false	Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral @DRUG$ produced an overall mean increase in ethinyl estradiol and @DRUG$ levels;
5008	DDI-false	Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in @DRUG$ and @DRUG$ levels;
5009	DDI-false	however, in some patients there were decreases up to 47% and 33% of @DRUG$ and @DRUG$ levels.
5010	DDI-mechanism	@DRUG$ reduces the metabolism of @DRUG$, glyburide, and glipizide and increases the plasma concentration of these agents.
5011	DDI-mechanism	@DRUG$ reduces the metabolism of tolbutamide, @DRUG$, and glipizide and increases the plasma concentration of these agents.
5012	DDI-mechanism	@DRUG$ reduces the metabolism of tolbutamide, glyburide, and @DRUG$ and increases the plasma concentration of these agents.
5013	DDI-false	DIFLUCAN reduces the metabolism of @DRUG$, @DRUG$, and glipizide and increases the plasma concentration of these agents.
5014	DDI-false	DIFLUCAN reduces the metabolism of @DRUG$, glyburide, and @DRUG$ and increases the plasma concentration of these agents.
5015	DDI-false	DIFLUCAN reduces the metabolism of tolbutamide, @DRUG$, and @DRUG$ and increases the plasma concentration of these agents.
5016	DDI-false	The data presently available indicate that the decreases in some individual @DRUG$ and @DRUG$ AUC values with fluconazole treatment are likely the result of random variation.
5017	DDI-false	The data presently available indicate that the decreases in some individual @DRUG$ and levonorgestrel AUC values with @DRUG$ treatment are likely the result of random variation.
5018	DDI-false	The data presently available indicate that the decreases in some individual ethinyl estradiol and @DRUG$ AUC values with @DRUG$ treatment are likely the result of random variation.
5019	DDI-mechanism	While there is evidence that @DRUG$ can inhibit the metabolism of @DRUG$ and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism.
5020	DDI-mechanism	While there is evidence that @DRUG$ can inhibit the metabolism of ethinyl estradiol and @DRUG$, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism.
5021	DDI-false	While there is evidence that @DRUG$ can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that @DRUG$ is a net inducer of ethinyl estradiol or levonorgestrel metabolism.
5022	DDI-false	While there is evidence that @DRUG$ can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of @DRUG$ or levonorgestrel metabolism.
5023	DDI-false	While there is evidence that @DRUG$ can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or @DRUG$ metabolism.
5024	DDI-false	While there is evidence that fluconazole can inhibit the metabolism of @DRUG$ and @DRUG$, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism.
5025	DDI-false	While there is evidence that fluconazole can inhibit the metabolism of @DRUG$ and levonorgestrel, there is no evidence that @DRUG$ is a net inducer of ethinyl estradiol or levonorgestrel metabolism.
5026	DDI-false	While there is evidence that fluconazole can inhibit the metabolism of @DRUG$ and levonorgestrel, there is no evidence that fluconazole is a net inducer of @DRUG$ or levonorgestrel metabolism.
5027	DDI-false	While there is evidence that fluconazole can inhibit the metabolism of @DRUG$ and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or @DRUG$ metabolism.
5028	DDI-false	While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and @DRUG$, there is no evidence that @DRUG$ is a net inducer of ethinyl estradiol or levonorgestrel metabolism.
5029	DDI-false	While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and @DRUG$, there is no evidence that fluconazole is a net inducer of @DRUG$ or levonorgestrel metabolism.
5030	DDI-false	While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and @DRUG$, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or @DRUG$ metabolism.
5031	DDI-false	While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that @DRUG$ is a net inducer of @DRUG$ or levonorgestrel metabolism.
5032	DDI-false	While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that @DRUG$ is a net inducer of ethinyl estradiol or @DRUG$ metabolism.
5033	DDI-false	While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of @DRUG$ or @DRUG$ metabolism.
5034	DDI-advise	When @DRUG$ is used concomitantly with these or other @DRUG$, blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary.
5035	DDI-false	When @DRUG$ is used concomitantly with these or other sulfonylurea oral hypoglycemic agents, blood glucose concentrations should be carefully monitored and the dose of the @DRUG$ should be adjusted as necessary.
5036	DDI-false	When DIFLUCAN is used concomitantly with these or other @DRUG$, blood glucose concentrations should be carefully monitored and the dose of the @DRUG$ should be adjusted as necessary.
5037	DDI-false	@DRUG$: Prothrombin time may be increased in patients receiving concomitant @DRUG$ and coumarin-type anticoagulants.
5038	DDI-false	@DRUG$: Prothrombin time may be increased in patients receiving concomitant DIFLUCAN and @DRUG$.
5039	DDI-effect	Coumarin-type anticoagulants: Prothrombin time may be increased in patients receiving concomitant @DRUG$ and @DRUG$.
5040	DDI-false	In post-marketing experience, as with other @DRUG$, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving @DRUG$ concurrently with warfarin.
5041	DDI-false	In post-marketing experience, as with other @DRUG$, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with @DRUG$.
5042	DDI-effect	In post-marketing experience, as with other azole antifungals, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving @DRUG$ concurrently with @DRUG$.
5043	DDI-advise	Careful monitoring of prothrombin time in patients receiving @DRUG$ and @DRUG$ is recommended.
5044	DDI-false	The interaction of @DRUG$, @DRUG$, with other drugs has not been well studied.
5045	DDI-false	Use of @DRUG$ and @DRUG$ -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.
5046	DDI-false	Use of @DRUG$ and Antiplatelet Agents -- @DRUG$, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.
5047	DDI-false	Use of @DRUG$ and Antiplatelet Agents -- Streptase, @DRUG$, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.
5048	DDI-false	Use of @DRUG$ and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with @DRUG$ and anticoagulants, may cause bleeding complications.
5049	DDI-false	Use of @DRUG$ and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and @DRUG$, may cause bleeding complications.
5050	DDI-false	Use of Anticoagulants and @DRUG$ -- @DRUG$, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.
5051	DDI-false	Use of Anticoagulants and @DRUG$ -- Streptase, @DRUG$, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.
5052	DDI-false	Use of Anticoagulants and @DRUG$ -- Streptase, Streptokinase, alone or in combination with @DRUG$ and anticoagulants, may cause bleeding complications.
5053	DDI-false	Use of Anticoagulants and @DRUG$ -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and @DRUG$, may cause bleeding complications.
5054	DDI-false	Use of Anticoagulants and Antiplatelet Agents -- @DRUG$, @DRUG$, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.
5055	DDI-effect	Use of Anticoagulants and Antiplatelet Agents -- @DRUG$, Streptokinase, alone or in combination with @DRUG$ and anticoagulants, may cause bleeding complications.
5056	DDI-effect	Use of Anticoagulants and Antiplatelet Agents -- @DRUG$, Streptokinase, alone or in combination with antiplatelet agents and @DRUG$, may cause bleeding complications.
5057	DDI-effect	Use of Anticoagulants and Antiplatelet Agents -- Streptase, @DRUG$, alone or in combination with @DRUG$ and anticoagulants, may cause bleeding complications.
5058	DDI-effect	Use of Anticoagulants and Antiplatelet Agents -- Streptase, @DRUG$, alone or in combination with antiplatelet agents and @DRUG$, may cause bleeding complications.
5059	DDI-false	Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with @DRUG$ and @DRUG$, may cause bleeding complications.
5060	DDI-false	In the treatment of acute MI, @DRUG$, when not otherwise contraindicated, should be administered with @DRUG$ ( see below ).
5061	DDI-false	Anticoagulation and @DRUG$ After Treatment for Myocardial Infarction -- In the treatment of acute myocardial infarction, the use of @DRUG$ has been shown to reduce the incidence of reinfarction and stroke.
5062	DDI-effect	The addition of @DRUG$ to @DRUG$ causes a minimal increase in the risk of minor bleeding (3.9% vs. 3.1%), but does not appear to increase the incidence of major bleeding (see
5063	DDI-effect	When @DRUG$ is used with other @DRUG$, potentiation of antihypertensive effect may occur.
5064	DDI-false	@DRUG$ does not interfere with measurement of @DRUG$ (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin.
5065	DDI-false	@DRUG$ does not interfere with measurement of VMA (@DRUG$), a test for pheochromocytoma, by those methods which convert VMA to vanillin.
5066	DDI-false	@DRUG$ does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert @DRUG$ to vanillin.
5067	DDI-false	@DRUG$ does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to @DRUG$.
5068	DDI-false	Methyldopa does not interfere with measurement of @DRUG$ (@DRUG$), a test for pheochromocytoma, by those methods which convert VMA to vanillin.
5069	DDI-false	Methyldopa does not interfere with measurement of @DRUG$ (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert @DRUG$ to vanillin.
5070	DDI-false	Methyldopa does not interfere with measurement of @DRUG$ (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to @DRUG$.
5071	DDI-false	Methyldopa does not interfere with measurement of VMA (@DRUG$), a test for pheochromocytoma, by those methods which convert @DRUG$ to vanillin.
5072	DDI-false	Methyldopa does not interfere with measurement of VMA (@DRUG$), a test for pheochromocytoma, by those methods which convert VMA to @DRUG$.
5073	DDI-false	Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert @DRUG$ to @DRUG$.
5074	DDI-advise	Patients may require reduced doses of @DRUG$ when on @DRUG$.
5075	DDI-advise	When @DRUG$ and @DRUG$ are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity.
5076	DDI-false	When @DRUG$ and lithium are given concomitantly the patient should be carefully monitored for symptoms of @DRUG$ toxicity.
5077	DDI-false	When methyldopa and @DRUG$ are given concomitantly the patient should be carefully monitored for symptoms of @DRUG$ toxicity.
5078	DDI-mechanism	Several studies demonstrate a decrease in the bioavailability of @DRUG$ when it is ingested with @DRUG$ or ferrous gluconate.
5079	DDI-mechanism	Several studies demonstrate a decrease in the bioavailability of @DRUG$ when it is ingested with ferrous sulfate or @DRUG$.
5080	DDI-false	Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with @DRUG$ or @DRUG$.
5081	DDI-advise	Coadministration of @DRUG$ with @DRUG$ or ferrous gluconate is not recommended.
5082	DDI-advise	Coadministration of @DRUG$ with ferrous sulfate or @DRUG$ is not recommended.
5083	DDI-false	Coadministration of methyldopa with @DRUG$ or @DRUG$ is not recommended.
5084	DDI-false	@DRUG$: Concurrent use of @DRUG$ and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride.
5085	DDI-false	@DRUG$: Concurrent use of procaine hydrochloride and @DRUG$ may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride.
5086	DDI-false	@DRUG$: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since @DRUG$ inhibit the breakdown of procaine hydrochloride.
5087	DDI-false	@DRUG$: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of @DRUG$.
5088	DDI-effect	Anticholinesterases: Concurrent use of @DRUG$ and @DRUG$ may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride.
5089	DDI-false	Anticholinesterases: Concurrent use of @DRUG$ and anticholinesterase agents may result in increased systemic toxicity since @DRUG$ inhibit the breakdown of procaine hydrochloride.
5090	DDI-false	Anticholinesterases: Concurrent use of @DRUG$ and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of @DRUG$.
5091	DDI-false	Anticholinesterases: Concurrent use of procaine hydrochloride and @DRUG$ may result in increased systemic toxicity since @DRUG$ inhibit the breakdown of procaine hydrochloride.
5092	DDI-false	Anticholinesterases: Concurrent use of procaine hydrochloride and @DRUG$ may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of @DRUG$.
5093	DDI-mechanism	Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since @DRUG$ inhibit the breakdown of @DRUG$.
5094	DDI-false	@DRUG$ medications: Concurrent use of @DRUG$ and CNS depressant medications may result in additive depressant effects.
5095	DDI-false	@DRUG$ medications: Concurrent use of procaine hydrochloride and @DRUG$ may result in additive depressant effects.
5096	DDI-effect	CNS depressant medications: Concurrent use of @DRUG$ and @DRUG$ may result in additive depressant effects.
5097	DDI-false	@DRUG$: @DRUG$ may increase the diffusion rate of procaine hydrochloride, resulting in a decreased time of onset, but an increase in systemic toxicity.
5098	DDI-false	@DRUG$: Hyaluronidase may increase the diffusion rate of @DRUG$, resulting in a decreased time of onset, but an increase in systemic toxicity.
5099	DDI-mechanism	Hyaluronidase: @DRUG$ may increase the diffusion rate of @DRUG$, resulting in a decreased time of onset, but an increase in systemic toxicity.
5100	DDI-false	@DRUG$ (such as @DRUG$): Concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade.
5101	DDI-false	@DRUG$ (such as suxamethonium chloride): Concurrent use of @DRUG$ and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade.
5102	DDI-false	@DRUG$ (such as suxamethonium chloride): Concurrent use of procaine hydrochloride and @DRUG$ may result in prolongation or enhancement of the neuromuscular blockade.
5103	DDI-false	Neuromuscular blocking agents (such as @DRUG$): Concurrent use of @DRUG$ and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade.
5104	DDI-false	Neuromuscular blocking agents (such as @DRUG$): Concurrent use of procaine hydrochloride and @DRUG$ may result in prolongation or enhancement of the neuromuscular blockade.
5105	DDI-effect	Neuromuscular blocking agents (such as suxamethonium chloride): Concurrent use of @DRUG$ and @DRUG$ may result in prolongation or enhancement of the neuromuscular blockade.
5106	DDI-false	@DRUG$: Concurrent use of @DRUG$ and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide.
5107	DDI-false	@DRUG$: Concurrent use of procaine hydrochloride and @DRUG$ may result in a reduction of the antibacterial action of the sulfonamide.
5108	DDI-false	@DRUG$: Concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the @DRUG$.
5109	DDI-effect	Sulfonamides: Concurrent use of @DRUG$ and @DRUG$ may result in a reduction of the antibacterial action of the sulfonamide.
5110	DDI-false	Sulfonamides: Concurrent use of @DRUG$ and sulfonamides may result in a reduction of the antibacterial action of the @DRUG$.
5111	DDI-false	Sulfonamides: Concurrent use of procaine hydrochloride and @DRUG$ may result in a reduction of the antibacterial action of the @DRUG$.
5112	DDI-false	@DRUG$: Concurrent use of @DRUG$ and procaine hydrochloride may extend the plasma half-life of procaine.
5113	DDI-false	@DRUG$: Concurrent use of acetazolamide and @DRUG$ may extend the plasma half-life of procaine.
5114	DDI-false	@DRUG$: Concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of @DRUG$.
5115	DDI-mechanism	Acetazolamide: Concurrent use of @DRUG$ and @DRUG$ may extend the plasma half-life of procaine.
5116	DDI-false	Acetazolamide: Concurrent use of @DRUG$ and procaine hydrochloride may extend the plasma half-life of @DRUG$.
5117	DDI-false	Acetazolamide: Concurrent use of acetazolamide and @DRUG$ may extend the plasma half-life of @DRUG$.
5118	DDI-false	@DRUG$: Patients on @DRUG$, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of ACEON    Tablets therapy.
5119	DDI-false	@DRUG$: Patients on diuretics, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of @DRUG$    Tablets therapy.
5120	DDI-effect	Diuretics: Patients on @DRUG$, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of @DRUG$    Tablets therapy.
5121	DDI-effect	The possibility of hypotensive effects can be minimized by either discontinuing the @DRUG$ or increasing the salt intake prior to initiation of treatment with @DRUG$.
5122	DDI-false	Use of a @DRUG$ may further increase the risk of @DRUG$ toxicity.
5123	DDI-false	@DRUG$: A controlled pharmacokinetic study has shown no effect on plasma @DRUG$ concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded.
5124	DDI-false	@DRUG$: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with @DRUG$    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded.
5125	DDI-false	@DRUG$: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of @DRUG$ on the plasma concentration of perindopril/perindoprilat has not been excluded.
5126	DDI-false	@DRUG$: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of @DRUG$/perindoprilat has not been excluded.
5127	DDI-false	@DRUG$: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/@DRUG$ has not been excluded.
5128	DDI-false	Digoxin: A controlled pharmacokinetic study has shown no effect on plasma @DRUG$ concentrations when coadministered with @DRUG$    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded.
5129	DDI-false	Digoxin: A controlled pharmacokinetic study has shown no effect on plasma @DRUG$ concentrations when coadministered with ACEON    Tablets, but an effect of @DRUG$ on the plasma concentration of perindopril/perindoprilat has not been excluded.
5130	DDI-false	Digoxin: A controlled pharmacokinetic study has shown no effect on plasma @DRUG$ concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of @DRUG$/perindoprilat has not been excluded.
5131	DDI-false	Digoxin: A controlled pharmacokinetic study has shown no effect on plasma @DRUG$ concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/@DRUG$ has not been excluded.
5132	DDI-false	Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with @DRUG$    Tablets, but an effect of @DRUG$ on the plasma concentration of perindopril/perindoprilat has not been excluded.
5133	DDI-false	Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with @DRUG$    Tablets, but an effect of digoxin on the plasma concentration of @DRUG$/perindoprilat has not been excluded.
5134	DDI-false	Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with @DRUG$    Tablets, but an effect of digoxin on the plasma concentration of perindopril/@DRUG$ has not been excluded.
5135	DDI-mechanism	Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of @DRUG$ on the plasma concentration of @DRUG$/perindoprilat has not been excluded.
5136	DDI-mechanism	Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of @DRUG$ on the plasma concentration of perindopril/@DRUG$ has not been excluded.
5137	DDI-false	Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of @DRUG$/@DRUG$ has not been excluded.
5138	DDI-false	@DRUG$: Animal data have suggested the possibility of interaction between @DRUG$ and gentamicin.
5139	DDI-false	@DRUG$: Animal data have suggested the possibility of interaction between perindopril and @DRUG$.
5140	DDI-int	Gentamicin: Animal data have suggested the possibility of interaction between @DRUG$ and @DRUG$.
5141	DDI-false	Food Interaction: Oral administration of @DRUG$    Tablets with food does not significantly lower the rate or extent of @DRUG$ absorption relative to the fasted state.
5142	DDI-false	However, the extent of biotransformation of @DRUG$ to the active metabolite, @DRUG$, is reduced approximately 43%, resulting in a reduction in the plasma ACE inhibition curve of approximately 20%, probably clinically insignificant.
5143	DDI-advise	If @DRUG$ cannot be interrupted, close medical supervision should be provided with the first dose of @DRUG$    Tablets, for at least two hours and until blood pressure has stabilized for another hour.
5144	DDI-false	The rate and extent of @DRUG$ absorption and elimination are not affected by concomitant @DRUG$.
5145	DDI-false	The bioavailability of @DRUG$ was reduced by @DRUG$, however, and this was associated with a decrease in plasma ACE inhibition.
5146	DDI-false	@DRUG$ Supplements and @DRUG$: ACEON    Tablets may increase serum potassium because of its potential to decrease aldosterone production.
5147	DDI-false	@DRUG$ Supplements and Potassium-Sparing Diuretics: @DRUG$    Tablets may increase serum potassium because of its potential to decrease aldosterone production.
5148	DDI-false	Potassium Supplements and @DRUG$: @DRUG$    Tablets may increase serum potassium because of its potential to decrease aldosterone production.
5149	DDI-false	Use of @DRUG$ (@DRUG$, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.
5150	DDI-false	Use of @DRUG$ (spironolactone, @DRUG$, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.
5151	DDI-false	Use of @DRUG$ (spironolactone, amiloride, @DRUG$ and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.
5152	DDI-false	Use of @DRUG$ (spironolactone, amiloride, triamterene and others), @DRUG$ supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.
5153	DDI-false	Use of @DRUG$ (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (@DRUG$, heparin, cyclosporine and others) can increase the risk of hyperkalemia.
5154	DDI-false	Use of @DRUG$ (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, @DRUG$, cyclosporine and others) can increase the risk of hyperkalemia.
5155	DDI-false	Use of @DRUG$ (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, @DRUG$ and others) can increase the risk of hyperkalemia.
5156	DDI-false	Use of potassium-sparing diuretics (@DRUG$, @DRUG$, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.
5157	DDI-false	Use of potassium-sparing diuretics (@DRUG$, amiloride, @DRUG$ and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.
5158	DDI-false	Use of potassium-sparing diuretics (@DRUG$, amiloride, triamterene and others), @DRUG$ supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.
5159	DDI-false	Use of potassium-sparing diuretics (@DRUG$, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (@DRUG$, heparin, cyclosporine and others) can increase the risk of hyperkalemia.
5160	DDI-false	Use of potassium-sparing diuretics (@DRUG$, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, @DRUG$, cyclosporine and others) can increase the risk of hyperkalemia.
5161	DDI-false	Use of potassium-sparing diuretics (@DRUG$, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, @DRUG$ and others) can increase the risk of hyperkalemia.
5162	DDI-false	Use of potassium-sparing diuretics (spironolactone, @DRUG$, @DRUG$ and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.
5163	DDI-false	Use of potassium-sparing diuretics (spironolactone, @DRUG$, triamterene and others), @DRUG$ supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.
5164	DDI-false	Use of potassium-sparing diuretics (spironolactone, @DRUG$, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (@DRUG$, heparin, cyclosporine and others) can increase the risk of hyperkalemia.
5165	DDI-false	Use of potassium-sparing diuretics (spironolactone, @DRUG$, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, @DRUG$, cyclosporine and others) can increase the risk of hyperkalemia.
5166	DDI-false	Use of potassium-sparing diuretics (spironolactone, @DRUG$, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, @DRUG$ and others) can increase the risk of hyperkalemia.
5167	DDI-false	Use of potassium-sparing diuretics (spironolactone, amiloride, @DRUG$ and others), @DRUG$ supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.
5168	DDI-false	Use of potassium-sparing diuretics (spironolactone, amiloride, @DRUG$ and others), potassium supplements or other drugs capable of increasing serum potassium (@DRUG$, heparin, cyclosporine and others) can increase the risk of hyperkalemia.
5169	DDI-false	Use of potassium-sparing diuretics (spironolactone, amiloride, @DRUG$ and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, @DRUG$, cyclosporine and others) can increase the risk of hyperkalemia.
5170	DDI-false	Use of potassium-sparing diuretics (spironolactone, amiloride, @DRUG$ and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, @DRUG$ and others) can increase the risk of hyperkalemia.
5171	DDI-false	Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), @DRUG$ supplements or other drugs capable of increasing serum potassium (@DRUG$, heparin, cyclosporine and others) can increase the risk of hyperkalemia.
5172	DDI-false	Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), @DRUG$ supplements or other drugs capable of increasing serum potassium (indomethacin, @DRUG$, cyclosporine and others) can increase the risk of hyperkalemia.
5173	DDI-false	Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), @DRUG$ supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, @DRUG$ and others) can increase the risk of hyperkalemia.
5174	DDI-false	Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (@DRUG$, @DRUG$, cyclosporine and others) can increase the risk of hyperkalemia.
5175	DDI-false	Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (@DRUG$, heparin, @DRUG$ and others) can increase the risk of hyperkalemia.
5176	DDI-false	Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, @DRUG$, @DRUG$ and others) can increase the risk of hyperkalemia.
5177	DDI-false	@DRUG$: Increased serum @DRUG$ and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.
5178	DDI-false	@DRUG$: Increased serum lithium and symptoms of @DRUG$ toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.
5179	DDI-false	@DRUG$: Increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant @DRUG$ and ACE inhibitor therapy.
5180	DDI-false	Lithium: Increased serum @DRUG$ and symptoms of @DRUG$ toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.
5181	DDI-false	Lithium: Increased serum @DRUG$ and symptoms of lithium toxicity have been reported in patients receiving concomitant @DRUG$ and ACE inhibitor therapy.
5182	DDI-false	Lithium: Increased serum lithium and symptoms of @DRUG$ toxicity have been reported in patients receiving concomitant @DRUG$ and ACE inhibitor therapy.
5183	DDI-int	@DRUG$ can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - @DRUG$: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine
5184	DDI-int	@DRUG$ can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - @DRUG$: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine
5185	DDI-false	@DRUG$ can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the @DRUG$ virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine
5186	DDI-int	@DRUG$ can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - @DRUG$: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine
5187	DDI-int	@DRUG$ can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - @DRUG$: may decrease patient's response to the vaccine
5188	DDI-false	@DRUG$ can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the @DRUG$
5189	DDI-false	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - @DRUG$: can increase seizure activity - @DRUG$: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine
5190	DDI-false	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - @DRUG$: can increase seizure activity - Live virus vaccines: may potentiate the replication of the @DRUG$ virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine
5191	DDI-false	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - @DRUG$: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - @DRUG$: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine
5192	DDI-false	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - @DRUG$: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - @DRUG$: may decrease patient's response to the vaccine
5193	DDI-false	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - @DRUG$: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the @DRUG$
5194	DDI-false	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - @DRUG$: may potentiate the replication of the @DRUG$ virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine
5195	DDI-false	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - @DRUG$: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - @DRUG$: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine
5196	DDI-false	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - @DRUG$: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - @DRUG$: may decrease patient's response to the vaccine
5197	DDI-false	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - @DRUG$: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the @DRUG$
5198	DDI-false	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the @DRUG$ virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - @DRUG$: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine
5199	DDI-false	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the @DRUG$ virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - @DRUG$: may decrease patient's response to the vaccine
5200	DDI-false	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the @DRUG$ virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the @DRUG$
5201	DDI-false	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - @DRUG$: may cause shortness of breath and bronchospasm - @DRUG$: may decrease patient's response to the vaccine
5202	DDI-false	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - @DRUG$: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the @DRUG$
5203	DDI-false	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - @DRUG$: may decrease patient's response to the @DRUG$
5204	DDI-mechanism	@DRUG$ inhibits some of the liver's ability to metabolize some other drugs - @DRUG$, astemizole, cisapride, cyclosporine, and tricyclic antidepressants.
5205	DDI-mechanism	@DRUG$ inhibits some of the liver's ability to metabolize some other drugs - terfenadine, @DRUG$, cisapride, cyclosporine, and tricyclic antidepressants.
5206	DDI-mechanism	@DRUG$ inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, @DRUG$, cyclosporine, and tricyclic antidepressants.
5207	DDI-mechanism	@DRUG$ inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, @DRUG$, and tricyclic antidepressants.
5208	DDI-mechanism	@DRUG$ inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and @DRUG$.
5209	DDI-false	Posicor inhibits some of the liver's ability to metabolize some other drugs - @DRUG$, @DRUG$, cisapride, cyclosporine, and tricyclic antidepressants.
5210	DDI-false	Posicor inhibits some of the liver's ability to metabolize some other drugs - @DRUG$, astemizole, @DRUG$, cyclosporine, and tricyclic antidepressants.
5211	DDI-false	Posicor inhibits some of the liver's ability to metabolize some other drugs - @DRUG$, astemizole, cisapride, @DRUG$, and tricyclic antidepressants.
5212	DDI-false	Posicor inhibits some of the liver's ability to metabolize some other drugs - @DRUG$, astemizole, cisapride, cyclosporine, and @DRUG$.
5213	DDI-false	Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, @DRUG$, @DRUG$, cyclosporine, and tricyclic antidepressants.
5214	DDI-false	Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, @DRUG$, cisapride, @DRUG$, and tricyclic antidepressants.
5215	DDI-false	Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, @DRUG$, cisapride, cyclosporine, and @DRUG$.
5216	DDI-false	Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, @DRUG$, @DRUG$, and tricyclic antidepressants.
5217	DDI-false	Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, @DRUG$, cyclosporine, and @DRUG$.
5218	DDI-false	Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, @DRUG$, and @DRUG$.
5219	DDI-effect	The concomitant use of @DRUG$ with other @DRUG$ or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects.
5220	DDI-false	Mean @DRUG$ plasma concentrations were approximately 2 fold higher when @DRUG$ was administered with ketoconazole, a potent CYP3A4 inhibitor.
5221	DDI-false	Mean @DRUG$ plasma concentrations were approximately 2 fold higher when DITROPAN XL was administered with @DRUG$, a potent CYP3A4 inhibitor.
5222	DDI-mechanism	Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when @DRUG$ was administered with @DRUG$, a potent CYP3A4 inhibitor.
5223	DDI-false	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as @DRUG$ (e.g., @DRUG$ and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).
5224	DDI-false	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as @DRUG$ (e.g., itraconazole and @DRUG$) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).
5225	DDI-false	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as @DRUG$ (e.g., itraconazole and miconazole) or @DRUG$ (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).
5226	DDI-false	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as @DRUG$ (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., @DRUG$ and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).
5227	DDI-false	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as @DRUG$ (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and @DRUG$), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).
5228	DDI-mechanism	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as @DRUG$ (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter @DRUG$ mean pharmacokinetic parameters (i.e., Cmax and AUC).
5229	DDI-false	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., @DRUG$ and @DRUG$) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).
5230	DDI-false	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., @DRUG$ and miconazole) or @DRUG$ (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).
5231	DDI-false	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., @DRUG$ and miconazole) or macrolide antibiotics (e.g., @DRUG$ and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).
5232	DDI-false	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., @DRUG$ and miconazole) or macrolide antibiotics (e.g., erythromycin and @DRUG$), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).
5233	DDI-mechanism	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., @DRUG$ and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter @DRUG$ mean pharmacokinetic parameters (i.e., Cmax and AUC).
5234	DDI-false	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and @DRUG$) or @DRUG$ (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).
5235	DDI-false	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and @DRUG$) or macrolide antibiotics (e.g., @DRUG$ and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).
5236	DDI-false	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and @DRUG$) or macrolide antibiotics (e.g., erythromycin and @DRUG$), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).
5237	DDI-mechanism	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and @DRUG$) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter @DRUG$ mean pharmacokinetic parameters (i.e., Cmax and AUC).
5238	DDI-false	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or @DRUG$ (e.g., @DRUG$ and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).
5239	DDI-false	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or @DRUG$ (e.g., erythromycin and @DRUG$), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).
5240	DDI-mechanism	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or @DRUG$ (e.g., erythromycin and clarithromycin), may alter @DRUG$ mean pharmacokinetic parameters (i.e., Cmax and AUC).
5241	DDI-false	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., @DRUG$ and @DRUG$), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).
5242	DDI-mechanism	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., @DRUG$ and clarithromycin), may alter @DRUG$ mean pharmacokinetic parameters (i.e., Cmax and AUC).
5243	DDI-mechanism	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and @DRUG$), may alter @DRUG$ mean pharmacokinetic parameters (i.e., Cmax and AUC).
5244	DDI-false	Concurrent ingestion of @DRUG$ (20 mL of @DRUG$ containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.
5245	DDI-false	Concurrent ingestion of @DRUG$ (20 mL of antacid containing @DRUG$, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.
5246	DDI-false	Concurrent ingestion of @DRUG$ (20 mL of antacid containing aluminum hydroxide, @DRUG$, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.
5247	DDI-false	Concurrent ingestion of @DRUG$ (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and @DRUG$) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.
5248	DDI-false	Concurrent ingestion of @DRUG$ (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of @DRUG$ or desethyloxybutynin.
5249	DDI-false	Concurrent ingestion of @DRUG$ (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or @DRUG$.
5250	DDI-false	Concurrent ingestion of antacid (20 mL of @DRUG$ containing @DRUG$, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.
5251	DDI-false	Concurrent ingestion of antacid (20 mL of @DRUG$ containing aluminum hydroxide, @DRUG$, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.
5252	DDI-false	Concurrent ingestion of antacid (20 mL of @DRUG$ containing aluminum hydroxide, magnesium hydroxide, and @DRUG$) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.
5253	DDI-false	Concurrent ingestion of antacid (20 mL of @DRUG$ containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of @DRUG$ or desethyloxybutynin.
5254	DDI-false	Concurrent ingestion of antacid (20 mL of @DRUG$ containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or @DRUG$.
5255	DDI-false	Concurrent ingestion of antacid (20 mL of antacid containing @DRUG$, @DRUG$, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.
5256	DDI-false	Concurrent ingestion of antacid (20 mL of antacid containing @DRUG$, magnesium hydroxide, and @DRUG$) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.
5257	DDI-false	Concurrent ingestion of antacid (20 mL of antacid containing @DRUG$, magnesium hydroxide, and simethicone) did not significantly affect the exposure of @DRUG$ or desethyloxybutynin.
5258	DDI-false	Concurrent ingestion of antacid (20 mL of antacid containing @DRUG$, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or @DRUG$.
5259	DDI-false	Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, @DRUG$, and @DRUG$) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.
5260	DDI-false	Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, @DRUG$, and simethicone) did not significantly affect the exposure of @DRUG$ or desethyloxybutynin.
5261	DDI-false	Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, @DRUG$, and simethicone) did not significantly affect the exposure of oxybutynin or @DRUG$.
5262	DDI-false	Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and @DRUG$) did not significantly affect the exposure of @DRUG$ or desethyloxybutynin.
5263	DDI-false	Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and @DRUG$) did not significantly affect the exposure of oxybutynin or @DRUG$.
5264	DDI-false	Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of @DRUG$ or @DRUG$.
5265	DDI-false	[Interaction between @DRUG$ and @DRUG$].
5266	DDI-false	The drug interaction between @DRUG$ and @DRUG$ has been the subject of much study in recent years.
5267	DDI-false	Contradictory results regarding the effect of @DRUG$ on platelet reactivity and on clinical outcome in @DRUG$-treated patients have been reported in literature.
5268	DDI-mechanism	Concomitant use of @DRUG$ and @DRUG$ was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme.
5269	DDI-false	Concomitant use of @DRUG$ and clopidogrel was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by @DRUG$ of CYP2C19, a cytochrome P450 (CYP) enzyme.
5270	DDI-false	Concomitant use of omeprazole and @DRUG$ was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by @DRUG$ of CYP2C19, a cytochrome P450 (CYP) enzyme.
5271	DDI-mechanism	@DRUG$ has a much weaker effect on @DRUG$'s pharmacokinetics and on platelet reactivity during concomitant use.
5272	DDI-false	The influence of the other @DRUG$ when used simultaneously with @DRUG$ has not yet been investigated in adequately randomized studies.
5273	DDI-advise	Regulatory agencies state that the combination of @DRUG$ and the CYP2C19 inhibitors @DRUG$ and esomeprazole should be avoided.
5274	DDI-advise	Regulatory agencies state that the combination of @DRUG$ and the CYP2C19 inhibitors omeprazole and @DRUG$ should be avoided.
5275	DDI-false	Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors @DRUG$ and @DRUG$ should be avoided.
5276	DDI-false	To date, there is no conclusive evidence of a clinically-relevant interaction between any of the @DRUG$ and @DRUG$.
5277	DDI-false	Interaction of @DRUG$ and @DRUG$, in vitro and in vivo, in human A375 melanoma cells.
5278	DDI-false	We evaluated mechanisms of interaction between the alkyating agent @DRUG$ (@DRUG$) and the pro-oxidant, imexon, in the human A375 melanoma cell line.
5279	DDI-false	We evaluated mechanisms of interaction between the alkyating agent @DRUG$ (DTIC) and the pro-oxidant, @DRUG$, in the human A375 melanoma cell line.
5280	DDI-false	We evaluated mechanisms of interaction between the alkyating agent dacarbazine (@DRUG$) and the pro-oxidant, @DRUG$, in the human A375 melanoma cell line.
5281	DDI-false	The effect of @DRUG$ and @DRUG$, alone and in combination, was evaluated for growth inhibition (MTT), radiolabeled drug uptake, cellular thiol content (HPLC), and DNA strand breaks (Comet assay).
5282	DDI-false	There was a >75% reduction in cellular glutathione and cysteine with @DRUG$ but not @DRUG$.
5283	DDI-effect	@DRUG$ and @DRUG$ show additive effects in vitro but not in vivo in human A375 melanoma cells.
5284	DDI-false	Enhancement of humoral immune responses to inactivated Newcastle disease and @DRUG$ by oral administration of @DRUG$ in chickens.
5285	DDI-false	The objective of this study was to evaluate the effect of oral administration of @DRUG$ (@DRUG$) on the humoral immune responses of chickens to inactivated ND and AI vaccines.
5286	DDI-false	The objective of this study was to evaluate the effect of oral administration of @DRUG$ (GSLS) on the humoral immune responses of chickens to @DRUG$.
5287	DDI-false	The objective of this study was to evaluate the effect of oral administration of @DRUG$ (GSLS) on the humoral immune responses of chickens to @DRUG$.
5288	DDI-false	The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (@DRUG$) on the humoral immune responses of chickens to @DRUG$.
5289	DDI-false	The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (@DRUG$) on the humoral immune responses of chickens to @DRUG$.
5290	DDI-false	The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to @DRUG-DRUG$.
5291	DDI-false	In experiment 1, oral administration of @DRUG$ at a dose of 5 mg/kg of BW for 7 d on the immune response in chickens intramuscularly injected with @DRUG$ was evaluated.
5292	DDI-effect	In experiment 2, the same regimen of @DRUG$ was administered to chickens inoculated with @DRUG$, and an enhanced serum antibody response to AI vaccination was also observed.
5293	DDI-false	Considering the safety of @DRUG$, because no adverse effect was found throughout the experiments, @DRUG$ may be a promising oral adjuvant to improve immunization in poultry.
5294	DDI-false	Protective effect of @DRUG$ and  @DRUG$ against the acute toxicity of diepoxybutane to human lymphocytes.
5295	DDI-effect	(ii) @DRUG$ elicits a significant protective effect on DEB induced toxicity, which was potentiated by  @DRUG$.
5296	DDI-false	In the present study, we tested whether the highly specific metabotropic glutamate receptor 5 antagonist, @DRUG$, reduces dopaminergic and noradrenergic neuronal loss in monkeys rendered parkinsonian by chronic treatment with low doses of @DRUG$.
5297	DDI-false	Weekly intramuscular @DRUG$ injections (0.2-0.5 mg/kg body weight), in combination with daily administration of @DRUG$ or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle).
5298	DDI-false	Weekly intramuscular @DRUG$ injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (@DRUG$/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle).
5299	DDI-false	Weekly intramuscular @DRUG$ injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/@DRUG$ versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle).
5300	DDI-false	Weekly intramuscular @DRUG$ injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus @DRUG$/vehicle).
5301	DDI-false	Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of @DRUG$ or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (@DRUG$/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle).
5302	DDI-false	Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of @DRUG$ or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/@DRUG$ versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle).
5303	DDI-false	Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of @DRUG$ or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus @DRUG$/vehicle).
5304	DDI-false	Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (@DRUG$/@DRUG$ versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle).
5305	DDI-false	Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (@DRUG$/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus @DRUG$/vehicle).
5306	DDI-false	Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/@DRUG$ versus @DRUG$/vehicle).
5307	DDI-false	After 21 weeks of @DRUG$ treatment, all @DRUG$/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected.
5308	DDI-false	After 21 weeks of @DRUG$ treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the @DRUG$/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected.
5309	DDI-false	After 21 weeks of @DRUG$ treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/@DRUG$-treated monkeys were significantly affected.
5310	DDI-false	After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all @DRUG$/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the @DRUG$/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected.
5311	DDI-false	After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all @DRUG$/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/@DRUG$-treated monkeys were significantly affected.
5312	DDI-effect	After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the @DRUG$/@DRUG$-treated monkeys were significantly affected.
5313	DDI-effect	These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in @DRUG$/@DRUG$-treated animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated monkeys.
5314	DDI-false	These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in @DRUG$/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated animals than in @DRUG$/vehicle-treated monkeys.
5315	DDI-false	These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/@DRUG$-treated animals than in @DRUG$/vehicle-treated monkeys.
5316	DDI-effect	The @DRUG$ treatment also had a significant effect on the @DRUG$-induced loss of norepinephrine neurons in the locus coeruleus and adjoining A5 and A7 noradrenaline cell groups.
5317	DDI-false	In @DRUG$/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in @DRUG$/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys.
5318	DDI-false	In @DRUG$/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/@DRUG$-treated monkeys.
5319	DDI-effect	In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in @DRUG$/@DRUG$-treated monkeys.
5320	DDI-effect	Our data demonstrate that chronic treatment with the metabotropic glutamate receptor 5 antagonist, @DRUG$, significantly reduces @DRUG$ toxicity towards dopaminergic and noradrenergic cell groups in non-human primates.
5321	DDI-false	In vitro activity of @DRUG$ combined with @DRUG$ against clinical isolates of methicillin-resistant Staphylococcus aureus.
5322	DDI-false	In vitro activity of @DRUG$ combined with fosfomycin against clinical isolates of @DRUG$-resistant Staphylococcus aureus.
5323	DDI-false	In vitro activity of minocycline combined with @DRUG$ against clinical isolates of @DRUG$-resistant Staphylococcus aureus.
5324	DDI-false	This study aimed to evaluate the in vitro activity of @DRUG$ combined with @DRUG$ against isolates of methicillin-resistant Staphylococcus aureus (MRSA).
5325	DDI-false	This study aimed to evaluate the in vitro activity of @DRUG$ combined with fosfomycin against isolates of @DRUG$-resistant Staphylococcus aureus (MRSA).
5326	DDI-false	This study aimed to evaluate the in vitro activity of minocycline combined with @DRUG$ against isolates of @DRUG$-resistant Staphylococcus aureus (MRSA).
5327	DDI-false	The susceptibility results for @DRUG$ and @DRUG$ were interpreted according to the most relevant criteria.
5328	DDI-effect	The combination of @DRUG$ and @DRUG$ can be synergistic against MRSA.
5329	DDI-effect	@DRUG$ enhances @DRUG$-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression.
5330	DDI-effect	Although it was previously reported that @DRUG$ combined with @DRUG$ improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.
5331	DDI-false	Although it was previously reported that @DRUG$ combined with Herceptin improved the progression-free survival rate compared with @DRUG$ alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.
5332	DDI-false	Although it was previously reported that @DRUG$ combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with @DRUG$-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.
5333	DDI-false	Although it was previously reported that lapatinib combined with @DRUG$ improved the progression-free survival rate compared with @DRUG$ alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.
5334	DDI-false	Although it was previously reported that lapatinib combined with @DRUG$ improved the progression-free survival rate compared with lapatinib alone for patients with @DRUG$-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.
5335	DDI-false	Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with @DRUG$ alone for patients with @DRUG$-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.
5336	DDI-false	We evaluated how @DRUG$ interacts with @DRUG$ in HER2-positive breast cancer, with a particular focus on Herceptin-mediated antibody-dependent cellular cytotoxicity (ADCC).
5337	DDI-false	We evaluated how @DRUG$ interacts with Herceptin in HER2-positive breast cancer, with a particular focus on @DRUG$-mediated antibody-dependent cellular cytotoxicity (ADCC).
5338	DDI-false	We evaluated how lapatinib interacts with @DRUG$ in HER2-positive breast cancer, with a particular focus on @DRUG$-mediated antibody-dependent cellular cytotoxicity (ADCC).
5339	DDI-effect	In an in vitro assay, @DRUG$ induced HER2 expression at the cell surface of HER2-positive breast cancer cell lines, leading to the enhancement of @DRUG$-mediated ADCC.
5340	DDI-effect	Furthermore, we present a case report in which a second @DRUG$ treatment following @DRUG$ resulted in the marked shrinkage of multiple metastatic tumors in HER2-positive breast cancer.
5341	DDI-false	@DRUG$ may have the potential to convert @DRUG$-refractory to Herceptin-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.
5342	DDI-false	@DRUG$ may have the potential to convert Herceptin-refractory to @DRUG$-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.
5343	DDI-false	Lapatinib may have the potential to convert @DRUG$-refractory to @DRUG$-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.
5344	DDI-false	Improved parathyroid hormone control by @DRUG$ is associated with reduction in @DRUG$ requirement in patients with end-stage renal disease.
5345	DDI-false	Uncontrolled hy-per-parathyroidism causes bone marrow fibrosis, leading to @DRUG$ (@DRUG$) resistance.
5346	DDI-effect	Reduction of PTH by @DRUG$ is associated with a decrease in @DRUG$ requirement.
5347	DDI-false	Medical treatment with @DRUG$ is effective in reducing plasma parathyroid hormone (PTH) levels, but its effect on @DRUG$ dosing is unknown.
5348	DDI-false	The primary objective of the study was to ascertain the difference in @DRUG$ responsiveness before and after 12 months of @DRUG$ therapy.
5349	DDI-false	@DRUG$ does not inhibit the absorption of 5 milligrams of @DRUG$ at doses less than 800 milligrams in nonpregnant women.
5350	DDI-false	@DRUG$ does not inhibit the absorption of 5 milligrams of nonheme or @DRUG$ at doses less than 800 milligrams in nonpregnant women.
5351	DDI-false	Calcium does not inhibit the absorption of 5 milligrams of @DRUG-DRUG$ at doses less than 800 milligrams in nonpregnant women.
5352	DDI-mechanism	@DRUG$ is the only known component in the diet that may affect absorption of both @DRUG$.
5353	DDI-mechanism	@DRUG$ is the only known component in the diet that may affect absorption of both nonheme and @DRUG$.
5354	DDI-false	Calcium is the only known component in the diet that may affect absorption of both @DRUG-DRUG$.
5355	DDI-mechanism	In conclusion, we demonstrated an isolated effect of @DRUG$ (as chloride) on absorption of 5 mg of iron provided as @DRUG$.
5356	DDI-mechanism	In conclusion, we demonstrated an isolated effect of @DRUG$ (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and @DRUG$.
5357	DDI-false	In conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as @DRUG-DRUG$.
5358	DDI-mechanism	However, the evidence for a @DRUG$ effect on @DRUG$ absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies.
5359	DDI-false	However, the evidence for a @DRUG$ effect on iron absorption mainly comes from studies that did not isolate the effect of @DRUG$ from that of other dietary components, because it was detected in single-meal studies.
5360	DDI-false	However, the evidence for a calcium effect on @DRUG$ absorption mainly comes from studies that did not isolate the effect of @DRUG$ from that of other dietary components, because it was detected in single-meal studies.
5361	DDI-false	Our objective was to establish potential effects of @DRUG$ on absorption of @DRUG$ and the dose response for this effect in the absence of a meal.
5362	DDI-false	Our objective was to establish potential effects of @DRUG$ on absorption of nonheme and @DRUG$ and the dose response for this effect in the absence of a meal.
5363	DDI-false	Our objective was to establish potential effects of calcium on absorption of @DRUG-DRUG$ and the dose response for this effect in the absence of a meal.
5364	DDI-false	We evaluated the effects of @DRUG$ doses between 200 and 1500 mg on absorption of 5 mg @DRUG$ (as ferrous sulfate).
5365	DDI-false	We evaluated the effects of @DRUG$ doses between 200 and 1500 mg on absorption of 5 mg nonheme iron (as @DRUG$).
5366	DDI-false	We evaluated the effects of calcium doses between 200 and 1500 mg on absorption of 5 mg @DRUG$ (as @DRUG$).
5367	DDI-false	We also evaluated the effects of @DRUG$ doses between 200 and 800 mg on absorption of 5 mg @DRUG$ [as concentrated RBC (CRBC)].
5368	DDI-false	@DRUG$ was administered as @DRUG$ in all studies and minerals were ingested on an empty stomach.
5369	DDI-false	@DRUG$ was administered as calcium chloride in all studies and @DRUG$ were ingested on an empty stomach.
5370	DDI-false	Calcium was administered as @DRUG$ in all studies and @DRUG$ were ingested on an empty stomach.
5371	DDI-mechanism	@DRUG$ doses   1000 mg diminished @DRUG$ absorption by an average of 49.6%.
5372	DDI-mechanism	A @DRUG$ dose of 800 mg diminished absorption of 5 mg @DRUG$ by 37.7%.
5373	DDI-int	Synergistic interaction between @DRUG$ and @DRUG$ is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.
5374	DDI-false	@DRUG$ as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of @DRUG$ followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.
5375	DDI-false	@DRUG$ as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by @DRUG$ is superior to sunitinib followed by docetaxel and concurrent administration.
5376	DDI-false	@DRUG$ as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to @DRUG$ followed by docetaxel and concurrent administration.
5377	DDI-false	@DRUG$ as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by @DRUG$ and concurrent administration.
5378	DDI-effect	Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of @DRUG$ followed by @DRUG$ is superior to sunitinib followed by docetaxel and concurrent administration.
5379	DDI-false	Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of @DRUG$ followed by sunitinib is superior to @DRUG$ followed by docetaxel and concurrent administration.
5380	DDI-false	Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of @DRUG$ followed by sunitinib is superior to sunitinib followed by @DRUG$ and concurrent administration.
5381	DDI-false	Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by @DRUG$ is superior to @DRUG$ followed by docetaxel and concurrent administration.
5382	DDI-false	Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by @DRUG$ is superior to sunitinib followed by @DRUG$ and concurrent administration.
5383	DDI-false	Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to @DRUG$ followed by @DRUG$ and concurrent administration.
5384	DDI-false	This study was aimed to investigate the efficacy of single use of @DRUG$ and that of concurrent or sequential administration of @DRUG$ and docetaxel in NSCLC cell lines that are resistant to EGFR TKIs.
5385	DDI-false	This study was aimed to investigate the efficacy of single use of @DRUG$ and that of concurrent or sequential administration of sunitinib and @DRUG$ in NSCLC cell lines that are resistant to EGFR TKIs.
5386	DDI-false	This study was aimed to investigate the efficacy of single use of sunitinib and that of concurrent or sequential administration of @DRUG$ and @DRUG$ in NSCLC cell lines that are resistant to EGFR TKIs.
5387	DDI-false	NSCLC cell lines with EGFR T790M mutation and K-ras mutation were exposed to either @DRUG$ or @DRUG$ or both based on various sequential administrations.
5388	DDI-false	@DRUG$ exhibited dose-dependent growth inhibition in NSCLC cell lines and arrested cell cycle at G1 phase, whereas @DRUG$ arrested at S phase.
5389	DDI-effect	Although single or concurrent use of @DRUG$ and @DRUG$ has some anti-proliferative effects, the sequential administrations of both drugs remarkably enhanced anti-tumor activity.
5390	DDI-effect	When cells were exposed to @DRUG$ followed by @DRUG$, synergism was observed.
5391	DDI-effect	The molecular basis of this synergism is that the signaling pathways that were initially activated by @DRUG$ exposure were efficiently suppressed by the subsequent exposure to @DRUG$.
5392	DDI-false	The @DRUG$ (@DRUG$), one of S-adenosylhomocysteine (AdoHcy) hydrolase inhibitors, has shown antitumor activities in a broad range of solid tumors and acute myeloid leukemia.
5393	DDI-false	We also found that Bcl-2 was overexpressed in @DRUG$ insensitive cells, and cotreatment with @DRUG$ and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells.
5394	DDI-false	We also found that Bcl-2 was overexpressed in @DRUG$ insensitive cells, and cotreatment with DZNep and @DRUG$, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells.
5395	DDI-false	We also found that Bcl-2 was overexpressed in @DRUG$ insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of @DRUG$ insensitive MM cells.
5396	DDI-effect	We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with @DRUG$ and @DRUG$, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells.
5397	DDI-false	We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with @DRUG$ and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of @DRUG$ insensitive MM cells.
5398	DDI-false	We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and @DRUG$, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of @DRUG$ insensitive MM cells.
5399	DDI-false	In addition, @DRUG$ insensitivity might be associated with overexpression of Bcl-2, and the combination of @DRUG$ and DZNep could synergistically induced apoptosis.
5400	DDI-false	In addition, @DRUG$ insensitivity might be associated with overexpression of Bcl-2, and the combination of ABT-737 and @DRUG$ could synergistically induced apoptosis.
5401	DDI-effect	In addition, DZNep insensitivity might be associated with overexpression of Bcl-2, and the combination of @DRUG$ and @DRUG$ could synergistically induced apoptosis.
5402	DDI-int	The authors report the case of an infant with confirmed congenital hypothyroidism on @DRUG$ who experienced a possible drug interaction with @DRUG$.
5403	DDI-false	Questioning revealed the child was taking @DRUG$ drops before feeds while on @DRUG$.
5404	DDI-false	Drug interaction of @DRUG$ with @DRUG$ has not been reported previously and is not listed in the British National Formulary for Children.
5405	DDI-false	@DRUG$ locomotor sensitization and conditioned place preference in adolescent male and female rats neonatally treated with @DRUG$.
5406	DDI-false	The objective was to analyze the effects of neonatal @DRUG$ treatment on effects of @DRUG$ in adolescent rats using locomotor sensitization and conditioned place preference procedures.
5407	DDI-effect	In female rats, neonatal @DRUG$ treatment enhanced @DRUG$ locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine.
5408	DDI-false	In female rats, neonatal @DRUG$ treatment enhanced amphetamine locomotor sensitization compared with @DRUG$-free controls sensitized to amphetamine.
5409	DDI-false	In female rats, neonatal @DRUG$ treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to @DRUG$.
5410	DDI-false	In female rats, neonatal quinpirole treatment enhanced @DRUG$ locomotor sensitization compared with @DRUG$-free controls sensitized to amphetamine.
5411	DDI-false	In female rats, neonatal quinpirole treatment enhanced @DRUG$ locomotor sensitization compared with quinpirole-free controls sensitized to @DRUG$.
5412	DDI-false	In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with @DRUG$-free controls sensitized to @DRUG$.
5413	DDI-false	Male rats demonstrated sensitization to @DRUG$, although this was muted compared with female rats, and were unaffected by neonatal @DRUG$.
5414	DDI-false	Rats treated with neonatal @DRUG$ enhanced time spent in the @DRUG$-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls.
5415	DDI-false	Rats treated with neonatal @DRUG$ enhanced time spent in the amphetamine-paired context compared with @DRUG$-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls.
5416	DDI-false	Rats treated with neonatal @DRUG$ enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with @DRUG$, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls.
5417	DDI-false	Rats treated with neonatal @DRUG$ enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with @DRUG$ spent more time in the drug-paired context compared with saline-treated controls.
5418	DDI-false	Rats treated with neonatal quinpirole enhanced time spent in the @DRUG$-paired context compared with @DRUG$-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls.
5419	DDI-false	Rats treated with neonatal quinpirole enhanced time spent in the @DRUG$-paired context compared with quinpirole-free controls conditioned with @DRUG$, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls.
5420	DDI-false	Rats treated with neonatal quinpirole enhanced time spent in the @DRUG$-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with @DRUG$ spent more time in the drug-paired context compared with saline-treated controls.
5421	DDI-false	Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with @DRUG$-free controls conditioned with @DRUG$, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls.
5422	DDI-false	Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with @DRUG$-free controls conditioned with amphetamine, but only female controls conditioned with @DRUG$ spent more time in the drug-paired context compared with saline-treated controls.
5423	DDI-false	Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with @DRUG$, but only female controls conditioned with @DRUG$ spent more time in the drug-paired context compared with saline-treated controls.
5424	DDI-false	Effect of @DRUG$-mediated CYP3A4 inhibition on clinical pharmacokinetics of @DRUG$ (LBH589), an orally active histone deacetylase inhibitor.
5425	DDI-false	Effect of @DRUG$-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (@DRUG$), an orally active histone deacetylase inhibitor.
5426	DDI-false	Effect of @DRUG$-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active @DRUG$.
5427	DDI-false	Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of @DRUG$ (@DRUG$), an orally active histone deacetylase inhibitor.
5428	DDI-false	Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of @DRUG$ (LBH589), an orally active @DRUG$.
5429	DDI-false	Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (@DRUG$), an orally active @DRUG$.
5430	DDI-false	Co-administration of @DRUG$ with CYP3A inhibitors is feasible as the observed increase in @DRUG$ PK parameters was not considered clinically relevant.
5431	DDI-false	Considering the variability in exposure following enzyme inhibition and the fact that chronic dosing of @DRUG$ was not studied with CYP3A inhibitors, close monitoring of @DRUG$-related adverse events is necessary.
5432	DDI-false	This study evaluated the effect of a potent CYP3A inhibitor, @DRUG$, on the pharmacokinetics and safety of @DRUG$.
5433	DDI-false	On day 8, a single @DRUG$ dose was co-administered with @DRUG$.
5434	DDI-mechanism	In the presence of @DRUG$, there was 1.6- and 1.8-fold increase in C (max) and AUC of @DRUG$, respectively.
5435	DDI-false	@DRUG$ and @DRUG$ had no effect, while quinidine appeared to augment precocene I toxicity.
5436	DDI-false	@DRUG$ and sulfaphenazole had no effect, while @DRUG$ appeared to augment precocene I toxicity.
5437	DDI-false	@DRUG$ and sulfaphenazole had no effect, while quinidine appeared to augment @DRUG$ toxicity.
5438	DDI-false	Furafylline and @DRUG$ had no effect, while @DRUG$ appeared to augment precocene I toxicity.
5439	DDI-false	Furafylline and @DRUG$ had no effect, while quinidine appeared to augment @DRUG$ toxicity.
5440	DDI-effect	Furafylline and sulfaphenazole had no effect, while @DRUG$ appeared to augment @DRUG$ toxicity.
5441	DDI-false	These results suggest that rat liver slices do not reproduce the reported in vivo biotransformation of @DRUG$ and therefore may not be an appropriate model for @DRUG$ metabolism.
5442	DDI-false	The incubations were performed in the absence and presence of the non-specific CYP inhibitor, @DRUG$ (@DRUG$) and isoform-specific inhibitors.
5443	DDI-effect	@DRUG$ decreased the toxicity of @DRUG$, increased exposure to parent compound, and decreased metabolite levels in a dose-dependent manner.
5444	DDI-false	Of the isoform-specific CYP inhibitors tested for an effect on the @DRUG$ metabolite profile, only @DRUG$ was noticeably effective, indicating a role of CYPs 2A6, 2C9, 2Cl9, and 2E1.
5445	DDI-false	With respect to toxicity, the order of CYP inhibitor effectiveness was @DRUG$>@DRUG$~tranylcypromine>ketoconazole.
5446	DDI-false	With respect to toxicity, the order of CYP inhibitor effectiveness was @DRUG$>diethyldithiocarbamate~@DRUG$>ketoconazole.
5447	DDI-false	With respect to toxicity, the order of CYP inhibitor effectiveness was @DRUG$>diethyldithiocarbamate~tranylcypromine>@DRUG$.
5448	DDI-false	With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>@DRUG$~@DRUG$>ketoconazole.
5449	DDI-false	With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>@DRUG$~tranylcypromine>@DRUG$.
5450	DDI-false	With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~@DRUG$>@DRUG$.
5451	DDI-false	To determine whether the co-injection of extracellular matrix degrading enzymes improves retinal transduction following intravitreal delivery of @DRUG$ (@DRUG$).
5452	DDI-false	@DRUG$ containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including @DRUG$, hyaluronan lyase, heparinase III, or chondroitin ABC lyase.
5453	DDI-false	@DRUG$ containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, @DRUG$, heparinase III, or chondroitin ABC lyase.
5454	DDI-false	@DRUG$ containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, @DRUG$, or chondroitin ABC lyase.
5455	DDI-false	@DRUG$ containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or @DRUG$.
5456	DDI-false	AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including @DRUG$, @DRUG$, heparinase III, or chondroitin ABC lyase.
5457	DDI-false	AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including @DRUG$, hyaluronan lyase, @DRUG$, or chondroitin ABC lyase.
5458	DDI-false	AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including @DRUG$, hyaluronan lyase, heparinase III, or @DRUG$.
5459	DDI-false	AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, @DRUG$, @DRUG$, or chondroitin ABC lyase.
5460	DDI-false	AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, @DRUG$, heparinase III, or @DRUG$.
5461	DDI-false	AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, @DRUG$, or @DRUG$.
5462	DDI-false	The addition of @DRUG$ or @DRUG$ greatly enhanced transduction of the retinal ganglion cell layer and increased the depth of transduction into the outer retina.
5463	DDI-false	@DRUG$ had a limited effect and @DRUG$ was ineffective.
5464	DDI-false	Electroretinograms survived with higher concentrations of @DRUG$ and @DRUG$ than were required for optimal retinal transduction.
5465	DDI-effect	@DRUG$-mediated retinal transduction is improved by co-injection of @DRUG$ or chondroitin ABC lyase.
5466	DDI-effect	@DRUG$-mediated retinal transduction is improved by co-injection of heparinase III or @DRUG$.
5467	DDI-false	AAV2-mediated retinal transduction is improved by co-injection of @DRUG$ or @DRUG$.
5468	DDI-false	@DRUG$ (@DRUG$)--better than clopidogrel (Plavix)
5469	DDI-false	@DRUG$ (Brilinta)--better than @DRUG$ (Plavix)
5470	DDI-false	@DRUG$ (Brilinta)--better than clopidogrel (@DRUG$)
5471	DDI-false	Ticagrelor (@DRUG$)--better than @DRUG$ (Plavix)
5472	DDI-false	Ticagrelor (@DRUG$)--better than clopidogrel (@DRUG$)
5473	DDI-false	Ticagrelor (Brilinta)--better than @DRUG$ (@DRUG$)
5474	DDI-false	The FDA has approved @DRUG$ (@DRUG$-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).
5475	DDI-false	The FDA has approved @DRUG$ (Brilinta-AstraZeneca), an oral @DRUG$, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).
5476	DDI-effect	The FDA has approved @DRUG$ (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose @DRUG$ to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).
5477	DDI-false	The FDA has approved ticagrelor (@DRUG$-AstraZeneca), an oral @DRUG$, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).
5478	DDI-effect	The FDA has approved ticagrelor (@DRUG$-AstraZeneca), an oral antiplatelet drug, for use with low-dose @DRUG$ to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).
5479	DDI-false	The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral @DRUG$, for use with low-dose @DRUG$ to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).
5480	DDI-false	It will compete with @DRUG$ (@DRUG$) and prasugrel (Effient) for such use.
5481	DDI-false	It will compete with @DRUG$ (Plavix) and @DRUG$ (Effient) for such use.
5482	DDI-false	It will compete with @DRUG$ (Plavix) and prasugrel (@DRUG$) for such use.
5483	DDI-false	It will compete with clopidogrel (@DRUG$) and @DRUG$ (Effient) for such use.
5484	DDI-false	It will compete with clopidogrel (@DRUG$) and prasugrel (@DRUG$) for such use.
5485	DDI-false	It will compete with clopidogrel (Plavix) and @DRUG$ (@DRUG$) for such use.
5486	DDI-effect	The role of p27(Kip1) in @DRUG$-enhanced @DRUG$ cytotoxicity in human ovarian cancer cells.
5487	DDI-effect	Treatment of HEY xenograft-bearing mice with @DRUG$ plus @DRUG$ inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);
5488	DDI-false	Treatment of HEY xenograft-bearing mice with @DRUG$ plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, @DRUG$ + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);
5489	DDI-false	Treatment of HEY xenograft-bearing mice with @DRUG$ plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + @DRUG$ vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);
5490	DDI-false	Treatment of HEY xenograft-bearing mice with @DRUG$ plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs @DRUG$: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);
5491	DDI-false	Treatment of HEY xenograft-bearing mice with dasatinib plus @DRUG$ inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, @DRUG$ + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);
5492	DDI-false	Treatment of HEY xenograft-bearing mice with dasatinib plus @DRUG$ inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + @DRUG$ vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);
5493	DDI-false	Treatment of HEY xenograft-bearing mice with dasatinib plus @DRUG$ inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs @DRUG$: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);
5494	DDI-false	Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, @DRUG$ + @DRUG$ vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);
5495	DDI-false	Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, @DRUG$ + paclitaxel vs @DRUG$: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);
5496	DDI-false	Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + @DRUG$ vs @DRUG$: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);
5497	DDI-false	@DRUG$ + @DRUG$ vs.
5498	DDI-false	The siRNA knockdown of p27(Kip1) decreased @DRUG$- and @DRUG$-induced apoptosis compared with a negative control siRNA (sub-G1 fraction, control siRNA vs. p27(Kip1) siRNA: 42.5% vs. 20.1%, difference = 22.4%, 95% CI = 20.1% to 24.7%, P = .017).
5499	DDI-effect	Studies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that @DRUG$-mediated induction of p27(Kip1) enhanced @DRUG$-induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression.
5500	DDI-effect	Inhibition of Src family and Abl kinases with either siRNAs or @DRUG$ enhances @DRUG$ sensitivity of ovarian cancer cells through p27(Kip1)-mediated suppression of Bcl-2 and Cdk1 expression.
5501	DDI-false	The effect of @DRUG$, an inhibitor of Src and Abl kinases, on @DRUG$ sensitivity was measured in ovarian cancer cells and HEY xenografts.
5502	DDI-false	The roles of p27(Kip1), Bcl-2, and Cdk1 in apoptosis induced by @DRUG$ and @DRUG$ were assessed using a terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay, siRNA knockdown of gene expression, transfection with Bcl-2 and Cdk1 expression vectors, and flow cytometry.
5503	DDI-effect	HEY cells treated with @DRUG$ plus @DRUG$ formed fewer colonies than did cells treated with either agent alone.
5504	DDI-false	Influence of @DRUG$ on @DRUG$ induced antinociception and its pharmacokinetics.
5505	DDI-effect	In the present study @DRUG$ (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of @DRUG$ evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen.
5506	DDI-false	In the present study @DRUG$ (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both @DRUG$ writhing and formalin test, when it was administered with ibuprofen.
5507	DDI-false	In the present study @DRUG$ (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with @DRUG$.
5508	DDI-false	In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of @DRUG$ evaluated by both @DRUG$ writhing and formalin test, when it was administered with ibuprofen.
5509	DDI-false	In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of @DRUG$ evaluated by both acetic acid writhing and formalin test, when it was administered with @DRUG$.
5510	DDI-false	In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both @DRUG$ writhing and formalin test, when it was administered with @DRUG$.
5511	DDI-mechanism	@DRUG$ plasma concentration was also increased when it was administered with @DRUG$.
5512	DDI-mechanism	The synergistic antinociception activity of @DRUG$ when administered with @DRUG$ can be attributed to increased plasma concentration of ibuprofen.
5513	DDI-false	The synergistic antinociception activity of @DRUG$ when administered with piperine can be attributed to increased plasma concentration of @DRUG$.
5514	DDI-false	The synergistic antinociception activity of ibuprofen when administered with @DRUG$ can be attributed to increased plasma concentration of @DRUG$.
5515	DDI-effect	From this study it can be concluded that @DRUG$ can be used as a bioenhancer along with @DRUG$.
5516	DDI-false	Prevention of emergence agitation in seven children receiving low-dose @DRUG$ and @DRUG$ total intravenous anesthesia.
5517	DDI-false	We retrospectively reviewed the records of 7 pediatric oncology patients who received low-dose @DRUG$ in conjunction with @DRUG$ for total intravenous anesthesia (TIVA) repeatedly for radiation therapy.
5518	DDI-false	EA signs were observed in all 7 patients in association with @DRUG$ TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose @DRUG$ was added to propofol.
5519	DDI-false	EA signs were observed in all 7 patients in association with @DRUG$ TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose ketamine was added to @DRUG$.
5520	DDI-false	EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose @DRUG$ was added to @DRUG$.
5521	DDI-effect	Based on this experience, we suggest that low-dose @DRUG$ added to @DRUG$ may be associated with prevention of EA in children with a history of EA with propofol TIVA.
5522	DDI-false	Based on this experience, we suggest that low-dose @DRUG$ added to propofol may be associated with prevention of EA in children with a history of EA with @DRUG$ TIVA.
5523	DDI-false	Based on this experience, we suggest that low-dose ketamine added to @DRUG$ may be associated with prevention of EA in children with a history of EA with @DRUG$ TIVA.
5524	DDI-false	[Efficacy of fixed combination @DRUG$/@DRUG$ in hospitalized patients with hypertensive disease]
5525	DDI-false	Efficacy and tolerability of fixed @DRUG$/@DRUG$ combination was studied in 86 patients with hypertensive disease hospitalized in departments of general internal medicine or cardiology.
5526	DDI-effect	We have demonstrated appropriateness of inhospital administration of fixed @DRUG$/@DRUG$ combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.
5527	DDI-false	We have demonstrated appropriateness of inhospital administration of fixed @DRUG$/valsartan combination as an approach allowing to achieve target BP in shorter time, with the use of fewer @DRUG$, and diminishing concealed inefficacy of treatment.
5528	DDI-false	We have demonstrated appropriateness of inhospital administration of fixed amlodipine/@DRUG$ combination as an approach allowing to achieve target BP in shorter time, with the use of fewer @DRUG$, and diminishing concealed inefficacy of treatment.
5529	DDI-false	All patients had indications for antihypertensive therapy and were randomized either to fixed combination @DRUG$/@DRUG$ (n=43) or to therapy which corresponded to the hospital formulary (n=43).
5530	DDI-false	Rate of achievement of target BP with fixed combination @DRUG$/@DRUG$ (93%) was comparable with that on traditional therapy (90%).
5531	DDI-effect	But the use of fixed combination @DRUG$/@DRUG$ compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05).
5532	DDI-false	But the use of fixed combination @DRUG$/valsartan compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of @DRUG$ (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05).
5533	DDI-false	But the use of fixed combination amlodipine/@DRUG$ compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of @DRUG$ (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05).
5534	DDI-false	The aim of the present study was to investigate whether HB-EGF is a therapeutic target for T-ALL, and to further elucidate the antitumor effects of a specific inhibitor of HB-EGF, @DRUG$ (@DRUG$).
5535	DDI-false	We elucidated the expression of HB-EGF in T-ALL cell lines, and evaluated the effect of @DRUG$ on these cells alone or in combination with @DRUG$.
5536	DDI-false	@DRUG$ induced apoptosis, and furthermore, the combination of @DRUG$ plus doxorubicin enhanced cytotoxicity in a T-ALL cell line.
5537	DDI-false	@DRUG$ induced apoptosis, and furthermore, the combination of CRM197 plus @DRUG$ enhanced cytotoxicity in a T-ALL cell line.
5538	DDI-effect	CRM197 induced apoptosis, and furthermore, the combination of @DRUG$ plus @DRUG$ enhanced cytotoxicity in a T-ALL cell line.
5539	DDI-false	Distinct synergistic action of @DRUG$ and @DRUG$ against Pseudomonas aeruginosa.
5540	DDI-effect	Synergism was also noted when @DRUG$ was combined with @DRUG$ and amikacin.
5541	DDI-effect	Synergism was also noted when @DRUG$ was combined with carbenicillin and @DRUG$.
5542	DDI-false	Synergism was also noted when methylglyoxal was combined with @DRUG$ and @DRUG$.
5543	DDI-false	Results revealed that the strains were resistant to many drugs at high levels, only @DRUG$, @DRUG$, amikacin and ciprofloxacin showed resistances at comparatively lower levels.
5544	DDI-false	Results revealed that the strains were resistant to many drugs at high levels, only @DRUG$, carbenicillin, @DRUG$ and ciprofloxacin showed resistances at comparatively lower levels.
5545	DDI-false	Results revealed that the strains were resistant to many drugs at high levels, only @DRUG$, carbenicillin, amikacin and @DRUG$ showed resistances at comparatively lower levels.
5546	DDI-false	Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, @DRUG$, @DRUG$ and ciprofloxacin showed resistances at comparatively lower levels.
5547	DDI-false	Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, @DRUG$, amikacin and @DRUG$ showed resistances at comparatively lower levels.
5548	DDI-false	Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, @DRUG$ and @DRUG$ showed resistances at comparatively lower levels.
5549	DDI-effect	Distinct and statistically significant synergism was observed between @DRUG$ and @DRUG$ by disc diffusion tests when compared with their individual effects.
5550	DDI-effect	@DRUG$   failure in an HIV-positive woman on @DRUG$ therapy resulting in two ectopic pregnancies.
5551	DDI-effect	We present an interesting case of an HIV-positive woman on @DRUG$ therapy having tubal pregnancies on two separate occasions with @DRUG$ in place.
5552	DDI-false	@DRUG$, an @DRUG$, is the standard hormone treatment for breast cancer.
5553	DDI-false	Depression does not always require @DRUG$ therapy, and @DRUG$ have no proven preventive impact on hot flushes linked to the menopause.
5554	DDI-advise	If in certain cases, an @DRUG$ is considered necessary, it may be advisable to replace @DRUG$ with anastrozole.
5555	DDI-false	If in certain cases, an @DRUG$ is considered necessary, it may be advisable to replace tamoxifen with @DRUG$.
5556	DDI-false	If in certain cases, an antidepressant is considered necessary, it may be advisable to replace @DRUG$ with @DRUG$.
5557	DDI-false	@DRUG$ and @DRUG$ reduce the plasma concentration of endoxifen by about 50%.
5558	DDI-mechanism	@DRUG$ and fluoxetine reduce the plasma concentration of @DRUG$ by about 50%.
5559	DDI-mechanism	Paroxetine and @DRUG$ reduce the plasma concentration of @DRUG$ by about 50%.
5560	DDI-advise	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with @DRUG$ for breast cancer, especially @DRUG$ such as paroxetine and fluoxetine.
5561	DDI-advise	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with @DRUG$ for breast cancer, especially SSRI antidepressants such as @DRUG$ and fluoxetine.
5562	DDI-advise	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with @DRUG$ for breast cancer, especially SSRI antidepressants such as paroxetine and @DRUG$.
5563	DDI-false	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially @DRUG$ such as @DRUG$ and fluoxetine.
5564	DDI-false	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially @DRUG$ such as paroxetine and @DRUG$.
5565	DDI-false	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as @DRUG$ and @DRUG$.
5566	DDI-false	Phase I trial of @DRUG$ and @DRUG$ in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
5567	DDI-false	Phase I trial of @DRUG$ and CCI-779 in patients with relapsed multiple myeloma: evidence for @DRUG$-CCI-779 interaction via P-glycoprotein.
5568	DDI-false	Phase I trial of @DRUG$ and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-@DRUG$ interaction via P-glycoprotein.
5569	DDI-false	Phase I trial of lenalidomide and @DRUG$ in patients with relapsed multiple myeloma: evidence for @DRUG$-CCI-779 interaction via P-glycoprotein.
5570	DDI-false	Phase I trial of lenalidomide and @DRUG$ in patients with relapsed multiple myeloma: evidence for lenalidomide-@DRUG$ interaction via P-glycoprotein.
5571	DDI-false	Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for @DRUG$-@DRUG$ interaction via P-glycoprotein.
5572	DDI-effect	The preclinical combination of @DRUG$ with the mTOR inhibitor @DRUG$ has displayed synergy in vitro and represents a novel combination in MM.
5573	DDI-false	In vivo CYP3A activity is significantly lower in @DRUG$-treated as compared with @DRUG$-treated renal allograft recipients.
5574	DDI-false	In vitro studies have identified @DRUG$ and @DRUG$ as CYP3A inhibitors.
5575	DDI-mechanism	Systemic and apparent oral @DRUG$ clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in @DRUG$-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20).
5576	DDI-false	Systemic and apparent oral @DRUG$ clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched @DRUG$-treated patients (n = 20).
5577	DDI-false	Systemic and apparent oral midazolam clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in @DRUG$-treated patients (n = 20) than in matched @DRUG$-treated patients (n = 20).
5578	DDI-false	The latter displayed @DRUG$ clearances similar to those in two larger cohorts of nonmatched @DRUG$-treated patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor-free regimen (n = 6).
5579	DDI-false	The latter displayed @DRUG$ clearances similar to those in two larger cohorts of nonmatched tacrolimus-treated patients (n = 58 and n = 80) and to those receiving a @DRUG$-free regimen (n = 6).
5580	DDI-false	The latter displayed midazolam clearances similar to those in two larger cohorts of nonmatched @DRUG$-treated patients (n = 58 and n = 80) and to those receiving a @DRUG$-free regimen (n = 6).
5581	DDI-false	This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving @DRUG$ than in those receiving @DRUG$, indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to CYP3A inhibition.
5582	DDI-false	This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving @DRUG$ than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice, @DRUG$ is the stronger of the two with respect to CYP3A inhibition.
5583	DDI-false	This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving cyclosporine than in those receiving @DRUG$, indicating that, at the doses generally used in clinical practice, @DRUG$ is the stronger of the two with respect to CYP3A inhibition.
5584	DDI-false	[Influence of @DRUG$ and @DRUG$ on MPTP-evoked behavior violations in C57BL/6 mice].
5585	DDI-false	The effects of @DRUG$ @DRUG$ [(2-adamantyl)hexamethylenimine] (10 mg/kg, p. o.)
5586	DDI-false	The effects of @DRUG$ hemantane [@DRUG$] (10 mg/kg, p. o.)
5587	DDI-false	The effects of anti-parkinsonian drug @DRUG$ [@DRUG$] (10 mg/kg, p. o.)
5588	DDI-false	and/or @DRUG$ @DRUG$ (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.)
5589	DDI-false	and/or @DRUG$ doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin @DRUG$ (MPTP) (4 x 20 mg/kg, i. p.)
5590	DDI-false	and/or @DRUG$ doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (@DRUG$) (4 x 20 mg/kg, i. p.)
5591	DDI-false	and/or antibiotic drug @DRUG$ (100 mg/kg, p. o.), as well as that of neurotoxin @DRUG$ (MPTP) (4 x 20 mg/kg, i. p.)
5592	DDI-false	and/or antibiotic drug @DRUG$ (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (@DRUG$) (4 x 20 mg/kg, i. p.)
5593	DDI-false	and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin @DRUG$ (@DRUG$) (4 x 20 mg/kg, i. p.)
5594	DDI-effect	Acute administration of @DRUG$ or @DRUG$ failed to influence locomotion in mice, while their combination normalized motor activity.
5595	DDI-false	Exposure to oral @DRUG$ is unaffected by @DRUG$ but greatly increased by ticlopidine.
5596	DDI-effect	Exposure to oral @DRUG$ is unaffected by itraconazole but greatly increased by @DRUG$.
5597	DDI-false	Exposure to oral S-ketamine is unaffected by @DRUG$ but greatly increased by @DRUG$.
5598	DDI-false	This study examined drug-drug interactions of oral @DRUG$ with the cytochrome P450 (CYP) 2B6 inhibitor @DRUG$ and the CYP3A inhibitor itraconazole.
5599	DDI-false	This study examined drug-drug interactions of oral @DRUG$ with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor @DRUG$.
5600	DDI-false	This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor @DRUG$ and the CYP3A inhibitor @DRUG$.
5601	DDI-false	In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg @DRUG$ after pretreatments with oral @DRUG$ (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks.
5602	DDI-false	In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg @DRUG$ after pretreatments with oral ticlopidine (250 mg twice daily), @DRUG$ (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks.
5603	DDI-false	In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral @DRUG$ (250 mg twice daily), @DRUG$ (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks.
5604	DDI-mechanism	@DRUG$ treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral @DRUG$ by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine.
5605	DDI-false	@DRUG$ treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas @DRUG$ treatment did not increase the exposure to S-ketamine.
5606	DDI-false	@DRUG$ treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to @DRUG$.
5607	DDI-false	Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral @DRUG$ by 2.4-fold, whereas @DRUG$ treatment did not increase the exposure to S-ketamine.
5608	DDI-false	Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral @DRUG$ by 2.4-fold, whereas itraconazole treatment did not increase the exposure to @DRUG$.
5609	DDI-false	Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas @DRUG$ treatment did not increase the exposure to @DRUG$.
5610	DDI-false	The ratio of @DRUG$ AUC(0-   ) to @DRUG$ AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo.
5611	DDI-false	The ratio of @DRUG$ AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the @DRUG$ (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo.
5612	DDI-false	The ratio of @DRUG$ AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and @DRUG$ phases (P = 0.006) as compared to placebo.
5613	DDI-false	The ratio of norketamine AUC(0-   ) to @DRUG$ AUC(0-   ) was significantly decreased in the @DRUG$ (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo.
5614	DDI-false	The ratio of norketamine AUC(0-   ) to @DRUG$ AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and @DRUG$ phases (P = 0.006) as compared to placebo.
5615	DDI-false	The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the @DRUG$ (P &lt; 0.001) and @DRUG$ phases (P = 0.006) as compared to placebo.
5616	DDI-false	In the @DRUG$ and @DRUG$ phases, the areas under the effect-time curves (self-reported drowsiness and performance) were significantly higher than those in the placebo phase (P < 0.05).
5617	DDI-advise	The findings suggest that the dosage of @DRUG$ should be reduced in patients receiving @DRUG$.
5618	DDI-effect	Interaction of @DRUG$ with different @DRUG$ is antagonistic in breast but not in other cancer cells.
5619	DDI-false	These results, if confirmed in-vivo, indicate that @DRUG$ is not a suitable chemosensitizer for breast cancer or with @DRUG$ for other cancers.
5620	DDI-false	This study investigates the ability of @DRUG$ to sensitize cells from different origins to several @DRUG$.
5621	DDI-false	The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to @DRUG$, @DRUG$, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.
5622	DDI-false	The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to @DRUG$, cisplatin, @DRUG$ and etoposide   celecoxib following different incubation schedules were analyzed.
5623	DDI-false	The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to @DRUG$, cisplatin, doxorubicin and @DRUG$   celecoxib following different incubation schedules were analyzed.
5624	DDI-false	The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to @DRUG$, cisplatin, doxorubicin and etoposide   @DRUG$ following different incubation schedules were analyzed.
5625	DDI-false	The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, @DRUG$, @DRUG$ and etoposide   celecoxib following different incubation schedules were analyzed.
5626	DDI-false	The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, @DRUG$, doxorubicin and @DRUG$   celecoxib following different incubation schedules were analyzed.
5627	DDI-false	The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, @DRUG$, doxorubicin and etoposide   @DRUG$ following different incubation schedules were analyzed.
5628	DDI-false	The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, @DRUG$ and @DRUG$   celecoxib following different incubation schedules were analyzed.
5629	DDI-false	The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, @DRUG$ and etoposide   @DRUG$ following different incubation schedules were analyzed.
5630	DDI-false	The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and @DRUG$   @DRUG$ following different incubation schedules were analyzed.
5631	DDI-false	We found antagonism between @DRUG$ and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between @DRUG$ and doxorubicin in all cell lines except for two combinations in HCT116 cells.
5632	DDI-false	We found antagonism between @DRUG$ and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and @DRUG$ in all cell lines except for two combinations in HCT116 cells.
5633	DDI-effect	We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between @DRUG$ and @DRUG$ in all cell lines except for two combinations in HCT116 cells.
5634	DDI-false	@DRUG$-@DRUG$ interaction and associated gastrointestinal bleeding risk in a case-control study.
5635	DDI-effect	@DRUG$ users who initiated @DRUG$, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.
5636	DDI-effect	@DRUG$ users who initiated citalopram, @DRUG$, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.
5637	DDI-effect	@DRUG$ users who initiated citalopram, fluoxetine, @DRUG$, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.
5638	DDI-effect	@DRUG$ users who initiated citalopram, fluoxetine, paroxetine, @DRUG$, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.
5639	DDI-effect	@DRUG$ users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or @DRUG$ had an increased risk of hospitalization for gastrointestinal bleeding.
5640	DDI-false	Warfarin users who initiated @DRUG$, @DRUG$, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.
5641	DDI-false	Warfarin users who initiated @DRUG$, fluoxetine, @DRUG$, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.
5642	DDI-false	Warfarin users who initiated @DRUG$, fluoxetine, paroxetine, @DRUG$, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.
5643	DDI-false	Warfarin users who initiated @DRUG$, fluoxetine, paroxetine, amitriptyline, or @DRUG$ had an increased risk of hospitalization for gastrointestinal bleeding.
5644	DDI-false	Warfarin users who initiated citalopram, @DRUG$, @DRUG$, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.
5645	DDI-false	Warfarin users who initiated citalopram, @DRUG$, paroxetine, @DRUG$, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.
5646	DDI-false	Warfarin users who initiated citalopram, @DRUG$, paroxetine, amitriptyline, or @DRUG$ had an increased risk of hospitalization for gastrointestinal bleeding.
5647	DDI-false	Warfarin users who initiated citalopram, fluoxetine, @DRUG$, @DRUG$, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.
5648	DDI-false	Warfarin users who initiated citalopram, fluoxetine, @DRUG$, amitriptyline, or @DRUG$ had an increased risk of hospitalization for gastrointestinal bleeding.
5649	DDI-false	Warfarin users who initiated citalopram, fluoxetine, paroxetine, @DRUG$, or @DRUG$ had an increased risk of hospitalization for gastrointestinal bleeding.
5650	DDI-false	We sought to evaluate whether initiation of an @DRUG$ increases the risk of hospitalization for gastrointestinal bleeding in @DRUG$ users.
5651	DDI-false	In total, 430,455 @DRUG$ users contributed 407,370 person-years of @DRUG$ use.
5652	DDI-effect	@DRUG$ users had an increased odds ratio of gastrointestinal bleeding upon initiation of @DRUG$ (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]).
5653	DDI-effect	@DRUG$ users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), @DRUG$ (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]).
5654	DDI-effect	@DRUG$ users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), @DRUG$ (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]).
5655	DDI-effect	@DRUG$ users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), @DRUG$ (OR   =   1.47 [95% CI, 1.02-2.11]).
5656	DDI-false	Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of @DRUG$ (OR   =   1.73 [95% CI, 1.25-2.38]), @DRUG$ (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]).
5657	DDI-false	Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of @DRUG$ (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), @DRUG$ (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]).
5658	DDI-false	Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of @DRUG$ (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), @DRUG$ (OR   =   1.47 [95% CI, 1.02-2.11]).
5659	DDI-false	Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), @DRUG$ (OR   =   1.63 [95% CI, 1.11-2.38]), @DRUG$ (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]).
5660	DDI-false	Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), @DRUG$ (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), @DRUG$ (OR   =   1.47 [95% CI, 1.02-2.11]).
5661	DDI-false	Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), @DRUG$ (OR   =   1.64 [95% CI, 1.27-2.12]), @DRUG$ (OR   =   1.47 [95% CI, 1.02-2.11]).
5662	DDI-effect	Also @DRUG$, which is not believed to interact with @DRUG$, increased the risk of GI bleeding (OR   =   1.75 [95% CI, 1.30-2.35]).
5663	DDI-effect	@DRUG$ enhances the antinociceptive effect of @DRUG$ in mice.
5664	DDI-false	The purpose of this study was to evaluate whether the psychostimulant drug @DRUG$ has any effect on @DRUG$-induced antinociception and locomotor inhibitor activity in mice in acute application.
5665	DDI-false	saline + saline, @DRUG$ (10   mg/kg) + saline, saline + @DRUG$ (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests.
5666	DDI-false	saline + saline, @DRUG$ (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and @DRUG$ (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests.
5667	DDI-false	saline + saline, @DRUG$ (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + @DRUG$ (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests.
5668	DDI-false	saline + saline, ephedrine (10   mg/kg) + saline, saline + @DRUG$ (15     g/kg) and @DRUG$ (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests.
5669	DDI-false	saline + saline, ephedrine (10   mg/kg) + saline, saline + @DRUG$ (15     g/kg) and ephedrine (10   mg/kg) + @DRUG$ (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests.
5670	DDI-false	saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and @DRUG$ (10   mg/kg) + @DRUG$ (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests.
5671	DDI-effect	In the hot plate test in mice, co-administration of 15     g/kg @DRUG$ with 10   mg/kg @DRUG$ intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine.
5672	DDI-false	In the hot plate test in mice, co-administration of 15     g/kg @DRUG$ with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by @DRUG$.
5673	DDI-false	In the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg @DRUG$ intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by @DRUG$.
5674	DDI-effect	At the same time, the locomotor inhibitory effect of @DRUG$ was counteracted by @DRUG$.
5675	DDI-effect	We concluded that the combined administration of @DRUG$ with @DRUG$ may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.
5676	DDI-false	We concluded that the combined administration of @DRUG$ with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of @DRUG$ as an analgesic in humans.
5677	DDI-false	We concluded that the combined administration of @DRUG$ with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an @DRUG$ in humans.
5678	DDI-false	We concluded that the combined administration of dexmedetomidine with @DRUG$ may have beneficial effects in the treatment of pain without causing sedation, which limits the use of @DRUG$ as an analgesic in humans.
5679	DDI-false	We concluded that the combined administration of dexmedetomidine with @DRUG$ may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an @DRUG$ in humans.
5680	DDI-false	We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of @DRUG$ as an @DRUG$ in humans.
5681	DDI-false	Interaction study of @DRUG$ and @DRUG$ with co-administered drugs.
5682	DDI-false	@DRUG$ and @DRUG$ are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections.
5683	DDI-false	@DRUG$ and lomefloxacin are @DRUG$ used in treating urinary and respiratory tract infections.
5684	DDI-false	Moxifloxacin and @DRUG$ are @DRUG$ used in treating urinary and respiratory tract infections.
5685	DDI-false	Being @DRUG$ and lomefloxacin @DRUG$ the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals.
5686	DDI-false	Being @DRUG$ and lomefloxacin fluoroquinolones the interaction study of was carried out with @DRUG$, gelusil, erythromycin and multi minerals.
5687	DDI-false	Being @DRUG$ and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, @DRUG$, erythromycin and multi minerals.
5688	DDI-false	Being @DRUG$ and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, @DRUG$ and multi minerals.
5689	DDI-false	Being @DRUG$ and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and @DRUG$.
5690	DDI-false	Being moxifloxacin and lomefloxacin @DRUG$ the interaction study of was carried out with @DRUG$, gelusil, erythromycin and multi minerals.
5691	DDI-false	Being moxifloxacin and lomefloxacin @DRUG$ the interaction study of was carried out with sucralfate, @DRUG$, erythromycin and multi minerals.
5692	DDI-false	Being moxifloxacin and lomefloxacin @DRUG$ the interaction study of was carried out with sucralfate, gelusil, @DRUG$ and multi minerals.
5693	DDI-false	Being moxifloxacin and lomefloxacin @DRUG$ the interaction study of was carried out with sucralfate, gelusil, erythromycin and @DRUG$.
5694	DDI-false	Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with @DRUG$, @DRUG$, erythromycin and multi minerals.
5695	DDI-false	Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with @DRUG$, gelusil, @DRUG$ and multi minerals.
5696	DDI-false	Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with @DRUG$, gelusil, erythromycin and @DRUG$.
5697	DDI-false	Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, @DRUG$, @DRUG$ and multi minerals.
5698	DDI-false	Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, @DRUG$, erythromycin and @DRUG$.
5699	DDI-false	Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, @DRUG$ and @DRUG$.
5700	DDI-false	The response of @DRUG$ and @DRUG$ after interaction with co-administered drugs at different conditions and temperature were noted using a Shimadzu HPLC system with PDA detector.
5701	DDI-false	@DRUG$ and @DRUG$ reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.
5702	DDI-mechanism	@DRUG$ and Lomefloxacin reacts faster with @DRUG$ and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.
5703	DDI-mechanism	@DRUG$ and Lomefloxacin reacts faster with sucralfate and @DRUG$ in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.
5704	DDI-mechanism	@DRUG$ and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with @DRUG$ in basic media and multi-minerals in neutral media.
5705	DDI-mechanism	@DRUG$ and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and @DRUG$ in neutral media.
5706	DDI-mechanism	Moxifloxacin and @DRUG$ reacts faster with @DRUG$ and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.
5707	DDI-mechanism	Moxifloxacin and @DRUG$ reacts faster with sucralfate and @DRUG$ in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.
5708	DDI-mechanism	Moxifloxacin and @DRUG$ reacts faster with sucralfate and gelusil in acidic media whereas with @DRUG$ in basic media and multi-minerals in neutral media.
5709	DDI-mechanism	Moxifloxacin and @DRUG$ reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and @DRUG$ in neutral media.
5710	DDI-false	Moxifloxacin and Lomefloxacin reacts faster with @DRUG$ and @DRUG$ in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.
5711	DDI-false	Moxifloxacin and Lomefloxacin reacts faster with @DRUG$ and gelusil in acidic media whereas with @DRUG$ in basic media and multi-minerals in neutral media.
5712	DDI-false	Moxifloxacin and Lomefloxacin reacts faster with @DRUG$ and gelusil in acidic media whereas with erythromycin in basic media and @DRUG$ in neutral media.
5713	DDI-false	Moxifloxacin and Lomefloxacin reacts faster with sucralfate and @DRUG$ in acidic media whereas with @DRUG$ in basic media and multi-minerals in neutral media.
5714	DDI-false	Moxifloxacin and Lomefloxacin reacts faster with sucralfate and @DRUG$ in acidic media whereas with erythromycin in basic media and @DRUG$ in neutral media.
5715	DDI-false	Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with @DRUG$ in basic media and @DRUG$ in neutral media.
5716	DDI-false	Evaluation of antidepressant like activity of @DRUG$ and its combination with @DRUG$ and imipramine: an acute and chronic study.
5717	DDI-false	Evaluation of antidepressant like activity of @DRUG$ and its combination with fluoxetine and @DRUG$: an acute and chronic study.
5718	DDI-false	Evaluation of antidepressant like activity of curcumin and its combination with @DRUG$ and @DRUG$: an acute and chronic study.
5719	DDI-false	In the present study, the antidepressant like activity of @DRUG$ and its combination with @DRUG$ and imipramine was studied in acute model (three doses 24, 5 and 1 h before test) of forced swimming test (FST) in glass jar and tail suspension test (TST) in mice and in chronic model (14 day study) of FST with water wheel in rats.
5720	DDI-false	In the present study, the antidepressant like activity of @DRUG$ and its combination with fluoxetine and @DRUG$ was studied in acute model (three doses 24, 5 and 1 h before test) of forced swimming test (FST) in glass jar and tail suspension test (TST) in mice and in chronic model (14 day study) of FST with water wheel in rats.
5721	DDI-false	In the present study, the antidepressant like activity of curcumin and its combination with @DRUG$ and @DRUG$ was studied in acute model (three doses 24, 5 and 1 h before test) of forced swimming test (FST) in glass jar and tail suspension test (TST) in mice and in chronic model (14 day study) of FST with water wheel in rats.
5722	DDI-false	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (@DRUG$ 50 mg/kg), group 3 (@DRUG$ 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg).
5723	DDI-false	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (@DRUG$ 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (@DRUG$ 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg).
5724	DDI-false	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (@DRUG$ 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (@DRUG$ 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg).
5725	DDI-false	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (@DRUG$ 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (@DRUG$ 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg).
5726	DDI-false	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (@DRUG$ 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus @DRUG$ 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg).
5727	DDI-false	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (@DRUG$ 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (@DRUG$ 100 mg/kg plus imipramine 15 mg/kg).
5728	DDI-false	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (@DRUG$ 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus @DRUG$ 15 mg/kg).
5729	DDI-false	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (@DRUG$ 100 mg/kg), group 4 (@DRUG$ 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg).
5730	DDI-false	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (@DRUG$ 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (@DRUG$ 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg).
5731	DDI-false	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (@DRUG$ 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (@DRUG$ 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg).
5732	DDI-false	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (@DRUG$ 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus @DRUG$ 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg).
5733	DDI-false	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (@DRUG$ 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (@DRUG$ 100 mg/kg plus imipramine 15 mg/kg).
5734	DDI-false	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (@DRUG$ 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus @DRUG$ 15 mg/kg).
5735	DDI-false	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (@DRUG$ 20 mg/kg), group 5 (@DRUG$ 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg).
5736	DDI-false	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (@DRUG$ 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (@DRUG$ 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg).
5737	DDI-false	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (@DRUG$ 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus @DRUG$ 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg).
5738	DDI-false	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (@DRUG$ 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (@DRUG$ 100 mg/kg plus imipramine 15 mg/kg).
5739	DDI-false	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (@DRUG$ 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus @DRUG$ 15 mg/kg).
5740	DDI-false	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (@DRUG$ 15 mg/kg), group 6 (@DRUG$ 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg).
5741	DDI-false	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (@DRUG$ 15 mg/kg), group 6 (curcumin 100 mg/kg plus @DRUG$ 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg).
5742	DDI-false	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (@DRUG$ 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (@DRUG$ 100 mg/kg plus imipramine 15 mg/kg).
5743	DDI-false	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (@DRUG$ 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus @DRUG$ 15 mg/kg).
5744	DDI-false	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (@DRUG$ 100 mg/kg plus @DRUG$ 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg).
5745	DDI-false	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (@DRUG$ 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (@DRUG$ 100 mg/kg plus imipramine 15 mg/kg).
5746	DDI-false	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (@DRUG$ 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus @DRUG$ 15 mg/kg).
5747	DDI-false	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus @DRUG$ 20 mg/kg) and group 7 (@DRUG$ 100 mg/kg plus imipramine 15 mg/kg).
5748	DDI-false	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus @DRUG$ 20 mg/kg) and group 7 (curcumin 100 mg/kg plus @DRUG$ 15 mg/kg).
5749	DDI-false	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (@DRUG$ 100 mg/kg plus @DRUG$ 15 mg/kg).
5750	DDI-false	The effect of @DRUG$ (100 mg/kg) was similar to that of @DRUG$ and imipramine (p > 0.05) but its addition to fluoxetine and imipramine did not improve their antidepressant activity (p > 0.05).
5751	DDI-false	The effect of @DRUG$ (100 mg/kg) was similar to that of fluoxetine and @DRUG$ (p > 0.05) but its addition to fluoxetine and imipramine did not improve their antidepressant activity (p > 0.05).
5752	DDI-false	The effect of @DRUG$ (100 mg/kg) was similar to that of fluoxetine and imipramine (p > 0.05) but its addition to @DRUG$ and imipramine did not improve their antidepressant activity (p > 0.05).
5753	DDI-false	The effect of @DRUG$ (100 mg/kg) was similar to that of fluoxetine and imipramine (p > 0.05) but its addition to fluoxetine and @DRUG$ did not improve their antidepressant activity (p > 0.05).
5754	DDI-false	The effect of curcumin (100 mg/kg) was similar to that of @DRUG$ and @DRUG$ (p > 0.05) but its addition to fluoxetine and imipramine did not improve their antidepressant activity (p > 0.05).
5755	DDI-false	The effect of curcumin (100 mg/kg) was similar to that of @DRUG$ and imipramine (p > 0.05) but its addition to @DRUG$ and imipramine did not improve their antidepressant activity (p > 0.05).
5756	DDI-false	The effect of curcumin (100 mg/kg) was similar to that of @DRUG$ and imipramine (p > 0.05) but its addition to fluoxetine and @DRUG$ did not improve their antidepressant activity (p > 0.05).
5757	DDI-false	The effect of curcumin (100 mg/kg) was similar to that of fluoxetine and @DRUG$ (p > 0.05) but its addition to @DRUG$ and imipramine did not improve their antidepressant activity (p > 0.05).
5758	DDI-false	The effect of curcumin (100 mg/kg) was similar to that of fluoxetine and @DRUG$ (p > 0.05) but its addition to fluoxetine and @DRUG$ did not improve their antidepressant activity (p > 0.05).
5759	DDI-false	The effect of curcumin (100 mg/kg) was similar to that of fluoxetine and imipramine (p > 0.05) but its addition to @DRUG$ and @DRUG$ did not improve their antidepressant activity (p > 0.05).
5760	DDI-false	@DRUG$ can be a useful @DRUG$ especially in cases which respond to drugs having mixed effects on serotonin and catecholamines levels in the brain.
